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Abstract
Modulation of internal environment and maintenance of cellular structure and stability are basic requirements
to ensure cell survival. These cellular functions are provided by the cell outer membrane, a phospholipid
bilayer characterised by the fluid mosaic model. Chemical reactivity at the membrane interface has previously
been identified between phospholipids and membrane binding species. Observed reactivity, termed intrinsic
lipidation, involves non-enzymatic acyl transfer from phospholipids to a nucleophilic membrane bound molecule.
Reactivity has been characterised for membrane active peptides and proteins, and been found influential to the
structure and function of both the newly modified species, and the bulk membrane. Research presented within
this thesis probes fundamental features of observed intrinsic lipidation reactivity at the membrane interface.
This work has expanded upon previous intrinsic lipidation research, facilitated by the development of informative
and robust analytical techniques for the study of reactivity. Optimised TLC has allowed improved routine
high throughput reactivity screening, compared to alternative fluorescence and solution state NMR techniques.
Informative analysis and mechanistic understanding of intrinsic lipidation has been achieved through LCMS
and solid state NMR analysis. Synthetic protocols for preparation of isotopically labelled 15N small molecules,
and 13C phospholipids, has facilitated solid state NMR in particular. Biological relevance of peptide intrinsic
lipidation has also been probed to determine the role of reactivity in natural function, and disease induction.
Biophysical techniques such as CD and tryptophan fluorescence revealed that solution phase intrinsically
lipidated melittin adopts an α-helical structure with central proline kink, in contrast to the random coil
of unmodified melittin. Furthermore, at µM concentrations, palmitoylated species were shown to undergo
spontaneous micelle formation. Disease related behaviour linked to peptide intrinsic lipidation includes moderate
antimicrobial activity, and possible induction of amyloid nucleation.
Additionally, this study has identified novel intrinsic lipidation of small molecules in vitro utilising chromato-
graphic and ionisation conditions optimised with synthetically prepared standards. Observed for multiple
cationic amphiphilic small molecules, intrinsic lipidation was promoted by primary amines in a hydrophilic
environment, due to increased proximity between reactive moieties. Small molecule intrinsic lipidation products
were shown to exhibit biological relevance, including spontaneous micelle formation, membrane disruption,
and phospholipidosis induction. Pharmaceutical propranolol displayed notable intrinsic lipidation in vitro,
and in Hep G2 cell culture. Initial transesterification from membrane phospholipids produced O-acylated
propranolol, followed by secondary N -acylated propranolol formation by intramolecular O to N migration.
Study of propranolol reactivity has revealed preferential eukaryotic transfer from the sn-1 phospholipid backbone
position, and reaction kinetics influenced by temperature, pH, and membrane composition.
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1 | Literature Review
1.1 Introduction
Cells are the building blocks of life, forming the basis of virtually all living things. Vital
to their survival are the many diverse roles carried out by the cell outer membrane. As a
protective outer layer, the membrane maintains cell structural integrity and stability, ensuring
robustness towards environmental stress. As a physical barrier, the membrane is able to
control the entry and exit of substances to the cell. By preventing access of toxic substances,
and promoting the uptake of necessary cellular components, the outer membrane ensures that
cells thrive. Furthermore, specialised domains within the membrane have unique composition
dependent cellular roles. Examples of these roles include control of enzyme activation and
membrane transport channels, ultimately regulating cellular pathways.1,2
Figure 1.1 The fluid mosaic model of a biological membrane, showing the phospholipid
bilayer and globular membrane active peptides/proteins.3
In 1972 Singer and Nicolson analysed the available physical and thermodynamic data to
characterise cell membrane structure.3 The resulting fluid mosaic model, Fig. 1.1, describes
the membrane as a single-phase dynamic fluid system able to adapt to environmental stresses.
The major component of this fluid system is a phospholipid bilayer, spontaneously formed
due to innate phospholipid properties. Three regions are present within phospholipids: (i)
12
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phosphate head group; (ii) glycerol backbone; (iii) two fatty acid tails. These regions, Fig. 1.2,
give rise to naming nomenclature, exemplified by 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC). Dioleoyl corresponds to the two oleoyl (18:1) fatty acid chains (green), glycero
to the glycerol backbone (red), and phosphocholine to the phosphate head group (blue).
A high proportion of electronegative elements combined with its ionic nature makes the
phosphate head group hydrophilic in nature. Variation in R3 modifies head group size and
charge, instilling an intrinsic phospholipid positional preference within the membrane. In
contrast, fatty acid tails ester linked to the phosphate via a glycerol backbone, are composed
of hydrophobic carbon chains. Table 1.1 summarises common fatty acid chain lengths and
levels of unsaturation. Acyl chain variation within individual phospholipids, and within
the bulk membrane modifies phospholipid bilayer packing and domain formation, impacting
physical membrane properties.4 Within aqueous environments, the balance of phospholipid
hydrophobicity and hydrophilicity results in spontaneous formation of multi-phospholipid
structures which maximise favourable interactions. Aggregate structures include micelles and
vesicles, however curvature and internal cell composition promotes bilayer formation for the
cell membrane.3
O
P
O
O
O
R3
H O
O R1
O
O
R2
Figure 1.2 Structure of a generic phospholipid: green indicates fatty acid chains where R1
= acyl chain at sn-1 position, and R2 = acyl chain at sn-2 position; red indicates glycerol
backbone; blue indicates phosphate head group with variable R3.
Fatty Acid Number of Carbons Number of Double Bonds
Myristoyl 14 0
Palmitoyl 16 0
Stearoyl 18 0
Oleoyl 18 1
Linoleoyl 18 2
Table 1.1 Common fatty acid chain types found as components of phospholipids.
Globular membrane active peptides and proteins are the second cell membrane component pre-
sented in the 1972 fluid mosaic model.3 Despite variation in length and amino acid composition,
membrane active peptides are linked by their amphiphilicity, including both a hydrophobic,
non-polar region containing alanine-like residues, and a hydrophilic region containing lysine
or arginine amino acids. Amphiphilicity allows spontaneous association of membrane active
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peptides with a phospholipid bilayer via α-helix formation. Association increases thermo-
dynamic stability by shielding hydrophobic residues from the aqueous environment, whilst
simultaneously promoting ionic/polar interactions between water and hydrophilic residues.
Whilst some membrane active peptides are unmodified, many undergo post-translational
modification to aid in regulation of peptide activity, interactions and localisation.5 Common
modifications include: (i) acylation, i.e. fatty acid substitution on to a nucleophilic amino
acid residue; (ii) phosphorylation, i.e. substitution of a phosphate onto serine, threonine or
tyrosine; (iii) glycosylation, i.e. substitution of a sugar moiety; (iv) alkylation, i.e. methylation
of an oxygen or nitrogen within an amino acid residue side chain.6 Whilst the key constituents
and characteristics remain unchanged, identification of additional cell membrane compo-
nents has occurred since 1972. Notable examples of this include the presence of cholesterol
and glycolipids.1,7 Furthermore, several other cellular components and external substances
such as pharmaceuticals have been observed to undergo transient interactions with the cell
membrane.8,9
Given the diverse composition and functionality of the cell membrane, it seems unlikely to be
a chemically inert structure. Predicted reactivity could result in unidirectional bond formation
between membrane components, even with molecules that only transiently interact with the
membrane. Any observed reactivity would be expected to greatly influence the structure
and properties of molecules involved, and change fundamental understanding of biological
pathways. Extrapolating from well characterised solution phase organic chemistry, two such
reactions have been identified in vitro. The first, intrinsic lipidation of peptides, involves
non-enzymatic acyl transfer from phospholipids to membrane-active peptides.10,11 The second,
lipid hydrolysis, produces a lysolipid product via non-enzymatic phospholipid hydrolysis.12
Whilst the identification of two novel membrane reactions is important, their power can only
be understood and harnessed through further research. Practical challenges and sensitivity
limitations have thus far presented barriers to identifying suitable techniques for the study of
reactions at the membrane interface, and as such research remains in its infancy. Through
developing analytical methods for the study of cell membrane reactivity, it is hoped that further
information can be gleaned regarding the biological influence of reactivity at the membrane
interface. One focus is understanding reactivity origins and the influence of environmental
factors such as membrane composition and physical parameters. Component modification has
powerful potential to alter molecular structure, properties and membrane affinity, ultimately
impacting upon cellular function. Furthermore, reactivity is predicted to influence bulk
membrane properties such as fluidity and curvature, compromising membrane stability and
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structural integrity. By studying both causes and consequences of membrane reactivity, the
door is opened to both a developed understanding of biological systems, and a means to
manipulate them.
1.2 Lysolipid Formation
Lysolipids, Fig. 1.3, are biomolecules similar in structure to phospholipids but with one acyl
chain replaced by a hydroxyl group.13 The remaining acyl chain can be attached to the
lysolipid backbone at either the sn-1 or sn-2 position. Chain migration between the two
positions occurs readily, and thus lysolipids exist predominately with the acyl chain in the
more stable sn-1 position. Biologically, lysolipids adopt a variety of important roles within
the cell membrane, including influencing phosphate signalling and regulation of vascular cell
function.14,15 Furthermore, lysolipids have a therapeutic role within drug delivery vehicles,
and as detergents for the formulation of numerous commercial products.16,17
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Figure 1.3 Structure of a generic lysolipid: green indicates fatty acid chain in either sn-1
or sn-2 position; red indicates glycerol backbone; blue indicates phosphate head group with
variable R3.
Phospholipase enzymes are a diverse family of enzymes which produce lysolipids via an
enzymatic mechanism of phospholipid hydrolysis.18,19 Phospholipase-A1 and phospholipase-
A2 enzymes cleave the sn-1 and sn-2 phospholipid acyl chains respectively. Within the
cell, phospholipase enzymes are tightly controlled, in order to modulate their activity and
subsequent levels of lysolipid production. Cellular lysolipid formation can also proceed through
less tightly regulated non-enzymatic mechanisms. Production of lysolipids as a by-product
of small molecule or peptide intrinsic lipidation is one example which will be revisited. The
aqueous cellular environment provides a further mechanism for lysolipid formation, via solution
phase phospholipid hydrolysis.20 Proceeding as observed for classic organic synthetic hydrolysis,
this solution phase mechanism is greatly influenced by local environment. Both acidic and
basic pH are known to promote the extent of phospholipid hydrolysis, and to increase the
rate of hydrolysis.21–24 Temperature, membrane composition, and local hydration levels, are
also observed to influence solution phase phospholipid hydrolysis.25,26 Catalytic effects of
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proximal biomolecules and membrane binding pharmaceuticals can also promote solution
phase phospholipid hydrolysis. Cationic amphiphilic drugs such as raclopride and haloperidol
are known to be particularly prolific in causing phospholipid hydrolysis, attributed to their
structure and functionalities.27–29
Lysolipid formation in vivo is tightly controlled, since even low levels cause significant
modification to bulk membrane properties and cellular activity.30,31 Containing a hydrophilic
phosphate head group and a single hydrophobic fatty acid chain, lysolipids aggregate in
aqueous solution. Above a critical micelle concentration (CMC) in the range of 1 µm, these
aggregates are characterised as micelles.32,33 Micelle forming lysolipids act as detergents
within the phospholipid bilayer, disrupting membrane fluidity and curvature.34 Even minor
fluctuations in these membrane properties result in problems for highly tuned membrane
activities such as signalling and trafficking. At worst, increased lysolipid levels result in
sufficient membrane perturbation such that structural integrity is lost. In this situation,
leakage of vital cellular components combined with a diminished barrier to toxic substances
ultimately results in cell death.35
1.3 Intrinsic Lipidation of Peptides
Post-translational peptide modification within the Golgi apparatus or endoplasmic reticulum
is an important biological tool for tuning peptide properties to cellular requirements.8 Modifi-
cations involve peptide folding, amino acid cleavage, or enzymatic covalent attachment of a
chemical moiety. Example chemical functionalities include: (i) phosphorylation; (ii) alkylation;
(iii) glycosylation; (iv) ubiquitination; (v) lipidation.6
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Figure 1.4 Example of post-translational modification of the cysteine residue of a peptide
by enzymatic addition of a palmitoyl moeity in vivo.
Post-translational lipidation is the addition of one or more acyl chains on to a nucleophilic
peptide residue. The process is enzyme mediated and may require a fatty acid analogue
to aid transfer.5 The N -terminus and thiolate of cysteine are common post-translational
lipidation sites, along with some specific amino acid motifs. Types of post-translational
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lipidation, Fig. 1.4, include myristoylation, addition of a saturated 14 carbon acyl chain, and
palmitoylation, addition of a saturated 16 carbon chain.6,36 Approximately 2 % of proteins
and peptides synthesised in the human body undergo prenylation, a form of post translational
lipidation in which an unsaturated, branched farnesyl (C15) or geranylgeranyl (C20) chain is
added.37 The final form of post-translational lipidation is the C -terminal phosphoethanolamine
bridge linkage to a glycosyl phosphatidylinositol (GPI) anchor, composed of a glycan sugar
group linked through inositol phosphodiester to a lipid moiety.38
Post-translational lipidation provides a powerful mechanism for tuning peptides by altering
their properties and activity.5,6 Acyl chain substitution dramatically increases peptide hy-
drophobicity and affinity for the relatively non-polar phospholipid bilyaer, compared to the
aqueous cellular environment. The range of acyl chain modifications available ensures this
membrane affinity is tunable and even reversible, such that peptides can undergo selective
targetting and adapt to external stimuli. In this way, post-translational lipidation facilitates
peptides in their roles of cell signalling and membrane trafficking. Examples of peptides which
rely on lipidation mechanisms to facilitate function include membrane localisation of the
Src-family of kinases, cellular attachment and protein-protein interaction modulation for the
Ras superfamily, and lipid raft formation for signalling and targetting roles.8,37,38
Figure 1.5 Schematic of non-enzymatic peptide intrinsic lipidation. Blue highlights phos-
pholipid head groups; green indicates phospholipid acyl chains; red indicates a membrane
active peptide which associates with the membrane and is acylated.39
An alternative mechanism for the important process of peptide lipidation is the innate
membrane reactivity of intrinsic lipidation, Fig. 1.5. This non-enzymatic process, observed
under physiological conditions in vitro, promotes lipidation of membrane bound peptides via
acyl transfer from membrane phospholipids.11 Mechanistically, intrinsic lipidation proceeds via
the characteristic solution phase pathway described in Scheme 1.1.39 Initial nucleophilic attack
is followed by a series of rearrangements of tetrahedral intermediates, ultimately resulting
in lipidated product formation. Key to determining reaction rate is either formation and
breakdown of the negatively charged tetrahedral intermediate, or breakdown of the neutral
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tetrahedral intermediate. External conditions known to influence these steps are thus believed
to be vital in controlling peptide intrinsic lipidation.
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Scheme 1.1 Mechanism of non-enzymatic peptide intrinsic lipidation. Blue highlights
phospholipid head group; green indicates phospholipid acyl chains; red indicates the reactive
nucleophile of a membrane active peptide.
Mechanistically, intrinsic lipidation creates great complexity, given the numerous potential
product combinations. Multi product formation is exemplified even in a simple system,
intrinsic lipidation of peptide melittin within a membrane mimic containing only the lipid
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC). In this situation, the phospholipid
bilayer contains both parent lipid POPC, and major intrinsic lipidation lysolipid by-products
1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (PPC), and 1-oleoyl-2-hydroxy-sn-glycero-
3-phosphocholine (OPC). Low abundance forms of minor lysolipids, 1-hydroxy-2-palmitoyl-sn-
glycero-3-phosphocholine, and 1-hydroxy-2-oleoyl-sn-glycero-3-phosphocholine, would also be
expected. Furthermore, the presence of both unmodified peptide melittin, and multiple forms
of modified peptide would be expected. Taking into account the potential for modification
at numerous sites (at least 5 in melittin), variation in fatty acid chain types, and potential
for up to two rounds of intrinsic lipidation, 50 modified forms of melittin exist.10 Recent
developments suggest the potential for triple lipidation, questioning the assumption that only
two rounds of intrinsic lipidation occur, and further adding to product complexity.40 The
diverse range of modified peptide products means that each is observed in low abundance, such
that high sensitivity instrumentation is required for visualisation. This sensitivity, along with
reaction mixture complexity, creates challenges in the study of intrinsic lipidation, limiting
current understanding.
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1.3.1 Studying Intrinsic Lipidation of Peptides
Study of peptide intrinsic lipidation is noted to be challenging, however succesful analytical
approaches have been developed. Preliminary in vitro studies of intrinsic lipidation utilised
thin layer chromatography (TLC) to visualise lipid and lysolipid products within the reaction
mixture, Fig. 1.6. By measuring spot intensity, TLC allows lipid and lysolipid quantification,
facilitating determination of the extent of reactivity.10 However, use of TLC to monitor
peptide intrinsic lipidation requires an extra lyophilisation step, in order to have a sufficient
concentration of the lipid and lysolipid for detection. Furthermore, TLC is impractical for
identification and quantification of intrinsic lipidation in vivo, since lysolipids are found
naturally in biological systems and their presence would not confirm reactivity. Study of
intrinsic lipidation by TLC is further complicated by background hydrolysis and other means
of lysolipid formation both in vivo and in vitro, which must therefore be considered to modify
observed results.41
Figure 1.6 TLC analysis of melittin intrinsic lipidation using aluminium-backed silica gel
plate, a mobile phase of CHCl3:MeOH:H2O (6:4:1), and staining with 10 % w/v solution of
phosphomolybdic acid (PMA) in EtOH. Rows from left to right: (i) DOPC; (ii) OPC; (iii)
Empty; (iv) reaction mixture of DOPC and melittin; (v) DOPC liposomes.10
Figure 1.7 Typical chromatogram observed during LCMS analysis of an intrinsic lipidation
reaction mixture.39
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An improved method for the study of peptide intrinsic lipidation in vitro is use of LCMS,
coupling reversed phase liquid chromatography to mass spectrometry. Optimised detection of
peptides and lipid is achievable by electrospray ionisation (ESI) combined with the sensitivity
of a high performance Fourier transform ion cyclotron resonance (FT-ICR) mass analyser.10,11
Gradient optimisation allows predictable chromatograms, Fig. 1.7, with the lipid, parent
peptide and modified peptide chromatographically separated. Benefits of this improved method
include: (i) visualisation of acylated peptide, a product with no alternative formation pathways
to intrinsic lipidation; (ii) mass resolution between transfer of different fatty acid chains;
(iii) retention time variation between different acylation positions, with modified peptide
residue assignable by tandem mass spectrometry (MSMS), facilitating study of preferential
acylation.39
The extent of intrinsic lipidation can be quantified by % conversion, using peak modelling
to calculate the ratio of modified to unmodified peptide in the LCMS chromatogram, and
assuming the sum is a total of 100 % peptide content, Equation 1.1. Whilst easily calculated,
this quantification method assumes equivalent ionisation of lipidated peptide and unmodified
peptide, the validity of which is unknown without standards. Furthermore, accurate peak
area modelling proves challenging for low abundance modified peptide peaks corresponding to
multiple acylation steps, assuming peaks are visible at all. Equation 1.2, the Beer-Lambert
Law, provides an alternative means of quantifying modified and unmodified peptide containing
a tryptophan, tyrosine or phenylalanine residue. UV absorbance at the relevant wavelength
is measured during LCMS analysis using a photodiode array (PDA) detector, and required
extinction coefficient parameters are known for the relevant amino acids.11 Unfortunately,
accurate quantification by absorbance requires a minimum peptide concentration to reached,
a value not fulfilled by acylated peptide under standard experimental conditions for intrinsic
lipidation. Altering the peptide:lipid ratio or injection volume to meet this concentration
requirement is impractical due to decreased resemblance to natural systems and poor chro-
matography. An improved method for peptide quantification involves the use of LCMS to
generate a calibration curve using a synthetic standard, against which the concentration of
the unknown can be determined.42,43
%Conversion = Modified(Modified+ Unmodified) × 100 (1.1)
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log
(
I0
I
)
= A = cl (1.2)
Where I0/I = A = absorbance;  = molar absorptivity coefficient; c = concentration; l =
path length.
Optimised LCMS combined with quantification facilitated further study of peptide intrinsic
lipidation. Standard conditions for in vitro study of intrinsic lipidation, 37 ◦C and a 10 mm
bicarbonate and 90 mm sodium chloride buffer at pH 7.4, closely mimic natural membrane
conditions. Modification of these conditions revealed that high temperature, high salt content,
and the presence of bicarbonate promote reactivity, increasing the rate of intrinsic lipidation
two fold.10 Furthermore, optimised LCMS conditions allowed Dods et al. to probe selectivity in
acylation of peptides with multiple nucleophilic residues.44 The preference of which nucleophile
dominates acyl transfer is found to be peptide specific, with the driving force currently unknown.
Potential driving forces include peptide binding orientation, membrane penetration depth,
local nucleophile environment, and nucleophile type. Additional selectivity arises from mixed
acyl lipids, with preference in the fatty acid chain transferred being down to positioning on the
lipid (sn-1 vs. sn-2 position) or chemical composition. Dods et al. probed this selectivity by
comparison of two chemically similar phospholipids, POPC and OPPC.44 Analysis determined
fatty acid positioning to be the dominant feature, with transfer from the sn-1 position observed
to be slightly more prevalent.
1.3.2 Reactivity of Different Membrane Active Peptides
Successful development of TLC and LCMS for the study of peptide intrinsic lipidation in vitro
allows for further investigation of membrane reactivity. By examining intrinsic lipidation in
this way, pathways to understanding biological relevance and therapeutic potential are revealed.
Parameters such as innate peptide properties, membrane composition, and environmental
conditions are likely to play a role in controlling reactivity rate. As such, further investigation
into the influence of these factors upon peptide intrinsic lipidation was carried out in vitro
using model systems.
Melittin, Fig. 1.8, is a 26 residue membrane active peptide, used as a model for membrane
study due to its amphiphilic nature and cationic C -terminus.45 A lytic peptide extracted from
honeybee venom, melittin is of particular interest due to its availability, well characterised
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structure and properties, similarity to other membrane active peptides, spontaneous membrane
association, and intrinsic fluorescence imparted by tryptophan at residue 19. Along with its
robustness to physiological conditions, and nucleophilic amino acid residues, these properties
made melittin a clear choice for initial study of peptide intrinsic lipidation.46
Figure 1.8 Membrane active peptide melittin in the helical wheel structure adopted upon
membrane binding. Colours indicate: polar residues (green); basic residues (blue); non-polar
residues (yellow); major acylation sites (magenta).
Figure 1.9 LCMS results for acylation of melittin in different conditions: (i) Total ion
chromatogram (TIC); (ii) Extracted ion chromatogram (EIC) for palmitoyl melittin (blue)
and stearoyl/oleoyl/linoleoyl melittin (red). Conditions shown are all 1:10 peptide:lipid molar
ratio, and unless otherwise stated use 90 mm NaCl, 10 mm NaHCO3, pH 7.4 and 37 ◦C. (a)
POPC, no NaHCO3, 72 h; (b) POPC, 20 ◦C, 150 mm NaCl, 72 h; (c) POPC, no NaHCO3 or
NaCl, 48 h; (d) POPC/SLPS (4:1), 72 h; (e) POPC/SLPG (4:1), 48 h; (f) POPC/SLPE (4:1),
72 h.39
Melittin undergoes intrinsic lipidation in vitro over a broad range of conditions, including
physiological conditions, Fig. 1.9.10 As predicted, the LCMS chromatogram produced a series
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of characteristic peaks, the first of which corresponds to unmodified melittin with m/z 949 for
triply charged and m/z 712 for a quadruply charged. Modified melittin peaks appear at a later
retention time, with the high performance and resolving power of the FTICR mass analyser
allowing distinction between transfer of different acyl chain types. Palmitoylated melittin
lies at m/z 618, 772, and 1029 for the [M+5H]5+, [M+4H]4+ and [M+3H]3+ respectively,
whereas these peaks for myristoylated melittin appear at m/z 612, 765, and 1019. These can
be further distinguished from oleoyl, linoleoyl and steareoyl modifications, which due to small
mass differences all show peaks at approximate m/z of 623, 778 and 1037.
Figure 1.10 Palmitoylated melittin EIC corresponding to modification at: (ii) S18; (iii)
K21; (iv) K7; (v) K23; (vi) N -terminal.39
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Figure 1.11 Characteristic ions formed by CID MSMS fragmentation of melittin.47–49
Optimised chromatographic conditions result in different retention times for acylated melittin
modified at different nucleophilic residues. Melittin, Fig. 1.8, has three nucleophilic sites of
acylation: (i) -amino groups of lysine (K) residues at positions 7, 21 and 23; (ii) serine (S) at
position 18; (iii) N -terminus. Each peak in the group of modified melittin peaks, Fig. 1.10, can
be assigned to one of these nucleophiles, with increasing retention time these are: S18, K21,
K7, K23 and the N -terminus, the final of which has been identified as the most favourable
site of acylation. Identification of the modified melittin nucleophiles is possible using tandem
mass spectrometry (MSMS). MSMS breaks the peptide apart at the backbone bonds linking
amino acids, in order to give a ladder of amino acids from each terminus, Fig. 1.11, one of
which will include the mass of amino acid plus the relevant acyl chain. Instability of the b1
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ion, breakage at the first peptide bond from the N -terminus, results in observation of this
ion being rare, thus the assignment of N -terminal acylation is driven by chemical intuition
considering the limited nucleophilicity of residue 2, isoleucine.10
Validation of intrinsic lipidation as a feasible lipidation alternative to post-translational
lipidation requires the process to be general to membrane active peptides rather than melittin
specific. Magainin II, Fig. 1.12, is a second well characterised membrane active peptide,
extracted from the skin of Xenopus laevis, suitable for study of intrinsic lipidation.50,51
Amphiphilicity aids magainin II in spontaneous helix formation and membrane association
from its random coil solution state structure, facilitating the peptide’s role in cation channel
formation, and antimicrobial activity in concentrations above 2 µm.52
Figure 1.12 Membrane active peptide magainin II in the helical wheel structure adopted
upon membrane binding. Colours indicate: polar residues (green); basic residues (blue); acidic
residues (red); non-polar residues (yellow); major acylation sites (magenta).
Confirming intrinsic lipidation as a generic process, magainin II is observed to undergo
non-enzymatic acylation over a wide range of conditions including physiological conditions,
Fig. 1.13.39 N -terminal lipidation is favoured, with secondary acylation sites including:
(i) serine residue 8; (ii) lysine residue 4; (iii) histidine residue 7. Variation in relative
acylation of serine and lysine between melittin and magainin II provides preliminary indications
relating nucleophile reactivity to position and local environment, rather than to chemical type.
Additionally, serine 8 resides adjacent to a histidine residue, indicating a potential catalytic
effect given speculative observations of histidine acylation and subsequent transfer observed
during peptide synthesis.53
Further confirmation of intrinsic lipidation as a generic process arises from study of other
membrane active peptides in vitro. PGLa, Fig. 1.14, is a 21 residue membrane active peptide
similar in nature to magainin II, and observed to undergo acylation at the N -terminus and
at a second position, thought to be serine 4 or lysine 5.39,54 Helical, with a conformationally
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free N -terminus confirmed by NMR, membrane bound PGLa is active towards acylation in a
more limited range of conditions than melittin or magainin II. Amphiphilic peptides LAK1,
LAK3 and penetratin, Table 1.2, require specific conditions for intrinsic lipidation: (i) LAK1
requires POPC:SLPS at a high salt concentration; (ii) LAK3 requires POPC:SLPS (1:1); (iii)
penetratin requires POPC at a high salt concentration. Each peptide is observed to have
multiple acylation sites, however low abundance of modified peptide prevents information
regarding nucleophile preferences from being obtained.39
Figure 1.13 LCMS results for acylation of magainin II under different experimental condi-
tions: (i) TIC; (ii) EIC for palmitoyl magainin II (blue) and oleoyl/linoleoyl/stearoyl magainin
II (red). Conditions shown are all 1:10 peptide:lipid molar ratio, and unless otherwise stated
use 90 mm NaCl, 10 mm NaHCO3, pH 7.4 and 37 ◦C. (a) POPC/SLPS (1:4), 72 h; (b)
POPC/SLPG (1:4), 72 h; (c) POPC/SLPE(1:4), 72 h; (d) 150 mm NaCl, 144 h.39
Figure 1.14 Membrane active peptide PGLa in the helical wheel structure adopted upon
membrane binding. Colours inducate: polar residues (green); basic residues (blue); non-polar
residues (yellow); major acylation sites (magenta).
Upon incubation of six membrane active peptides with biological membrane mimics under
physiological conditions, all undergo reactivity with membrane phospholipids in vitro. This
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intrinsic lipidation reactivity occurs upon a biological timescale, and is therefore relevant to
both natural processes and laboratory studies. Novel modified peptides form as a result of
reactivity, predicted to have distinct properties and functionalities compared to the unmodified
peptides. Preliminary studies indicate preferential nucleophile reactivity, however further work
is required in order to confirm the relationship between intrinsic lipidation and nucleophile
type, nucleophile environment, neighbouring group effects and pK a.
Peptide Amino Acid Sequence
LAK1 KKLALALALALKALALALALKKA
LAK3 KKLALALAKALAKALKLALALAKK
Penetratin RQIKIWFQNRRMKWKK
Table 1.2 Amino acid sequences of LAK1, LAK3 and penetratin.
1.3.3 Reactivity of Different Membrane Types
Further investigation into the mechanism and reactivity of intrinsic lipidation with respect
to its second key component, the phospholipid bilayer, confirms its status as a generic intra-
membrane reaction in vitro.44 Natural phospholipid bilayers display tremendous complexity,
incorporating fatty acid chain types of differing length and saturation, and both zwitterionic
and negatively charged phosphate head groups, the structure and size of which instil a positional
leaflet preference upon the lipid. The intrinsic complexity of the natural bilayer, combined with
the variety of products formed by intrinsic lipidation, results in the requirement of simplified
models in order to ensure initial studies probing lipid influence on intrinsic lipidation are
beneficial. DPPC membranes provide the simplicity of a single acyl chain type combined with
the eukaryotic phosphatidylcholine (PC) head group, however intrinsic lipidation of melittin
is not observed in this membrane type. By contrast DOPC, also containing a single type of
acyl chain and PC head group, facilitates intrinsic lipidation to a variety of peptides within
24 hours in physiological conditions.11 Predicted driving forces behind this difference include
transition temperature, peptide binding strength and orientation, and curvature, however
comparison of these two membrane types only cannot reveal further information.
Dods et al. working with melittin utilised a POPC model membrane, incorporating a PC
head group characteristic to eukaryotic membranes and two different fatty acid chains for
probing positional preferences.10,39 Further mimicry of the more complex membranes of
eukaryotic cells is possible through the inclusion of additional phosphate head group types,
with varied fatty acid chains allowing precise tracking of acyl transfer. Phosphatidylserine
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(PS), is a small negatively charged phospholipid head group common to the inner leaflet
of eukaryotic membranes.55,56 Cationic membrane active peptide melittin shows increase
membrane affinity for PS containing membranes, driven by increased ionic interactions and the
decreased conformational freedom they trigger upon binding. Increased peptide binding in this
case appears to correlate with increased intrinsic lipidation rate, given that 50 % conversion
from melittin to acylated melittin requires 16 days in a POPC membrane, compared to 24
hours for PS containing membranes DOPC:DPPS (4:1) and POPC:SLPS (4:1).10,44 Of further
interest are the acyl transfer characteristics of the DOPC:DPPS membrane, which indicates no
palmitoyl transfer from the PS membrane component, whereas for the POPC:SLPS membrane
acyl transfer from both components is observable, Fig. 1.15(a). Membrane demixing into a
melittin-bound PC membrane and a separate PS phase, observed by deuterium NMR where
melittin is bound to a PC:PS membrane in a ratio above 5:1, is one explanation for this
characteristic transfer.46
Figure 1.15 EIC showing myristoyl melittin (blue) and oleoyl melittin (red) within (a)
DOPC:DPPS (4:1); (b) DOPC:DMPG (4:1); membranes under physiological conditions (1:10
peptide:lipid molar ratio, 90 mm NaCl, 10 mm NaHCO3, pH 7.4 and 37 ◦C) for 72 hours.44
Phosphatidylglycerol (PG), is also a negatively charged phospholipid found in eukaryotic
membranes and observed by NMR to undergo demixing with a PC phase in the presence
of melittin.57 Despite reported demixing, both DOPC:DMPG (4:1) and POPC:SLPG (4:1)
membranes undergo intrinsic lipidation, Fig. 1.15(b). Acyl transfer is observed from both PC
and PG components, indicative of either a mixed membrane or melittin bound to each of the
two demixed phases. Further support for the mixed membrane hypothesis arises from the
decreased rate of intrinsic lipidation in a PC:PG membrane compared to PC:PS, given that
peptides in mixed membranes exhibit decreased conformational freedom and phospholipid
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contact. Despite this, correlation of negative charge and intrinsic lipidation rate is again
displayed, with DOPC:DMPG (4:1) forming oleoyl melittin in 28 hours and myristoyl in 95
hours, faster than a PC only membrane, Fig. 1.16.11
Figure 1.16 A comparison of conversion (1-θ) of melittin to acylated melittin within
phospholipid membrane types: POPC (blue circles); OPPC (red squares); DOPC:DMPG
(purple diamonds); DOPC:DPPS (black triangles).44
Phosphatidylethanolamine (PE), was the final phosphate head group observed in eukaryotic
membranes to be tested. Unlike PS and PG, PE head groups are zwitterionic at physiological
pH, and thus neutral in charge, limiting the likelihood of ionic interactions between melittin and
a PC:PE membrane. Whilst information regarding transfer rate is limited, for a POPC:SLPE
(4:1) membrane, modified melittin is observed within 3 hours, with stearoyl and linoleoyl
transfer 25 % of palmitoyl and oleoyl transfer, consistent with the 4:1 ratio.44
Prokaryotes such as bacteria, fungi and some microbes differ in their membrane composition
compared to the eukaryotic PC containing membranes discussed previously.58 Knowledge
of these prokaryotic membranes, and in particular their differences from the membranes of
higher eukaryotic organisms, is vital for antimicrobial drug design. Exploitation of differences
in intrinsic lipidation is one novel mechanism that could be targeted for antimicrobial design,
considering the novel properties of lipidated peptide products, and their potential roles in
targeting and signalling. Intrinsic lipidation of two model prokaryotic membrane types was
monitored, with the aim of harnessing intrinsic lipidation in such a way that it could be
detrimental to bacterial survival.
Gram-negative bacteria, such as E. coli, have an outer lipopolysaccharide layer comprised of
lipid anchors and specific sugar chains, surrounding a thin peptidoglycan cell wall comprised
of a N -acetylated muramic acid and N -acetylated glucosamine glycan backbone, cross-linked
with amino acid chains.58 Modeling of gram-negative bacteria, Fig. 1.17, is achieved using a
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POPE:SLPG (3:1) membrane, containing varied fatty acid chains and a negative PG compo-
nent to increase binding of cationic model peptide melittin. At physiological conditions in
vitro, gram-negative membranes did not exhibit intrinsic lipidation of melittin on a biologically
relevant timescale, a clear difference compared to eukaryotic membrane models, with antimi-
crobial potential.59 The innate increased ionic interactions between melittin and PG have
evidently been overcome by other rate-controlling factors driving the reaction. Furthermore,
probing of lipid phase and domain formation by incubation of the gram-negative model at 21
◦C did not afford acylated melittin on a biological timescale, again pointing to the presence of
other reaction driving forces.
Figure 1.17 Schematic of gram-positive and gram-negative bacteria. Colours indicate: cell
membrane (pale blue); peptidoglycan cell wall (mid blue); lipopolysaccharide layer (dark
blue).59
S. aureus and other gram-positive bacteria, Fig. 1.17, lack the lipopolysaccharide outer
membrane associated with gram-negative bacteria. Additionally, the peptidoglycan cell wall
of gram-positive bacteria infers increased strength and adaptability due to increased thickness
and crosslinking between peptide chains and the glycan backbone. Mimicry of gram-positive
bacterial membranes by use of POPE:SLPG (1:3), resulted in increased anionic PG component,
expected to favour binding and membrane-affinity of cationic melittin.56 Intrinsic lipidation
in vitro was not observable in gram-positive membranes at both physiological (37 ◦C) and
ambient temperatures (21 ◦C) up to six days.59 Despite the increased ionic interactions,
these observations are in line with those made for gram-negative model membranes, implying
membrane binding and lipid phase do not act solely as driving forces of lipidation. However,
the natural role of melittin as a lytic peptide must be considered, and thus further focus
on intrinsic lipidation of antimicrobial peptides such as magainin II is required prior to the
harnessing of intrinsic lipidation for antimicrobial drug design.
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1.3.4 Other Influences Upon Intrinsic Lipidation
Successful experimentation confirmed intrinsic lipidation in vitro as a process generic to both
membrane active peptides and eukaryotic membrane models.11 However, full understanding
of the complex nature of reactivity at the membrane interface required further investigation
into potential controlling factors. Introduction of single targeted modifications enabled the
impact of individual features upon reactivity to be pinpointed. To this end, modifications
were applied to both membrane composition and peptide sequence.
1.3.4.1 Influence of Cholesterol
Cholesterol, Fig. 1.18, is an amphiphilic component of eukaryotic membranes, comprised of a
polar OH group and a rigid, hydrophobic, fused ring structure.7 Cholesterol containing model
membranes exhibit altered properties compared to phospholipid only membranes, and provide
a more accurate mimic of natural membranes. Physical properties altered by cholesterol
insertion into a membrane include: (i) increased uniformity of transition temperatures (Tm),
for example the Tm of DOPC (1 ◦C) is increased in the presence of cholesterol, whereas DPPC
with a Tm of 41 ◦C is made more fluid.7,60 For mixed acyl systems the impact of cholesterol on
Tm is harder to predict, although some systems have been modelled; (ii) decreased membrane
binding affinity of amphiphilic peptides, as confirmed by measurement of circular dichroism
(CD) and environment dependent tryptophan emission for the model peptide melittin; (iii)
structural changes to the membrane upon peptide binding, including membrane degradation
and breakage into small, highly curved micelle-like particles.45,61,62 Given the numerous
physical changes to the membrane upon the inclusion of cholesterol, it appears likely that the
molecule would also have a major influence upon reactivity of intrinsic lipidation.
HO
Figure 1.18 The structure of cholesterol.
Natural eukaryotic membranes contain lipid:cholesterol molar ratios between 1:1 and 4:1. Lipo-
somes containing reactive phospholipid DOPC were therefore prepared containing DOPC:cholesterol
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(4:1) and DOPC:cholesterol (1:1), in order to examine melittin intrinsic lipidation within
these systems.59 Similarly to DOPC membranes, melittin intrinsic lipidation was observed in
DOPC:cholesterol containing membranes under physiological conditions, Fig. 1.19. Reactivity
was observed within 24 hours across all systems, suggesting minimum impact of cholesterol
upon reaction rate in the presence of DOPC. However, by 72 hours maximum reactivity
was observed within the DOPC:cholesterol (4:1) membrane, followed by DOPC:cholesterol
(1:1), and finally DOPC. Modification in DOPC only membranes occurs predominantly at the
N -terminus. However, whilst N -terminal modification remains most prevalent upon inclusion
of cholesterol, reactivity at additional sites is observed. MSMS confirmed the locations of
reactivity as K23, K21, K7, and S18.
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Figure 1.19 TIC for acylation of melittin in membranes containing: (a) DOPC; (b)
DOPC:cholesterol (4:1); (c) DOPC:cholesterol (1:1). Inserts show EIC for oleoyl melit-
tin (red). Conditions shown use 1:10 peptide:lipid ratio and incubate in 90 mm NaCl, 10 mm
NaHCO3 buffer, pH 7.4 and 37 ◦C for 72 hours.59
Analogous studies were conducted using gel phase phospholipid DPPC, which has a transition
temperature of 41 ◦C, above physiological temperature.59 Melittin was not observed to undergo
intrinsic lipidation in DPPC only membranes, attributed to decreased membrane fluidity.
Incorporation of cholesterol into DPPC liposomes caused induction of melittin intrinsic
lipidation, Fig. 1.20. Low level product was observed in the DPPC:cholesterol (1:1) system,
whereas within DPPC:cholesterol (4:1) liposomes, 30 % conversion to palmitoyl melittin is
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observed within 24 hours. In contrast to DOPC containing systems, K23 was observed as
the most prevalent site of acylation, followed by the N -terminus. Additional minor sites of
reactivity, K21 and K7, were observed within the DPPC:cholesterol (4:1) system only.
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Figure 1.20 TIC for acylation of melittin in membranes containing: (a) DPPC; (b)
DPPC:cholesterol (4:1); (c) DPPC:cholesterol (1:1). Inserts show EIC for palmitoyl melittin
(blue). Conditions shown use 1:10 peptide:lipid ratio and incubate in 90 mm NaCl, 10 mm
NaHCO3 buffer, pH 7.4 and 37 ◦C for 72 hours.59
Additional cholesterol studies used mixed acyl lipid POPC in 1:1 and 4:1 phospholipid:cholesterol
molar ratio.59 Acyl transfer was observed across all systems from 24 hours. Oleoylated melittin
was the sole modified product observed from POPC membranes after 24 hours, however choles-
terol containing membranes exhibit oleoyl and palmitoyl transfer, indicative of preferential
acylation. Later time point 72 hours, Fig. 1.21, revealed palmitoyl and oleoyl transfer across
all membrane types. Observed reactivity patterns mimic those noted within DOPC and
DPPC systems, with POPC:cholesterol (4:1) exhibiting twice the quantity of modified melittin
compared to the POPC:cholesterol (1:1) system. Inclusion of cholesterol was also observed to
alter relative product distribution, with K23 acylation favoured in POPC:cholesterol systems,
and the N -terminus in POPC only.
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Figure 1.21 TIC for acylation of melittin in membranes containing: (a) POPC; (b)
POPC:cholesterol (4:1); (c) POPC:cholesterol (1:1). Inserts show EIC for palmitoyl melittin
(blue) and oleoyl melittin (red). Conditions shown use 1:10 peptide:lipid ratio and incubate in
90 mm NaCl, 10 mm NaHCO3 buffer, pH 7.4 and 37 ◦C for 72 hours.59
Membrane affinity, membrane Tm, and membrane disruption alter dramatically upon inclusion
of cholesterol within a membrane. However, previous research suggests neither membrane
affinity nor Tm are rate determining for intrinsic lipidation.44 Membrane disruption by
cholesterol into highly curved micellar aggregates would be expected to bind membrane
active peptides increasingly strongly and in an orientation with increased contact between
peptide nucleophiles and phospholipid fatty acid chains, thus aiding intrinsic lipidation.45,57
Comparisons of small unilamellar vesicles (SUV), Fig. 1.22, highly curved up to 100 nm
particles with large unilamellar vesicles (LUV) of > 100 nm in diameter provide a crude
test of this theory. Incubation under physiological conditions of DPPC SUVs and LUVs
with model peptide melittin yielded no acylation up to 9 days in either case, potentially
due to the increased reactivity instilled by increased curvature being too small for detection
given the unreactivity of DPPC. Highly reactive DOPC:SLPG (3:1) LUVs yielded both
N -terminal and K23 acylation of melittin within 4 hours, 23 % conversion within 24 hours,
and 49 % within 4 days, including double acylation.59 By contrast DOPC:SLPG (3:1) SUVs
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generated 11 % acylated melittin within 24 hours and 36 % conversion over 4 days, indicative
of decreased curvature favouring intrinsic lipidation. However, consideration must be given
to the stabilisation of highly curved particles induced by cholesterol, compared to the highly
unstable SUVs which merge over time, which may explain such irregularities.63
LUV
> 100 nm
SUV
20 - 100 nm
Figure 1.22 Diagram indicating the differences between LUVs (large unilamellar vesicles)
and SUVs (small unilamellar vesicles).
1.3.4.2 Influence of the Nucleophile
Differences in rate of intrinsic lipidation are observable between different nucleophiles within a
single membrane active peptide, believed to be driven by the surrounding environment altering
pK a and peptide binding orientation with respect to the nucleophile. Melittin, Fig. 1.8,
contains three lysine residues of decreasing reactivity: (i) K23, surrounded predominately by
hydrophobic residues favouring contact with hydrophobic phospholipid tails; (ii) K21, at a
hydrophobic-hydrophilic boundary; (iii) K7, in a hydrophilic region favouring exposure to
aqueous cell environment.10 Influence of surrounding environment upon intrinsic lipidation
nucleophiles focused upon four peptides, Fig. 1.23: (i) control peptide 21 containing an
N -terminal nucleophile only; (ii) peptide 22 containing lysine at position 6 surrounded by
hydrophilic arginine residues; (iii) peptide 23 containing lysine at position 7, a hydrophilic-
hydrophobic boundary; (iv) peptide 24 containing lysine at position 8 within a hydrophobic
environment of leucine residues.
Incubation of peptides 21 to 24 with membrane mimics varying in lipid head group types, and
with mixed acyl chains for preference tracking, yielded the intrinsic lipidation results given in
Table 1.3.39,59 Despite complications associated with chromatographic crossover, successful
acylation with palmitoyl and oleoyl/stearoyl/linoleoyl was observed for control peptide 21
with a POPC:SLPG (4:1) membrane within 6 days, and peptide 23 with POPC within 5
days, indicative of nucleophiles at a hydrophobic-hydrophilic boundary facilitating acylation
due to binding orientation. Unfortunately, the minimal quantities of acylated peptide formed
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combined with inconsistency between lipid systems prevent identification of a definitive trend
of nucleophile reactivity.
Figure 1.23 The helical wheel structures of peptides: (a) 21; (b) 22; (c) 23; (d) 24. Colours
indicate: lysine residues (magenta); hydrophobic residues (yellow); polar, uncharged residues
(green); basic residues (blue).
Lipid
Acylation
of Peptide
21
Acylation
of Peptide
22
Acylation
of Peptide
23
Acylation
of Peptide
24
POPC No No Yes No
POPC:Chol (4:1) No No No No
POPC:SLPG (4:1) Yes No No No
POPC:SLPE (4:1) No No No No
POPC:POPS (4:1) No No No No
Table 1.3 Observed intrinsic lipidation of peptides 21, 22, 23, and 24 within different
membrane types. The conditions shown are 1:10 peptide:lipid molar ratio and incubated in
90 mm NaCl, 10 mm NaHCO3 buffer at pH 7.4 and 37 ◦C for 72 hours.59
Nucleophiles of membrane active peptides observed to be involved in intrinsic lipidation
include lysine, serine and histidine, however chemical intuition suggests other amino acids
also have the relevant functional groups to carry out the role. Peptides containing relevant
amino acids, Fig. 1.24, include: sterically unhindered thiolate cysteine (25); highly hindered,
hard and moderately electronegative nitrogen containing histidine (28) and tryptophan
(29); and weak nucleophile oxygen in sterically unhindered serine (26), slightly hindered
threonine (27), and aromatic residue tyrosine (30). Despite low level intrinsic lipidation and
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chromatographic crossover, incubation of peptides 26-30 under physiological conditions with a
POPC:SLPG (4:1) membrane yielded the rate of acylation 29(W)>27(T)>26(S)>30(Y)>28(H).
Peptide 29, containing membrane binding tryptophan, underwent acylation with palmitoyl
and oleoyl/stearoyl/linoleoyl chains by day 3 at two locations, determined by MSMS to
both be N -terminal. Two isomers, cis and trans caused by peptide membrane binding, were
thought to cause these two distinct acylation sites, however testing of this was limited by
solubility issues.59 Noticeably, cysteine containing peptide 25 is not included in the scale of
reactivity, since it was observed to undergo both oxidation and dimerisation via disulfide
bond formation. Further study showed that use of a reducing agent, dithiothreitol (DTT) to
prevent dimerisation only worked for a limited time and was proposed to cleaved sulphur-acyl
bonds formed, as indicated by peaks corresponding to loss of thiol esters at m/z 743.64
L R N L L N C A N R L A
Peptide 25
L R N L L N S A N R L A
Peptide 26
L R N L L N T A N R L A
Peptide 27
L R N L L N H A N R L A
Peptide 28
L R N L L N W A N R L A
Peptide 29
L R N L L N Y A N R L A
Peptide 30
Figure 1.24 Sequences of peptides 25 to 30 designed to test the influence of nucleophile
type upon intrinsic lipidation. Nucleophile variation is highlighted in green.
Difficulties studying the relationship between different nucleophiles and nucleophile environ-
ments, and intrinsic lipidation, result from membrane affinity and solubility limitations. As a
result, the impact of individual physical parameters upon intrinsic lipidation rate is prevented,
stunting growth of the field of reactions at the membrane interface. Intrinsic lipidation is
likely driven by a multitude of factors working together, and in the future these factors
must be segregated such that each can be explored and their effects monitored. Extending
understanding of intrinsic lipidation in this way may facilitate reaction harnessing in biological
organisms, laboratory systems, and pharmaceutical development.
1.4 Intrinsic Lipidation of Small Molecules
Given intrinsic lipidation of membrane active peptides in vitro, similar acyl transfer reactions
to other nucleophile containing components with membrane affinity might be expected, for
example cholesterol or sugars. Small organic molecules have the potential to exhibit such
reactivity, providing they have: (i) affinity for biological membranes; (ii) a suitable nucleophilic
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group. These criteria are satified by tryptophan-like molecules, containing nucleophilic
nitrogen moieties and an indole ring. Indole, Fig. 1.25, exhibits high membrane affinity due to
enhanced electrostatic interactions with hydrophilic phospholipid head groups, combined with
hydrophobic interactions between the aromatic ring and phospholipid tails.65–68 Interestingly,
the tryptophan-like family includes several known drug molecules targeted to membranes
for their disease-related roles. Intrinsic lipidation of small molecules provides analogous
functionality to chemical conjugaton with hydrophobic fatty entities, altering hydrophobicity
and membrane affinity. Furthermore, lipidated small molecules have been observed to exhibit
lytic properties, resulting in membrane degradation and broad-spectrum antibiotic properties
against both gram-positive and gram-negative bacteria.69,70 These physical features facilitate
potential therapeutic applications for intrinsic lipidation, without the problems of toxicity,
stability and cost associated with peptides.71,72
N
H
Figure 1.25 The structure of indole.
Phospholipidosis is a lysosomal storage disorder characterised by accumulation of phospholipids
in tissues such as the lungs, liver and kidneys.73 Drug-induced phospholipidosis, in which a
drug contributes to this aggregation, is caused by over 50 cationic amphiphillic drug molecules.
These drugs, related by structural incorporation of both hydrophobic and a hydrophilic
region, cover a variety of different classes, including antidepressants and cholesterol reducing
agents.28,74 Although reversed swiftly by stopping drug administration, problems associated
with drug failure and the unknown relationship to drug toxicity make phospholipidosis
problematic.75 Intrinsic lipidation of small organic molecules has potential to be a key stage
in drug-induced phospholipidosis, and thus provides a viable target for increased mechanistic
understanding and prevention. Preliminary data suggests that the known phospholipidosis
inducing drug molecules shown in Fig. 1.26, propranolol 1, procaine 2 and tetracaine 3,
undergo intrinsic lipidation. However, the influence of this membrane reactivity upon their
physical properties and pharmaceutical activity remains largely unknown.76 Probing the
mechanism and rate-determining influences on intrinsic lipidation of small organic molecules
is thus of further interest.77
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Figure 1.26 Phospholipidosis inducing drug molecules propranolol 1, procaine 2, and
tetracaine 3.
Indole based compounds were designed containing an aromatic region and an amine nucleophile,
in order to comply with membrane affinity and nucleophile criteria required for intrinsic
lipidation.77 Variation in pK a, partition coefficient (logP), and distribution coefficient (logD)
between these compounds aimed to probe the influence of each of these factors upon intrinsic
lipidation. The diversity of these molecules combined with functionality differences provided
an ideal initial screen for intrinsic lipidation of small drug molecules. The 84 designed organic
small molecules were screened with three membrane types: (i) DOPC, a mimic for eukaryotic
membranes; (ii) DOPC:DOPS (4:1), a mimic for viral membranes; (iii) DOPE:DOPG (3:1),
a mimic for prokaryotic bacterial membranes. Of key importance for medicinal purposes is
selective reactivity between membrane types, particularly selective lipidation within prokaryotic
membranes, resulting in the lipidated small molecule having a lytic effect upon the membrane.
Unlike analysis of peptide intrinsic lipidation by LCMS, direct monitoring of lipidated small
molecules was not attempted due to low concentrations, small size, and poor ionisation
efficiency. Instead, lipidation of small molecules was monitored by the quantity of lysolipid
by-product produced compared to a background level of formation. Lysolipids provide a
common reaction mixture component, simplifying the screening of a diverse range of small
molecules. However, monitoring lysolipid formation is limited by the assumption that intrinsic
lipidation of the small molecule is the sole mechanism of lysolipid formation. Furthermore,
whilst OPC and OPE lysolipids are quantifiable under the analytical conditions employed, not
all lysolipid species are. OPS and OPG for example, produced poor chromatographic peaks
and require negative mode ESI ionisation for optimum visualisation.
Preliminary results from high throughput screening of 84 small organic molecules, indicated
three categories of molecules: (i) increased lysolipid formation compared to the control sample,
indicative of acylated small molecule formation; (ii) decreased lysolipid formation, due to
decreased background hydrolysis or a lipidation reaction between lysolipid and the small
molecule; (iii) lysolipid levels equal to the control, due to a lack of intrinsic lipidation, or a an
equal rate of small molecule acylation with lipid and lysolipid, thus keeping the net quantity
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constant. Molecules with high reactivity in prokaryotic PE:PG and PC:PS membranes, com-
bined with low reactivity in eukaryotic PC membranes included compounds 4 (3-aminoindole),
5 (5-aminoindole), 6 ((1H-indazol-7-yl)methanamine) and 7 (3-(2-aminoethyl)-1H-indol-5-
ol).77 These small molecules, Fig. 1.27, are all indoles with free amines, however the amine
position and attachment type varies, indicating no clear reactivity trend. A major increase
in lysolipid production, 1054 % compared to the background rate, was observed for small
molecule 8 (7-amino-4-(1H)-quinolinone) in a PE:PG membrane. Despite this, the result was
not reproducible and lipidated small molecule was not observed, indicating either increased
lipid degradation induced by compound 8, or formation by intrinsic lipidation and subsequent
hydrolysis of the acylated small molecule, supported by the observation of oleic acid by LCMS.
N
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Figure 1.27 Key small organic molecules indicated to be of interest from small molecule
intrinsic lipidation studies due to increased lysolipid production.
Considering the potential application of small molecule intrinsic lipidation in antimicrobial or
antifungal drug design, candidates were screened for antimicrobial activity against E. coli and
S. aureus.78 Molecules, Fig. 1.27 and Fig. 1.28, with selective reactivity in PE:PG or PC:PS
membranes were chosen: 6 ((1H-indazol-7-yl)methanamine), 8 (7-amino-4(1H)-quinolinone),
9 (6-aminoindole), 10 (1H-benzimidazol-4-amine), and 11 (2-aminomethylbenzimidazole). At
concentrations above 10 mm, minor effects upon E. coli growth were evident for compounds
6, 9 and 11. Simultaneously, complete inhibition of S. aureus growth was observed for
compounds 8, 9, and 10. Small molecules believed to undergo intrinsic lipidation also have
antimicrobial activity, however further work probing the antimicrobial activity of the lipidated
small molecules is still required. Additionally, proof of lipidation by visualisation of lipidated
small molecules and experimentation of lipidation in vitro with E. coli and S. aureus
membrane extracts are necessary for better understanding. Whilst initial screening of small
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molecule lipidation in vitro has provided promising results, knowledge is still in its infancy
and further work is required to develop the method and to gain the understanding required
for drug development.
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Figure 1.28 Key small organic molecules indicated to be of interest from small molecule
intrinsic lipidation studies, and selected for study of antimicrobial activity.
1.5 Conclusions
Knowledge and understanding of the cell membrane has developed considerably since Singer
and Nicolson first proposed the fluid mosaic model.3 Despite these advances, the potential for
chemical reactivity within the membrane has been the subject of only limited investigation.
Three reactions at the membrane interface have been studied thus far: (i) lysolipid formation;
(ii) peptide intrinsic lipidation; (iii) small molecule intrinsic lipidation. Each reactivity is
predicted to have distinct implications on cellular activity and membrane integrity.10,12,77 Un-
derstanding membrane reactivity is key to comprehend the fields of drug activity mechanisms,
induction of drug side effects and disease, and the therapeutic potential of such reactions.
Considerable early stage research is required in order to fully realise the implications and
applications of cell membrane reactivity. Challenges in sensitivity and complexity observed
during previous study mean new analytical techniques are required. Analysis time, suitability
for both in vitro and in vivo systems, and informative value, are important factors when
considering analytical technique selection. Development of suitable analytical techniques
for in depth study of membrane reactions would facilitate better understanding of reaction
mechanisms and implications. Investigation is required into the role of substrate structure and
functionalities, local environment, and membrane composition, upon reactivity. Furthermore,
biophysical properties of lysolipids and lipidated reaction products require consideration. The
research undertaken within this thesis works to develop methodology for study of reactions at
the membrane interface, and to apply this methodology in order to better understand these
reactions, and their wider implications.
2 | Instrumentation
In 1912 British physicist J. J. Thomson took the first steps in developing the analytical
technique now known as mass spectrometry, when he first observed singly and multiply charged
ions. By detecting these ions hitting a photographic plate, Thomson was able to generate a
spectrum of mass to charge (m/z).79,80 Modern day mass spectrometry applies Thomson’s
work in separating ions by m/z in order to calculate the molecular weight of a species, and
thus identify it. However, the field of mass spectrometry has developed significantly since its
1912 origins and is now a far more popular, powerful, and diverse technique.81
Major developments in the field of mass spectrometry over the last century include changes in
ionisation techniques to accommodate a wider range of molecules, and particularly biomolecules.
Most notably, this includes the 2002 Nobel Prize winning work on the advent of electrospray
ionisation (ESI) by John Fenn, and Koichi Tanaka’s work pioneering soft laser desorption
ionisation.82–87 A further Nobel Prize in the field of mass spectrometry was awarded in 1989
to Hans Dehmelt and Wolfgang Paul for their development of techniques for trapping charged
particles, leading to the ion trap mass analyser.88,89 These developments paved the way for
current instrumentation such as the FT-ICR and the Orbitrap mass analysers, which have
high mass accuracy and resolving power.90,91 Furthermore, additional new facets of mass
spectrometry have been developed, aiming to provide increased insight into molecular structure.
Two such examples are tandem mass spectrometry (MSMS), a technique which fragments
precusor ions of interest into smaller product ions, and ion mobility mass spectrometry (IMMS),
which separates ions by their mobility through a carrier gas.92–94
Modern day mass spectrometers can be seen as hugely complex instruments, however by
breaking them down into their constituent parts it is possible to simplify the understanding
of how they work and how they can be manipulated for a desired purpose. The first step in
analysing a sample by mass spectrometry is the introduction of the sample into the instrument.
Direct infusion is possible for samples containing only one species, however more complex
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mixtures require separation so that each mixture component is introduced into the mass
spectrometer individually. Following sample introduction the usually neutral starting species
undergoes conversion into a gas phase ion in a process known as ionisation. Ionisation
techniques range from hard ionisation suitable for small stable molecules such as electron
ionisation (EI), through to soft techniques such as matrix-assisted laser desorption/ionisation
(MALDI) optimal for large biomolecules. Once formed, ions enter the third constituent part
of the mass spectrometer, known as the mass analyser. The mass analyser separates the
ions based upon their m/z, and directs them onwards to the detector. At the detector, ion
abundance is measured and this information is converted into a signal which can provide
meaningful data on the sample identity. Several instrumentation examples exist for each
constituent part of the mass spectrometer. The optimum configuration required to create
an indispensable analytical tool can be determined by the mass range, ionisation potential
and complexity of the sample to be studied. For the purposes of this research project, the
following instrumentation has been selected:
• Synapt G2-S (Waters Corp., UK), utilised with an ESI source. The mass analyser
components include a quadrupole, two T-wave collision cells and a ToF mass analyser
connected in series. An ion mobility cell is fitted for ion mobility separation, and an
Acquity UPLC for chromatographic separation.
• Autoflex II ToF/ToF (Bruker Daltonics Ltd., UK), a MALDI ionisation source with
ToF mass analyser.
2.1 Chromatography
Complex mixtures prove to be challenging mass spectrometry samples, due to issues of ion
suppression and spectrum complexity. By preceding mass analysis with a separatory technique,
it is possible to introduce components of a complex mixture into the mass spectrometer
individually, mitigating these issues. Mass spectrometry compatible separation techniques
are required to maintain the integrity of sample components, give consistent and predictable
separation, and not to introduce background interference. Chromatography, a technique
which separates components in a mixture by partitioning them between two phases, meets
this specification.95,96 Reversed phase liquid chromatography (LC) using an Acquity UPLC
(Waters Corp., UK) is the specific technique selected for the separatory analysis carried
out within this thesis. Hydrophobic molecules interact strongly with the reversed phase LC
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stationary phase and thus are retained for longer than polar molecules, providing separation.
Reversed phase liquid chromatography-mass spectrometry (LCMS) utilises a non-polar chem-
ically modified silica column stationary phase. Several modified stationary phases exist,
Table 2.1, with molecular features developed to improve chromatographic separation for
specific classes of analytes. A C18 column is the classic stationary phase employed for reversed
phase LC analysis, whilst more recent developments of the C8 or C4 column improve analytical
flexibility by decreasing stationary phase hydrophobicity.96 Phenyl modified stationary phases
provide excellent separation for both aromatic small molecules and peptides with a high
proportion of aromatic amino acids. The mobile phase adopted for reversed phase LCMS
is a polar mass spectrometry compatible solvent in which the analytes studied are soluble.
Favourable solvents include water (H2O), acetonitrile (MeCN), methanol (MeOH) and iso-
propanolol (IPA). The Acquity UPLC (Waters Corp., UK) affords the user a binary pump
such that two miscible solvents can be used simultaneously in a gradient, aiding separation.
Factors such as solvent temperature and flow rate are known to be important in order to
achieve successful separation of components by LCMS. Furthermore, pH is known to play an
important role in ensuring reproducible chromatographic peaks, particularly in the case of
zwitterionic species.97,98
Column Type Column Chemistry Analyte Suitability
C18 C18 bonded to silica All
C8 C8 bonded to silica All
C4 C4 bonded to silica Proteins and large biomolecules
Phenyl C6 phenyl bonded to silica Aromatic and polyaromatic analytes
Amide Amide bonded to silica Polar analytes
HILIC Silica solid core particle Polar, basic, and water-soluble analytes
Table 2.1 Common stationary phase column chemistries utilised for LCMS.99
Achieving good chromatographic separation and quality data requires careful selection of
chromatographic parameters such as the nature of the the stationary and mobile phases. Two
key features are considered important for judging the success of a separation.96 The first
feature, deemed especially important within an industrial environment, is completing the
separation with the minimum time expenditure possible. A short separation time increases
the throughput rate of analysis, and provides a more efficient use of materials. The second
factor of importance is chromatographic resolution, a measurement of how well differentiated
two chromatogram peaks are. Resolution (Rs) between two peaks, defined in Equation 2.1,
can be calculated from average peak width (wav) and difference in retention time (∆ r.t.).
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These values depend upon three key parameters: (i) efficiency; (ii) selectivity; (iii) retention.
It is by altering instrument parameters affecting these three components that improved
chromatographic resolution can be achieved. Optimising these parameters is particularly
challenging for hydrophobic analytes, due to their strong column retention and subsequent
peak broadness.
Figure 2.1 Depiction of two resolved peaks in a chromatogram.
Rs =
∆r.t.
wav
(2.1)
Where Rs = resolution; ∆r.t. = difference in retention time; wav = average peak width.
2.2 Ion Sources
Ionisation is the conversion of neutral molecules into the more desirable charged ions required
for analysis by mass spectrometry. These ions can be manipulated within the mass spectrometer
using electric and magnetic fields, thus allowing for separation and detection. Several ionisation
techniques exist, some of the most common of which are shown in Fig. 2.2. Correctly matching
ionisation method with sample type allows for effective ionisation and quality mass analysis.
Factors such as analyte structure, properties and stability can be taken into account in order to
inform this decision. Highly energetic ionisation techniques such as EI and chemical ionisation
(CI), are termed hard techniques. EI proceeds via electron ejection resulting in formation of a
radical cation. These radical cations have increased internal energy, and thus their formation
often results in in-source fragmentation of the analyte.80 Softer ionisation techniques, such
as ESI and MALDI, achieve ion formation via protonation/deprotonation or ion attachment.
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This mechanism aids in maintenance of an intact molecular ion, proving particularly useful
for unstable analytes and biomolecules.83,100 ESI and MALDI will be further discussed as the
most suitable techniques for samples studied within this thesis.
Hard Soft
Ionisation Techniques
Nano-Electrospray 
Ionisation
Electrospray 
Ionisation
Desorption Electrospray 
Ionisation
Matrix Assisted Laser 
Desorption/Ionisation
Fast Atom 
Bombardment
Atmospheric Pressure 
Chemical Ionisation
Atmospheric Pressure 
Solids Analysis Probe
Chemical 
Ionisation
Electron 
Ionisation
Figure 2.2 Comparison of a selection of currently available ionisation techniques.
2.2.1 Electrospray Ionisation
A favoured ionisation technique within the mass spectrometry community, ESI has wide
applicability for molecule types across the pharmaceutical, agricultural and petroleum in-
dustries.83,100,101 The popularity of ESI stems from its soft nature, successfully balancing
effective ionisation with minimal in-source fragmentation. Additionally, ESI is an example of
atmospheric pressure ionisation (API), a family of ionisation techniques which perform the
ionisation process at atmospheric pressure, removed from the rest of the mass spectrometer.102
Positive mode ESI utilises protonation or formation of adducts such as Na+, K+ or NH4+, to
form ions. Similarly, negative ESI proceeds via deprotonation or formation of HCOO-, Cl- or
Br- adducts.103 The resulting charged ion depends upon the composition of the solution in
which the sample is introduced. Since ESI performs well when the sample is introduced from
a polar solvent, the technique is often interfaced with chromatography such as LC or size
exclusion chromatography (SEC).84 Chromatography solvents can be prepared to include 0.1
% formic acid (FA) promoting analyte protonation. Alternatively, salt ions can be doped into
samples or chromatography solvents to promote adduct formation if desired. Small molecule
ionisation via ESI can be limited to singular protonation, however larger biomolecules with
multiple potential protonation sites typically present as multiply charged.83 Multiply charged
biomolecules require reduced m/z range compared to single ionisation, facilitating ESI paired
with limited range mass analysers e.g. a quadrupole.
ESI proceeds by flowing ions in solution through a capillary needle with an applied voltage and
heated N2 nebulisation gas. This potential difference between the capillary tip and the mass
spectrometer creates an electric field, causing positive or negative charge to collect in solution
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at the capillary tip. This collection of charge distorts the solution into forming a Taylor cone,
Fig. 2.3. At the Taylor Cone tip, an aerosol of droplets containing multiple positive charges
is released. This plume of droplets enters a heated inert N2 atmosphere, designed to shrink
the charged droplets via solvent evaporation. As solvent evaporates the charge density of the
droplets increases until the Rayleigh limit is reached, Equation 2.2. At this point, Coulomb
repulsion exceeds droplet surface tension, resulting in droplet explosion into smaller charged
droplets. This process of desolvation and subsequent explosion continues to repeat, forming
smaller and smaller droplets.85,104,105 Finally, ions are completely desorped from the droplets
via one of three mechanisms: (i) Ion Evaporation Model (IEM) - solvent evaporation and
droplet explosion continue until one analyte ion is lifted from a multi ion droplet; (ii) Charge
Residue Model (CRM) - solvent evaporation and droplet explosion continue until one ion
surrounded by a layer of solvent remains and the solvent is then evaporated to get a single
desolvated ion; (iii) Chain Ejection Model (CEM) - unfolded protein chains migrate to the
droplet surface, become charged, and are expelled from the droplet in stepwise fashion starting
at the chain terminus. All models are supported by experimentation, with the model adopted
thought to depend upon factors such as analyte type, instrument parameters, and solvent.
To this end, the CRM is believed to be in effect for hydrophilic molecules, whereas the IEM
better supports hydrophobic analytes.106
Figure 2.3 Mechanism of ESI ionisation. Inset shows Taylor cone formation.107
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qRy = 8pi2(0γR3)
1
2 (2.2)
Where qRy = charge; 0 = permittivity of the vacuum; γ = surface tension; R = radius of the
spherical droplet.
The instrument utilised for ESI throughout the research presented within this thesis is a
Synapt G2-S (Waters Corp., UK). ESI proceeds using a Z-spray ion source, Fig. 2.4, such
that the ESI capillary is perpendicular to the sample cone. A gradient in both vacuum and
voltage is set between the capillary and the sample cone, pulling desired ions through the
source and into the rest of the mass spectrometer. By contrast, neutral molecules and ions of
undesired charge are prevented from passing through the sample cone by the perpendicular
arrangement of the capillary and the cone.
Figure 2.4 ESI source of Waters Synapt G2-S courtesy of Waters Corp., UK.
2.2.2 Matrix-Assisted Laser Desorption/Ionisation
In 1988 Karas and Hillenkamp developed MALDI from laser desorption/ionisation (LDI).108
Tanaka and team then further developed the technique into what is known today.86 MALDI
is a soft ionisation technique ideal for high molecular weight species such as polymers or
biomolecules. Only singly charged ions are produced via protonation, cation attachment, or
proton abstraction for all but the largest molecules of m/z higher than 10 kDa, which may
multiply charge to a small degree. This single ionisation means that a high mass range analyser
is required for pairing with a MALDI ion source. A further drawback is that MALDI is rarely
integrated with any chromatographic separation instrumentation, thus ion suppression can
be an issue when viualising low abundance or poorly ionising analytes. However, MALDI
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has many benefits, including easy sample preparation, and high tolerance of buffers, solvents,
salts and solid hydrophobic material in samples.87,109
MALDI is characterised by the inclusion of a matrix in order to aid ionisation. Several
MALDI matrices have been developed, with the most common and the one selected for this
research being α-cyano-4-hydroxycinnamic acid (CHCA).41 Successful MALDI matrices are
characterised by a number of key properties including: (i) ability to absorb at laser wavelength
and become excited; (ii) solvent compatibility with analyte; (iii) low sublimation temperature;
(iv) suitable proton affinity such that the matrix has the ability to protonate/deprotonate
under experimental conditions and then transfer this ionisation to the analyte.
Figure 2.5 MALDI mechanism of ionisation.107
Excess matrix is mixed in solution with analyte sample and dried onto a MALDI target plate
to form a co-crystalline layer of analyte fully embedded in matrix. A laser beam is pulsed
towards the sample irradiating a portion of the sample. In the case of this PhD research, the
instrumentation utilised for MALDI-MS is an Autoflex II ToF/ToF (Bruker Daltonics Ltd).
This instrument has a 337 nm N2 laser with 3 ns pulse length and pulse energy of 100 µJ. The
laser pulse causes localised rapid heating, triggering desorption of matrix and analyte from the
target plate into the gas phase. In addition, the focused laser beams causes excitation of the
matrix molecules and subsequent matrix ionisation. Proton transfer from matrix to analyte
creates gas phase analyte ions, as indicated by the mechanism in Fig. 2.5. In addition to this
mechanism, several other ionisation pathways are likely used in the desorption plume.110,111
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2.3 Mass Analysers
The mass analyser is the portion of the mass spectrometer following on from the ion source.
The role of the mass analyser is to separate gas phase ions by their mass to charge ratio in
order to aid detection. Several mass analysers exist, each relying on different principles of
separation, which allows the optimum analyser to be selected for the analysis of any given
analyte. Several factors are taken into account when choosing a mass analyser, including cost,
mass range, scan speed, limit of detection, and time to complete one MS analysis termed the
duty cycle. However, there are two factors prioritised above all else when selecting a mass
analyser, mass accuracy and resolving power.
Mass accuracy is the difference in m/z measured by the mass analyser compared to the
theoretical m/z value.112 The value is converted into parts-per-million (ppm), Equation 2.3, to
give the proposed accuracy of the predicted elemental formula. High accuracy mass analysers
allow for the reliable determination of elemental composition, and thus provides more definitive
characterisation of the molecule by mass spectrometry. In addition, analysers with high mass
accuracy are able to aid in molecule characterisation by distinguishing between ions of the
same nominal mass. An example of this is in the case of CO2 (m/z 43.98928) and CH3CHO
(m/z 44.02567), which both have nominal m/z 44.
Accuracy(ppm) = (Observed(m/z)− Theoretical(m/z))
Theoretical(m/z) × 1000000 (2.3)
The second key performance factor utilised when selecting a mass analyser is the resolving
power.80,81 Resolving power is the ability of the analyser to distinguish and separate between
ions with a small mass difference. For two overlapping peaks of equal intensity, Fig. 2.6, the
resolving power can be defined by Equation 2.4. In this case m is the m/z of the peak and ∆m
is the mass difference between the two peaks separated by 10 % peak height. Mass resolution
of an isolated peak can also be determined, Fig. 2.6. In this case ∆m is taken as the peak
width at 50 % of the peak height, termed full width at half maximum (FWHM).
R = m∆m (2.4)
Where R = resolution; m = mass; ∆m = difference in mass.
50 2.3. Mass Analysers
Figure 2.6 Resolving power of a given mass analyser for two overlapping peaks (a) or a
single peak (b).107
2.3.1 Quadrupole Mass Analysers
A quadrupole is the simplest mass analyser commercially available, being low in resolving
power and mass accuracy compared to other available mass analysers, but robust and not
requiring high vacuum.81,113 As such, single quadrupole analysers tend to be employed in
small footprint mass spectrometers designed with cost and mobility in mind, rather than
power and performance. Alternatively, quadrupoles appear as components of hybrid mass
analysers, where several quadrupoles are used together or in conjunction with another analyser
type in order to increase performance.91,114
Quadrupole mass analysers create a quadrupolar field within a series of parallel rod electrodes,
arranged symmetrically around the z axis. A traditional quadrupole utilises four electrode
rods to create the quadrupolar field, Fig. 2.7, however analysers with six (hexapole) and eight
(octapole) rods have been developed in order to increase the mass range and bandwidth of
the analyser. RF and DC voltages are applied to the electrode rods acting in pairs. The DC
component (U) applied is identical in magnitude for the electrode pairs, however the two
pairs are 180◦ out of phase. The applied RF voltage is Vcos(ωt) where V is the amplitude, ω
the angular frequency (Hz) and t (s) is time. The alternating RF and DC voltages within
the quadrupole analyser create an oscillating electric field. Ions entering the quadrupole are
attracted to the electrode rods of opposite charge, thus the oscillating field causes the ions to
oscillate through the quadrupole.
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Figure 2.7 Schematic of a quadrupole mass analyser.107
au =
8zeU
mω2r02
(2.5)
Where au = the x-coordinate of an ion travelling through the quadrupole; z = charge; e =
charge of an electron; U = applied DC voltage; m = mass; ω = angular frequency; r0 =
quadrupole radius.
qu =
4zeV
mω2r02
(2.6)
Where qu = the y-coordinate of an ion travelling through the quadrupole; z = charge; e =
charge of an electron; V = RF voltage amplitude; m = mass; ω = angular frequency; r0 =
quadrupole radius.
Ion motion and stability within a quadrupole is described by the Mathieu Equations, 2.5 and
2.6.81 The Matheiu equation describes the parameters q and a as functions of the RF and
DC voltages applied to the quadrupole respectively. The equation can be converted into a
graphical representation by plotting these two parameters against each other, Fig. 2.8. At the
optimum RF:DC ratio, indicated by the blue line in Fig. 2.8, ions are transmitted through the
quadrupole with sufficient separation to allow resolution of peaks of differing m/z. Decreasing
the RF:DC ratio, shown by the red line in Fig. 2.8, maintains ion transmission, however the
resolution decreases as ions of differing m/z are not well separated. Increasing the RF:DC
ratio, indicated by the green line in Fig. 2.8, causes instability in the ion trajectories. In
this case, ions collide and discharge on the electrode rods of the quadrupole and thus are not
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transmitted to the detector.
Figure 2.8 Stability profile of a quadrupole mass analyser.107
Quadrupole mass analysers are extremely versatile in their capabilities, which can be tuned by
manipulating the applied RF and DC voltages. Single ion monitoring is possible by selecting
RF and DC components such that only one ion m/z is stabilised and able to traverse the
quadrupole. Alternatively, continuous scanning is possible by applying RF and DC voltages in
constant ratio but increasing in magnitude. As Fig. 2.8 shows, different m/z ions are stabilised
and transmitted as the magnitude increases, allowing for ion separation. Finally, applying
an RF voltage only to the quadrupole allows ions of all m/z to transmit without separation.
Addition of an inert gas to this region transforms the quadrupole into a collision cell such
that fragmentation experiments can be carried out.
2.3.2 Time-of-Flight Mass Analysers
Wiley and McLaren first published a design for the time-of-flight (ToF) mass analyser in
1955.115 Since this publication ToF analysers have developed into commercial instruments,
improving in resolving power and mass accuracy. ToF mass analysers separate ions of differing
m/z spatially, by measuring the time taken for ions to move through a fixed distance.116,117
Ions are expelled from the ion source with an accelerating voltage (V) into a drift region, free
from electric or magnetic fields. Ions entering the drift region have a kinetic energy (Ekin) as
described in Equation 2.7, which is dependent upon their mass (m) and charge (z). Since
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velocity (v) is equivalent to the distance travelled (d) in a given time (t), it is possible to
further substitute and rearrange Equation 2.7 into Equation 2.8. Given that the mass of an
electron (e), accelerating voltage (V ), and distance (d) are constants in a ToF analyser, the
equation can be further simplified such that m/z is proportional to time2 (t2). As a result,
ions of low m/z move quickly through the drift tube of a ToF analyser, whereas high m/z ion
are much slower resulting in ion separation within the analyser.118
Ekin =
1
2mv
2 = zeV (2.7)
Where Ekin = kinetic energy; m = mass; v = velocity; z = charge; e = charge on an electron;
V = accelerating voltage.
m
z
= 2eV ( t
d
)2 (2.8)
Where m = mass; z = charge; e = charge on an electron; V = accelerating voltage; t = time;
d = distance.
Commercial linear ToF mass analysers contain a linear drift tube region to achieve the desired
separation of ions by m/z, Fig. 2.9. These analysers have poor mass accuracy of approximately
200 ppm, and resolution of around 5000 FWHM. Increased ToF analyser resolution is
achievable by increasing the distance over which ions separate. However, lengthening the drift
tube increases instrument size and quickly becomes impractical. An alternative method for
lengthening the drift tube, increasing ToF mass accuracy and resolving power, is to use a
reflectron. A reflectron is an ion mirror, which deflects ions hitting it back along the drift tube
thus increasing the overall travel distance. An additional benefit is that ions of higher m/z
penetrate further into the reflectron, thus experiencing higher voltages and further increasing
ion separation. Reflectron ToF mass analysers have mass accuracy of 10 ppm or better with
internal calibration, and resolving power of approximately 20,000 FWHM.117
MALDI ion sources are particularly well suited for integration with a ToF analyser due to the
pulsed laser action providing discrete ion packets. Indeed, the Autoflex II ToF/ToF (Bruker
Daltonics Ltd) utilised for MALDI MS throughout this PhD research utilises a ToF mass
analyser. The ToF analyser in this particular instrument can be used as a linear ToF analyser
when studying analytes of high m/z so as to increase the instrument mass range and improve
sensitivity. Alternatively, if analytes of m/z less than 10,000 amu are studied, reflectron mode
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can be applied to the ToF increasing resolution and mass accuracy of the resulting data.
Figure 2.9 Schematic of a linear time of flight (ToF) mass analyser.107
2.3.3 QToF Mass Analysers
Mass analyser power and performance can be increased by combining multiple analyser types
within one mass spectrometer, termed a hybrid mass analyser.117,119 One example of this is
the Synapt G2-S (Waters Corp., UK) utilised throughout this research. The Synapt G2-S
(Waters Corp., UK) contains a QToF mass analyser, a hybrid which combines a quadrupole
and a ToF analyser. The quadrupole analyser, labelled in Fig. 2.10, can be utilised to transmit
ions in RF only mode, or to isolate a known m/z in single ion monitoring mode for MSMS
analysis. In addition, the Synapt G2-S (Waters Corp., UK) contains a ToF mass analyser,
labelled in Fig. 2.10. The ToF analyser in the Synapt G2-S (Waters Corp., UK) is preceded
by a perpendicular pusher. The pusher uses orthogonal acceleration to convert the continuous
stream of ions produced by the ESI ion source into the discrete ion packets required for a
ToF analyser.120 Three reflectron ion mirrors are present in the Synapt G2-S (Waters Corp.,
UK) ToF analyser. If all three are used, a W ion path configuration is achieved, effectively
lengthening the drift tube and improving resolution. Alternatively, the analyser can be used
with only one reflectron in which case a V ion path is followed. This pathway instils the mass
analyser with less resolving power, however the sensitivity of the instrument is increased due
to reduced ion loss.
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Figure 2.10 Schematic of Waters Synapt G2-S courtesy of Waters Corp., UK.
2.4 Tandem Mass Spectrometry
Tandem mass spectrometry (MSMS) is a technique utilised by mass spectrometrists in order
to glean further structural and elemental information about an analyte, enabling improved
characterisation.81,92,94 MSMS proceeds by the selection and isolation of a precursor ion of
interest, followed by bond dissociation and thus fragmentation of the precursor ion into product
ions and neutral losses. Fragmentation is achieved by increasing the internal energy of the ion
using mechanisms such as photodissociation, the introduction of electrons to the trapped ions,
or collisions between ions and uncharged molecules. Examples of fragmentations techniques
include Collision Induced Dissociation (CID)/Collisionally Activated Dissociation (CAD),
Electron Capture Dissociation (ECD), Infrared Multiphoton Dissociation (IRMPD), and
Electron Transfer Dissociation (ETD).121 MSMS analyses are routine across many industries
due to their highly informative nature and reproducibility providing a fingerprint for known
molecules. Biomarker monitoring and drug test screening are particularly common examples.
MSMS analyses can be carried out such that the two key steps, precursor ion isolation and
fragmentation, are separated either by space or by time. Instruments whereby stages are
separate events in time, including FT-ICR analysers and Paul traps, are able to perform
multiple MSMS cycles such that higher order MSn spectra can be obtained.90,91 By contrast,
instruments whereby each stage of the process is spatially separated, are limited in the
number of MSMS cycles that can be carried out by the physical locations available within
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the instrument to perform the required steps.117 The MSMS analyses carried out throughout
this research are performed on the Synapt G2-S (Waters Corp., UK), an MSMS in space
instrument. MSMS analyses up to MS3 are possible utilising the Synapt G2-S (Waters Corp.,
UK) instrument platform, due to the presence of two T-wave collision cells.122 These collision
cells, termed the trap and transfer respectively, are stacks of ring electrodes with opposing
RF voltages applied to adjacent electrodes. Application of a DC voltage to the system
creates a travelling wave, propelling ions through a inert buffer gas towards the cell exit. The
precursor ion isolation step required prior to these collision cells can be carried out in either
the quadrupole, the ion mobility cell, or both. Pseudo-MS4 analyses are also possible for the
Synapt G2-S (Waters Corp., UK), if the initial MSMS cycle is performed by applying a high
capillary voltage to unstable ions in the ESI source, resulting in in-source fragmentation.
The Synapt G2-S (Waters Corp., UK) is equipped to perform MSMS analyses using both CID
and ETD fragmentation mechanisms. However, since ETD requires multiply charged precursor
ions, it is deemed inappropriate for the analyses performed herein. CID MSMS analysis,
involves colliding precursor ions of high kinetic energy with neutral inert gas molecules.123
Inelastic collisions between these two entities allows energy transfer from the gas molecules
to the ions, creating a vibrationally excited ion intermediate. This high internal energy
redistributes throughout the precursor ion, causing unimolecular dissociation of the weakest
bonds within the ion, and thus forming product ions. Quasi-Equilibrium Theory (QET)
informs that this redistribution of energy proceed via all available degrees of freedom, and that
the bond dissociation is unidirectional thus non-reversible. To this end, instrument parameters
are vital in determining the range of product ions formed by CID, and thus their informational
value. Altering the DC voltage in the Synapt G2-S (Waters Corp., UK) collision cells can
increase the velocity of the ions entering, promoting ion collisions with the gas molecules.
Additionally, buffer gas type and pressure are important, with gases of larger cross-sectional
area at higher pressure increasing the likelihood of ion collisions. Further, gases of larger cross
sectional area transfer more energy in any given collision than a small gas molecule, allowing
bond dissociation through higher energy pathways.119 An example of one such high energy
fragmentation pathway is the dissociation of bonds within a stable aromatic structure.
2.4.1 Tandem Mass Spectrometry of Peptides
MSMS is a useful and informative mechanism for peptide sequencing and the elucidation of
structural information, whilst maintaining both speed and sensitivity of analysis.49,114,124,125
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Peptides are predictable in their MSMS fragmentation patterns, with the peptide backbone
bonds known to preferentially dissociate. This predictability gives rise to a widely accepted
nomenclature for peptide ion fragments, as shown in Fig. 2.11. According to this nomenclature,
N -terminal fragments are known as a, b, and c product ions, whereas C -terminal fragments
use the labels x, y, and z.47 CID favours the formation of b and y ions which form as a result
of amide bond dissociation along the peptide backbone, separating off one amino acid at a
time. This fragmentation allows the amino acid sequence of the peptide to be determined,
along with the positions of any post-translational modifications (PTM). However, complexity
can arise when amino acids of equivalent m/z are present in the peptide sequence, such as
leucine (L) and isoleucine (I). In this case, increased sequence coverage and fragmentation
can be achieved by the selection of a higher charge state precursor ion, which tend to exhibit
more instability.126,127 Alternatively, use of CID in combination with other ion fragmentation
mechanisms can prove successful in increasing sequence coverage and ion types.
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Figure 2.11 Characteristic peptide CID MSMS fragmentation ions.47
Figure 2.12 CID MSMS of palmitoyl melittin precursor ion m/z 772.0 showing key b and
y ions used to distinguish modification position at the N -terminus.44
Fragmentation of intrinsically lipidated melittin is one example where MSMS of peptides has
proved vitally important in relation to this research project in the past. MSMS has been used
to determine the location of acyl chain modifications on melittin amino acid side chains. As
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Fig. 2.12 shows, observation of b and y ions in the CID spectrum allows for the position of the
modification to be placed within the two N -terminal amino acids.11,44 N -terminal b1 ions are
rarely observed in CID spectra due to the relatively small m/z and preferential stability of the
b2 ion. Thus observation of the b2 ion combined with chemical knowledge and intuition must
be utilised in order to determine the position of the modification as the N -terminal amine.
2.4.2 Tandem Mass Spectrometry of Small Molecules
MSMS of small organic molecules comprises a large proportion of research in the field of mass
spectrometry, due to the importance of the technique in providing structural and elemental
characterisation information.100,117,128 Key applications include differentiation of isomers,
identification of unknown analytes, biomarker identification, and reaction monitoring. MSMS
of known small molecules by the same fragmentation mechanism is highly reproducible,
resulting in a fingerprint unique to that molecule. To this end, certain molecule classes have
known product ions. For example, CID of a diacyl phospholipid produces a product ion
corresponding to the phosphate head group, allowing for identification of phospholipid class.41
Similarly, sugar rings are observed to fragment depending upon the orientation of groups axial
or equitorial to the ring, differentiating between isomers.129
Due to significant structural differences between small molecules, their fragmentation patterns
are less predictable and systematic than those of peptides. However, it is possible to identify
some key trends in product ion formation by MSMS in order to simplify data interpretation.102
Common cleavages in small molecule MSMS occur at locations in which the charge can be
stabilised by the surrounding groups, due to their electron withdrawing or electron donating
nature. Weak carbon-heteroatom bonds often dissociate for this reason, since heteroatoms
aid in charge stabilisation.130 In fact, certain species have been identified as having a high
probability of being eliminated by MSMS: (i) neutral losses including H2O, CO2, NO2, SO2,
and HX where X is a halide; (ii) radicals such as OH·, CO·, NH ·2 , and X·; (iii) charged species
including PO33-.131,132 It is worth noting that due to the high energy required to separate an
electron pair, even electron precursor ions prefer to fragment into even electron product ions
rather than radicals. By contrast, highly stable structures such as aromatic rings are unlikely
to fragment, and are thus expected to carry through from precursor to product ions. In some
cases MSMS results are complicated when bond breakage within a precursor ion results in a
subsequent rearrangement of the structure in order to stabilise the product ion.
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2.5 Ion Mobility Mass Spectrometry
Ion mobility mass spectrometry (IMMS) is a technique combining mass spectrometry with ion
mobility spectrometry.93,133 Since taking off in popularity in the 1990s, the technique has found
applications in a range of fields including proteomics, metabolomics and lipidomics.94,134–137
Ion mobility spectrometry is a method of separating gas phase ions depending upon their
mobility in a carrier gas through a mobility cell. The speed of mobility through the cell is
altered by the size and shape of the ions, and thus mobility can be related to the collision
cross section (CCS) of the ion.138,139 Ion mobility provides an added dimension to mass
spectrometric analysis, providing both structural information about an ion and an alternative
mechanism of separation for ions of similar structure or functionality, for which classic GC or
LC separation is challenging.
The Synapt G2-S (Waters Corp., UK) utilises travelling wave ion mobility spectrometry
(TWIMS) to achieve ion mobility separation.122 TWIMS has been utilised in combination with
mass spectrometry since 2006, and is best understood from its basis in drift tube ion mobility
spectrometry (DTIMS). DTIMS separates ions by introducing them into a helium filled drift
tube mobility cell with a constant electric field applied across the cell. Ions travel through the
drift tube propelled by the electric field, however they are slowed down by collisions with the
gas. Statistically ions of smaller size and shape undergo fewer collisions with gas molecules,
and thus are considered to have greater mobility. The combination of propulsion by the field
and deceleration by the gas results in an overall velocity specific to that ion. As such, different
ions travel through the cell at different velocities, reaching the exit at different times. In this
way, ions are separated and their CCS can be calculated from their specific time taken to
travel through the mobility cell.
TWIMS uses a similar design to DTIMS, based upon ions moving through a gas filled drift
tube.140 However, instead of a uniform electric field being applied across the whole cell, a
TWIMS cell is comprised of a series of stacked ring electrodes of alternating fields. Opposing
RF waveforms are applied to adjacent rings, which when combined with the movement of a
DC potential from one ring to the next, creates a moving electric field or travelling wave. In
portions of the cell with a positive electric field, ions separate based upon their mobility by
the same mechanism as is observed for DTIMS. However, improved separation is achieved
through the wave formed in the regions with diminished electric field. Ions of high mobility
spend more time at the crest of the wave due to their increased velocity, thus "surf" the wave
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and move through the cell quickly. By contrast, ions with lower mobility roll over the wave
and are carried along, slowing their motion through the mobility cell. Speed and magnitude
of the travelling wave can be tuned, affording improved control over ion mobility separation
to the user. Following calibration, travel time through the TWIMS mobility cell can be used
to calculate ion CCS.
Several examples of IMMS using TWIMS exist which bear relevance to the research presented
throughout this thesis. Notably, IMMS has been utilised to separate out complex samples of
cellular phospholipids. Unlike traditional LC separation, optimised ion mobility is able to
separate phospholipids with only minor structural differences such as cis or trans nature of
a double bond, double bond position, and carbon chain length.141–144 Further, IMMS has
been documented to separate peptides with minor structural variations in PTM location, and
even interactions of non-covalently bound drug or co-factors.8,145,146 Small molecule IMMS is
also evident in current literature, with separation of isomers a key focus.134,135,147 One theme
evident throughout all IMMS applications is that optimisation of instrument parameters is
vital for successful mobility separation.
3 | Analytical Techniques for Study
of Intrinsic Lipidation
3.1 Introduction
Mass spectrometry provides a reliable and informative analytical technique for study of innate
reactivity at the membrane interface. Applicable to both peptide and small molecule systems,
LCMS facilitates identification and characterisation of acylated reaction products and lysolipid
by-products.39,77 Unfortunately, study of intrinsic lipidation by mass spectrometry also has
limitations. The required chromatographic separation of reaction mixture components prior to
analysis prevents high throughput study or on-line reaction monitoring. Product quantification,
necessary for kinetics determination, proves challenging and requires additional synthetic and
analytical steps. Furthermore, mass spectrometry of accurate biological models containing
high lipid concentrations prevents visualisation of low abundant products without undesirable
side effects, such as column overload or detector saturation. It is therefore desirable to examine
alternative analytical techniques, in order to determine their feasibility for study of intrinsic
lipidation. The work undertaken within this chapter covers two experimental approaches for
study of intrinsic lipidation, with differing desired outcomes. The first approach aimed to
investigate methodologies for identifying membrane reactivity through routine high throughput
screening of reaction mixtures. The second approach investigated analytical techniques which
could be employed for the robust and informative study of more accurate biological models.
It was hoped that these methodologies may provide complementary information to mass
spectrometry analysis, for example informing on reaction kinetics.
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3.2 Routine Reaction Monitoring
Identification and development of analytical techniques for routine monitoring of intrinsic
lipidation at the membrane interface was conducted. Desirable techniques exhibit robust
and reliable sample analysis in a quick high throughput manner. Techniques adaptable to
automated or on-line reaction monitoring provide additional benefits for future exploitation.
Ideal analytical methods require minimal sample modification and preparation prior to use,
and are applicable to multiple systems including peptides and small molecules. Techniques
are not required to be deeply informative, as samples of interest can be taken forward for
analysis by mass spectrometry whilst minimising time and solvent wastage. Solution state
NMR, fluorescence spectroscopy, and TLC were identified as analytical techniques meeting
these requirements. Candidate methods were therefore tested in order to further determine
their success and applicability.
3.2.1 Solution State NMR
In principle, solution state NMR provides an efficient and reliable methodology for routine
study of intrinsic lipidation. Additional desirable attributes, such as automation and simplistic
quantification using peak integrations, can also be attributed to the technique.148,149 However,
solution state NMR monitoring of peptides, small molecules or their acylated analogues within
complex biological matrices is impractical due to technique sensitivity limits. Furthermore,
peptide and protein NMR is complex to analyse and interpret, preventing high throughput
routine analysis.150–152 Monitoring lysolipid by-product formation by solution state NMR
provides a practical alternative for studying intrinsic lipidation. Background phospholipid
hydrolysis has previously made lysolipid monitoring an unreliable method for analysing intrinsic
lipidation. However, NMR facilitates total speciation, such that lysolipid production attributed
to background hydrolysis can be subtracted following quantification of fatty acid by-product.
Lysolipid levels resulting from intrinsic lipidation can thus be determined, identifying and
quantifying reactivity.153
Initially, sensitivity limits of solution state NMR were tested in order to determine applicability
of the technique to the study of intrinsic lipidation. Experimental focus was upon confirming
whether sufficient proportions of phospholipid, lysolipid and fatty acid exist within reaction
mixtures to facilitate solution state NMR study. POPC liposomes, utilised for study of
intrinsic lipidation in vitro, were prepared in buffer (90 mm NaCl, 10 mm NaHCO3, pH 7.4) at
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reaction mixture concentration 0.02 mg mL−1. Modelling intrinsic lipidation and background
hydrolysis, liposomes were divided into triplicate portions prior to addition of 5 mol% lysolipid
OPC or palmitic acid. Samples were lyophilised and re-suspended in deuterated solvents
required for NMR analysis. Selected solvents include CDCl3, MeOD, D2O, CDCl3:MeOD
(1:1) and MeOD:D2O (1:1). Detection of POPC, or less concentrated counterparts OPC and
palmitic acid, by solution state NMR proved impossible under the applied conditions. Solution
state NMR was thus deemed insufficiently sensitive for study of intrinsic lipidation, and was
not pursued for future routine reaction monitoring.
3.2.2 Fluorescence Spectroscopy
Fluorescence spectroscopy is a diverse biophysical technique with applications in the study of
multiple biological systems. Phospholipid aggregates are one such system, with fluorescence
spectroscopy providing insights into membrane organisation, structure and dynamics.7,57,154
Study is facilitated by an extrinsic fluorescent probe exhibiting similar physical characteristics
to natural phospholipids, for example a cationic fluorophore with two saturated aliphatic tails.
Indirect intrinsic lipidation monitoring of lysolipid reaction by-products has been conducted
using rapid fluorescence spectroscopy, with limited success. Liposomes were prepared from fluo-
rescent phospholipid BODIPY PC-A2 (1-O-(6-BODIPY™ 558/568-Aminohexyl)-2-BODIPY™
FL C5-Sn-Glycero-3-Phosphocholine), Fig. 3.1, containing FRET donor-FRET acceptor acyl
chains.153 Reduced FRET was observed in the presence of small molecules, indicative of acyl
chain cleavage and lysolipid formation. However, study of intrinsic lipidation by lysolipid
abundance is deemed inaccurate without background hydrolysis correction. Furthermore,
fluorescent phospholipid analogues are noted to modify membrane structure and dynamics,
which may alter behaviour and reactivity at the membrane interface.154,155 As a result, intrinsic
lipidation study using extrinsic fluorescence probes was not considered a suitable method for
routine high throughput analysis of intrinsic lipidation.
Harnessing intrinsic molecular fluorescence provides an alternative pathway for fluorescence
study of intrinsic lipidation. Aromatic rings, including those within amino acids such as
tryptophan and cationic amphiphilic small molecules, exhibit natural fluorescence.156–158
Their fluorescence wavelength is dependent upon external environment, with hydrophobic en-
vironments producing a blueshift in fluorescence wavelength. As a result, emission wavelength
of a parent molecule would be expected to differ from that of its increasingly hydrophobic
acylated analogue, formed following intrinsic lipidation. Observed emission intensity ratios
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could therefore inform upon the presence and extent of species reactivity at the membrane
interface.
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Figure 3.1 Structure of BODIPY PC-A2, containing FRET donor-FRET acceptor acyl
chains.
Viability of fluorescence spectroscopy for monitoring intrinsic lipidation was tested using
extensively studied model peptide melittin.159,160 Emission spectra were obtained using a
280 nm excitation wavelength, for unmodified melittin and four synthetically acylated analogues.
Acylated peptides containing a palmitoyl or oleoyl acyl chain modification at either the N -
terminus or K23. Differential emission spectra were observed for modified and unmodified
melittin, highlighted by emission maxima presented in Table 3.1, and comparison of melittin
and N -oleoyl melittin in Fig. 3.2. Acylated peptides all exhibit an emission maximum close to
355.5 nm, blueshifted compared to unmodified melittin at 362.5 nm. Although minor, variation
in emission maxima are sufficient to distinguish between modified and unmodified species.
However, it is unclear whether the observed blueshift is a direct consequence of lipidation
caused by increased peptide hydrophobicity, or a secondary consequence of lipidation, such as
folding.
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Figure 3.2 Emission of 10 µg mL−1 melittin (solid green line) and N -oleoyl melittin (dashed
red line) in aqueous buffer solution (90 mm NaCl, 10 mm NaHCO3, pH 7.4) following excitation
at 280 nm.
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Peptide Emission Maximum (nm)
Melittin 362.5
N -palmitoyl melittin 355.5
K23-palmitoyl melittin 355.5
N -oleoyl melittin 354.5
K23-oleoyl melittin 356.5
Table 3.1 Emission maxima for solution phase melittin analogues based upon tryptophan
emission following excitation at 280 nm.
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Figure 3.3 I(355.5 nm)/I(362.5 nm) ratio for solution phase melittin upon addition of
differing molar % of: N -palmitoyl melittin (solid red); K23-palmitoyl melittin (dashed orange);
N -oleoyl melittin (dotted and dashed blue); K23-oleoyl melittin (dotted green).
The ratio of emission intensities at 355.5 nm and 362.5 nm (I(355.5 nm)/I(362.5 nm)) was
calculated for solutions of melittin plus between 0 mol% and 20 mol% acylated melittin, in
order to establish a correlation between extent of acylation and I(355.5 nm)/I(362.5 nm) ratio.
Despite indications of a slight upward trend, shown in Fig. 3.3, insufficient correlation is
observed to utilise in the study of intrinsic lipidation. Consistency in I(355.5 nm)/I(362.5 nm)
ratio suggests that fluorescence exhibits inadequate sensitivity to detect the presence of low
abundance acylated species. Based upon literature precedent, I(336.0 nm)/I(352.0 nm) ratio
was also calculated and compared at different molar ratios of acylated melittin, Fig. 3.4.45
I(336.0 nm)/I(352.0 nm) ratio is widely employed to measure melittin partitioning in en-
vironments of differing polarity, for example binding to a liposome in aqueous solution.
I(336.0 nm)/I(352.0 nm) ratio exhibits an initial increase correlating with proportion of acy-
lated peptide, followed by a plateau. Significant initial ratio increases in combination with the
observed plateau suggests promotion of melittin folding in the presence of acylated melittin,
producing a similar emission blueshift. Small quantities of acylated melittin exhibit power to
modify bulk peptide solution, preventing accurate calculation of the proportion of acylated
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species from I(336.0 nm)/I(352.0 nm) ratio. Associated data complexity, combined with addi-
tional challenges upon inclusion of a membrane, suggest intrinsic fluorescence is unsuitable
for routine monitoring of intrinsic lipidation.
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Figure 3.4 I(336.0 nm)/I(352.0 nm) ratio calculated for solution phase melittin upon addi-
tion of differing molar % of: N -palmitoyl melittin (solid red); K23-palmitoyl melittin (dashed
orange); N -oleoyl melittin (dotted and dashed blue); K23-oleoyl melittin (dotted green).
3.2.3 Thin Layer Chromatography
Thin layer chromatography (TLC), routinely used for reaction monitoring in organic chemistry,
provides an alternative technique for intrinsic lipidation study.161–163 Normal phase (NP)
TLC has been reported for the study of peptide intrinsic lipidation, following optimisation of
solvent systems and visualisation techniques.41 However, TLC study focussed upon monitoring
lysolipid, an intrinsic lipidation and phospholipid hydrolysis by-product. Lysolipid origin is
indistinguishable by TLC, therefore results are not diagnostic of intrinsic lipidation and are of
limited use. Furthermore, a time consuming lyophilisation step was required prior to TLC
analysis, preventing swift routine reaction monitoring.
3.2.3.1 Normal Phase TLC
Development of an improved TLC methodology for intrinsic lipidation reaction monitoring
requires direct visualisation of acylated products, and minimal sample manipulation prior to
analysis. NP TLC cannot facilitate these needs for peptides, however small molecules provide
a suitable system. Propranolol 1, along with synthetically acylated analogues N -palmitoyl
propranolol 12 and N -oleoyl propranolol 13, were selected in order to further examine this
possibility.
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Development of suitable NP TLC conditions for the study of small molecule intrinsic lipidation
began by identification of a sufficiently sensitive visualisation technique.163 Stock solutions
of propranolol 1, N -palmitoyl propranolol 12 and N -oleoyl propranolol 13, were prepared
in MeOH at concentration 1.27 mM. A standard volume (1 µL) of each stock solution was
applied to a NP TLC plate, and seven visualisation techniques were tested. Results of the
screen, summarised in Table 3.2, revealed three techniques to be unsuitable for further study.
Ultraviolet (UV) detection did not enable small molecule visualisation, whilst I2 revealed only
N -oleoyl propranolol 13 due to the presence of a carbon-carbon double bond. Coomassie
staining produced poorly defined spots, making visualisation unclear and challenging.
Visualisation Technique Response
UV No spots observed
PMA Well defined dark blue spots on pale blue background
Ninhydrin Well defined orange/yellow spots on white background
Coomassie Poorly defined white spots on blue background
p-Anisaldehyde Well defined black spots on pink background
I2 Yellow spots observed for species containing alkene only
KMnO4 Well defined yellow spots on pink background
Table 3.2 Observed visualisation response from different staining techniques during NP
TLC analysis of 1.27 mM stock solutions of propranolol 1, N -palmitoyl propranolol 12, and
N -oleoyl propranolol 13.
Sensitivity of PMA, ninhydrin, p-anisaldehyde, and KMnO4 staining at relevant reaction
mixture concentrations was tested to determine applicability to NP TLC of intrinsic lipidation.
Reaction mixture concentration propranolol 1 (127 µM), was spotted onto a TLC plate in
quantities from 1 µL up to 20µL. Visualisation was observed for all four staining techniques
down to 1 µL, equal to 0.03 µg of material, suggesting all exhibit suitable propranolol 1
sensitivity. N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 solutions were prepared
at the lower concentration of 1.27 µM. Concentration mimics 1 % conversion of propranolol 1
into acylated product through intrinsic lipidation. Staining of 1 µL to 20 µL quantities with
p-anisaldehyde proved unsuccessful, due to poor spot clarity compared to the bright pink
background colour. Alternative staining techniques indicated weak staining despite low small
molecule concentrations, as summarised in Table 3.3. A 1 µL quantity equates to 0.63 ng of
N -palmitoyl propranolol 12, and 0.66 ng of N -oleoyl propranolol 13. Generic stain PMA is
determined as the most sensitive staining technique, observing N -oleoyl propranolol 13 at
2 µL, compared to 13 µL and 5 µL for ninhydrin and KMnO4 respectively. Direct visualisation
of acylated propranolol following 1 % conversion provides an excellent basis for study of small
molecule intrinsic lipidation. Sufficient sensitivity suggests no need for lyophilisation prior to
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analysis, supporting a routine high throughput analytical method.
Visualisation Technique N -palmitoyl propranolol 12 N -oleoyl propranolol 13
PMA 2 µL 2 µL
Ninhydrin 10 µL 13 µL
KMnO4 3 µL 5 µL
Table 3.3 Summary of the minimum quantity of 1.27 µM solution of N -palmitoyl propranolol
12 orN -oleoyl propranolol 13 applied to NP TLC plate required for visualisation under different
staining techniques. A 1 µL quantity equates to 0.63 ng of N -palmitoyl propranolol 12, and
0.66 ng of N -oleoyl propranolol 13.
(i)
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Figure 3.5 NP TLC analysis of small molecule intrinsic lipidation reaction mixture
components under three solvent systems: (i) EtOAc:MeOH:NH3 (14% aq) (98:1:1); (ii)
EtOAc:MeOH:NH3 (14% aq) (38:1:1); (iii) CHCl3:MeOH:H2O (6:4:1). A = propranolol 1;
B = N -palmitoyl propranolol 12; C = N -oleoyl propranolol 13; D = POPC; E = PPC; F =
OPC.
Solvent system optimisation is also required to facilitate study of small molecule intrinsic
lipidation by NP TLC. Literature precedent for propranolol 1 TLC reveals three possible sol-
vent systems: (i) Ethyl acetate (EtOAc):MeOH:NH3 (14% aq) (98:1:1); (ii) EtOAc:MeOH:NH3
(14% aq) (38:1:1); (iii) CHCl3:MeOH:H2O (6:4:1).10,41,164 Propranolol 1 and acylated analogues
were studied under these conditions, along with additional reaction mixture components
POPC, PPC, and OPC, to identify coelution issues. NP TLC analysis of each solvent system
is shown in Fig. 3.5. Phospholipid, lysolipid and propranolol 1 remain on or close to the
plate baseline under solvent systems (i) and (ii). Excellent separation between modified and
unmodified propranolol 1 is achieved, however overall results are undesirable. Solvent system
(iii) exhibits movement and separation of reaction mixture components, although all appear
high up the plate. N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 travel with the
solvent front, making visualisation challenging.
Ideal separation was not achieved across three initial solvent systems, therefore system
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CHCl3:MeOH:H2O (6:4:1) was taken forward for further optimisation. Solvent systems of
decreased polarity were employed, aiming to retain excellent separation whilst reducing analyte
movement up the TLC plate. Modified solvent systems selected were: (i) CHCl3:MeOH:H2O
(12:10:1); (ii) CHCl3:MeOH:H2O (12:8:1). Results of reaction mixture component separation
are depicted in Fig. 3.6, along with initial system CHCl3:MeOH:H2O (6:4:1) for comparison.
Novel solvent systems exhibit excellent separation between propranolol 1 and acylated ana-
logues, combined with distinction between the solvent front and the spots of N -palmitoyl
propranolol 12 and N -oleoyl propranolol 13. However, clear separation between phospholipid
and lysolipid species is evident only under solvent system (ii). Optimum solvent condi-
tions for NP TLC of small molecule intrinsic lipidation were therefore considered to be
CHCl3:MeOH:H2O (12:8:1).
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Figure 3.6 NP TLC analysis of small molecule intrinsic lipidation reaction mixture com-
ponents under two solvent systems: (i) CHCl3:MeOH:H2O (12:10:1); (ii) CHCl3:MeOH:H2O
(12:8:1); plus original system CHCl3:MeOH:H2O (6:4:1). A = propranolol 1; B = N -palmitoyl
propranolol 12; C = N -oleoyl propranolol 13; D = POPC; E = PPC; F = OPC.
Optimised solvent system and visualisation method have been determined for study of small
molecule intrinsic lipidation by NP TLC. Compared to current mass spectrometry methodology,
these conditions facilitate routine, high-throughput reaction monitoring. Additional benefits,
compared to previous TLC development, include direct acylated product visualisation down to
1 % conversion, and no lyophilisation requirement prior to analysis. However, whilst optimised
conditions are suitable for study of propranolol 1 intrinsic lipidation, they may not apply
to small molecules of differing structural and functional features. Testing applicability of
conditions to an individual small molecule system would be required prior to analysis of each
distinct new molecule.
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3.2.3.2 Reversed Phase TLC
Reversed phase (RP) TLC provides an alternative analytical system for routine monitoring of
peptide and small molecule intrinsic lipidation through direct product observation.162,163 RP
TLC of peptidic systems was studied using reactive model peptide melittin, in combination
with acylated analogues. Correlating with fluorescence studies, acylated analogues utilised
were N -palmitoyl melittin, K23-palmitoyl melittin, N -oleoyl melittin, and K23-oleoyl melittin.
1 µL of 1 mg mL−1 stock solution in H2O was applied to a RP TLC plate for each peptide.
Seven visualisation techniques were tested, summarised in Table 3.4, in order to determine
stain applicability to study of peptide intrinsic lipidation. Clear, well-defined spots of melittin
and acylated analogues were observed for four methods: (i) UV; (ii) ninhydrin; (iii) coomassie;
(iv) p-anisaldehyde. Furthermore, PMA staining proved successful despite reduced clarity
attributed to background interference. Neither I2 not KMnO4 produced a positive staining
result.
Visualisation Technique Response
UV Weak glow with well defined spots
PMA Poorly defined black spots on blue background
Ninhydrin Well defined yellow/brown spots
Coomassie Well defined blue spots on white background
p-Anisaldehyde Well defined purple spots on pink background
I2 No response
KMnO4 No response
Table 3.4 Observed visualisation response from different staining techniques during RP
TLC analysis of 1 mg mL−1 stock solutions of melittin, N -palmitoyl melittin, K23-palmitoyl
melittin, N -oleoyl melittin, and K23-oleoyl melittin.
In-depth analysis of stain sensitivity was conducted for the five successful visualisation
techniques: (i) UV; (ii) PMA; (iii) ninhydrin; (iv) coomassie; (v) p-anisaldehyde. Peptide
stock solutions were diluted with H2O to reaction mixture melittin concentration of 50µg mL−1.
Reaction mixture concentration of acylated melittin is actually predicted to be between 10
and 100 times more dilute than 50 µg mL−1. Using a graduated TLC spotter, peptides were
spotted onto a RP TLC plate in quantities from 1 µL up to 20µL. Visualisation revealed
identical staining of melittin and acylated counterparts, attributed to similarities in structure
and physical characteristics. Visualisation results, summarised in Table 3.5, indicate a lack of
staining sensitivity for all but coomassie. Peptide detection by coomassie is evident down to
4 µL, equivalent to 0.2 µg of material, attributed to increased background contrast provided by
the applied destaining step.165 However, given actual concentrations of acylated peptide are
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10 to 100 fold more dilute than 50µg mL−1, even coomassie detection is insufficiently sensitive
for direct study of peptide intrinsic lipidation. Lyophilisation, and subsequent rehydration into
a reduced solvent volume, provides a possible answer, however an additional step unfavourably
reduces the routine and high throughput nature of analysis.
Visualisation Technique Minimum Quantity Observed
UV 16µL
PMA 13µL
Ninhydrin 13µL
Coomassie 4 µL
p-Anisaldehyde 14µL
Table 3.5 Summary of the minimum quantity of 50 µg mL−1 solutions of melittin and
acylated melittin applied to RP TLC plate required for visualisation under different staining
techniques. A 1 µL quantity equates to 50 ng of peptide.
Development of solvent systems for the study of peptide intrinsic lipidation by RP TLC
proved challenging. Multiple applied solvent systems failed to move either melittin or acylated
analogues from the TLC baseline. Plate susceptibility towards polar and aqueous solvents
suggests that plate silica is insufficiently alkylated to provide suitable analysis of peptide
intrinsic lipidation. High performance RP TLC plates, boasting increased alkyl coverage,
were purchased as an alternative stationary phase for RP TLC analysis.166 Increased plate
hydrophobicity prevented visualisation by previously optimised aqueous based stains, due
to solvent repulsion. Furthermore, plates lack a fluorescent coating, such that UV detection
proved impossible. Literature reporting suggests the majority of high performance RP TLC
staining techniques to be bespoke and compound specific.167,168 However, four suitable general
staining methodologies were identified:
• PMA in EtOH
• Ninhydrin in t-Butanol (t-BuOH)
• Ninhydrin in IPA
• Ninhydrin in EtOH
1 µL portions of 1 mg mL−1 stock solutions in H2O:EtOH (1:1) of melittin and acylated
counterparts were applied to a high performance RP TLC plate. EtOH was required within the
stock solution to facilitate application onto the hydrophobic plate. Visualisation was conducted
with the four identified high performance RP TLC stains, however insufficient stain sensitivity
prevented detection of peptide species.167,168 Considering TLC analysis was conducted at
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stock solution concentration, samples were at least 200 times more concentrated than reaction
mixture acylated melittin. Lyophilisation and rehydration are therefore impractical, and RP
TLC was not considered viable for routine reaction monitoring of peptide intrinsic lipidation.
Despite minimal success in the study of peptide intrinsic lipidation by high performance RP
TLC, the technique may still be applicable to small molecules. In analogous fashion to NP
TLC analysis, stain sensitivity was tested using 1.27 mM stock solutions of propranolol 1,
N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 in MeOH.167,168 Staining with high
performance RP TLC stains revealed successful small molecule visualisation with PMA in
EtOH only. Solutions were prepared at reaction mixture concentrations of 127 µM and 1.27 µM,
for propranolol 1 and acylated analogues respectively. PMA visualisation of quantities from
1 µL up to 20 µL revealed sufficient stain sensitivity for all species down to 1 µL, equivalent
to 0.63 ng of N -palmitoyl propranolol 12, and 0.66 ng of N -oleoyl propranolol 13. Detection
is considered ideal for monitoring small molecule intrinsic lipidation through direct product
visualisation at 1 % conversion without prior lyophilisation.
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Figure 3.7 High performance RP TLC analysis of small molecule intrinsic lipidation re-
action mixture components under four solvent systems: (i) CHCl3:MeOH:H2O (12:8:1); (ii)
CHCl3:MeOH (1:1); (iii) CHCl3; (iv) DCM. A = propranolol 1; B = N -palmitoyl propranolol
12; C = N -oleoyl propranolol 13; D = POPC; E = PPC; F = OPC.
High performance RP TLC of small molecule intrinsic lipidation also requires development
of suitable solvent conditions. Literature precedent suggests four suitable systems: (i)
CHCl3:MeOH:H2O (12:8:1); (ii) CHCl3:MeOH (1:1); (iii) CHCl3; (iv) DCM.41,165,169 To
identify coelution issues, solvent systems were applied to all reaction mixture components,
including propranolol 1, N -palmitoyl propranolol 12, N -oleoyl propranolol 13, POPC, OPC,
and PPC. TLC analyses, pictured in Fig. 3.7, suggest DCM is an unsuitable solvent system
for intrinsic lipidation study, due to coelution of propranolol 1 and acylated derivatives.
Simultaneous baseline retention of phospholipid and lysolipid species further highlights solvent
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unsuitability. In contrast, solvent systems (i), (ii), and (iii) facilitate separation of propranolol
1 from acylated analogues. However, poor resolution of multiple species combined with high
elution suggest further optimisation is required.
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Figure 3.8 High performance RP TLC analysis of small molecule intrinsic lipidation reaction
mixture components under five solvent systems: (i) CHCl3:MeOH (6:4); (ii) CHCl3:MeOH
(7:3); (iii) CHCl3:MeOH (3:1); (iv) CHCl3:MeOH (8:2); (v) CHCl3:MeOH (9:1). A = propra-
nolol 1; B = N -palmitoyl propranolol 12; C = N -oleoyl propranolol 13; D = POPC; E =
PPC; F = OPC.
Optimisation modified the solvent system CHCl3:MeOH (1:1), aiming to maintain small
molecule separation in tandem with reduced movement up the plate, and improved resolution
of phospholipid and lysolipid species. Selected solvent systems varied CHCl3:MeOH ratio:
(i) CHCl3:MeOH (6:4); (ii) CHCl3:MeOH (7:3); (iii) CHCl3:MeOH (3:1); (iv) CHCl3:MeOH
(8:2); (v) CHCl3:MeOH (9:1). High performance RP TLC analyses, shown in Fig. 3.8,
indicate excellent separation of phospholipid and lysolipids across all systems, promoted
by an increased proportion of CHCl3. However, increased CHCl3 proportion undesirably
decreases separation of propranolol 1 from acylated counterparts N -palmitoyl propranolol
12 and N -oleoyl propranolol 13. Solvent system CHCl3:MeOH (3:1) facilitates separation
of all reaction mixture components, and is thus considered optimum for full small molecule
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intrinsic lipidation speciation. However, focussed separation of small molecule components is
best achieved by screening with solvent system CHCl3:MeOH (1:1). Solvent system selection
dependent upon desired visualisation creates a flexible method of routine reaction monitoring
for sensitive study of small molecule intrinsic lipidation.
3.3 In-depth Reaction Monitoring
In-depth study of peptide and small molecule intrinsic lipidation aims to provide insights into
reactivity, not obtained through current mass spectrometry methodology. Development of
a suitable analytical technique requires identification of an informative methodology, which
can provide insight into intrinsic lipidation. Solid state NMR (ssNMR) provides a suitable
technique in order to meet the desired outcomes of in-depth monitoring.170–172 Facilitating
continuous speciation, intrinsic structural data, and routine quantification, ssNMR offers
potential insights into reaction kinetics and product formation. Furthermore, employment of
multiple ssNMR isotopic probes, including 31P and 15N, enables selective visualisation and
simplification within complex biological matrices.
Preliminary tests were conducted, in order to determine the feasibility of ssNMR for study
of intrinsic lipidation. Reaction mixture concentration (0.2 mg mL−1) DPPC liposomes in
D2O prepared by: (i) extrusion; (ii) sonication; were analysed by 31P solid state NMR
without success. Comparison to 31P ssNMR standard, phosphoric acid, revealed lack of
visualisation could be attributed to a lipid concentration below the detection limit. Liposomes
of increased concentration (2 mg mL−1) were prepared by both extrusion and sonication,
however ssNMR indicated visualisation of sonicated liposomes only. Detection of 2 mg mL−1
extruded liposomes was prevented by either sample loss during extrusion, or liposome size
and physical nature. Additional sonicated DPPC liposomes were prepared at a concentration
of 2 mg mL−1, containing 50 mol% and 5 mol% PPC. Liposomes containing lysolipid aimed
to mimic reaction conditions, probing intrinsic lipidation through by-product detection.
Visualisation of lysolipid proved successful at 50 mol% and 5 mol% PPC, suggesting suitable
sensitivity at the applied concentration for study of intrinsic lipidation.173
Initial studies suggest ssNMR monitoring of intrinsic lipidation requires a minimum phos-
pholipid concentration of 2 mg mL−1. Considering the 1:10 molar ratio of peptide/small
molecule:phospholipid employed during study of intrinsic lipidation, high peptide or small
molecule concentrations would also be required. Use of increased substrate quantities is
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impractical, particularly for peptides, due to being both wasteful and expensive. An alterna-
tive experimental approach reduces substrate and phospholipid concentrations required for
detection, by employing isotopically labelled analogues. A further benefit of this approach is
increased ssNMR sensitivity, facilitated by diagnostic 15N-13C coupling observed only after
lipidation. Isotopic labels can be incorporated into small molecules and phospholipids through
synthetic preparation.
3.3.1 Isotopically Labelled Small Molecules
Small molecules selected for isotopic labelling, in order to facilitate their study by ssNMR, were
propranolol 1 and benzimidazole 11. Excellent model systems, these small molecules exhibit
high propensity towards intrinsic lipidation combined with feasible synthetic preparation and
label incorporation. A 15N isotopic label was selected for incorporation into small molecules,
positioned at the reactive amine functionality in order to induce the greatest observable shift
upon acylation. Development of synthetic methodology was conducted for each small molecule
using unlabelled starting materials, then applied to labelled substrates.
Epichlorohydrin, 
pyridine, RT, 24 h
OH
O Cl
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O O
O Cl
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O N
HOH
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HCl, CHCl3, < 5 °C, 1 h
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IPA, 10 % NaOH (aq), 
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+
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*
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Scheme 3.1 Synthetic protocol for preparation of 15N propranolol 1. Positioning of 15N
label is indicated by N and *.
Scheme 3.1 depicts the proposed synthetic protocol for preparation of 15N propranolol 1,
based upon literature precedent.174 Initial preparation proceeds through substitution of 1-
naphthol with epichlorohydrin, resulting in mixed product formation following removal of
excess epichlorohydrin by Kugelrohr distillation. Mixed epoxidised and chlorinated products
were stirred with HCl in CHCl3 for one hour, in order to drive formation of desired racemic
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intermediate 14. Subsequent reactivity with isopropylamine indicated propranolol 1 formation
following TLC monitoring at 16 hours. Excess amine was collected by Kugelrohr distillation,
minimising wastage of future labelled material, and desired unlabelled propranolol 1 was
isolated by flash column chromatography.
Unlabelled isoproylamine is readily available, however its 15N labelled analogue requires
synthetic preparation. Traditional methodology, using 15N ammonia, results in undesirable
side product formation, and loss of labelled starting material due to volatility. Alternative
methodology, shown in Scheme 3.1, proceeds through formation of 15N isopropylphthalimide
intermediate 15 from 2-bromoproprane and 15N phthalimide.175,176 Subsequent acid cleavage
results in formation of the stable HCl salt of 15N isopropylamine 16, following isolation by
freeze drying. 15N isopropylamine 16 reacted with intermediate 14, successfully resulting in
preparation and isolation of 15N propranolol 1.
The synthetic protocol for preparation of 15N benzimidazole 11 is summarised in Scheme 3.2.177,178
Successful preparation of unlabelled benzimidazole 11 was achieved, despite slow reaction
rate, by refluxing glycine and o-phenylenediamine in concentrated HCl for 5 days. However,
application of experimental conditions to 15N labelled glycine did not yield labelled benzimi-
dazole 11 formation, even with increased reaction time. Furthermore, troubleshooting did
not reveal issues with reaction substrates or conditions. Since reactivity variation cannot be
attributed to the presence of a 15N label, the reasons behind this observed lack of reactivity
remain a mystery. Inability to optimise reaction conditions on unlabelled substrates prevented
further pursuit of 15N benzimidazole 11 synthesis, preventing wastage of expensive labelled
material.
37 % HCl, reflux, 120 h
HO
O
NH2
H2N
H2N
N
N
H
H2N*
*
94%
11
Scheme 3.2 Proposed synthetic route for preparation of 15N benzimidazole 11. Positioning
of 15N label is indicated by N and *.
3.3.2 Isotopically Labelled Lipids
Preparation of bespoke isotopically labelled small molecules may facilitate ssNMR analysis,
however this approach was not deemed practical for all small molecules, or for peptides.
Synthesis of 13C labelled phospholipids provides a more versatile alternative to isotopic label
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incorporation, facilitating study of intrinsic lipidation by ssNMR. The optimum position for
13C phospholipid labelling is at the carbonyl moiety of reactive ester linkages, facilitating
shift observation resulting from acyl transfer. Development of synthetic methodology was
conducted for each phospholipid using unlabelled starting materials, then applied to labelled
substrates.
(i) CdCl2, MeOH/H2O 
(2:1), 0 °C␣, 4 h
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Scheme 3.3 Two proposed synthetic methods for the preparation of 13C labelled DPPC.
Positioning of 13C labels are indicated by *.
The simplest phospholipids for synthetic preparation are 1,2-diacyl-sn-glycero-3-phosphocholines,
containing two identical acyl chains, in combination with a eukaryotic PC head group. Syn-
thetic methodology was therefore developed for production of doubly labelled 13C DPPC based
upon literature precedent, as summarised in Scheme 3.3 (i).179–181 Palmitic anhydride 17 was
successfully prepared in high yield from palmitic acid and palmitoyl chloride 18. However,
subsequent conversion from palmitic anhydride 17 into DPPC proved unsuccessful when using
either pyridine or 4-dimethylaminopyridine (DMAP) as the base. Employing an alternative
literature method, shown in Scheme 3.3 (ii), proved more successful.182–184 Following glyc-
erophosphocholine (GPC) activation as a GPC-CdCl2 complex, reactivity with 4 equivalents of
palmitic acid resulted in production of unlabelled DPPC, purified by trituration. Considering
the expense of isotopically labelled molecules, the reduced palmitic acid manipulation prior
to reaction with GPC is favourable. Minimising equivalents of palmitic acid from 4 to 2.5
aimed to further prevent wastage of isotopically labelled substrate, however the concurrent
reduction in DPPC yield prevented further pursuit. Doubly labelled 13C DPPC was therefore
synthesised in high yield and purity by following the synthetic route described in Scheme 3.3
(ii).
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The measured DPPC transition temperature of 41 ◦C places it within the gel phase under
physiological conditions, believed to reduce intrinsic lipidation reactivity.59 Doubly labelled 13C
DOPC therefore provides an improved phospholipid for study of intrinsic lipidation by ssNMR.
Preparation of unlabelled DOPC was successfully attempted using optimised methodology
developed for DPPC synthesis, shown in Scheme 3.4.182–184 Synthesis was replicated using
13C oleic acid, resulting in formation of doubly labelled 13C DOPC. However, the low product
yield of doubly labelled 13C DOPC prevented complete product isolation and characterisation.
(i) CdCl2, MeOH/H2O 
(2:1), 0 °C␣, 4 h
Me3N O P
OHO
O
OH
OH
Me3N O P
OHO
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O
O
O
O
(CH2)7CH3(ii) Oleic acid, DMAP, 
DIC, DCM, RT, 48 h (CH2)7CH3
*
*
57% (over 2 steps)
Scheme 3.4 Synthetic route for preparation of 13C labelled DOPC. Positioning of 13C
labels are indicated by *.
Isotopically labelled mixed acyl phospholipids are also of interest for the study of intrinsic
lipidation by ssNMR, to inform upon preferential acyl chain transfer. Synthesis of mixed
acyl phospholipid POPC requires selective sn-1 palmitoylation and subsequent sn-2 oleoy-
lation. Commercial POPC preparation proceeds by diacyl phospholipid synthesis followed
by enzymatic sn-2 cleavage. However, this synthetic method is unsuitable for the synthesis
of isotopically labelled species due to waste of 13C labelled fatty acids. Scheme 3.5 depicts
an alternative synthetic protocol for POPC preparation, exploiting dibutyltin oxide coordi-
nation to GPC in order to achieved selective sn-1 acylation.183,185,186 Isolation of lysolipid
intermediate 19 from excess tin proved impossible, and therefore was avoided by adopting
a one pot synthesis. Oleoyl chloride 20 addition to the reaction mixture resulted in tin
displacement, forming POPC, however product characterisation suggests excess tin remains
following purification.
(i) Dibutyltin oxide, 
IPA, reflux, 1 h
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O
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OH
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O
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O
O
O
(CH2)14CH3
O
O
(CH2)7CH3
(ii) Palmitoyl chloride, 
NEt3, RT, 0.5 h
Oleoyl chloride, 
NEt3, RT, 48 h
49%
97% (over 2 steps)
19
Scheme 3.5 Synthetic method for preparation of mixed-acyl lipid POPC.
Distinguishing between palmitoyl and oleoyl transfer from POPC by 13C ssNMR requires
differential acyl chain labelling. Single 13C labelling of acyl chain ester moieties, exhibited in
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commercially available products, results in comparable ssNMR shifts, preventing determination
of transfer origin. Incorporation of one singly labelled acyl chain, and one doubly labelled acyl
chain overcomes this issue. Synthetic preparation of doubly 13C labelled palmitic acid ethyl
ester 21 was therefore attempted, following Scheme 3.6 methodology to incorporate labels at
positions 1 and 2.187,188 Ethylbromoacetate 22 preparation was carried out from bromoacetic
acid starting material, due to its commercial availability in the doubly 13C labelled form.
Bromoacetic acid was converted into acid chloride 23, then esterified in the presence of excess
EtOH. Oxalyl chloride removal in vacuo prior to esterification is key in order to prevent
formation of oxalic acid ethyl ester, resulting in challenging product purification.189 Catalyst
24 was simultaneously prepared in high yield and purity, however subsequent reactivity with
ethylbromoacetate 22 proved unsuccessful in synthesising intermediate 25.190 The adopted
synthetic pathway therefore did not proceed further into the synthesis of intermediate 26,
palmitic acid, or their 13C labelled counterparts.
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Scheme 3.6 Procedure designed for the synthesis of palmitic acid ethyl ester 21. Positioning
of double 13C labels are indicated by *.
Preparation of doubly labelled 13C oleic acid provides an alternative substrate for synthesis of
POPC containing distinguishable acyl chains. Scheme 3.7 presents the proposed synthetic
pathway to be adopted, designed with late label incorporation to prevent wastage. Initial cou-
pling of 1-decyne and 1,6-dibromohexane successfully produced intermediate 27 in high yield,
following purification by distillation. Subsequent synthesis of intermediate 28 using a modified
Reformatsky methodology proved unsuccessful, due to the challenging nature of alkyl bond
formation. Suzuki coupling provides an alternative synthetic pathway, requiring preparation
of a 1-pinacolborane-7-hexadecyne 29 intermediate.191–193 Optimisation of palladium catalyst,
phosphine derivative and salt content facilitated successful synthesis of intermediate 28 via 1-
pinacolborane-7-hexadecyne 29.194 Compound purification was complicated by excess B2pin2,
requiring an ethanolamine wash or vacuum distillation prior to flash column chromatography.
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Reduction of the alkyne moiety of intermediate 28 to the cis alkene present in oleic acid
requires Lindlar’s catalyst and H2. Literature precedent suggested a solvent system of
EtOH:hexane, however reduction proved unsuccessful under these conditions, attributed to
poor substrate solubility.195,196 Reduction of intermediate 28 in EtOAc, suitable for solubility
and hydrogenation, also proved unsuccessful, returning only starting material. Increased
quantities of starting material 28 were required to conduct further optimisation of reduction
conditions. However upon repetition of Suzuki protocol, desired product 28 was not produced,
preventing further pursuit of doubly labelled 13C oleic acid synthesis.
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Scheme 3.7 Procedure designed for the synthesis of oleic acid ethyl ester 30. Positioning
of double 13C labels are indicated by *.
3.4 Conclusions
Analytical techniques have been investigated in order to determine their suitability for study
of intrinsic lipidation. Desirable techniques provide routine, high throughput reaction mixture
screening, in a reliable and accurate fashion. Investigation of solution state NMR and
fluorescence spectroscopy deemed these techniques unsuitable for reaction monitoring, due to
insufficient sensitivity and complex data interpretation respectively. Reaction monitoring by
TLC also proved unsuccessful for peptide intrinsic lipidation, necessitating high performance
RP TLC plates requiring insufficiently sensitive visualisation techniques. Development of
NP and RP TLC conditions, including visualisation technique and solvent system, proved
successful for routine monitoring of propranolol 1 intrinsic lipidation. Validation of TLC
conditions is required prior to monitoring intrinsic lipidation of additional small molecules.
ssNMR was identified as an analytical technique with potential to provide robust and infor-
mative study of intrinsic lipidation within accurate biological molecules. Complementary
to mass spectrometry, ssNMR provides intrinsic structural information, full speciation, and
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quantification, ultimately facilitating study of reaction kinetics. Preliminary ssNMR studies
suggest that undesirably high concentrations of reaction components are required for analy-
sis, leading to expense and wastage. Isotopic substrate labelling was considered a suitable
alternative, facilitating ssNMR analyses at a reduced concentration. Synthetic methodologies
for 15N labelled propranolol 1 and benzimidazole 11 preparation were developed, resulting in
successful isolation of the former. Furthermore, synthetic preparation of versatile 13C labelled
phospholipids was explored, resulting in optimised methodology for preparation of doubly 13C
labelled DPPC and DOPC. Synthetic steps were taken towards the challenging synthesis of
mixed acyl phospholipid POPC, incorporating doubly labelled fatty acid chains for study of
preferential acyl transfer.
4 | Peptide Intrinsic Lipidation
4.1 Introduction
Innate reactivity between membrane active peptides, and phospholipids or lysolipids at
the membrane interface, has been characterised in vitro as peptide intrinsic lipidation.10,11
Increased study of peptide intrinsic lipidation has been conducted compared to small molecule
and protein analogues, however further investigation is required towards understanding the
biological impact of reactivity. Naturally lipidated peptides, formed by enzymatic post-
translational modification, exhibit increased hydrophobicity compared to their unmodified
counterparts. The resulting increased membrane association serves to benefit the natural
roles of lipidated peptides in cell signalling and membrane trafficking.6,197 Analogous physical
properties and biological activities are predicted for peptides lipidated by intrinsic lipidation,
compared to enzymatic lipidation. Investigation of acylated peptide properties by employing
biophysical techniques aims confirm this theory of analogous behaviour. Furthermore, study
of intrinsic lipidation within disease related peptides aims to probe biological behaviour, and
establish the therapeutic relevance of intrinsically lipidated peptides.
4.2 Characterisation of Acylated Melittin
Peptides targeted by intrinsic lipidation in vitro do not undergo post-translational lipidation,
therefore knowledge of their structure and properties following acylation is limited. Lytic
peptide melittin is well characterised in solution and membrane bound forms, however its
intrinsically lipidated analogues have received little scientific focus.198 Properties of acylated
melittin, in comparison to its unmodified counterpart, were therefore probed in order to better
understand their biological relevance. The advent of N -stearylated melittin used as a gene
transfection vector, serves to highlight the need for improved understanding.199 Four acylated
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melittin analogues were selected for study, N -palmitoyl melittin, K23-palmitoyl melittin, N -
oleoyl melittin and K23-oleoyl melittin. Species mirror the most common acylation sites and
fatty acid chains identified during study of intrinsic lipidation within eukaryotic membranes.
4.2.1 Structure of Acylated Melittin
Solution phase melittin adopts a random coil configuration of undefined structure at low
concentration, and a tetrameter shielding hydrophobic residues from the aqueous external envi-
ronment at high concentration.200–202 Increasingly hydrophobic acylated melittin is predicted
to exhibit modified structural behaviour in aqueous solution, shielding the fatty acid chain
from the unfavourable external environment. Fatty acid chain chemistry and modification
position may influence this solution phase structural behaviour. Biophysical techniques were
therefore employed in order to probe the solution phase structure of four acylated melittin
derivatives, N -palmitoyl melittin, K23-palmitoyl melittin, N -oleoyl melittin and K23-oleoyl
melittin.
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Figure 4.1 CD spectra of solution state melittin (black); N -palmitoyl melittin (red); K23-
palmitoyl melittin (orange); N -oleoyl melittin (blue); K23-oleoyl melittin (green).
Circular dichroism (CD) creates a characteristic spectrum based upon peptide interactions
with left circularly polarised light and right circularly polarised light. Comparison to literature
standards then facilitates identification of peptide secondary structure.203,204 CD spectra of
four acylated melittin derivatives in aqueous solution, Fig. 4.1, exhibit considerable variation
from the random coil of solution phase melittin. Increased negative dichroism at approximately
220 nm suggests acylated melittin derivatives adopt an α-helical conformation in solution.
Within error, % helicity is consistent across all forms of acylated melittin, suggesting secondary
structure formation occurs irrespective of acyl chain chemistry or position. Comparison to
α-helical structures of unmodified melittin suggests the solution phase conformation of acylated
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melittin is α-helical with a central kink attributed to the proline residue. However, it is unclear
whether bulk peptide structure mimics the individual helices of membrane bound unmodified
melittin, or aggregates, mirroring the tetrameric structure observed in solution at high melittin
concentrations.205,206
The solution phase structure of acylated melittin derivatives can be further probed by employing
the intrinsic fluorescence of aromatic amino acid residue tryptophan. Tryptophan emission
is susceptible towards external environment, undergoing a blueshift in response to increased
local hydrophobicity. Spontaneous melittin helix formation is characterised by a blueshift in
maximum tryptophan fluorescence from 352 nm to 336 nm.45,62 The extent of helix formation
can therefore be approximated by the I(336 nm)/I(352 nm) ratio. Analogous tryptophan
fluorescence behaviour is predicted for acylated melittin, such that helicity can be determined
by the I(336 nm)/I(352 nm) ratio. Fig. 4.2 shows tryptophan emission following excitation at
280 nm for melittin and N -acylated analogues. K23-acylated melittin species have been omitted
for clarity, however spectra resemble those of their N -acylated counterparts. Acylated melittin
species exhibit a blueshift in emission maxima compared to unmodified melittin, suggesting
tryptophan resides in an increasingly hydrophobic environment. The I(336 nm)/I(352 nm) ratio
is presented for solution phase melittin species in Table 4.1. Increased ratios are observed for
all acylated species compared to melittin, supporting tryptophan residence in the increasingly
hydrophobic environment associated with α-helix formation. The I(336 nm)/I(352 nm) ratio
is not observed to be dependent upon either acyl chain chemistry or modification position.
Furthermore, the origin of the heightened I(336 nm)/I(352 nm) ratio attributed to N -oleoyl
melittin remains unclear.
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Figure 4.2 Tryptophan emission following excitation at 280 nm for melittin (solid black
line); N -palmitoyl melittin (dotted and dashed red line); N -oleoyl melittin (dashed blue line).
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Peptide Emission Maximum (nm) I(336 nm)/I(352 nm)
Melittin 362.5 0.67
N -palmitoyl melittin 355.5 0.74
K23-palmitoyl melittin 355.5 0.77
N -oleoyl melittin 354.5 0.86
K23-oleoyl melittin 356.5 0.73
Table 4.1 Emission maxima and I(336 nm)/I(352 nm) ratio for solution phase melittin
analogues based upon tryptophan emission following excitation at 280 nm.
Combined CD and trytophan emission data suggest solution phase acylated melittin adopts
an α-helical structure. Based upon the constrained nature of secondary amino acid proline,
combined with similarities between CD of solution phase acylated melittin and membrane
bound unmodified melittin, it is further speculated that the structure contains a kink at
proline. Comparison of palmitoyled and oleoylated peptides suggests adopted structure is not
influenced by modification position or acyl chain length. However, literature studies suggest
that more significant reductions in carbon chain length may favour random coil formation in
favour of an α-helix.207 Similarly, internal acyl chain modifications may exhibit structural
differences compared to the N -terminal and K23 modified species tested.
4.2.2 Critical Micelle Concentrations for Acylated Melittin
Acylated melittin, comprised of a hydrophobic fatty acid chain and hydrophilic cationic
C -terminus, can be characterised as amphiphilic. Amphiphilic molecules often aggregate in
aqueous solution, in order to promote the maximum number of favourable hydrophobic and
hydrophilic interactions. Micelles, depicted in Fig. 4.3, are spherical amphiphilic aggregate
structures adopted by detergents, including lysolipids.208 Micelle formation requires substrate
concentrations above a critical micelle concentration (CMC), below which only monomers
of undefined structure exist. Naturally lipidated peptides have been reported to undergo
micellisation in aqueous solution at concentrations above 0.1 µm.209,210 Biologically relevant
examples are summarised in Table 4.2. Therefore, whilst unmodified melittin does not exhibit
micelle formation in aqueous solution, it may be induced by the increased hydrophobicity of
acylated melittin analogues.
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Figure 4.3 Schematic representation of a typical micelle.
Lipidated Peptide CMC
Arthrofactin 10 µm
Surfactin 70 µm
Pseudofactin II 130 µm
Table 4.2 CMC of known lipidated peptides available from literature sources.209,210
Acylated melittin micellisation was studied over the concentration range 100 µm to 1 µm
using a Rhodamine 6G assay. Selected due to the cationic nature of melittin, Rhodamine
6G emission at 550 nm is quenched upon micelle formation due to the localised hydrophobic
environment.211,212 Four acylated melittin analogues were tested, N -palmitoyl melittin, K23-
palmitoyl melittin, N -oleoyl melittin, and K23-oleoyl melittin, in order to distinguish CMC
variation dependent upon substitution location or acyl chain chemistry. Rhodamine 6G
emission in the presence of palmitoylated melittin derivatives, Fig. 4.4, exhibits quenching
associated with micelle formation. In the presence of N -palmitoylated melittin, Rhodamine
6G emission decreases upon initial peptide addition, indicating immediate micelle formation,
and a CMC value of 1 µm or less. In contrast, the observed emission profile in the presence of
K23-palmitoyl melittin is reminiscent of literature studies, with an initial plateau followed by
a decrease denoting the CMC at 5 µm.211 Calculated CMC values for palmitoylated melittin
derivatives are low compared to the lipidated peptides evidenced in Table 4.2. Observed
values fall in a similar concentration range to CMC of lysolipid, for example the CMC of PPC
reported in the range 4 µM to 8.3 µM.213
Rhodamine 6G emission in the presence of oleoylated melittin derivatives, Fig. 4.5, exhibited
different behaviour compared to their palmitoylated counterparts. N -oleoyl melittin is not
observed to quench Rhodamine 6G emission over the concentration range studied, suggesting
lack of micelle formation. Emission of Rhodamine 6G in the presence of K23-oleoyl melittin
proves more challenging to interpret. A slight decrease in Rhodamine 6G emission is observed,
however it is unclear as to whether this can be attributed to micelle formation, or to background
emission variation. Attributing a CMC to K23-oleoyl melittin gives the value 7.5 µm, within the
predicted concentration range for palmitoylated melittin and naturally acylated peptides.209,210
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Furthermore, a K23-oleoyl melittin CMC of 7.5 µm fits with observed lysolipid CMC trends,
in which unsaturated species exhibit higher CMC than their saturated counterparts.33,214
However, attributing the observed decrease in Rhodamine 6G emission in the presence of
K23-oleoyl melittin to background variation suggests oleoylated melittin derivatives do not
undergo micelle formation. This observed distinction between palmitoylated and oleoylated
species can be attributed to the reduced packing ability of unsaturated acyl chains.
0 50 100
0
50
100
Concentration (µM)
In
te
n
s
it
y
(a
rb
.
u
n
it
s
)
Figure 4.4 Rhodamine 6G emission at 550 nm in the presence of increasing concentrations
of N -palmitoyl melittin (solid red); K23-palmitoyl melittin (dashed orange). Vertical line
denotes the CMC of K23-palmitoyl melittin at approximately 5 µm.
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Figure 4.5 Rhodamine 6G emission at 550 nm in the presence of increasing concentrations
of N -oleoyl melittin (solid blue); K23-oleoyl melittin (dashed green). The vertical line indicates
the possible CMC of K23-oleoyl melittin at approximately 7.5 µm.
4.2.3 Antimicrobial Properties of Acylated Melittin
Naturally lipidated peptides exhibit bacterial toxicity associated with membrane disruption
caused by their fatty acid substitutions. Toxicity can be quantified by Minimum Inhibitory
Concentration (MIC), defined as the minimum concentration required to inhibit microorganism
growth. MIC values attributed to lipidated peptides fall within the concentration range of
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0.5 µm to 20 µm.72 Unmodified melittin boasts MIC of 5.6 µm for S. aureus and 11.3 µm for
E. coli, therefore acylated melittin is predicted to exhibit significant bacterial toxicity.215 This
theory was probed by testing the antibacterial activity of four acylated melittin derivatives,
N -palmitoyl melittin, K23-palmitoyl melittin, N -oleoyl melittin, and K23-oleoyl melittin.
The MIC for acylated melittin derivatives were determined against gram-negative E. coli
following 16 hour incubation with serial peptide dilutions of 32 µm to 0.5 µm.216 Optical
density measurements were used to determine the extent of bacterial growth compared to an
untreated control, with complete growth inhibition defining the MIC. Unrestricted bacterial
growth was observed in the presence of all acylated melittin analogues at concentrations below
32 µm, suggesting a lack of bacterial toxicity. At 32 µm inhibition was observed for all species,
as shown in Table 4.3, with the exception of K23-oleoyl melittin. However, insufficient bacterial
growth inhibition was observed to consider this concentration the MIC. Acylated melittin
species are therefore noted to exhibit decreased E. coli toxicity compared to unmodified
melittin, which has an MIC in E. coli of 11.3 µm.215 Bacterial growth relative an untreated
control is determined to be 74 % and 77 % for N -palmitoyl melittin and K23-palmitoyl melittin
respectively, indicating a slight inhibition increase attributed to the N -terminal modification.
N -oleoyl melittin exhibits 84 % E. coli growth compared an untreated control, suggesting
oleoyl modifications are associated with reduced antimicrobial activity compared to their
palmitoylated counterparts, despite increased hydrophobicity.
Peptide E. coli S. aureus
N -palmitoyl melittin 74 % 90 %
K23-palmitoyl melittin 77 % 100 %
N -oleoyl melittin 84 % 100 %
K23-oleoyl melittin 100 % 100 %
Table 4.3 % bacterial growth observed for E. coli and S. aureus treated with 32 µm acylated
melittin analogues. 100 % growth was determine by normalisation to untreated controls.
Analogous studies were conducted in order to determine acylated melittin induced growth
inhibition over the concentration range 32 µm to 0.5 µm for gram-positive S. aureus. Measured
optical densities suggested a lack of bacterial growth inhibition for all acylated peptide
derivatives across the concentration range tested, as shown in Table 4.3, with the exception
of 32µm N -palmitoyl melittin. N -palmitoyl melittin at 32 µm exhibits 90 % S. aureus
growth compared to an untreated control, highlighting the increased toxicity of this acylated
derivative compared to its counterparts. Antimicrobial activity of lipidated melittin in gram-
positive bacteria is therefore decreased compared to unmodified melittin, which has a MIC of
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5.6 µm.215 Observed toxicity correlates with E. coli data, suggesting N -terminal modification
and palmitoylation promote antimicrobial activity compared to alternative locations and chain
chemistries.
4.3 Amyloid Intrinsic Lipidation
Amyloids are a class of disease-related peptides and proteins observed to undergo aggregation
in vivo, resulting in the formation of insoluble plaques.217 Plaques are 10 µm to 200 µm in
size, Fig. 4.6 (c), comprising an amyloid fibril core surrounded by other biological entities such
as nerve terminals. Cytotoxicity of amyloid plaques is attributed to the involvement of nerve
terminals and to plaque structure and insolubility, rather than to the sequence or structure of
peptide monomers. Amyloid plaque formation is a hallmark of many degenerative diseases,
particularly those associated with the brain or peripheral tissues, such as Alzhiemer’s disease.
Other diseases attributed to amyloid plaque formation include type 2 diabetes, cystic fibrosis,
some forms of emphysema and Parkinson’s disease.218
Figure 4.6 (a) The proposed mechanism of amyloid fibril formation, resulting in amyloid
plaques linked to degenerative disease induction; (b) Graph showing rate of amyloid assembly;
(c) Electron microscopy of typical amyloid fibrils.219
Successful treatment of amyloid related diseases requires mechanistic understanding of plaque
formation.9,219 Fig. 4.6 (a) and (b) summarise three key steps involved in plaque formation:
1. Rate-limiting lag phase: monomers undergo folding, unfolding, dimerisation and denat-
uration, eventually nucleating into small globular amyloidogenic oligomers.
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2. Fibril growth phase: amyloidogenic oligomers above a concentration threshold aggregate
into an amyloid seed, which then elongates into rod-like filaments. Filaments bundle
and intertwine forming first protofibrils then filaments.
3. Saturation: filament elongation ceases and β-sheet filaments form the dense central core
of amyloid plaques.
Despite considerable study of the amyloid aggregation process, the trigger for initial amyloid
monomer nucleation remains unclear. One theory suggests that protein misfolding exposes
novel protein regions normally shielded, inducing aggregation through hydrophobic inter-
actions.9 Alternative theories include membrane induced proximity facilitating monomer
aggregation, or excess peptide accumulation resulting from increased production or reduced
clearance.9 Peptide intrinsic lipidation provides a further possible mechanism for induction of
amyloid plaque formation. Synthetic addition of a hydrophobic N -terminal membrane anchor
analogous to intrinsic lipidation acylation, has been observed to double the rate of amyloid
aggregation, shielding the hydrophobic chain from aqueous surroundings.220,221 Furthermore,
intrinsic lipidation induced nucleation is consistent with both the observed lag phase, and
the necessity for a catalytic lipid membrane in vitro in order to accurately mimic aggrega-
tion rates in vivo.219,220 Finally, fluorescent amyloid plaques are formed in the presence of
phospholipids comprised of fluorescently labelled acyl chains, suggesting incorporation during
fibril formation.222
Investigation into the relationship between peptide intrinsic lipidation and amyloid aggregation
was probed using three amyloid peptides, Fig. 4.7. Forty amino acid amyloid-β, is formed
upon cleavage of APP precursor protein by membrane bound protease β-secretase, and the γ-
secretase complex.9,223,224 Implicated in Alzheimer’s disease, the 11-28 residue active region of
amyloid-β includes two lysine, one serine and two histidine moieties, primed to undergo intrinsic
lipidation. Sixty-seven residue hormone amylin is naturally produced by signal sequence
cleavage from proamylin, and subsequence post-translational modification.225 Implicated in
the loss of islet β-cells associated with type 2 diabetes, amylin contains three serine residues
capable of intrinsic lipidation within its active region of residues 20-29. β-2 microglobulin, a
one hundred nineteen residue component of the major histocompatibility complex, is known
to aggregate in joint spaces causing dialysis related amyloidosis.226 Agregation prone regions
of β-2 microglobulin, residues 22–31 and 60–70, contain three lysine residues and one serine
prone to intrinsic lipidation reactivity.227
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Figure 4.7 (a) Amino acid sequence of amyloid-β; (b) Amino acid sequence of amylin; (c)
Amino acid sequence of β-2 microglobulin. Active regions are highlighted in green.
Amyloid stock solutions were prepared at 5 µg mL−1 in hexafluoro-2-propanol (HFIP) to prevent
aggregation during storage.228 Stock solution portions were incubated under physiological
conditions for 72 hours in 1:10 molar ratio with POPC:SLPS (4:1) liposomes. Membrane
model selection mimics plaque forming conditions in vivo, and facilitates origin of transfer
determination through acyl chain diversity. Sample analysis was conducted by MALDI MS on
an Autoflex II ToF/ToF (Bruker Daltonics Ltd., UK), rather than standard LCMS with ESI
ionisation optimised for study of peptide intrinsic lipidation.39,40 MALDI instrumentation
provides a robust analytical alternative to ESI, compatible with study of amyloid aggregates
and increased solvent diversity, which can prove problematic for LCMS.109,229,230 Neither
modified nor unmodified amyloid monomers were observed for amylin, amyloid-β, or β-2
microglobulin following 72 hour incubation with liposomes. Lack of visualisation was considered
likely due to amyloid aggregation, preventing sample solubilisation and detection by MALDI
MS.
Confirmation of amyloid aggregation under experimental conditions was determined by em-
ploying two biophysical techniques, a Thioflavin T fluorescence assay, and electron microscopy
(EM).231 Thioflavin T emission at 485 nm is dependent upon polarity of the dye’s external
environment.232–234 Fluorescence is quenched in aqueous solution, therefore increased fluo-
rescence is observed upon amyloid fibril formation providing a hydrophobic environment for
Thioflavin T intercalation. Fig. 4.8 shows normalised Thioflavin T emission at 485 nm for
amyloids amylin, amyloid-β, and β-2 microglobulin, in solution and in the presence of a lipid
membrane. Consistent with monomer detection by MALDI MS, solution phase amyloids
do not exhibit the increased Thioflavin T fluorescence indicative of plaque formation, over
the time period of study. In contrast, amyloid species in the presence of a lipid membrane
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exhibit increased Thioflavin T fluorescence, reaching emission maxima within approximately
15 minutes of incubation. Emission plateaus, indicative of complete amyloid aggregation and
dye intercalation, then decreases due to solvent evaporation.
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Figure 4.8 Thioflavin T fluorescence at 485 nm under physiological conditions for amylin
(solid red), amyloid-β (dashed green), or β-2 microglobulin (dotted and dashed blue) in
solution (lighter colours) and in the presence of a POPC:SLPS (4:1) liposomal membrane
(darker colours).
Transmission electron microscopy (TEM) provides confirmation of amyloid aggregation in
the presence of a lipid membrane through direct visualisation.235–237 Fig. 4.9 presents one
example of plaque formation following 72 hour incubation of amyloid-β with POPC:SLPS
(4:1). Fibril length is limited in vitro by the initial concentration of amyloid peptide available
for aggregation. Combined TEM, Thioflavin T fluorescence, and MALDI MS data support the
theory of amyloid aggregation occurring under experimental conditions. Observed aggregation
under known peptide intrinsic lipidation conditions serves to support acyl transfer as a possible
mechanism for the induction of amyloid nucleation.
Figure 4.9 TEM of amyloid plaques formed upon 72 hour incubation of amyloid-β with a
POPC:SLPS (4:1) lipid membrane under physiological conditions.
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Modification to environmental parameters is predicted to aid in the study of amyloid intrinsic
lipidation by diminishing amyloid aggregation, and facilitating product visualisation. Lit-
erature reports suggest amyloid aggregation can be prevented by employing reduced NaCl
concentrations, low temperatures, and by sonicating samples prior to incubation.228,238 In-
fluence of temperature reduction upon aggregation cannot be tested using a Thioflavin T
assay, due to instrument limitations. However, Thioflavin T emission was studied for amyloids
in the presence of a lipid membrane using low salt buffer (10 mM NaHCO3 pH 7.4), and
following sonication. Amyloid aggregation, indicated by increased Thioflavin T emission,
was not observed over 6 hours of study for modified reaction conditions. Aggregation is
therefore reduced compared to initial experimental conditions, where emission increase was
observed within 15 minutes. Modified experimental conditions were taken forward for 72 hour
incubation and MALDI MS analysis, hoping to detect amyloid intrinsic lipidation. However,
monomer visualisation was not improved under modified experimental conditions, suggesting
amyloid aggregation is slowed by not completely prevented.
Considering the predicted link between intrinsic lipidation and amyloid nucleation, preventing
aggregation is likely to simultaneously prevent acyl transfer. Aggregate depolymerisation,
and subsequent composition determination, provides an alternative mechanism for the study
of amyloid intrinsic lipidation. Aggregates were isolated by centrifugation following 72 hour
incubation of amyloids with POPC:SLPS (4:1) liposomes under standard intrinsic lipidation
conditions. Amyloid plaques were treated with HFIP, a known depolymerising agent, and
analysed directly by MALDI MS.228 Unmodified monomer and amyloid aggregates were
observed for all three amyloid species, suggesting incomplete depolymerisation. Acylated
amyloids were not observed, however since this be attributed to either inclusion within
remaining aggregates, or to ion suppression, intrinsic lipidation cannot be ruled out.
Literature precedent suggests an alternative method of amyloid depolymerisation is overnight
incubation of aggregates at pH 3 in formic acid.223,224 Isolated amyloid plaques were there-
fore treated with formic acid and analysed by MALDI MS. Incomplete depolymerisation
was observed for all amyloids, characterised by detection of small multi amyloid aggregates.
Insufficient depolymerisation occurred to facilitate visualisation of either unmodified or mod-
ified amyloid monomers. Determination of intrinsic lipidation reactivity therefore proved
inconclusive following formic acid depolymerisation.
Enzymatic digestion provides a third potential mechanism for depolymerisation of amyloid
aggregates.40,223,224,239 Digestion conditions were optimised using monomer β2-microglobulin,
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due to its superior size and complexity compared to amylin and amyloid-β. Initial digestion
was conducted with trypsin, trypsin:lys C, and pepsin enzymes, in order to determine peptide
suitability. Trypsin:lys C was selected for further study, due to increased cleavage at lysine
and arginine residues facilitating superior sequence coverage. Cleavage conditions were further
modulated as shown in Table 4.4, in order to maximise observed sequence coverage based
upon predicted digestion fragments shown in Fig. 4.10. Optimised conditions achieved 96 %
β2-microglobulin sequence coverage, as shown in Fig. 4.11, within a 3 hour digestion time.
Dithiothreitol (DTT) addition improves sequence coverage from 71 % to 96 % by facilitating
amyloid denaturation, whereas iodoacetamide (IAA) addition reduced coverage to 90 %,
suggesting cysteine capping is unnecessary. Optimised digestion conditions were applied to
monomer amyloid-β, resulting in 100 % sequence coverage as shown in Fig. 4.11. Amylin
digestion was not attempted due to lack of relevant lysine or arginine cleavage sites.
Trypsin/LysC:Protein Time NH4HCO3 Buffer DTT IAA % Coverage
1:40 24 hours 25 mM Yes No 20 %
1:40 24 hours 25 mM Yes Yes 20 %
1:40 3 hours 50 mM No No 71 %
1:40 5 hours 50 mM No No 50 %
1:40 3 hours 50 mM Yes No 96 %
1:40 3 hours 50 mM Yes Yes 90 %
1:40 3 hours 100 mM No No 70 %
1:20 3 hours 50 mM Yes No 66 %
Table 4.4 Enzymatic digestion conditions employed for study of β2-microglobulin, and
resulting sequence coverage determined by LCMS.
Optimised digestion conditions were applied to isolated amyloid aggregates, and analysis
conducted by both MALDI MS and ESI LCMS.240 However, amyloid digestion was not
observed in the presence of amyloid plaques, attributed to the insoluble and impenetrable
nature of aggregates. Increased digestion times, up to the point of trypsin autolysis, were
applied in the hope of facilitating digestion, however this too proved unsuccessful. Enzymatic
digestion, along with HFIP and formic acid, was therefore considered unsuitable for aggregate
depolymerisation. Inability to disrupt aggregates prevented further study of amyloid intrinsic
lipidation, therefore a definitive link between amyloid nucleation and innate acyl transfer
remains to be established.
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Figure 4.10 Sequence and predicted trypsin:lys C digestion fragments of: (a) β2-
microglobulin; (b) amyloid-β.
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Figure 4.11 TIC of amyloids digested under optimised conditions: (a) β2-microglobulin;
(b) amyloid-β.
4.4 Conclusions
Insight into the activities and physical properties of intrinsically lipidated peptides is vital to
understanding the biological relevance of innate peptide reactivity. Biophysical techniques
have been employed to probe the properties of acylated model peptide melittin, facilitating this
understanding. CD and intrinsic tryptophan fluorescence confirm that unlike its unmodified
counterpart, acylated melittin exhibits solution phase structure. Predicted to be α-helical
with a possible central kink at secondary amino acid proline, structural formation is driven
by favourably shielding the hydrophobic acyl moiety from external aqueous environment.
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However, it remains unclear as to whether this structure is attributed to monomers or to bulk
peptide structure, such as the tetramer adopted by unmodified melittin at high concentrations.
Bulk structure was probed by employing fluorescent Rhodamine 6G dye to examine possible
micelle formation. Palmitoylated melittin derivatives underwent micellisation, with calculated
CMCs of 1 µm and 5 µm for N -terminal and K23 modifications respectively. Oleoylated
derivatives did not exhibit spontaneous aggregation into micelles, attributed to reduced
packing of unsaturated acyl chains. The antimicrobial activity of acylated melittin derivatives
was investigated, given the potency of unmodified melittin and similar lipidated peptides.
However, only minimal bacterial growth inhibition of E. coli and S. aureus was observed at
32 µm for acylated melittin. Preferential antimicrobial activity was attributed to palmitoylated
and N -terminally modified derivatives.
The biological relevance of innate acyl transfer was further probed by investigating links
between intrinsic lipidation and disease related peptides. Literature studies suggested intrinsic
lipidation could induce the process of amyloid nucleation, ultimately resulting in disease related
plaque formation. Significant support for this prediction is attributed to the doubled rate
of plaque formation observed for amyloid-β modified with a hydrophobic N -terminal anchor.
Three amyloids, amylin, amyloid-β, and β2-microglobulin, subjected to peptide intrinsic
lipidation conditions, underwent aggregation confirmed by Thioflavin T fluorescence and
EM. This observation supports a link between amyloid nucleation and aggregation, however
confirmation requires visualisation of acylated amyloid. In an attempt to aid visualisation of
acylated amyloid, modified experimental conditions were employed, including reduced salt
content, temperature, and sonication. Slowed aggregation was observed under these modified
experimental conditions, but not sufficiently eliminated to study acyl transfer. Aggregate
depolymerisation and subsequent content analysis was considered a preferable method to
facilitate acylated amyloid visualisation. HFIP, formic acid and optimised trypsin:lys C enzy-
matic digestion were studied, but ultimately proved unsuccessful in complete depolymerisation.
Therefore at present a link between intrinsic lipidation and amyloid nucleation can be neither
definitively proved nor disregarded.
5 | Small Molecule Intrinsic Lipida-
tion
5.1 Introduction
Small molecule intrinsic lipidation is a non-enzymatic acyl transfer reaction between membrane
phospholipids and a small organic molecule.76,77 The major reaction product from small
molecule intrinsic lipidation is the small molecule modified with a hydrophobic acyl chain
derived from the membrane. The increased hydrophobicity of the modified small molecule
dramatically changes its structure, properties and action. Such modification is particularly
important if the small molecule substrate is a pharmaceutical, given the likely resulting
changes to activity and side effect induction.
Past research into small molecule intrinsic lipidation has utilised lysolipids, the reaction
by-product, as means of studying the reaction.76,77 Since alternative mechanisms of lysolipid
production exist, notably enzymatically in vivo and by solution phase hydrolysis, their presence
is not diagnostic of small molecule intrinsic lipidation. To definitively prove the existence of
small molecule intrinsic lipidation at the membrane interface, direct observation of modified
acyl small molecules is necessary. LCMS is the optimum technique for direct observation, due
to its informative nature, sensitivity, and robustness towards complex samples. Additional
benefits of pursuing LCMS for the study of small molecule intrinsic lipidation include the
observed success of the technique for the analysis of peptide intrinsic lipidation, and the ability
to tune instrumentation for optimum results.
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5.2 Preliminary MS Experiments
Durham University Chemistry Department operates an analytical mass spectrometry service,
utilising a QToF Premier (Waters Corp., UK) with ESI source to obtain routine accurate
mass data for samples. In the case of complex samples, the instrument can be utilised in
combination with an Acquity UPLC (Waters Corp., UK) running a seven minute linear
gradient of either H2O:MeCN or H2O:MeOH. Initially, it was considered that this validated
accurate mass system of moderate sensitivity may be suitable for the study of small molecule
intrinsic lipidation, focussing on direct observation of acylated small molecules.
In order to test the instrumentation system described, several test samples were required.
Given the complexity of natural biological cell membranes, a model system was deemed
more appropriate for initial experiments in order to simplify the resulting data. Use of a
model eliminates factors which may cause confusion during data interpretation, including
the presence of enzymes, the variety of acyl chain types present within the membrane, and
the potential loss of material through solvent extraction steps. Liposomes, Fig. 5.1, also
known as large unilamellar vesicles (LUV) were selected for study due to their robustness,
simple preparation, the abundance of available research, and their widely accepted similarity
to natural membranes.241 Additionally, since liposomes are single bilayer structures prepared
from solution phase phospholipids, their lipid composition can be tuned as desired. In order
to assimilate biological conditions, liposomes utilised within this research were prepared via
the extrusion method at a diameter of 100 nm and in 10 mm ammonium bicarbonate buffer
at pH 7.4.
Figure 5.1 A liposome formed of a bilayer of phospholipids. Head groups are shown in blue
and acyl chains in green.
Liposomes were prepared at a known concentration containing, for simplicity, only one type of
phospholipid, DOPC. DOPC contains oleoyl (18:1) acyl chains at both the sn-1 and the sn-2
position of the phospholipid backbone. These chains, highlighted purple in Fig. 5.2, are one
of the most common acyl chains known to be present in natural cell membranes. In addition,
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DOPC contains the PC phosphate head group, highlighted blue in Fig. 5.2, the primary
phospholipid head group present in eukaryotic membranes. A eukaryotic model membrane
system is deemed appropriate due to the therapeutic relevance of small molecule intrinsic
lipidation.
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(CH2)7CH3
Figure 5.2 Chemical structure of the membrane phospholipid DOPC. Key structural
features highlighted: (i) oleoyl chains in purple; (ii) glycerol backbone in green; (iii) phosphate
in red; (iv) choline head group in blue.
In order to accurately mimic a natural biological system, the ideal small molecule:lipid molar
ratio utilised within this research would be in the range of 1:10000-100000. Unfortunately,
samples containing lipid in this excess would require significant dilution in preparation for
analysis by mass spectrometry to prevent overloading the chromatography column. This
required dilution would therefore reduce the concentration of the modified small molecule
injected into the instrument to below the limit of detection. Since visualisation of modified
small molecule is key to proving the existence of small molecule intrinsic lipidation, a 1:10
small molecule:lipid molar ratio was utilised. Although the proportion of small molecule
is high, this ratio provides the best balance between upper concentration capacity of the
instrument and the limit of detection.
Fig. 5.3 details the small molecules selected for the initial study of small molecule intrinsic
lipidation. Six cationic amphiphilic small molecules were selected, each containing an amine
nucleophile in order to facilitate nucleophilic attack on the phospholipid acyl chains. The small
molecules were selected due to their predicted reactivity towards intrinsic lipidation, based on
previous research monitoring lysolipid levels in their presence.77 Further, the small molecules
selected cover a range of aromatic moieties and exhibit significant structural variation, in
order to ensure the greatest likelihood of observing reactivity. Simultaneously, three cationic
amphiphilic commercial pharmaceuticals were selected for study: (i) propranolol 1; (ii) procaine
2; (iii) tetracaine 3. The three pharmaceutical containing samples were at this time prepared
by undergraduate student Sanna Appleby.76
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Figure 5.3 Cationic amphiphilic small molecules studied during preliminary screening of
small molecule intrinsic lipidation by LCMS on a QToF Premier (Waters Corp., UK).
In accordance with previous research conducted into small molecule intrinsic lipidation, small
molecule:phospholipid mixtures were incubated under physiological conditions of pH 7.4 and
37 ◦C.77 After 72 hours, samples were centrifuged and vortexed in order to combine and mix
the contents. A portion of the sample was diluted in 1:1 H2O:MeCN to a concentration of
small molecule approximated to be 0.1 mg mL−1. Samples were then analysed on a QToF
Premier (Waters Corp., UK) with Acquity C18 BEH stationary phase, using a five minute
linear gradient from H2O (0.1% formic acid):MeCN (99:1) to H2O (0.1% formic acid):MeCN
(1:99), followed by a four minute organic wash. Analyses were then repeated with a five minute
linear gradient from H2O (0.1% formic acid):MeOH (99:1) to H2O (0.1% formic acid):MeOH
(1:99), followed by a four minute organic wash. Instrument parameters applied to samples
were those used as standard for all accurate mass samples analysed by Durham University
mass spectrometry service, summarised in the Experimental section of this thesis.
Fig. 5.4 shows one example of the data obtained following analysis of phospholipid:small
molecule samples under the standard analytical conditions employed by Durham University
mass spectrometry service. Several problems are evident upon analysis of the data, including
poor chromatographic resolution and insufficient sensitivity. Particularly problematic is the
presence of considerable levels of background interference. Given the low levels of desired
modified small molecule product expected, combined with poor ionisation resulting from
their increased hydrophobicity, background interference may suppress the signal and prevent
visualisation. Overall, it is clear that the instrumentation and conditions utilised for routine
analysis of samples by Durham University mass spectrometry service is insufficient for the
study of small molecule intrinsic lipidation.
Chapter 5. Small Molecule Intrinsic Lipidation 101
0
20
40
60
80
100
M
o
b
ile
P
h
a
s
e
B
(%
)
0 5 10
0
10000
20000
30000
40000
Time (min)
In
te
n
s
it
y
(a
rb
.
u
n
it
s
)
Figure 5.4 Example TIC chromatogram of small molecule incubated for 72 hours with
phospholipid, and analysed by LCMS on a QToF Premier (Waters Corp., UK) under non-
optimised conditions. No distinct peaks attributed to acylated small molecule or lysolipid
species are observed. Analysis was conducted on a BEH C18 column (Waters Corp., UK) with
the ten minute gradient of mobile phase A (H2O containing 0.1 % formic acid) and mobile
phase B (MeOH) shown in grey.
5.3 Preparation of Synthetic Standards
Bespoke analytical conditions are required in order to successfully develop mass spectrometry
for the study of small molecule intrinsic lipidation. Further, given the challenges experienced
utilising a QToF Premier (Waters Corp., UK) for the study of small molecule intrinsic
lipidation, it is clear that an instrument with high sensitivity, mass accuracy and minimal
background interference is required. These criteria, along with other benefits such as increased
resolution and the ability to perform IMMS, can be achieved by utilising a Synapt G2-S
(Waters, UK) for analysis of small molecule intrinsic lipidation. However, simply performing
analysis on an alternative instrument is not sufficient in order to successfully study small
molecule intrinsic lipidation. Chromatographic conditions and mass spectrometry instrument
parameters require careful tuning in order to improve data quality and analysis.
Optimisation of analytical conditions for the study of small molecule intrinsic lipidation
requires experimental standards. Proof of small molecule reactivity at the membrane interface
requires visualisation of acylated small molecule, making this the desired standard. These
specialised acylated small molecules are unavailable for purchase, and as such organic synthetic
techniques were employed for their preparation.242,243 Propranolol 1, procaine 2 and tetracaine
3 were selected from the initial intrinsic lipidation screen to undergo synthetic acylation. All
three molecules, Fig. 5.5, are readily available as starting materials, hold pharmaceutical
relevance, and produce lysolipid in contact with the membrane, suggesting reactivity towards
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intrinsic lipidation. Further, all are amphiphilic, containing a hydrophobic ring structure
highlighted in red, and a hydrophilic nucleophile containing region, highlighted in green.
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Figure 5.5 Three pharmaceutical molecules selected for acylation in order to develop
analytical conditions for the study of small molecule intrinsic lipidation. They are propranolol
1, procaine 2, and tetracaine 3. Hydrophobic regions (red) and hydrophilic regions (green)
are highlighted.
Selection of acyl chain types for the preparation of synthetic acylated small molecule standards
is also required. Intrinsic lipidation products exhibit an acylation profile mirroring the acyl
chain profile of membrane phospholipids. As such, palmitoyl (16:0) and oleoyl (18:1) acyl
chains, observed in high abundance within eukaryotic cell membranes, are appropriate choices
for synthetic acylation of small molecules. Scheme 5.1 outlines the proposed synthetic strategy
for the preparation of six acylated small molecule products. Initially, the desired palmitoyl or
oleoyl acid chloride is prepared from the relevant fatty acid by refluxing with oxalyl chloride and
anhydrous DCM.179,244–246 Anhydrous conditions are required in order to minimise hydrolysis
of oxalyl chloride and the acid chloride product resulting in diminished yield. Small molecules
were then combined with the acid chloride, anhydrous pyridine, and anhydrous DCM to
perform the acylation step.242,243 Four of the six purified products were obtained successfully
via this synthetic methodology: (i) N -palmitoyl procaine 35; (ii) N -oleoyl procaine 36; (iii)
N -palmitoyl tetracaine 37; (iv) N -oleoyl tetracaine 38.
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H
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Scheme 5.1 Synthetic protocol for preparation of acylated small molecules: (i) N -palmitoyl
propranolol 12; (ii) N -oleoyl propranolol 13; (iii) N -palmitoyl procaine 35; (iv) N -oleoyl
procaine 36; (v) N -palmitoyl tetracaine 37; (vi) N -oleoyl tetracaine 38. Palm represents the
palmitoyl group (CH2)14CH3 and oleo represents the oleoyl group (CH2)7CHCH(CH2)7CH3.
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Complex results were obtained following application of the synthetic methodology described
in Scheme 5.1 to propranolol 1. Product purification proved challenging, and the resulting
NMR and MS data did not suggest formation of the desired N -acylated propranolol products.
Improved understanding of the reaction was achieved by repeating the synthetic methodology
with a simplified acyl chain. Acetyl chloride, in which the long carbon chain is replaced
by a methyl group, was applied to the synthetic methodology in the place of palmitoyl or
oleoyl chloride, Scheme 5.2. The improved clarity achieved through the use of acetyl chloride
allowed the reaction product, diacetylated propranolol 39, to be identified. Complexity in the
NMR and MS data observed previously is thus attributed to a combination of partial product
hydrolysis, unreacted propranolol, and the cis/trans nature of the amide bond in diacylated
and N -acylated propranolol species.
O N
O
Acetyl chloride, DCM, 
pyridine, RT, 24 h O
O
O N
HOH
88%
39
Scheme 5.2 Application of original protocol for preparation of N -palmitoyl propranolol 12
and N -oleoyl propranolol 13 using acetyl chloride. Resulting analysis revealed diacetylated
propranolol 39 product formation.
Considering the propensity of propranolol 1 to diacylate in the presence of an acid chloride, a
modified synthetic methodology was developed as shown in Scheme 5.3. Initially, formation
of diacetylated propranolol 39 is promoted by increasing the number of equivalents of acid
chloride from 1.1 to 2.5. Secondly, the O-acyl chain is removed by alkaline ester hydrolysis
using K2CO3 in MeOH.247 Application of this protocol to propranolol 1, utilising acetyl
chloride as the acid chloride, resulted in successful formation of purified product N -acetylated
propranolol 40.
O N
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O Propranolol, DCM, 
pyridine, RT, 24 h O
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39 40
Scheme 5.3 Synthesis protocol for preparation of N -acetylated propranolol 40 via diacety-
lated propranolol 39. Analogous procedure can be applied to preparation of N -palmitoyl
propranolol 12 and N -oleoyl propranolol 13.
Given the successful synthesis of N -acetylated propranolol 40, the synthetic methodology was
applied to the synthesis of N -palmitoyl propranolol 12 and N -oleoyl propranolol 13. The
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process progressed via the relevant dipalmitoyled propranolol 41 and dioleoylated propranolol
42 intermediates, ultimately resulting in formation of the desired N -acylated products. How-
ever, problems were encountered during product purification due to the modified properties
of palmitic and oleic acid, byproducts of the ester hydrolysis step, compared to acetic acid.
Palmitic and oleic acid are amphiphilic in nature, resulting in micelle formation in aqueous
solution. N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 are also amphiphilic and
likely to form micelles. Within the polar mobile phase required for flash column purification
of N -acylated propranolol derivatives, mixed micelles are predicted to form. These mixed
micelles containing fatty acid and N -acylated propranolol prevent separation and purification
of the two species. A solution to this problem is presented in Scheme 5.4.248 Prior to column
chromatography the fatty acid is converted into a methyl ester, reducing hydrophilicity of the
compound and preventing mixed micelle formation. Desired products N -palmitoyl propranolol
12 and N -oleoyl propranolol 13 can then be separated from the relevant methyl ester by flash
column chromatography.
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O HO R1
O O N
OH
R1
O MeO R1
OMeOH, H2SO4, reflux, 1 h
R1 = Palm
R1 = Oleo
R1 = Palm
R1 = Oleo
R1 = Palm
R1 = Oleo
R1 = Palm
R1 = Oleo
1212
1313
Scheme 5.4 Synthetic method employed to methylate excess fatty acids, facilitating pu-
rification of N -palmitoyl propranolol 12 and N -oleoyl propranolol 13. Palm represents the
palmitoyl group (CH2)14CH3 and oleo represents the oleoyl group (CH2)7CHCH(CH2)7CH3.
5.4 Optimisation of ESI Parameters
Armed with synthetic acylated small molecule standards, analytical conditions for the study
of small molecule intrinsic lipidation can be developed. ESI was selected as the ionisation
technique, due to its reputation for effective ionisation with minimal in-source fragmentation.105
Optimising ESI instrument parameters allows for efficient ionisation of the hydrophobic acylated
small molecules, given their diminished ionisation potential following conversion of an amine in
the original small molecule into an amide. The presence of a hydrophobic acyl chain connected
via a relatively weak amide bond within the acylated small molecules, means conditions for
effective ionisation must be carefully balanced with minimal fragmentation of the desired
molecular ion.
Chapter 5. Small Molecule Intrinsic Lipidation 105
Ionisation parameters were optimised by direct infusion of a 0.5 µg mL−1 solution of N -
palmitoyl procaine 35 in 1:1 H2O:MeCN into the mass spectrometer at a flow rate of 5 µL/min.
The mass spectrum was collected over one minute for each set of conditions, and the resulting
data compared in order to determine optimal ionisation parameters. Data quality was
determined based upon ion intensity, signal to noise, and level of in-source fragmentation.
Ionisation parameters determined to play major role in analyte ionisation for ESI on a Synapt
G2-S (Waters Corp., UK) mass spectrometer are:
• Desolvation gas temperature
• Desolvation gas flow rate
• Source temperature
• Capillary voltage
• Sampling cone voltage
• Source offset voltage
Nitrogen is the desolvation gas utilised within the ESI source throughout the study of small
molecule intrinsic lipidation by mass spectrometry. It is selected due to its availability at
the necessary purity, inert nature, and stability at high temperatures. The desolvation gas
promotes the desolvation of solvated ions released in an aerosol from the capillary needle into
gas phase ions. Desolvation gas temperature and flow rate are two vital parameters which can
be used to control the desolvation process and modify analyte ionisation. Increased desolvation
temperature and increased gas flow rate provide more energy to the gas particles, promoting
ion desolvation. However, an increase in desolvation gas energy can also increase collisions
between ions and the inert gas, resulting in energy transfer to the ion which is then distributed
among all the available degrees of freedom causing bond dissociation. As such, modification to
desolvation gas flow rate and temperature were expected to influence ionisation of N -palmitoyl
procaine 35. Surprisingly, alterations to the desolvation gas resulted in minimal change to
the ionisation profile of N -palmitoyl procaine 35. Optimised values of 350 ◦C and 600 L h−1
were selected for desolvation temperature and flow rate respectively, determined by published
research into small molecule ESI.249 Similarly, the source temperature was maintained at 150
◦C in accordance with both literature data and compatibility with other instrument users.40,77
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5.4.1 Capillary Voltage
Capillary voltage is an instrument parameter which describes the voltage applied at the
tip of an ESI capillary needle.81 Voltage application creates a potential difference between
the needle and the rest of the mass spectrometer. As a result, selection of correct capillary
voltage is vital to ensure charge transfer and motion of ESI droplets formed at the needle tip.
Typical positive ESI capillary voltages are in the range of 0.5 to 4.0 kV, however the optimum
value is highly dependent upon analyte properties and sample matrix, including solvent.
Application of a capillary voltage that is too low prevents development of a Taylor cone at
the capillary tip, resulting in formation of large droplets with little horizontal directionality.
As a result, droplet desolvation becomes more challenging and sensitivity is reduced, resulting
in diminished ionisation. Application of a higher capillary voltage is necessary for certain
solvent systems such as those lacking acidic additives or with a high aqueous proportion, due
to its corresponding increases in ionisation and sensitivity. However, application of too high a
capillary voltage for a given analyte also causes ionisation issues. Major problems include
loss of the Taylor cone resulting in rim emission and poor droplet formation, and discharge
reducing ionisation stability.250
To investigate the effect of capillary voltage upon the ionisation of acylated small molecules a
0.5 µg mL−1 solution of N -palmitoyl procaine 35 in 1:1 H2O:MeCN was direct infused into
the mass spectrometer. Data was collected over a one minute period with all parameters kept
consistent apart from the capillary voltage, which underwent incremental increases for each
analysis. Fig. 5.6 presents the ionisation profile of N -palmitoyl procaine 35 at a selection of
these capillary voltages. Below 1.0 kV the ion intensity of N -palmitoyl procaine 35 is greatly
reduced, as indicated by the profile at a capillary voltage of 0.5 kV. The reduction in ionisation
results in a corresponding signal to noise decrease, making the capillary voltage inappropriate
for the study of intrinsic lipidation. High capillary voltages of 2.0 kV and 2.5 kV exhibit
increased ion intensity, however in-source fragmentation to ion m/z 193.0736 of molecular
formula C10H11NO3 is observed in tandem. Between 1.0 kV and 1.5 kV capillary voltage
modification has minimum impact upon ion abundance or fragmentation of N -palmitoyl
procaine 35. Considering these observations, and stability issues associated with a high
capillary voltages, 1.0 kV was deemed most appropriate for the ionisation of acylated small
molecules.250
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Figure 5.6 Ion profiles of N -palmitoyl procaine 35 upon application of differing capillary
voltages: (a) 0.5 kV; (b) 1.0 kV; (c) 1.5 kV; (d) 2.0 kV; (e) 2.5 kV.
5.4.2 Sampling Cone Voltage
The sampling cone is an orifice within the ESI source which lies perpendicular to the plume
of droplets produced at the capillary needle tip. A voltage in the region of 10 - 100 V is
applied to the sampling cone in order to draw ions from the atmospheric pressure region
and into the intermediate vacuum region of the mass spectrometer.81 Voltage application
aids in ion transmission, exclusion of unwanted neutral species and declustering of heavily
hydrated ions. Selection of an appropriate sampling cone voltage is highly dependent upon
analyte type and charge state, with ions of increased mass requiring application of a higher
cone voltage. Two key factors are taken into account when tuning the sampling cone voltage
for a particular analyte. Firstly, the voltage must be sufficiently high in order to pull the
maximum number of ions into the mass spectrometer. Maximising ion transmission results in
an increase in instrument sensitivity and aids detection of low abundance or poorly ionising
species. However, the increased ion acceleration and transmission associated with a high
sampling cone voltage also promotes collisions with molecules of desolvation gas. Inelastic
collisions result in increased ion internal energy, causing breakage of weak internal bonds.
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This in-source fragmentation process has the undesirable side effect of reducing abundance of
the molecular ion, however it can be manipulated for use in MSMS analyses.
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35Figure 5.7 Ion profiles of N -palmitoyl procaine 35 upon application of differing sampling
cone voltages: (a) 30 V; (b) 40 V; (c) 50 V; (d) 60 V; (e) 70 V.
Retaining an intact acylated small molecule molecular ion is vital for detection of small
molecule intrinsic lipidation. Prevention of in-source fragmentation at the weak amide bond
is vital when selecting an appropriate sampling cone voltage. Mass spectra of N -palmitoyl
procaine 35 were collected over one minute whilst increasing the sampling cone voltage in 10 V
increments. Fig. 5.7 presents the ionisation profiles of N -palmitoyl procaine 35 over the region
of interest. Across values 30 V to 70 V, the sampling cone voltage promotes transmission
of the molecular ion m/z 475.3928 with minimal evidence of in-source fragmentation. The
maximum molecular ion intensity is reached at a sampling cone voltage of 50 V, therefore this
is considered the optimum value for further study.
5.4.3 Source Offset Voltage
Following transmission through the sampling cone into the intermediate vacuum region of
the mass spectrometer, ions must continue into the high vacuum region.81 Ions are pulled
down a potential gradient set by the source offset voltage into the StepWave ion transfer,
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facilitating entry to the mass analyser region of the mass spectrometer. High source offset
voltages increase ion transmission into the mass spectrometer, increasing ion abundance and
sensitivity. However, as with a high sampling cone voltage, the increased ion acceleration
promotes collisions with gas phase molecules resulting in ion fragmentation.
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35Figure 5.8 Ion profiles of N -palmitoyl procaine 35 upon application of differing source
offset voltages: (a) 20 V; (b) 30 V; (c) 40 V.
Minimisation of in-source fragmentation at the weak amide bond of N -palmitoyl procaine 35
is a key consideration throughout tuning of the ESI source offset voltage. Ionisation profiles
obtained over one minute from the direct infusion of N -palmitoyl procaine 35 are shown in
Fig. 5.8. The source offset voltage was modified over the range of 20 V to 40 V in increments
of 10 V. In-source fragmentation of N -palmitoyl procaine 35 was not noted to contribute
significantly to observed ion profiles across the voltage range tested. Optimum source offset
voltage is selected as 30 V based upon its ability to produce the maximum observed ion
intensity by facilitating ion transmission.
5.4.4 Summary of Optimised ESI Parameters
Table 5.1 summarises the optimised ESI instrument parameters for the study of N -palmitoyl
procaine 35. However, suitability of the parameters for studying acylated small molecules
in general, and thus small molecule intrinsic lipidation, must be determined. Utilising the
optimised instrument parameters, the five other synthetic acylated small molecule standards
were direct infused into the mass spectrometer. These were N -oleoyl procaine 36, N -palmitoyl
tetracaine 37, N -oleoyl tetracaine 38, N -palmitoyl propranolol 12 and N -oleoyl propranolol
13. Mass spectra for each acylated small molecule standard under optimised condition are
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shown in Fig. 5.9. Molecular [M+H]+ ions are observed with good signal to noise for each
desired analyte, with additional sodium adduct formation and dimerisation noted for N -
palmitoyl propranolol 12 and N -oleoyl propranolol 13 due to preparation methodology. Low
level in-source fragmentation is observed for all species, along with in-source double bond
oxidation for N -oleoyl procaine 36. However, observed issues are minimal and successful
ionisation of all acylated small molecules cements the optimised parameters as those to be
utilised for the study of small molecule intrinsic lipidation.
Parameter Optimised Value
Capillary Voltage (kV) 1.0
Source Temperature (◦C) 150.0
Sampling Cone Voltage (V) 50.0
Source Offset Voltage (V) 30.0
Desolvation Temperature (◦C) 350.0
Cone Gas Flow (L/Hr) 60.0
Desolvation Gas Flow (L/Hr) 600.0
Nebuliser Gas Flow (Bar) 6.0
Table 5.1 Optimised positive mode electrospray parameters for mass spectrometry analysis
of acylated small molecules.
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Figure 5.9 Ionisation profiles of synthetically prepared acylated small molecules under
optimised instrument parameters given in Table 5.1: (a) N -oleoyl procaine 36; (b) N -
palmitoyl tetracaine 37; (c) N -oleoyl tetracaine 38; (d) N -palmitoyl propranolol 12; (e)
N -oleoyl propranolol 13 .
Chapter 5. Small Molecule Intrinsic Lipidation 111
5.5 Optimisation of Chromatography
Ionisation of hydrophobic small molecules with poor ionisation potential in a complex mixture
is challenging. These ions are suppressed in favour of ions corresponding to species with higher
abundance or propensity towards ionisation.106,251 Ion suppression can be avoided by the
separation of components in a mixture such that each analyte within the sample is introduced
individually into the mass spectrometer. The separation process is carried out by reversed
phase LC on an Acquity UPLC (Waters Corp., UK). Reversed phase LC separation can
be challenging for hydrophobic analytes due to high column affinity and poor solubility in
the polar mobile phase. As a result analyses can be time consuming and exhibit issues with
poor peak shape and separation of components. These issues can be avoided by developing
optimised chromatography for the system of interest, in this case small molecule intrinsic
lipidation.
Development of chromatography for the study of small molecule intrinsic lipidation requires
selection of a suitable stationary phase. A BEH C18 column (Waters Corp., UK) provides
an excellent option due to availability, understanding of the column chemistry, and previous
success in the separation of small molecules including hydrophobic analytes.11,39
A binary mixture of H2O (0.1 % formic acid) and MeCN (0.1 % formic acid) was selected
as the mobile phase for analysis, given the compatibility with reversed phase LC, solubility
of analytes in the solvent, and previous success in small molecule analysis. Building upon
previous LC carried out for small molecules, the two solvents ran in a linear gradient at
a flow rate of 0.400 mL/min over a nine minute period.77 Ensuring parity with ionisation
optimisation, procaine 2 was selected as the small molecule utilised to develop chromatography
for small molecule intrinsic lipidation. Inclusion of N -acylated procaine and lysolipid standards
provide a full picture of the predicted contents of a small molecule intrinsic lipidation reaction
mixture. As such, 0.5 µg mL−1 solutions in 1:1 H2O:MeCN were prepared for procaine 2,
N -palmitoyl procaine 35, and the lysolipid OPC.
Fig. 5.10 combines the the individual chromatograms for each of the predicted components
of procaine lipidation under the chromatographic conditions described. Symmetrical and
sharp peaks are observed, suggesting success in this aspect of chromatography. However, poor
chromatographic resolution is observed for the peaks corresponding to N -palmitoyl procaine
35, and lysolipid OPC. Given the low abundance of acylated small molecule expected to
form through small molecule intrinsic lipidation, and the poor ionisation potential of these
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products, such poor resolution was predicted to result in ion suppression issues.
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36Figure 5.10 Combined traces of procaine 2 (red), N -palmitoyl procaine 35 (green), and
lysolipid OPC (blue). Analysis was conducted on a BEH C18 column (Waters Corp., UK)
with the nine minute linear gradient of mobile phase A (H2O containing 0.1 % formic acid)
and mobile phase B (MeCN containing 0.1 % formic acid) shown in grey.
Modification to the linear gradient was attempted in order to improve chromatographic
resolution between N -palmitoyl procaine 35 and lysolipid by-products, thus avoiding ion
suppression. Two modified gradients were developed, each reducing the gradient increase
prior to acylated small molecule and lysolipid elution, thus facilitating improved resolution.
Fig. 5.11 presents chromatographic traces for species of interest under the two modified
gradients highlighted in grey. Improved chromatographic resolution between N -palmitoyl
procaine 35 and OPC is observed for both new gradients, however the second provides
better separation attributed to its extended shallow gradient. Given sharp and symmetrical
peak shape is also maintained, modified gradient two was determined to provide optimum
chromatographic conditions for study of procaine 2 intrinsic lipidation.
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35 Figure 5.11 Chromatographic traces of procaine 2 (red), N -palmitoyl procaine 35 (green),
and lysolipid OPC (blue) run on a BEH C18 column (Waters Corp., UK): (a) modified
gradient one; (b) modified gradient two. Gradients both use mobile phase A (H2O containing
0.1 % formic acid), and mobile phase B (MeCN containing 0.1 % formic acid) shown in grey.
Validation of the chromatographic conditions developed through the study of procaine 2 is
required in order to confirm their suitability for the more general study of small molecule
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intrinsic lipidation. One validation mechanism is the analysis of synthetically prepared acylated
standards N -palmitoyl propranolol 12, N -palmitoyl tetracaine 37, and N -oleoyl procaine 36.
Comparing chromatograms of these acylated small molecules with those of lysolipid OPC,
Fig. 5.12, allows for success of the optimised chromatography conditions to be determined.
Analysis revealed defined peak shapes and separation between reaction mixture components
for all small molecule systems studied, validating the developed chromatography conditions.
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Figure 5.12 Chromatographic traces of lysolipid OPC (blue) synthetically acylated small
molecules (green): (a) N -palmitoyl propranolol 12; (b) N -palmitoyl tetracaine 37; (c) N -oleoyl
procaine 36. Analysis was conducted using modified gradient two on a BEH C18 column
(Waters Corp., UK). Mobile phase A (H2O containing 0.1 % formic acid) and mobile phase B
(MeCN containing 0.1 % formic acid) are shown in grey.
Application of optimised chromatography conditions of real small molecule intrinsic lipidation
reaction mixtures is necessary to fully validate them. Samples containing DOPC liposomes
and small molecule were prepared and incubated under physiological conditions for 72 hours.
Fig. 5.13 presents the small molecules selected for this validation process. Propranolol 1,
procaine 2 and tetracaine 3 are included due to their pharmaceutical relevance and key
role within the optimisation process. Small molecules 4 and 8 from the original screen
of small molecule intrinsic lipidation of the QToF Premier (Waters Corp., UK) are also
included. Otherwise, changes have been made to small molecules included within the set due
to availability of small molecules, reassessment of potential reactivity, and the necessity of
structural and functional diversity to ensure chromatographic validation.
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Figure 5.13 Cationic amphiphilic small molecules studied during preliminary screening
of small molecule intrinsic lipidation, in an attempt to validate optimised chromatographic
conditions.
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Figure 5.14 Chromatographic traces highlighting key issues associated with analysis of
reaction mixtures under optimised chromatographic conditions on a BEH C18 column: (a)
broad phospholipid peak (red) coelutes with acylated small molecule (*) resulting in ion
suppression; (b) retention time fluctuation of second oleoylated propranolol peak (*) between
analyses; (c) phospholipid eluting in blank run between analysis indicating column retention.
Validation of the optimised chromatographic conditions proved unsuccessful when faced with
this more diverse selection of small molecules. Under the optimised conditions ion suppression
of some acylated small molecules is likely, given their observed co-elution with phopholipid,
shown in Fig. 5.14 (a). Furthermore, hydrophobic phospholipid present at high concentrations
within the samples is retained by the BEH C18 column, Fig. 5.14 (c), causing poor peak shape
and crossover contamination between samples. Propranolol 1 reaction mixtures exhibit peaks
corresponding to the m/z of protonated oleoyl propranolol at two separate retention times. The
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later eluting of these peaks coelutes with phospholipid and undergoes significant fluctuations
in retention time, Fig. 5.14 (b), making examination challenging under the chromatographic
conditions.
Development of chromatography for the study of small molecule intrinsic lipidation proved
impossible using a BEH C18 column (Waters Corp., UK). Improved chromatography was
therefore developed by considering alternative stationary phases with proven records in the
separation of hydrophobic or aromatic small molecules. Table 5.2 presents four available
columns which fit this criteria, and describes the differences in their column chemistry.99
Column Name Column Chemistry
Acquity CSH C18
Trifunctional C18 ligand bonded to a Charged Surface Hybrid
(CSH) particle substrate
Acquity BEH Phenyl Trifunctional C6 Phenyl, bonded to Ethylene Bridged Hybrid(BEH) substrate
Acquity BEH Shield RP18 Monofunctional embedded polar C18, bonded to EthyleneBridged Hybrid (BEH) substrate
Acquity BEH C8
Trifunctional C8, bonded to Ethylene Bridged Hybrid (BEH)
substrate
Table 5.2 Stationary phase column chemistries known to excel in the separation of hy-
drophobic or aromatic small molecules.99
Considering the previous challenges associated with developing chromatography for small
molecule intrinsic lipidation utilising acylated standards, a different approach was adopted
on this occasion. In an analogous fashion to previously attempted validation experiments,
reaction mixtures containing liposomes with either propranolol 1 or compound 46 were
prepared. Propranolol 1 was selected due the interesting observation of multiple peaks of
oleoylated propranolol m/z, one of which elutes at a late retention time. Compound 46 was
selected due to the co-elution of acylated product and lysolipid, and its significant structural
and functional differences to propranolol 1. Liposomes were prepared from phospholipid
POPC, increasing the diversity of acyl chains available for transfer, and providing a wider
variety of acylated small molecule and lysolipid products.
After 72 hours samples were analysed on each of the four stationary phases using first a linear
gradient of H2O:MeCN (both containing 0.1 % formic acid) at a flow rate of 0.400 mL/min over
nine minutes, and then a linear gradient of H2O:MeOH (H2O containing 0.1 % formic acid) at
a flow rate of 0.400 mL/min over nine minutes. MeOH was included within the mobile phase in
this optimisation step due to the increased solubility of lysolipids and phospholipids in MeOH
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compared to MeCN, and the lack of success in previous optimisation attempts. However,
MeOH was immediately ruled out as a mobile phase component based on chromatograms
resulting from the linear nine minute gradient, Fig. 5.15. Delays were observed in the elution
of reaction mixture components across all column types when MeOH was employed as a mobile
phase. Delayed elution proved particularly problematic for hydrophobic analytes, including
acylated small molecules, resulting in an undesirable increase in run time, coelution, and
reduced peak quality.
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Figure 5.15 Examples of propranolol 1 reaction mixtures with POPC analysed on five
stationary phase types: (a) Acquity BEH C18; (b) Acquity CSH C18; (c) Acquity BEH Phenyl;
(d) Acquity BEH Shield RP18 ; (e) Acquity BEH C8. Mobile phase conditions shown in grey
employed a 9 minuted linear gradient of H2O(0.1 % formic acid):MeOH. * indicates the peak
corresponding to propranolol 1, the earliest eluting species in the mixture.
Fig. 5.16 and Fig. 5.17 show chromatograms of propranolol 1 and compound 46 reaction
mixtures respectively, using a nine minute linear H2O:MeCN gradient. The Acquity CSH C18
(Waters Corp., UK) stationary phase provides little improvement compared to its Acquity
BEH C18 (Waters Corp., UK) counterpart, exhibiting similar issues in separating mixture
components and retention of phospholipids. Both the Acquity BEH C8 (Waters Corp., UK)
and Acquity BEH Shield RP18 (Waters Corp., UK) stationary phases give improved separation
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of components compared to the Acquity BEH C18 (Waters Corp., UK) column, however
issues remain with lipid retention and peak broadening. By contrast, the Acquity BEH
Phenyl (Waters Corp., UK) stationary phase designed for aromatic small molecules achieves
excellent component separation. Further, the Acquity BEH Phenyl (Waters Corp., UK) column
consistently elutes phospholipid in a distinct peak even at high concentrations, minimising
co-elution and preventing contamination between samples.
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Figure 5.16 TIC (black) of propranolol 1 reaction mixture with POPC, analysed on four
stationary phase types: (a) Acquity CSH C18; (b) Acquity BEH Phenyl; (c) Acquity BEH
Shield RP18 ; (d) Acquity BEH C8. Mobile phase conditions used a 9 minuted linear gradient
of H2O:MeCN (both containing 0.1 % formic acid). Key species highlighted: (i) propranolol 1;
(ii) lysolipids PPC and OPC; (iii) POPC. Insets show EIC (red) for m/z 524.4, corresponding
to protonated oleoyl propranolol 1 intrinsic lipidation products.
The Acquity BEH Phenyl (Waters Corp., UK) with a nine minute linear H2O:MeCN gradient
clearly provided superior chromatographic results compared to other stationary and mobile
phases. No further modifications to the linear gradient were deemed necessary, due to the
elution and separation of all reaction components. As such, these conditions were considered
suitable for the study of small molecule intrinsic lipidation, and were taken forward for this
purpose.
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Figure 5.17 TIC (black) of compound 46 reaction mixture with POPC, analysed on four
stationary phase types: (a) Acquity CSH C18; (b) Acquity BEH Phenyl; (c) Acquity BEH
Shield RP18 ; (d) Acquity BEH C8. Mobile phase conditions used a 9 minuted linear gradient
of H2O:MeCN (both containing 0.1 % formic acid). Key species highlighted: (i) lysolipids
PPC and OPC; (ii) POPC. Insets show EIC (red) for m/z 412.3 corresponding to protonated
oleoyl compound 46 intrinsic lipidation products.
5.6 Proving Small Molecule Intrinsic Lipidation
5.6.1 Pharmaceutical Small Molecules
Development of LCMS parameters for the study of small molecule intrinsic lipidation centred
upon direct observation of acylated small molecules. In comparison to previous analysis
monitoring lysolipid by-product, these conditions allow for small molecule reactivity at the
membrane interface to be proved. Propranolol 1, procaine 2 and tetracaine 3, are the small
molecules selected to provide proof of small molecule intrinsic lipidation. Acylated standards
of all three have been synthesised, providing predictable retention times under the developed
chromatographic conditions and aiding identification. DOPC liposomes were selected for the
study due to their mimicry of eukaryotic membranes. DOPC contains a single acyl chain type
(oleoyl) such that acylated product formation is limited to the oleoylated products, maximising
the abundance and minimising complexity.
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Figure 5.18 TIC corresponding to DOPC liposomes incubated for 72 hours under physio-
logical conditions with: (a) propranolol 1; (b) procaine 2; (c) tetracaine 3. The inserts show
EIC for m/z of relevant protonated oleoylated products.
After 72 hours, mass spectrometry confirmed the presence of phospholipid, lysolipid and the
relevant small molecule in each reaction mixture, Fig. 5.18. Study of the relevant retention
time windows for acylated products did not yield a result for either procaine 2 or tetracaine
3. As shown by the extracted ion chromatograms, Fig. 5.18 inserts, neither N -oleoyl procaine
36 or N -oleoyl tetracaine 38 were present. From this it can be concluded that under the
conditions tested procaine 2 or tetracaine 3 are unreactive towards intrinsic lipidation.
The reaction mixture containing small molecule propranolol 1 contains two chromatographically
distinct peaks attributed to the m/z of oleoylated propranolol. These two peaks, Fig. 5.18 (a)
insert, correspond to products eluting at 6.1 min and 7.4 min. As Table 5.3 shows, accurate
mass attributes both peaks to the molecular formula C34H54NO3 with a ring-plus-double
bonds (RDB) value of 8.5. This information aligns with that expected of protonated oleoylated
propranolol, suggesting one or both peaks may be a result of small molecule intrinsic lipidation
of propranolol.
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Retention Time (min) Observed m/z Molecular Formula RDB Error (ppm)
6.1 524.4095 C34H54NO3 8.5 -0.2
7.4 524.4092 C34H54NO3 8.5 0.4
Table 5.3 Peaks observed in propranolol reaction mixture with DOPC under physiologi-
cal conditions, determined to be of nominal m/z 524, attributed to protonated oleoylated
propranolol.
Although accurate mass confirms that the chromatographic peaks at retention times 6.1 min
and 7.4 min can both be attributed to the molecular formula C34H54NO3, further confirmation
is necessary to prove that the species are derived from the parent small molecule propranolol
1. CID MSMS was performed on each of the two peaks, with the resulting data presented in
Fig. 5.19. The presence of ions at m/z 260.1646 and m/z 260.1645 for the peaks at retention
times 6.1 min and 7.4 min respectively, can be attributed to the molecular formula C16H22NO2
with errors of -1.9 ppm and -2.7 ppm. This formula corresponds to the molecular ion of
propranolol 1. Additional ions at nominal m/z of 183 and 155 correspond to propranolol 1
product ions reported in the literature.128,252,253
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Figure 5.19 CID MSMS carried out at two chromatographic peaks representing nominal
m/z 524, attributed to protonated oleoylated propranolol.
The species associated with peaks at retention times 6.1 min and 7.4 min are both propranolol
derived with the molecular formula C34H54NO3. The peak at retention time 7.4 min matches
the retention time of synthetically prepared N -oleoylated propranolol 13, and is attributed to
this species. The peak at retention time 6.1 min was attributed to an alternative oleoylated
propranolol species, hypothesised to be O-oleoylated propranolol 47. Investigation into the
nature and relationship of these species will be pursued in Chapter 6 of this thesis, including
complete analysis of the associated MSMS data presented in Fig. 5.19. The formation of
oleoylated propranolol species observed in the reaction mixture are only possible as a result of
non-enzymatic reactivity with the membrane. Considering this, the observation provides the
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first definitive proof of the existence of small molecule intrinsic lipidation.
Despite the observed reactivity of propranolol 1 with a DOPC membrane, there is a lack of
reactivity for procaine 2 and tetracaine 3. One mechanism predicted to increase reactivity
involves increasing the proportion of small molecule bound to the phospholipid membrane by
promoting electrostatic attraction. Given the cationic amphiphilic nature of all three small
molecules, increased binding can be achieved by modification of the liposome composition
to include negatively charged phospholipids. A DOPC:DOPS (4:1) phospholipid mixture
is utilised to prepare one set of liposomes, mimicking the composition of a viral membrane.
DOPS contains a negatively charged PS phosphate head group, highlighted blue in Fig. 5.20,
and two oleoyl fatty acid chains. The second set of liposomes provide a model of a bacterial
cell membrane, contain a mixture of DOPE:DOPG (3:1).254 DOPE and DOPG contain the
PE and PG phosphate head groups, which are zwitterionic and negatively charged in nature
respectively.
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Figure 5.20 Chemical structure of the membrane phospholipids DOPS, DOPE and DOPG.
Key structural features highlighted: (i) oleoyl chains in purple; (ii) glycerol backbone in green;
(iii) phosphate in red; (iv) head group in blue.
Propranolol 1 undergoes intrinsic lipidation resulting in formation of two distinct oleoylated
products in both DOPC:DOPS (4:1) and DOPE:DOPG (3:1) membranes. The two products
are determined by retention time and MSMS analysis to be equivalent to those observed
within a DOPC only membrane. This reactivity confirms that intrinsic lipidation is possible
in models of eukaryotic, prokaryotic and viral membranes irrespective of composition. By
contrast, procaine 2 and tetracaine 3 were not observed to undergo intrinsic lipidation in
any of the three membrane types. This occurs despite the increased electrostatic attraction
between the cationic amphiphilic small molecules and negatively charged phospholipids.
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Limited available research into small molecule intrinsic lipidation provokes challenges in
understanding the unreactive nature of procaine 2 and tetracaine 3. However, it is possible
to speculate on the reasons behind this lack of reactivity by considering key small molecule
properties, Table 5.4.255,256 Determined in liposomal membrane (DMPC)-water systems at
pH 7.4, logD values take into account membrane partitioning for both ionised and unionised
forms of small molecule species. Procaine 2 and tetracaine 3 exhibit logD values of 1.00
and 2.35 respectively, indicating a decreased preference for membrane binding compared to
reactive propranolol 1.255 Furthermore, under physiological conditions membrane association
is promoted to a greater extent for the ionised unreactive forms of procaine 2 and tetracaine
3, compared to propranolol 1.255 Consideration of pK a values for procaine 2, tetracaine 3,
and propranolol 1, Table 5.4, further supports the observation that the predominant species
at physiological pH are unreactive ionised forms. Reduced binding affinity combined with
similarly unfavourable speciation, provides insight into the unreactive nature of procaine 2
and tetracaine 3 compared to reactive propranolol 1.
Small Molecule pK a logD (pH 7.4) Polar Surface Area (Å2)
Propranolol 1 9.53 2.63 41.49
Procaine 2 8.49 1.00 55.56
Tetracaine 3 9.04 2.35 41.57
Table 5.4 Physical properties attributed to propranolol 1, procaine 2, and tetracaine 3.257
logD values were determined using a liposomal membrane (DMPC)-water system at pH 7.4
and 21 ◦C.255 These and all future reported pK a values correspond to the calculated pK a of
the conjugate acid of the most basic site.
In addition to pK a and logD values, membrane binding orientation is predicted to influence a
small molecule’s ability to undergo intrinsic lipidation. Fortunately, interactions of procaine
2 and tetracaine 3 with the cell membrane have been studied extensively, due to the role
of membrane penetration depth and orientation in their anaesthetic activity. Boulanger et
al. determined that both procaine 2 and tetracaine 3 have multiple composition dependent
binding sites and orientations within the cell membrane, each of which has a distinct binding
strength.258 However, combined NMR, linear dichroism (LD) and molecular dynamics simula-
tions (MDS) studies reveal one favoured binding orientation per compound, Fig. 5.21.256,259,260
Tetracaine 3 penetrates the membrane deeply upon binding, burying its reactive amine nucle-
ophile within the hydrophobic bilayer region. The lack of tetracaine 3 reactivity may therefore
be accounted for by insufficiently close proximity between the reactive amine and a phospho-
lipid ester linkage. Procaine 2 penetrates the membrane less deeply upon binding, lying in
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the hydrophilic head group region of the bilayer. However, the reactive amine of procaine
2 does not penetrate the ester containing bilayer region, preventing proximity between the
two. Membrane fluidity is altered upon small molecule binding, modulating local hydration
levels predicted to have an effect upon intrinsic lipidation through the catalytic activity of
H2O.11,261
Figure 5.21 MDS modelling predictions for the predominant membrane binding orientation
of procaine 2 and tetracaine 3.256
Several small molecule and membrane characteristics are speculated to influence small molecule
intrinsic lipidation of procaine 2 and tetracaine 3. It is possible to predict the influence of some
factors, such as membrane composition, pK a, logD and small molecule binding orientation.
However, the extent of the contribution of each factor towards the small molecule intrinsic
lipidation reactivity is unknown. In summary, small molecule intrinsic lipidation is a highly
complex process dependent upon several variables, and significant work remains in order to
develop a clear understanding of the reaction.
5.6.2 Other Small Molecules
Propranolol 1 reactivity provides proof of small molecule intrinsic lipidation. However it
remains to be discovered whether this is a unique property of one small molecule or a more
generic process. Investigation into this was pursued using the cationic amphiphilic small
molecules shown in Fig. 5.22, studied previously without success during chromatographic
optimisation. Under optimised analytical conditions each small molecule was screened for the
presence of intrinsic lipidation reaction product in combination with DOPC, DOPC:DOPS
(4:1) and DOPE:DOPG (3:1) bilayers.
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Figure 5.22 Cationic amphiphilic small molecules used to investigate whether small molecule
intrinsic lipidation is a generic process.
Table 5.5 summarises observations of acylated product formation for each small molecule
tested in the three membrane types. Small molecules 4, 8 and 7 either do not undergo small
molecule intrinsic lipidation or have product levels below the instrument limit of detection.
Four of the seven small molecules, 5, 45, 46 and 6 exhibited formation of acylated product,
confirmed by accurate mass. Where intrinsic lipidation products were observed, formation
was consistent across all membrane systems tested in all but the case of compound 5. This
observation may suggest the role of membrane composition is minimised in controlling small
molecule intrinsic lipidation, however without quantification of products this cannot be said
with certainty. These results prove a stark contrast to past research monitoring intrinsic
lipidation via lysolipid by-product formation, supporting the belief that monitoring of lysolipid
is not a reliable mechanism for studying small molecule intrinsic lipidation.
Small
Molecule
Oleoylated
Product
Molecular
Formula
Oleoylated
Product
Theoretical
m/z
DOPC
Observed
Error
(ppm)
PC:PS
Observed
Error
(ppm)
PE:PG
Observed
Error
(ppm)
4 C26H41ON2 397.3219 - - -
5 C26H41ON2 397.3219 -2.3 - -4.0
45 C25H40ON3 398.3173 -1.8 -3.8 -2.8
46 C26H42ON3 412.3328 -2.7 -4.9 -3.2
6 C26H42ON3 412.3328 -1.7 -2.9 -0.7
8 C27H41O2N2 425.3168 - - -
7 C28H45O2N2 441.3481 - - -
Table 5.5 Protonated oleoylated products formed by small molecule intrinsic lipidation
observed by LCMS within different membrane types: (i) DOPC; (ii) PC:PS is DOPC:DOPS
(4:1); (iii) PE:PG is DOPE:DOPG (3:1).
Observation of oleoylated product formation for small molecules 5, 45, 46 and 6 confirms
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that small molecule intrinsic lipidation is general process. As such, other cationic amphiphilic
small molecules of greater structural and functional diversity were tested to look for evidence
of intrinsic lipidation. The small molecules in Fig. 5.23 were combined with eukaryotic, viral
and prokaryotic membrane models and analysed by mass spectrometry. Table 5.6 summarises
the results of this screening process. Oleoylated product formation was observed for five small
molecules, compounds 49, 50, 52, 58, and 59. Membrane composition was not observed
to modify the propensity of a small molecule towards intrinsic lipidation for compounds
49, 58, and 59, given the comparable results between liposome types. However, membrane
selectivity was observed for compound 50, exhibiting reactivity in a DOPC membrane only,
and compound 52, exhibiting reactivity in both DOPC and DOPC:DOPS (4:1) membrane
systems. These observations suggest preferential eukaryotic reactivity irrespective of increased
electrostatic attraction associated with prokaryotic model systems. Further study is required
in order to determine whether this observed selective reactivity is small molecule specific, a
result of low product abundance, or a general feature of small molecule intrinsic lipidation.
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Figure 5.23 Cationic amphiphilic small molecules used to investigate whether small molecule
intrinsic lipidation is a generic process.
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Small
Molecule
Oleoylated
Product
Molecular
Formula
Oleoylated
Product
Theoretical
m/z
DOPC
Observed
Error
(ppm)
PC:PS
Observed
Error
(ppm)
PE:PG
Observed
Error
(ppm)
48 C24H40O2N 374.3059 - - -
49 C25H41ON3 399.3250 -5.8 -4.3 -5.3
50 C27H43ON2 411.3375 -8.3 - -
31 C27H44ON2 412.3454 - - -
51 C25H40O2N3 414.3121 - - -
32 C24H40O2N4 416.3151 - - -
52 C27H41O2N2 425.3168 -3.8 -2.6 -
53 C27H42O2N2 426.3246 - - -
54 C27H44ON3 426.3484 - - -
55 C27H43O2N2 427.3325 - - -
33 C27H44O2N2 428.3403 - - -
56 C29H47ON2 439.3688 - - -
57 C29H47ON2 439.3688 - - -
34 C28H44O2N2 440.3403 - - -
58 C28H46ON3 440.3641 -4.3 -4.3 -4.5
59 C28H47O2N2 443.3638 -5.2 -3.6 -2.3
60 C25H40O3N2SF3 505.2712 - - -
61 C25H40O3N2SF3 505.2712 - - -
Table 5.6 Protonated oleoylated products formed by small molecule intrinsic lipidation
observed by LCMS within different membrane types: (i) DOPC; (ii) PC:PS is DOPC:DOPS
(4:1); (iii) PE:PG is DOPE:DOPG (3:1).
Probing the physical parameters associated with all cationic amphiphilic small molecule
studied facilitates examination of factors controlling intrinsic lipidation reactivity. Table 5.7
provides available pK a, logP and logD values for the small molecules screened for intrinsic
lipidation, with reactive species highlighted in green. pK a values corresponding to reactive
species are not indicative of a trend, spanning a range of 3.72 up to 11.91. Despite the low pK a
of compound 8 increasing the proportion of reactive neutral amine at physiological pH, there
is no indication of reactivity. By contrast, compound 58 is active towards intrinsic lipidation
despite its pK a of 11.91 minimising the proportion of available reactive species. Similarly, no
trend between intrinsic lipidation reactivity and either logP or logD value is observed. Even
compounds with similar logP and logD values, such as 51 and 52 differ in their propensity
towards membrane reactivity. Unfortunately, properties and membrane binding activity of
small molecules within this study are poorly characterised compared to their pharmaceutical
counterparts. As a result, information regarding membrane binding orientation and membrane
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penetration depth is unavailable. Considering the variation in physical parameters observed
between reactive species, these factors may play a vital role in modulating intrinsic lipidation
of small molecules.
Small Molecule pK a logP logD (pH 7.4)
4 5.31 1.55 1.53
5 4.94 0.85 0.85
45 6.93 1.15 0.72
46 8.16 0.83 -0.61
6 8.99 -1.19 -1.01
8 2.58 -0.40 -0.40
7 9.52 0.54 -2.04
48 4.74 0.50 0.49
49 3.72 1.46 1.46
50 10.48 1.61 -1.27
31 0.61 1.54 1.54
51 5.61 0.20 0.17
32 7.25 -0.20 -0.58
52 3.79 0.14 0.14
53 3.12 0.50 0.50
54 7.26 2.94 1.37
55 3.96 1.22 1.22
33 4.16 1.17 1.17
56 10.63 1.81 -1.18
57 10.86 2.28 -0.75
34 9.00 1.08 -0.52
58 11.91 1.68 -0.97
59 9.85 0.89 -1.63
60 4.85 2.01 0.31
61 2.98 1.99 0.69
Table 5.7 Physicochemical properties of small molecules screened for intrinsic lipidation
calculated using ChemAxon.262 Reactive small molecules are highlighted in green.
5.7 Conclusions
Small molecule intrinsic lipidation is characterised by an acyl transfer reaction from a membrane
phospholipid to a small organic molecule. Previous research has attempted to study the reaction
through monitoring of lysolipid, a reaction by-product.77 Given that lysolipid formation is not
diagnostic of reactivity, a novel approach seeks to monitor the acylated small molecule product
directly by mass spectrometry. Unfortunately, visualisation of acylated small molecules is
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analytically challenging due to their hydrophobicity and poor ionisation potential. As a result,
bespoke analytical conditions are required beyond those utilised routinely within Durham
University mass spectrometry service.
Successful development of mass spectrometry for the study of small molecule intrinsic lipidation
requires instrument parameters to be tuned using acylated small molecule standards. Organic
synthetic methodologies facilitated the preparation of N -palmitoyl procaine 35, N -oleoyl
procaine 36, N -palmitoyl tetracaine 37, and N -oleoyl tetracaine 38 standards. N -palmitoyl
propranolol 12 and N -oleoyl propranolol 13 were also prepared synthetically despite technical
challenges resulting from micelle formation during purification.
Preparation of synthetic acylated small molecules facilitated the optimisation of ESI parameters
for their study. Capillary voltage, sample cone voltage and source offset voltage proved key
parameters in balancing maximum ionisation with minimum in-source fragmentation. In
addition, synthetic standards aided the development of chromatographic conditions for the
study of small molecule intrinsic lipidation. Initial conditions utilised a H2O:MeCN gradient
on a BEH C18 (Waters Corp., UK) stationary phase. However, these conditions exhibited
issues with co-elution and contamination when faced with real reaction mixtures containing
increasingly diverse small molecules. Modification of the stationary phase to a BEH Phenyl
column (Waters Corp., UK) resolved these issues, ultimately resulting in successful optimisation
of chromatographic conditions.
Definitive proof of small molecule intrinsic lipidation in vitro occurred through the observation
of acylated propranolol using the bespoke analytical conditions developed. Two intrinsic
lipidation products of propranolol 1 were confirmed by accurate mass andMSMS in the presence
of eukaryotic, viral and prokaryotic model membranes. Screening of a more structurally and
functionally diverse family of small molecules revealed nine further small molecules able to
undergo intrinsic lipidation. This observation serves as proof that intrinsic lipidation in vitro
is a general process and not unique to propranolol 1. However, it is noted that not all cationic
amphiphilic small molecules undergo intrinsic lipidation upon binding the membrane. Factors
such as logP, pK a, membrane composition, and binding orientation, are predicted to play a
role in this. Without further research it is impossible to determine the extent to which each
factor has an effect, and whether there are additional factors in play.
6 | Propranolol Intrinsic Lipidation
in vitro
6.1 Introduction
James W. Black discovered propranolol 1 in 1964, a drug in the β blocker family found to affect
the heart and circulatory system.263,264 Prescribed either orally or intravenously, propranolol
1 treats a range of conditions including high blood pressure, angina and migraines. The
subject of the 1988 Nobel Prize in Medicine, propranolol 1 is considered to be both safe and
effective, featuring on the World Health Organisation’s List of Essential Medicines.265 Despite
its popularity within the pharmaceutical industry, study of propranolol 1 has revealed poorly
understood promiscuous behaviour.158,258,266–268 This behaviour, linked to propranolol’s 1
lipid solubility, raises questions about the drug’s safety, mechanism of activity, and side effects.
O N
HOH
1
Figure 6.1 The structure of β blocker propranolol 1.
Cationic amphiphilic in nature, propranolol 1 has a logD value at physiological pH 7.4 of 2.63,
promoting membrane binding.269 Interactions between propranolol 1 and the cell membrane
are observed to impact the membrane structure and composition.28,157,268,270 Increases in
membrane fluidity, disorder and curvature occur upon propranolol 1 binding, impacting not
only the local area but the bulk membrane. Bulk membrane modifications influence the
activity of membrane bound components. Thus propranolol 1 binding is observed to alter
enzymatic activity and block sodium ion channels.261 Anaesthetic behaviour of propranolol
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1 has also been linked to interactions with the cell membrane, given similar mechanisms of
action observed for anaesthetics such as procaine 2 and tetracaine 3.256,261 Phospholipidosis, a
major but poorly understood side effect of propranolol 1 and other drugs, is linked to the cell
membrane. A lysosomal storage disorder, phospholipidosis is characterised by phospholipid
accumulation in tissues.73,74,271
Small molecule intrinsic lipidation is one membrane-drug interaction which may play a role
in the promiscuous behaviour of propranolol 1. Preliminary studies presented in Chapter
5 of this thesis observe formation of acylated propranolol derivatives in the presence of a
membrane mimic. This non-enzymatic acyl transfer is attributed to an innate reactivity
between propranolol 1 and phospholipids. Further investigation is required in order to
determine the significance of this reactivity. This includes characterisation of product nature
and quantity, influence upon the physiochemical properties of propranolol 1, and impact of
environmental factors.
6.2 Products of Propranolol Intrinsic Lipidation
Mass spectrometry reveals the presence of two propranolol 1 derived products upon incubation
of propranolol 1 with a DOPC phospholipid membrane under physiological conditions. Accu-
rate mass information obtained using a Synapt G2-S (Water Corp., UK) mass spectrometer,
attributes the molecular formula C34H54NO3 to both propranolol 1 derived species. Based on
the molecular formula, these species are hypothesised to be oleoylated propranolol formed via
acyl transfer from the membrane. CID MSMS supports this theory, revealing product ions
attributed to both intact propranolol 1 and known propranolol 1 MSMS fragments. However,
the two propranolol 1 derived products are clearly chemically and structurally distinct, given
their chromatographic differences. As shown in Fig. 6.2, the retention times attributed to the
two products are 6.1 min and 7.4 min respectively.
Considering both the analytical data obtained and the solution phase reactivity of propranolol
1, the nature of the two propranolol 1 derived species can be hypothesised. Propranolol 1
contains two nucleophilic functionalities able to perform intrinsic lipidation, an alcohol and
a secondary amine. Accordingly, the two products are predicted to be the ester O-oleoyl
propranolol 47 and the amide N -oleoyl propranolol 13, shown in Fig. 6.3. Confirmation that
these are the observed propranolol 1 derived species can be achieved by comparison to their
synthetically prepared analogues.
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Figure 6.2 EIC for m/z 524.4102 attributed to the molecular formula C34H54NO3, within
a reaction mixture of propranolol 1 with DOPC phospholipid membrane under physiological
conditions.
O N
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O
(CH2)7CH347 13
Figure 6.3 The two predicted products of propranolol 1 intrinsic lipidation: (i) O-oleoyl
propranolol 47; (ii) N -oleoyl propranolol 13.
6.2.1 O-Acylated Propranolol
Confirmation of O-oleoyl propranolol 47 as a propranolol 1 derived intrinsic lipidation product
requires comparison to a synthetic standard of the molecule. Accordingly, synthetic methodol-
ogy for the preparation of O-oleoyl propranolol 47 is presented in Scheme 6.1.179,244,245,272
O-palmitoyl propranolol 62 can also be synthesised via this methodology. Preparation of both
species allows the influence of acyl chain type upon analytical parameters such as retention
time and MSMS fragmentation to be determined. Palmitoyl and oleoyl are the preferred acyl
chains due to their synthetic availability, and commonality to eukaryotic cell membranes.
The initial step in the preparation of an O-acylated propranolol species is synthesis of N -Boc
propranolol 63. Boc protection of propranolol 1 under standard conditions acts to shield the
amine moiety and prevent future reactivity. N -Boc propranolol 63 is then exposed to the
relevant acid chloride, palmitoyl chloride 18 or oleoyl chloride 20. Stirring under argon in
anhydrous DCM and pyridine results in formation of the intermediates N -Boc-O-palmitoyl
propranolol 64 and N -Boc-O-oleoyl propranolol 65.
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O
Boc2O, NEt3, DCM, 
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Acid chloride, pyridine, 
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HCl, DCM, 
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47
Scheme 6.1 Synthetic protocol for preparation of O-acylated propranolol derivatives O-
palmitoyl propranolol 62 and O-oleoyl propranolol 47. Palm represents the palmitoyl group
(CH2)14CH3 and oleo represents the oleoyl group (CH2)7CHCH(CH2)7CH3.
The final synthetic step is cleavage of the Boc protecting group from the N -Boc-O-palmitoyl
propranolol 64 and N -Boc-O-oleoyl propranolol 65 intermediates. Boc removal must proceed
whilst preventing loss of the desired product through secondary reactions. Product loss can
occur as a result of either propranolol 1 formation via ester hydrolysis, or via O to N acyl
chain migration, producing N -acylated propranolol. Traditional conditions for Boc cleavage
utilise trifluoroacetic acid (TFA) in DCM, followed by by-product removal in vacuo.272 Acidic
conditions combined with limited time in solution prevent unwanted hydrolysis or migratory
side reactions. As a result, the TFA salts of O-palmitoyl propranolol 62 and O-oleoyl
propranolol 47 were successfully synthesised. However, the presence of large non-natural TFA
counter ion modifies properties of the O-acylated propranolol TFA salts compared to the
O-acylated propranolol products of intrinsic lipidation. These modifications cause analytical
problems, particularly chromatographically, resulting in isolation of products as their TFA
salts being deemed undesirable.
Boc cleavage can also be performed using HCl, resulting in the formation of a chloride salt
product with increased biological relevance. N -Boc-O-palmitoyl propranolol 64 and N -Boc-
O-oleoyl propranolol 65 were stirred with HCl in ethyl acetate (EtOAc), and the organic
layer washed with 10 % HCl solution to remove aqueous soluble impurities. Despite the
acidic conditions maintained throughout, the increased time in solution resulted in migratory
side reactions. As a result, the final products were identified as N -palmitoyl propranolol 12
and N -oleoyl propranolol 13 rather then the desired O-acylated counterparts. HCl in DCM
provides an alternative HCl based Boc cleavage methodology, whilst allowing impurities to be
removed in vacuo rather than through an aqueous work up. This synthetic route promotes
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product solubility, reduces time in solution, and maintains acidic conditions for the prevention
of intramolecular O to N migration or hydrolysis reactions. As a result, purified HCl salts of
the desired products O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 were isolated.
The identities of O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 were determined
through characterisation by accurate mass MS, IR, 1H and 13C NMR. The species were
then analysed by MS under the conditions developed for the study of small molecule intrinsic
lipidation. 3 µL of a 1 µg mL−1 solution of either O-palmitoyl propranolol 62 or O-oleoyl
propranolol 47 in 1:1 H2O:MeCN was injected into the LC of the mass spectrometer at time
point zero. Retention times of 6.0 min and 6.1 min were observed for O-palmitoyl propranolol
62 and O-oleoyl propranolol 47 respectively. As indicated in Fig. 6.4, this provides sufficient
chromatographic separation to distinguish between the two chemically similar species. O-
palmitoyl propranolol 62 produces a molecular ion at m/z 498.3961 corresponding to the
correct molecular formula C32H52NO3 with an error of 2.8 ppm. O-oleoyl propranolol 47
produces a molecular ion at m/z 524.4111 corresponding to the molecular formula C34H54NO3
with an error of 1.3 ppm. Neither species produces ions attributed to in-source fragmentation,
adduct formation or dimerisation under the ionisation conditions tested.
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Figure 6.4 EIC for O-acylated propranolol species O-palmitoyl propranolol 62 (green) and
O-oleoyl propranolol 47 (red) analysed by LCMS under optimised conditions.
CID MSMS of O-acylated propranolol derivatives provides increased structural information
and a characteristic fingerprint for comparison with propranolol intrinsic lipidation products.
Table 6.1 presents the product ions resulting from CID MSMS of the molecular [M+H]+
ions of O-palmitoyl propranolol 62 and O-oleoyl propranolol 47. Notably, product ions are
consistent for both O-acylated propranolol species, irrespective of acyl chain. The low energy
required for dissociation of the weak ester bond makes loss of the acyl chain favourable,
preventing its retention within product ions. This favourable loss of the acyl chain also
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prevents the formation of product ions associated with fragmentation at the oleoyl double
bond, a phenomenon observed in similar species.
Theoretical
m/z
Molecular
Formula
Accuracy
O-palmitoyl
propranolol 62
(ppm)
Accuracy
O-oleoyl
propranolol 47
(ppm)
RDB
74.0606 C3H8NO -5.4 1.4 0.5
98.0970 C6H12N 1.0 0.0 1.5
116.1075 C6H14NO -1.7 0.0 0.5
155.0861 C12H11 -2.6 -1.9 7.5
157.0653 C11H9O -1.9 -2.5 7.5
183.0810 C13H11O -1.6 -2.2 8.5
218.1181 C13H16NO2 -3.7 -6.4 6.5
260.1651 C16H22NO2 -2.3 -1.9 6.5
Table 6.1 MSMS fragments observed from CID MSMS of protonated O-palmitoyl propra-
nolol 62 m/z 498.3961 and protonated O-oleoyl propranolol 47 m/z 524.4111.
O N
H OOH
O NH2 O
OH
N
HOH
N
H
NH2
OH
m/z 260.1651 m/z 218.1181 m/z 183.0810 m/z 157.0653
m/z 155.0861 m/z 116.1075 m/z 98.0970 m/z 74.0606
H
H H
H
H
1
Figure 6.5 Predicted CID MSMS ion assignments for O-acylated propranolol derivatives
47 and 62.
Considering the labile nature of the acyl chain, it is unsurprising that all product ions resulting
from CID MSMS of O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 are derived from
parent drug propranolol 1.128,252,253 In fact, the product ion at m/z 260.1651 corresponds
to the molecular formula C16H22NO2, which is attributed to propranolol 1. Further product
ions are a result of the dissociation of weak bonds within propranolol 1 producing favourable
neutral losses, for example H2O or an isopropyl (iPr) moiety. Predicted cleavages resulting in
formation of these ions are presented in Fig. 6.5. One product ion is of particular interest,
m/z 155.0861 corresponding to the molecular formula C12H11. Formation of this ion is only
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possible through bond dissociation combined with a gas phase rearrangement. The driving
force for this rearrangement is presumed to be the increased stability of the resulting ion,
attributed to its aromaticity.132
It could be argued that the product ions resulting from CID MSMS of O-palmitoyl propranolol
62 and O-oleoyl propranolol 47, are not greatly informative. However, they do prove that
the species are propranolol 1 derived. In addition, the product ions provide a characteristic
fingerprint of fragmentation from a known precursor ion, allowing for comparison with
propranolol intrinsic lipidation products. Whilst it is acknowledged that further structural
information may be gleaned from complimentary fragmentation techniques such as EID, this
is considered unnecessary since the information obtained is sufficient for the requirements.
6.2.2 N -Acylated Propranolol
N -oleoyl propranolol 13 is hypothesised to be the second product of propranolol 1 intrinsic
lipidation within a DOPC membrane. Confirmation of this hypothesis requires comparison of
reaction mixture species with synthetically prepared N -acylated standards. Preparation of
both N -oleoyl propranolol 13 and N -palmitoyl propranolol 12 has been described in Chapter
5 of this thesis, for the development of analytical conditions for the study of small molecule
intrinsic lipidation. The identity of the species, shown in Fig. 6.6, have been confirmed by
accurate mass MS, IR, and 1H and 13C NMR characterisation.247 These analyses also confirm
product purity, revealing no residual propranolol 1 or O-acylated propranolol impurities.
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12 13
Figure 6.6 Structure of N -palmitoyl propranolol 12 and N -oleoyl propranolol 13.
Samples containing 1 µg mL−1 solution of either N -palmitoyl propranolol 12 or N -oleoyl
propranolol 13 in 1:1 H2O:MeCN were prepared. A small volume (3 µL) of each sample was
injected into the LC of the mass spectrometer and analysed under the conditions developed for
study of small molecule intrinsic lipidation. Analysis of N -palmitoyl propranolol 12 produced
the chromatogram depicted in Fig. 6.7, containing a single major product peak at retention
time 7.3 min. The ion m/z 498.3949 corresponds to that peak, and is attributed to the
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molecular formula C32H52NO3. The accuracy of this formula is 0.8 ppm, well within the 4.0
ppm accuracy limit of the Synapt G2-S (Waters Corp., UK). This molecular formula supports
attribution of the m/z 498.3949 ion to the [M+H]+ molecular ion of N -palmitoyl propranolol
12. Ions corresponding to other adducts, dismerisation or in-source fragmentation were not
observed.
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Figure 6.7 EIC of m/z 498.4 corresponding to protonated N -palmitoyl propranolol 12.
Observed m/z Molecular Formula Accuracy (ppm) RDB
74.0609 C3H8NO +2.7 0.5
98.0970 C6H12N -2.0 1.5
116.1073 C6H14NO -2.6 0.5
155.0860 C12H11 -0.6 7.5
157.0653 C11H9O -0.6 7.5
183.0808 C13H4O -1.1 8.5
218.1178 C13H16NO2 -2.3 6.5
260.1648 C16H22NO2 -1.2 6.5
312.2896 C19H38NO2 -2.2 1.5
354.3364 C22H44NO2 -2.5 1.5
480.3835 C32H50NO2 -0.6 8.5
Table 6.2 MSMS fragments observed following CID of protonated N -palmitoyl propranolol
12.
CID MSMS of N -palmitoyl propranolol 12 was carried out in order to obtain a reproducible
fingerprint of the species for comparison with propranolol intrinsic lipidation products. Product
ions resulting from this fragmentation are presented in Table 6.2. Similarly to CID MSMS of
O-acylated propranolol derivatives, the majority of product ions observed can be attributed to
propranolol 1.128,252,253 The characteristic parent drug product ion is present at m/z 260.1648
with molecular formula C16H22NO2. Further characteristic propranolol 1 fragments observed
include ions of m/z 183.0808 corresponding to loss of both amine and alcohol moieties, and the
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rearrangement product at m/z 155.0860. This result is unsurprising considering the relatively
weak nature of the internal N -palmitoyl propranolol 12 amide bond. Dissociation is favourable
under CID MSMS condition, and thus a high proportion of product ions exhibit acyl chain
loss.
Three unique CID MSMS product ions of N -palmitoyl propranolol 12, in which the acyl
chain is maintained have been identified. Molecular formulae attributed to these ions are
given in Table 6.2, and their predicted structures, based upon favourable bond dissociation,
are presented in Fig. 6.8. Product ion m/z 480.3835 corresponds to the molecular formula
C32H50NO2, most likely a result of the loss of H2O from N -palmitoyl propranolol 12. The
other two product ions m/z 354.3364 and 312.2894 correspond to the molecular formulae
C22H44NO2 and C19H38NO2 respectively. Fragmentation is predicted to occur at the weak
ether bond linking the naphthol oxygen to the backbone of propranolol 1, resulting in a neutral
loss of the stable aromatic species. The two product ions differ in the presence of the amine
bound iPr group, primed for dissociation via a weak carbon-heteroatom bond destabilised
by the proximal amide. These two species are analogous to propranolol 1 product ions m/z
116.1073 and 74.0609, but with the acyl chain retained. The presence of these three ions
provides a distinction between the MSMS fingerprints of N -palmitoyl propranolol 12 and
O-palmitoyl propranolol 62, aiding intrinsic lipidation product determination.
O N
(CH2)14CH3O
N
(CH2)14CH3OOH
NH
(CH2)14CH3OOH
m/z 480.3835
H
m/z 354.3364 m/z 312.2896
H H
12
Figure 6.8 Predicted CID MSMS ion assignments for N -palmitoyl propranolol 12.
The analytical experiments carried out on N -palmitoyl propranolol 12, were applied to syn-
thetically prepared N -oleoyl propranolol 13 for comparison. Fig. 6.9 depicts the chromatogram
resulting from this analysis, with the major product peak at retention time 7.4 min. The ion
attributed to this peak is of m/z 524.4102, attributed to the molecular formula C34H54NO3
with an error of 0.6 ppm. The molecular formula corresponds to the [M+H]+ peak of N -oleoyl
propranolol 13, with no observation of in-source fragmentation or adduct formation.
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Figure 6.9 EIC of m/z 524.4 corresponding to protonated N -oleoyl propranolol 13.
Observed m/z Molecular Formula Accuracy (ppm) RDB
74.0603 C3H8NO -10.8 0.5
98.0959 C6H12N -11.2 1.5
116.1074 C6H14NO -0.9 0.5
155.0859 C12H11 -0.6 7.5
157.0654 C11H9O +0.6 7.5
183.0808 C13H4O -1.1 8.5
218.1173 C13H16NO2 -4.1 6.5
260.1645 C16H22NO2 -2.7 6.5
338.3053 C21H40NO2 -1.8 2.5
380.3523 C24H46NO2 -1.3 2.5
506.3989 C34H52NO2 -1.0 9.5
Table 6.3 MSMS fragments observed following CID of protonated N -oleoyl propranolol 13.
CID MSMS of N -oleoyl propranolol 13 was also performed, resulting in formation of the
product ions detailed in Table 6.3. The majority of fragmentation can be attributed to known
propranolol 1 product ions, corresponding to amide bond dissociation.128,252,253 Two of these
product ions, m/z 98.0970 and 74.0609, exhibit low mass accuracy to their assigned molecular
formulae, with values of -11.2 ppm and -10.8 ppm respectively. Increased error (ppm) is
attributed to the low observed m/z of these species, with error conversion into atomic mass
units (amu) producing acceptable error values of 0.0010 and 0.0003 for m/z 98.0970 and
74.0609 respectively. Unique product ions of N -oleoyl propranolol 13 are observed at m/z
506.3989, 380.3523, and 338.3053. Predicted structures for these species, featured in Fig. 6.10,
mirror those observed in the CID MSMS profile of N -palmitoyl propranolol 12, in which the
acyl chain is retained. Molecular formula C34H52NO2 corresponds to loss of H2O, C24H46NO2
to loss of the 1-naphthol ring, and C21H40NO2 to loss of both the 1-naphthol ring and an
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iPr moiety. No additional product ions attributed to cleavage at the oleoyl double bond
were observed, despite this being a known phenomenon.273 This is likely due to preferential
dissociation of one of multiple carbon-heteroatom bonds with lower dissociation energy.
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12
Figure 6.10 Predicted CID MSMS ion assignments for N -oleoyl propranolol 13.
6.2.3 Diacylated Propranolol
Considering that both the alcohol and amine moieties of propranolol 1 participate in intrinsic
lipidation individually, resulting in the formation of N -acylated propranolol and O-acylated
propranolol species. Logic dictates that it may also be possible for both nucleophilic moieties
within a single molecule to react, resulting in formation of a diacylated propranolol species.
Observations from solution phase chemistry support this hypothesis, since propranolol 1
preferentially forms diacylated propranolol in the presence of an acid chloride, rather than
a singly acylated species.247,274 In order to determine whether diacylated propranolol is
formed by intrinsic lipidation, synthetic standards are required for comparison. Standards
are particularly important given that observation of diacylated propranolol derivatives by
mass spectrometry is challenging, due to their hydrophobicity, insolubility in standard LCMS
solvent systems, and poor ionisation. Dipalmitoyl propranolol 41 and dioleoyl propranolol 42,
depicted in Fig. 6.11, were available for this purpose, having been isolated as intermediates in
the preparation of their corresponding N -acylated propranolol analogues.
O N
O CO(CH2)14CH3
CO(CH2)14CH3
O N
O CO(CH2)7CHCH(CH2)7CH3
CO(CH2)7CHCH(CH2)7CH3
41 42
Figure 6.11 Structures of dipalmitoyl propranolol 41 and dioleoyl propranolol 42.
Solutions at concentration 1 µg mL−1 of either dipalmitoyl propranolol 41 or dioleoyl propra-
nolol 42 in 1:1 H2O:MeCN were prepared for the study of diacylated propranolol analogues.
A 3 µL portion of these samples was injected into the mass spectrometer for analysis under
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the conditions developed to study small molecule intrinsic lipidation. Success of the chromato-
graphic conditions were considered initially, since the hydrophobicity of diacylated propranolol
species increases their column retention. Under the optimised nine minute chromatographic
gradient, dipalmitoyl propranolol 41 and dioleoyl propranolol 42 eluted at retention times
of 8.7 min and 8.8 min respectively, Fig. 6.12 (a). These retention times place elution within
the aqueous post gradient wash phase of the chromatogram, with mobile phase conditions of
95:5 H2O (0.1 % formic acid):MeCN (0.1 % formic acid). Late elution is concerning, since
observation may be prevented by minor fluctuations in mobile or stationary phase, or by
complex biological matrices which delay elution. An extended ten minute gradient added
0.5 minutes to both the aqueous wash (95:5 H2O (0.1 % formic acid):MeCN (0.1 % formic
acid)) and the preceding organic wash (5:95 H2O (0.1 % formic acid):MeCN (0.1 % formic
acid)). Under the extended gradient, retention times of 8.6 min and 8.7 min were observed for
dipalmitoyl propranolol 41 and dioleoyl propranolol 42 respectively, Fig. 6.12 (b). Within
the organic wash, these retention times are sufficiently early to ensure elution irrespective of
chromatographic fluctuations. As a result, the more robust ten minute gradient was utilised
for all future study of small molecule intrinsic lipidation.
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Figure 6.12 EIC of dipalmitoyl propranolol 41 m/z 736.6 (green) and dioleoyl propranolol
42 m/z 788.7 (red) using gradients: (a) optimised conditions determined in Chapter 5; (b)
extended ten minute gradient. Analysis was conducted using a BEH Phenyl column (Waters
Corp., UK). Mobile phase A (H2O containing 0.1 % formic acid) and mobile phase B (MeCN
containing 0.1 % formic acid) are shown in grey.
Ionisation of hydrophobic diacylated propranolol species also causes concern, given the loss
of primary ionisation sites from propranolol 1 following acyl transfer. Fig. 6.13 depicts the
observed ion profile attributed to the major chromatographic peak at retention time 8.6 min
during analysis of dipalmitoyl propranolol 41. Several ionic species related to dipalmitoyl
propranolol 41 are observed, and these are summarised in Table 6.4. The ions of m/z
736.6249 and 758.6068 are determined to be the [M+H]+ and [M+Na]+ ions of dipalmitoylated
propranolol 41. Sodium adduct formation despite low sodium availability occurs due to
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interactions between sodium ions and the naphthol aromatic ring.275 In dipalmitoyl propranolol
41, this interaction becomes more favourable due to a lack of available protonation sites.
Proton and sodium bound dimers are also observed in low abundance. These species, of m/z
1472.2426 and 1494.2242, form due to the poor ionisation potential of dipalmitoyl propranolol
41 making adduct sharing more favourable.276,277 A final ion observed in the ion profile of
dipalmitoyl propranolol 41 is attributed to in-source fragmentation. At m/z 480.3844, this
ion is also observed during CID MSMS of N -palmitoyl propranolol 12, and is attributed to
loss of the palmitoyl ester group.
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Figure 6.13 Positive mode ESI ion profile of dipalmitoyl propranolol 41. Ions of interest
are labelled.
Observed m/z Molecular Formula Accuracy (ppm) RDB Assignment
480.3844 C32H50NO2 0.4 8.5 -
736.6249 C48H82NO4 0.7 8.5 [M+H]+
758.6068 C48H81NO4Na 0.7 8.5 [M+Na]+
1472.2426 C96H193N2O8 1.2 16.5 [2M+H]+
1494.2242 C96H192N2O8Na 0.9 16.5 [2M+Na]+
Table 6.4 Observed ions and relevant assignments from ESI MS of dipalmitoyl propranolol
41.
Ionisation of a single chemical species which results in the formation of multiple ionic species,
as is the case for dipalmitoyl propranolol 41, spreads the total ion abundance. The reduced
abundance of each individual ion may cause visualisation issues at low concentrations. Several
options exist in order to overcome this issue, including minimising in-source fragmentation
by modifying ionisation parameters, altered acid selection favouring protonation, and doping
sodium into samples to promote sodium adduct formation in favour of protonation. Unfortu-
nately, none of these options are viable for the study of small molecule intrinsic lipidation
due to the complex multi species reaction mixture. Instead, data mining for all known ions
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attributed to dipalmitoyl propranolol 41 at retention time 8.6 min in intrinsic lipidation
reaction mixtures will be required in order to identify product formation.
Solvent System [M+H]+ (%) [M+H]+:[M+Na]+
MeCN 75 1:0.88
MeCN:H2O (9:1) 61 1:1.02
MeCN:H2O (1:1) 50 1:1.11
MeCN:DCM (10:0.01) 83 1:0.77
MeCN:H2O:DCM (9:1:0.01) 100 1:0.76
MeCN:H2O:DCM (1:1:0.01) 66 1:0.92
MeCN:DCM (10:0.1) 79 1:0.90
MeCN:H2O:DCM (9:1:0.1) 90 1:0.81
MeCN:H2O:DCM (1:1:0.1) 87 1:0.76
Table 6.5 Comparison of dipalmitoyl propranolol 41 derived ions observed following sample
preparation in different solvent systems. [M+H]+ (%) is normalised relative to the highest
observed [M+H]+ peak.
Solubility of hydrophobic dipalmitoyl propranolol 41 in the polar mobile phase associated with
reversed phase LC must also be considered. Precipitation resulting from low solubility has the
potential to both damage instrumentation and limit analytical results. Samples of dipalmitoyl
propranolol 41 at a concentration of 1 µg mL−1 were prepared in nine different solvent systems.
Ratios of H2O:MeCN were varied between the systems, given the increased analyte solubility
in organic solvents. DCM was added to some solvent systems in order to determine whether its
positive effects on analyte solubility outweighed any negative effects on ESI due to volatility
or immiscibility. Samples were direct infused into the mass spectrometer at a flow rate of
0.4 µL/min, and scan data collected over 1 minute. Solvent system success was determined
based upon maximising intensity of the [M+H]+ ion and minimising [M+H]+:[M+Na]+. The
ratios of [M+H]+ to other ionic species associated with dipalmitoyl propranolol 41 were
not considered as they remained unchanged between solvent systems. The solvent screen
results, presented in Table 6.5, show increased [M+H]+ ionisation in solvent systems with an
increased proportion of organic solvent MeCN. Inclusion of DCM in the solvent system does
not provide a predictable trend in [M+H]+ intensity. The three preferred solvent systems
are MeCN:H2O:DCM (9:1:0.01), MeCN:H2O:DCM (9:1:0.1) and MeCN:H2O:DCM (1:1:0.1).
Since injection of a largely organic solvent into the initial aqueous chromatographic conditions
is undesirable, MeCN:H2O:DCM (1:1:0.1) is considered the preferred solvent system for future
use.
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Figure 6.14 CID MSMS of dipalmitoyl propranolol 41 using precursor ions [M+H]+ m/z
736.6249 or [M+Na]+ m/z 758.6068.
Dipalmitoyl propranolol 41 was subjected to CID MSMS for characterisation and comparison
purposes. Both the [M+H]+ ion of m/z 736.6249 and the [M+Na]+ of m/z 758.6068 were
selected as precursor ions. Variation in adduct type and location can modify bond dissociation
by CID MSMS, resulting in differing fragmentation patterns. However, as shown in Fig. 6.14,
both the [M+H]+ and [M+Na]+ precursor ions fragment into a single major product ion. The
sole product ion, m/z 480.3839, is attributed to the same ionic species formed by in-source
fragmentation of dipalmitoyl propranolol 41. The production of this ion by CID MSMS is
testament to its stability, which can be attributed to resonance charge stabilisation. Hoping
to glean further structural and functional information, CID MSMS was carried out using the
precursor ion m/z 480.3844. The product ions, summarised in Table 6.6, correspond to known
propranolol 1 fragments. Conspicuously absent is a peak at m/z 260, corresponding to the
molecular ion of propranolol 1. However, considering the nature of the precursor ion this is
unsurprising, since the ester group including the alcohol moiety of propranolol 1 has already
been lost.
Theoretical m/z Molecular Formula Accuracy (ppm) RDB
155.0863 C12H11 1.3 7.5
157.0651 C11H9O -1.3 7.5
183.0810 C13H11O 0.0 8.5
Table 6.6 Observed ions following CID MSMS of dipalmitoyl propranolol 41 derived pre-
cursor ion m/z 480.3844.
Analysis of dioleoyl propranolol 42 under optimised small molecule intrinsic lipidation condi-
tions produces a chromatographic peak at retention time 8.7 min. Mirroring observations for
dipalmitoyl propranolol 41, several ionic species are present under that chromatographic peak.
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The ions, depicted in Fig. 6.15, correspond to the ionic species [M+H]+, [M+Na]+, [2M+H]+
and [2M+Na]+. In-source fragmentation resulting in loss of the dioleoyl propranolol 42 ester
group produces the ion of m/z 506.3991. Three additional ionic species of high intensity
are observed, corresponding to m/z 396.2531, 678.5083 and 700.4902. Molecular formulae
for these ionic species have been determined, however beyond that their identities have not
been established. Fragmentation and rearrangement involving at least one oleoyl double bond
is predicted as the cause, given the lack of equivalent species observed in the ion profile of
dipalmitoyl propranolol 41.
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Figure 6.15 Positive mode ESI ion profile of dioleoyl propranolol 42. Ions of interest are
labelled.
Observed m/z Molecular Formula Accuracy (ppm) RDB Assignment
396.2530 C25H34NO3 -2.0 9.5 -
506.3991 C34H52NO2 -1.4 9.5 -
678.5083 C41H66N4O4 0.2 11.0 -
700.4901 C41H65N4O4Na 0.4 11.0 -
788.6539 C52H86NO4 2.3 11.0 [M+H]+
810.6351 C52H85NO4Na 3.5 11.0 [M+Na]+
1576.2990 C104H171N2O8 0.3 20.5 [2M+H]+
1598.2795 C104H170N2O8Na 3.7 20.5 [2M+Na]+
Table 6.7 Observed ions and relevant assignments from ESI MS of dioleoyl propranolol 42.
Solvation of dioleoyl propranolol 42 in different solvent systems, and the influence upon
[M+H]+ ion intensity and [M+H]+:[M+Na]+ ratio was considered. The results, summarised in
Table 6.8, project similar conclusions to those made in the study of dipalmitoyl propranolol 41
solubility. Ion ratios beyond [M+H]+:[M+Na]+ were largely unaffected by solvent system, an
increased proportion of MeCN resulted in increased [M+H]+ intensity, and the effects of DCM
were varied. In summary, the results support the observation that MeCN:H2O:DCM (1:1:0.1)
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is the optimum solvent system to be used for diacylated propranolol sample preparation.
Solvent System [M+H]+ (%) [M+H]+:[M+Na]+
MeCN 51 1:0.93
MeCN:H2O (9:1) 61 1:0.85
MeCN:H2O (1:1) 26 1:1.37
MeCN:DCM (10:0.01) 87 1:0.70
MeCN:H2O:DCM (9:1:0.01) 100 1:0.59
MeCN:H2O:DCM (1:1:0.01) 62 1:0.87
MeCN:DCM (10:0.1) 87 1:0.69
MeCN:H2O:DCM (9:1:0.1) 75 1:0.75
MeCN:H2O:DCM (1:1:0.1) 77 1:0.74
Table 6.8 Comparison of dioleoyl propranolol 42 derived ions observed following sample
preparation in different solvent systems. [M+H]+ (%) is normalised relative to the highest
observed [M+H]+ peak.
Precursor ions [M+H]+ m/z 788.6539 and [M+Na]+ m/z 810.6351 were selected for CID
MSMS of dioleoyl propranolol 42. As shown in Fig. 6.16, both precursor ion species fragmented
into a single product ion of m/z 506.3994. This resonance stabilised ion, also a product of
N -oleoyl propranolol 13 CID MSMS, is attributed to loss of the ester moiety. Given the
limited information available from CID MSMS of either molecular ion, CID MSMS using a
m/z 506.3994 precursor ion was attempted. Multiple product ions were observed, summarised
in Table 6.9. However, no unique product ions were observed, all could be attributed to known
propranolol 1 fragments. The absence of a propranolol 1 molecular ion due to loss of the ester
group prior to precursor ion isolation, was once again noted.
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Figure 6.16 CID MSMS of dioleoyl propranolol 42 precursor ions [M+H]+ m/z 788.6539
and [M+Na]+ m/z 810.6351.
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Theoretical m/z Molecular Formula Accuracy (ppm) RDB
155.0863 C12H11 2.1 7.5
157.0651 C11H9O 0.3 7.5
183.0810 C13H11O 0.1 8.5
Table 6.9 Observed ions following CID MSMS of dioleoyl propranolol 42 derived precursor
ion m/z 506.3994.
Analysis of dioleoyl propranolol 42 under optimised intrinsic lipidation analytical conditions
produced some unidentified ions through in-source fragmentation. Molecular formulae for these
species were determined in Table 6.7, however CID MSMS may aid in further structural and
functional characterisation. Accurate mass information suggests that two of these ionic species,
m/z 678.5085 and 700.4901 are the protonated and sodiated adducts of the same chemical
species. Sodiated adduct m/z 700.4901 was selected as the precursor ion for CID MSMS due
to its increased ion intensity compared to protonated adduct m/z 678.5085. Product ions are
presented in Table 6.10 along with their corresponding molecular formulae, and the predicted
structures are given in Fig. 6.17. Product ion m/z 183.0800 has been observed throughout
previous CID MSMS of propranolol 1 and its derivatives, attributed to loss of both the ester
and amide moieties. Similarly, product ion m/z 242.1551 can be attributed to dissociation of
the amide bond combined with loss of the ester moiety. Neither species attributed to these
product ions provides information regarding the structure of precursor ion m/z 700.4901. The
product ion of m/z 506.3989 was characterised during CID MSMS of N -oleoyl propranolol
13, and is attributed to loss of the ester moiety. Observation of this product ion indicates
that the aromatic ring and amide moiety of dioleoyl propranolol 42 are retained throughout
in-source fragmentation into ions m/z 678.5085 and 700.4901. Observation of this product ion
thus suggested that the in-source fragmentation is located within the ester bound oleoyl chain.
Considering the molecular formula C41H65N4O4Na of precursor ion m/z 700.4901 and its
protonated analogue m/z 678.5085, the relevant in-source dissociation is located at the ester
bound oleoyl double bond. This theory is supported by additional in-source fragmentation and
CID MSMS product ion m/z 396.2530, Fig. 6.17, wherein the same dissociation is observed at
the double bond of the amide bound oleoyl chain, following loss of the ester moiety.
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Theoretical m/z Molecular Formula Accuracy (ppm) RDB
183.0810 C13H4O 5.4 8.5
242.1545 C16H20NO 2.5 7.5
396.2539 C25H34NO3 2.2 9.5
506.3998 C34H52NO2 1.8 9.5
Table 6.10 Observed ions following CID MSMS of dioleoyl propranolol 42 in-source fragment
m/z 700.4901.
m/z 506.3998
H
O
m/z 183.0810
O N
CO(CH2)7CHCH(CH2)7CH3
m/z 242.1551
H
O N
H
m/z 396.2530
H
O N
CO(CH2)6CCHOH
41
Figure 6.17 Predicted structures of ions observed following CID MSMS of dioleoyl propra-
nolol 42 in-source fragment m/z 700.4907.
6.2.4 Reaction Mixture Products
Synthetic standards of potential propranolol 1 intrinsic lipidation products have been synthe-
sised and characterised under the analytical conditions developed in Chapter 5 of this thesis to
study the reaction. By comparing the oleoylated synthetic standards with a reaction mixture
containing propranolol 1 and DOPC liposomes, the chemical nature of propranolol 1 intrinsic
lipidation products can be determined. Fig. 6.18 compares chromatograms of the reaction
mixture, synthetic O-oleoyl propranolol 47, and synthetic N -oleoyl propranolol 13. Retention
times suggest that the two reaction mixture species correspond to O-oleoyl propranolol 47
eluting at retention time 6.1 min, and N -oleoyl propranolol 13 eluting at 7.4 min. Comparison
of CID MSMS product ions for each species, Fig. 6.19, confirms this observation. O-oleoyl
propranolol 47 and N -oleoyl propranolol 13 have been succesfully determined as the products
of propranolol 1 intrinsic lipidation.
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13Figure 6.18 EIC corresponding to oleoylated propranolol species observed: (a) in propra-
nolol 1 reaction mixture with DOPC (blue); (b) during analysis of O-oleoyl propranolol 47
(green) and N -oleoyl propranolol 13 (red).
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Figure 6.19 CID MSMS corresponding to oleoylated propranolol species observed: (a) in
propranolol 1 reaction mixture with DOPC at retention time 6.1 min (blue); (b) in propranolol
1 reaction mixture with DOPC at retention time 7.4 min (blue); (c) during analysis of O-oleoyl
propranolol 47 (green); (d) during analysis of N -oleoyl propranolol 13 (red).
Dioleoyl propranolol 42 is an additional potential intrinsic lipidation product of propranolol
1 in the presence of a DOPC membrane. Retention time and ionic species associated with
dioleoyl propranolol 42 have been determined using a synthetic standard. However, no
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evidence of dioleoyl propranolol 42 formation via intrinsic lipidation has been observed. One
possible explanation is that dioleoyl propranolol 42 forms in low abundance, below the limit of
detection for the analytical instrumentation, preventing visualisation. Alternatively, dioleoyl
propranolol 42 production may proceed at a slow rate, such that the species is not formed
within the 72 hour time period studied. However, it is also possible that dioleoyl propranolol
42 may simply not be an intrinsic lipidation product. A secondary acylation step may prove
impossible in the modified membrane binding orientation adopted following primary acylation.
Modified orientation could result in reduced proximity between nucleophilic moieties and the
phospholipid ester linkages, preventing reactivity.
6.3 Quantifying Propranolol Intrinsic Lipidation
Products of propranolol 1 intrinsic lipidation have been successfully characterised through
comparison with synthetically prepared standards. The two major product types, O-acylated
propranolol and N -acylated propranolol, are chemically and structurally distinct. This
distinction is mirrored in their properties, and in their response to analytical conditions.
Understanding the relationship between these two products over a variety of conditions is
vital in order to understand the mechanistic details of propranolol 1 intrinsic lipidation.
Quantification of intrinsic lipidation product formation provides an accurate and informative
method of increasing this understanding.42,43 Further, product quantification paves the
way towards understanding the influence of environmental factors upon intrinsic lipidation.
By determining the proportion of each acylated propranolol product present under various
conditions, the influence of factors such as temperature, pH, and membrane composition can
be determined.
6.3.1 Preparation of Calibration Curves
Quantification is a challenging area within the field of mass spectrometry.42,43 Variation
between molecules greatly influences both their elution time and ionisation potential and
as a result, the analytical response. Quantification of species irrespective of ionisation
differences requires preparation of a calibration curve for each molecule studied. Calculation
of chromatographic peak area at a variety of concentrations can be used to prepare a dose-
response curve, allowing for future concentration determination. The synthetically prepared
standards of propranolol 1 intrinsic lipidation products allows for this calibration approach
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to be adopted. For each synthetic standard, a 1000 ng mL−1 solution in H2O:MeCN (1:1)
was prepared with accuracy and precision. The solutions were then subjected to seven 1:1
serial dilutions with H2O:MeCN (1:1). The concentration range covered by these dilutions,
1 µg mL−1 to 7.8 ng mL−1, is sufficient for all possible reaction mixture components. Each
concentration point was prepared and analysed in triplicate by mass spectrometry to ensure
accurate analytical responses were obtained.
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Figure 6.20 Chromatographic peak area response observed for varying concentrations of
propranolol 1. These and all future reported errors are calculated through analysis of triplicate
samples, as detailed in the Experimental of this thesis. Trend fitting at 125 ng mL−1 and
below shown by the solid green line. Trend fitting at 250 ng mL−1 and above shown by the
dashed red line.
The concentration dependent analytical response of propranolol 1 over the concentration range
of 1 µg mL−1 to 7.8 ng mL−1 is presented in Fig. 6.20. Determination of the concentration
for a given chromatographic peak area requires this calibration curve data to be fitted to
an equation. However, trend fitting proves challenging in the case of propranolol 1. At
concentrations of 125 ng mL−1 and below, the data can be fitted with a positive linear trend
line described by Equation 6.1:
y = 1034.7x (6.1)
Indicated by the solid green linear trend line in Fig. 6.20, Equation 6.1 fits the experimental
data at 125 ng mL−1 and below with a reasonable R2 value of 94.8 %. However, at concentra-
tions of 250 ng mL−1 and above, this linear trend is poorly maintained, and fluctuations in
chromatographic peak area are observed, leading to increased error. The observed change in
analytical response at high concentrations is attributed to instrument saturation and difficulties
with modelling tailing chromatographic peaks. As a result, trend fitting the calibration data
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of propranolol 1 at high concentrations requires application of a polynomial curve described
by Equation 6.2:
y = −0.8x2 + 1589.9x (6.2)
Exhibiting a slightly reduced R2 value of 93.2 %, trend fitting of Equation 6.2 is represented
by the dashed red line in Fig. 6.20. Intrinsic lipidation reaction mixture concentrations of
propranolol 1 fall within this curved, high error portion of the calibration data, in order to
ensure visualisation of low abundance acylated intrinsic lipidation products. As a result,
interpretation of propranolol 1 concentration using this curve must take into account the
associated error. It may not be possible to distinguish between small reductions in propranolol
1 concentration attributed to intrinsic lipidation, however application to the detection of
incorrect sample preparation and dilution remains informative.
Fig. 6.21 presents average chromatographic peak areas for N -palmitoyl propranolol 12 and
N -oleoyl propranolol 13 over the concentration range 1 µg mL−1 to 7.8 ng mL−1. The trends
in peak area for both species can be modelled over the entire concentration range with a
positive linear gradient passing through the origin. Instrument saturation resulting in a drop
in response at higher concentrations is not observed, due to the poor ionisation efficiency
of N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 compared to propranolol 1. An
associated reduction in error is also observed, with consistent peak areas observed across the
three samples prepared at each concentration. Trend fitting for N -palmitoyl propranolol 12
was achieved as shown by the solid green line in Fig. 6.21, by Equation 6.3 with an excellent
R2 value of 99.6 %:
y = 167.3x (6.3)
Similarly N -oleoyl propranolol 13 trend fitting was achieved, shown by the red dashed line in
Fig. 6.21. The resulting trend, exhibiting an R2 value of 99.9 %, is described by Equation 6.4:
y = 242.9x (6.4)
Shallow gradients are observed for trends associated with both N -palmitoyl propranolol 12 and
N -oleoyl propranolol 13, attributed to loss of a primary propranolol 1 ionisation site following
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conversion from an amine to an amide. Poor ionisation efficiently is further highlighted by
challenges in quantification at concentrations of 7.8 ng mL−1 and below, signifying the limit
of quantification for N -acylated propranolol derivatives. N -oleoyl propranolol 13 exhibits a
steeper gradient than N -palmitoyl propranolol 12, suggesting increased ionisation and charge
stabilisation are facilitated by the oleoyl double bond.132
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Figure 6.21 Chromatographic peak area response observed for varying concentrations of
N -palmitoyl propranolol 12 (circles) and N -oleoyl propranolol 13 (triangles). Trend fitting
for N -palmitoyl propranolol 12 shown by the solid green line, and N -oleoyl propranolol 13 by
the dashed red line.
Analytical response over the concentration range 1 µg mL−1 to 7.8 ng mL−1 was also determined
for O-palmitoyl propranolol 62 and O-oleoyl propranolol 47. The propensity of O-acylated
propranolol derivatives to hydrolyse or migrate in solution increases the challenge in generat-
ing calibration data for these species.278 Swift preparation and immediate analysis of each
individual sample was required to ensure neither O to N migration nor hydrolysis affected
the resulting data, shown in Fig. 6.22. Data fitting revealed linear trends and reduced error
for both O-palmitoyl propranolol 62 and O-oleoyl propranolol 47, indicating improved peak
shape compared to propranolol 1, and no instrument saturation. The linear trend of R2 value
99.9 % associated with O-palmitoyl propranolol 62, shown by the solid green line in Fig. 6.22,
is described by Equation 6.5:
y = 498.5x (6.5)
Trend fitting associated with O-oleoyl propranolol 47, shown by the red dashed line in Fig. 6.22,
is described by Equation 6.6 with excellent R2 value 99.9 %:
Chapter 6. Propranolol Intrinsic Lipidation in vitro 153
y = 731.7x (6.6)
The fitted gradients indicate a reduced ionisation potential of O-palmitoyl propranolol 62
and O-oleoyl propranolol 47 compared to propranolol 1. However, ionisation of O-palmitoyl
propranolol 62 and O-oleoyl propranolol 47 is increased compared to their N -acylated pro-
pranolol counterparts, due to their retention of the favourable amine protonation site. As
a result, the limit of quantification for O-acylated propranolol derivatives lies below that of
7.8 ng mL−1 attributed to N -acylated derivatives. O-oleoyl propranolol 47 exhibits increased
ionisation compared to O-palmitoyl propranolol 62, attributed once again to the oleoyl double
bond. Differences in calibration data obtained for propranolol 1 and its acylated derivatives
indicates the importance of generating calibration curves for the quantification of propranolol
1 intrinsic lipidation.
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Figure 6.22 Chromatographic peak area response observed for varying concentrations of
O-palmitoyl propranolol 62 (circles) and O-oleoyl propranolol 47 (triangles). Trend fitting for
O-palmitoyl propranolol 62 shown by the solid green line, and O-oleoyl propranolol 47 by the
dashed red line.
6.3.2 Relationship Between O-Acylated and N -Acylated Propranolol
Generation of calibration data for the quantification of propranolol 1 intrinsic lipidation
products, unleashes great potential for better understanding the observed reactivity between
propranolol 1 and the membrane. One aspect of reactivity that can be better understood via
quantification is the relationship between the two products of propranolol intrinsic lipidation,
O-acylated propranolol and N -acylated propranolol. Under standard solution phase conditions
employed for organic synthesis, the two acylated species are deeply intertwined.278–280 The
alcohol functionality of the hydrochloride salt of propranolol 1 acts as the primary nucleophile
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in the presence of anhydrides and N -hydroxysuccinimide (NHS) esters, forming O-acylated
propranolol.243,247 However, O-acylated propranolol is highly unstable, such that competing
hydrolysis and intramolecular rearrangement swiftly deplete the product. For example, in
pH 7.4 aqueous solution at room temperature, O-acetyl propranolol 66 is fully converted
into N -acetyl propranolol 40 and propranolol 1 within 50 minutes.278 Intramolecular O to N
migration is the most favourable mechanism of N -acyl propranolol formation at physiological
pH, due to amine protonation diminishing its nucleophilic activity. However in the presence of
a base and a reactive acid chloride electrophile direct amine reactivity is possible, resulting in
formation of diacyl propranolol andN -acyl propranolol species.243,247 Based upon these solution
phase observations, a relationship between O-acylated propranolol and N -acylated propranolol
derivatives was proposed, predicting the propranolol 1 intrinsic lipidation pathway summarised
in Fig. 6.23 (a). Propranolol 1 intrinsic lipidation was predicted to proceed through initial
transesterification, forming primary product O-acylated propranolol. Unstable O-acylated
propranolol then decomposes into secondary intrinsic lipidation productN -acylated propranolol
through intramolecular O to N migration, described by rate constant k1. Simultaneously
O-acylated propranolol hydrolyses back into propranolol 1 with rate constant k2. Fig. 6.23 (b)
serves to highlight further complexity associated with this proposed pathway of propranolol
1 intrinsic lipidation, by separating propranolol 1 derived species by ionisation state and
membrane association.
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Figure 6.23 Predicted pathway for propranolol 1 intrinsic lipidation: (a) simplistic overview;
(b) complete overview including all steps in the pathway. A represents propranolol 1, B
O-acylated propranolol derivatives, and C N -acylated propranolol derivatives. Subscript N
indicates the neutral form, and I the ionised form. Inside the green box are membrane bound
species, outside are in solution; (c) curly arrow mechanism of O to N migration.
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Analysing the behaviour of O-acylated propranolol and N -acylated propranolol within the
confines of a membrane allowed determination of the accuracy of the pathway for propranolol
1 intrinsic lipdation proposed in Fig. 6.23. Reaction mixtures containing a 1:10 molar ratio
of relevant acylated propranolol derivative to membrane phospholipid were incubated under
physiological conditions. Portions of the reaction mixture were taken over a time period up to
144 hours, and analysed under optimised MS conditions for small molecule intrinsic lipidation.
Chromatographic peak areas corresponding to propranolol 1 derived species were calculated,
and the relative product concentrations determined using calibration data presented in Section
6.3.1. DOPC liposomes were utilised for incubation with O-palmitoyl propranolol 62 and
N -palmitoyl propranolol 12, and DPPC liposomes for O-oleoyl propranolol 47 and N -oleoyl
propranolol 13. Selection of membrane phospholipids comprised of opposing acyl chain type
to those of the small molecule allows for determination of acyl chain origin. Two preparation
methods were utilised in order to combine phospholipids with the relevant propranolol 1
derivatives. The first combined an aqueous solution of the relevant acylated small molecule
species with solution phase phospholipid liposomes prepared by the extrusion method. The
second involved preparation of a thin dried film of combined phospholipid and small molecule,
followed by hydration and liposome preparation by the extrusion methodology. Comparison
of the two preparation methods allows for the impact of lag time associated with membrane
binding, upon variation in hydrolysis and O to N rate to be determined.
An overview of the resulting data reveals some key trends observed for all four acylated pro-
pranolol 1 derivatives. Comparable results were obtained for both of the preparation methods
tested, indicating negligible O to N migration or hydrolysis during the lag time associated
with membrane binding. This observation is unsurprising considering the hydrophobic nature
of the species and their associated logD values at physiological pH, presented in Table 6.11,
likely aiding in swift membrane association. Additionally, at time point zero all reaction
mixtures contained a small proportion (< 9 %) of unmodified propranolol 1. Formation is
attributed to hydrolysis following synthetic purification or during reaction mixture preparation.
Further, in reaction mixtures containing O-palmitoyl propranolol 62 or O-oleoyl propranolol
47, some of the Boc protected analogue remained. The presence of the Boc-protected analogue
is attributed to insufficient deprotection time during O-palmitoyl propranolol 62 and O-oleoyl
propranolol 47 synthesis. However, the peak area associated with the Boc protected species
remains constant and thus is not considered problematic.
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Species LogD (pH 7.4)
Propranolol 1 2.6
O-palmitoyl propranolol 62 7.7
N -palmitoyl propranolol 12 8.7
O-oleoyl propranolol 47 8.2
N -oleoyl propranolol 13 9.2
Table 6.11 LogD values for propranolol derivatives at pH 7.4 calculated using ChemAxon.262
Reaction mixtures containing N -palmitoyl propranolol 12 in the presence of a DOPC mem-
brane, and N -oleoyl propranolol 13 in the presence of a DPPC membrane were analysed. Over
the 144 hours studied no modification to the analytical profile of N -palmitoyl propranolol 12
was observed, Fig. 6.24, indicating small molecule stability within the membrane. N -oleoyl
propranolol 13 was observed to undergo hydrolysis, Fig. 6.24, however the observed rate
is slow, with less than 10 % reduction in N -oleoyl propranolol 13 concentration over the
144 hour time period studied. Furthermore, formation of diacylated propranolol was not
observed for either N -palmitoyl propranolol 12 or N -oleoyl propranolol 13, suggesting a lack
of reactivity between membrane phospholipids and N -acylated propranolol derivatives. This
observation supports previous indications that double intrinsic lipidation of propranolol 1
does not occur, attributed to unfavourable nucleophile position within the binding orientation
of the singly acylated species. The observed stability and robustness of membrane bound
N -acylated propranolol derivatives is consistent with solution phase studies, and supports the
pathway of propranolol 1 intrinsic lipidation proposed in Fig. 6.23.
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Figure 6.24 Quantity of N -palmitoyl propranolol 12 present in a DOPC membrane (green
circles), and N -oleoyl propranolol 13 present in a DPPC membrane (red squares) under
physiological conditions over 144 hours.
By contrast, membrane bound O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 do
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not exhibit stability under physiological conditions. As shown in Fig. 6.25, the proportion of
total propranolol 1 content attributed to O-palmitoyl propranolol 62 decreases exponentially
from 99 % to less than 1.5 % over 144 hours. In parallel, the proportion of O to N migration
product N -palmitoyl propranolol 12, fitted by the dashed line in Fig. 6.25, increases from 0 %
up to 84 % of the total propranolol 1 derived content. The proportion of hydrolysis product
propranolol 1 also increases from 1 % to approximately 15 % of the total propranolol 1 derived
content, as shown by the dotted and dashed line in Fig. 6.25. Decomposition of O-palmitoyl
propranolol 62 can therefore be attributed to simultaneous non-reversible hydrolysis and O to
N migration reactions. These observed changes in the nature of propranolol 1 derived content
are consistent with solution phase observations, and the pathway of propranolol 1 intrinsic
lipidation proposed in Fig. 6.23.
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Figure 6.25 Analysis of propranolol 1 derived species present upon incubation of O-
palmitoyl propranolol 62 with a DOPC membrane under physiological conditions over 144
hours: (i) O-palmitoyl propranolol 62 experimental data points are indicated by circles, and
fitting by the solid line; (ii) N -palmitoyl propranolol 12 experimental data points are indicated
by squares, and fitting by the dashed line; (iii) propranolol 1 experimental data points are
indicated by triangles, and fitting by the dotted and dashed line. Error bars are omitted for
clarity.
Further understanding of the mechanism of propranolol 1 intrinsic lipidation can be achieved by
considering the relative rates of O to N migration and hydrolysis. O-palmitoyl propranolol 62
decomposition within the membrane displays first-order kinetics, and thus can be considered
using the rate equation defined in Equation 6.7:
[62] = [62]0e−kobst (6.7)
Where [62] = concentration of O-palmitoyl propranolol 62; [62]0 = concentration of O-
palmitoyl propranolol 62 at time point 0; kobs = observed rate constant; t = time.
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Figure 6.26 Plot of ln([O-palmitoyl propranolol 62]) present in a DOPC membrane under
physiological conditions over 144 hours. Circles indicate experimental data, and the trend is
fitted with the solid green line.
Plotting relevant time and concentration parameters in a semi-log plot, as demonstrated in
Fig. 6.26, facilitates data fitting with a linear trend. The resulting trend gradient is equal to
the observed rate constant (kobs), determined to be 12.5× 10−3 h−1. Given that O-palmitoyl
propranolol 62 decomposition is attributed to both hydrolysis and intramolecular migration,
this observed rate constant (kobs) can be further defined as the sum of the rate constant of
O to N migration (k1) and the rate constant of hydrolysis (k2). Given the consistent ratio
between the two decomposition products over time, rate constants for O to N migration
(k1) and hydrolysis (k2) also remain consistent.278 As a result these rate constants can be
determined by Equations 6.8 and 6.9 respectively:
k1 = kobs[12]/([12] + [1]) (6.8)
Where k1 = rate constant for intramolecular O to N migration; kobs = observed rate constant;
[12] = concentration of N -palmitoyl propranolol 12; [1] = concentration of propranolol 1
k2 = kobs − k1 (6.9)
Where k2 = rate constant for hydrolysis; kobs = observed rate constant; k1 = rate constant
for intramolecular O to N migration.
The rate constant attributed to formation of propranolol 1 by hydrolysis (k2) was therefore
determined to be 2.7× 10−3 h−1. By contrast an increased k1 value of 9.8× 10−3 h−1 was
calculated for formation of N -palmitoyl propranolol 12. Respective rate constants indicate
O to N migration as the primary form of membrane bound O-palmitoyl propranolol 62
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decomposition under physiological conditions, resulting in build up of stable N -palmitoyl
propranolol 12.
Equivalent experiments conducted utilisingO-oleoyl propranolol 47 revealed a similar analytical
response to those of O-palmitoyl propranolol 62, as depicted in Fig. 6.27. The proportion of
total propranolol 1 derived content attributed to O-oleoyl propranolol 47 decreased from 91
% to less that 4 % over the 144 hours studied. However, unlike O-palmitoyl propranolol 62
decomposition, increased propranolol 1 formation was not observed, indicating that O-oleoyl
propranolol 47 decomposition cannot be attributed to hydrolysis. This observation is due to
either a lower propensity of O-oleoyl propranolol 47 towards hydrolysis, or to reduced aqueous
availability within the gel phase DPPC membrane. Decomposition of O-oleoyl propranolol
47 is wholly attributed to non-reversible O to N acyl chain migration. This is reflected in
the increased proportion of N -oleoyl propranolol 13 from 0 % up to 87 % over 144 hours, as
shown by the dashed line in Fig. 6.27.
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Figure 6.27 Analysis of propranolol 1 derived species present upon incubation of O-oleoyl
propranolol 47 with a DPPC membrane under physiological conditions over 144 hours: (i)
O-oleoyl propranolol 47 experimental data points are indicated by circles, and fitting by the
solid line; (ii) N -oleoyl propranolol 13 experimental data points are indicated by squares,
and fitting by the dashed line; (iii) propranolol 1 experimental data points are indicated by
triangles. Error bars are omitted for clarity.
O-oleoyl propranolol 47 decomposition within the membrane also displays first-order kinetics,
and can be considered using the rate equation defined in Equation 6.10:
[47] = [47]0e−kobst (6.10)
Where [47] = concentration of O-oleoyl propranolol 47; [47]0 = concentration of O-oleoyl
propranolol 47 at time point 0; kobs = observed rate constant; t = time.
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Plotting relevant experimental parameters and fitting the data with a linear trend, Fig. 6.28,
allows determination of an observed rate constant (kobs) for O-oleoyl propranolol 47 decom-
position of 9.5× 10−3 h−1. As previously demonstrated in Fig. 6.27, O-oleoyl propranolol
47 decomposition proceeds via intramolecular O to N migration only. Therefore, the rate
constant attributed to O to N migration (k1) is equal to kobs, with a value of 9.5× 10−3 h−1.
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Figure 6.28 Plot of ln([O-oleoyl propranolol 47]) present in a DPPC membrane under
physiological conditions over 144 hours. Circles indicate experimental data, and the trend is
fitted with the solid red line.
Intramolecular O to N migration is the predominant method of O-palmitoyl propranolol 62
and O-oleoyl propranolol 47 decomposition in the presence of a membrane under physiological
conditions. Migration has been characterised in solution under neutral and basic environmental
conditions, however variation upon introduction of a membrane must be considered.280,281
The presence of the neutral form of O-acylated propranolol species is presumed as an O to N
migration requirement both in solution and in the presence of a membrane. Considering the
reported decrease in pK a associated with O-acylation of propranolol 1, an increased proportion
of the neutral species would be present under physiological conditions to facilitate migration.278
Additionally, consideration must be given to the location of O to N migration. Membrane
bound O-acylated propranolol may have flexibility and freedom to allow O to N migration, or
alternatively the process may be limited to the solution phase. Based upon available data, it
is unclear as to which of these proposed O to N migration locations is relevant. Considering
relative solution phase rates of hydrolysis compared to O to N migration at physiological
pH, hydrolysis would be expected to dominate, supporting localisation of O to N migration
within the membrane.278 Furthermore, given the hydrophobicity of O-acylated propranolol
and associated heightened logP, limited neutral solution phase species would be available to
facilitate migration. However, without knowledge of the impact of acylated propranolol upon
membrane integrity, it is unclear as to whether the membrane even remains intact following
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intrinsic lipidation. Micellisation or membrane disruption may provide sufficient flexibility to
aid intramolecular O to N migration whilst retaining phospholipid aggregate structure.
Compiling the results of stability studies of membrane bound acylated propranolol 1 derivatives
provides insight into the mechanism of propranolol 1 intrinsic lipidation. Observations support
the predicted pathway of propranolol 1 intrinsic lipidation proposed previously in Fig. 6.23.
Experimentation suggests that O-acylated propranolol species are the primary kinetic products
of propranolol 1 intrinsic lipidation. O-acylated propranolol formation via intrinsic lipidation
can be reversed through general acid or general base catalysed hydrolysis. However, the
resulting formation of propranolol 1 is slow within the membrane under physiological conditions
and does not comprise the primary pathway of O-acylated propranolol decomposition. This
observation is at odds with solution phase behaviour at pH 7.4, whereupon O-acylated
propranolol derivatives containing saturated acyl chains up to 10 carbons exhibit 90 %
hydrolysis to propranolol 1 following decomposition.278 The difference is attributed to reduced
accessibility of water or hydroxide ions within the membrane compared to in solution. Instead,
O-acylated propranolol derivatives decompose via an intramolecular rearrangement in the
form of an O to N acyl chain migration. The resulting N -acylated propranolol derivatives are
thermodynamically stable products, and remain intact within the membrane over the relevant
time period for intrinsic lipidation. Rate constants for O to N migration (k1) are determined to
be 9.8× 10−3 h−1 and 9.5× 10−3 h−1 for O-palmitoyl propranolol 62 and O-oleoyl propranolol
47 respectively. Whilst similar between the two species, these rate constants differ significantly
from the value of 4.0 h−1 attributed to O-acetyl propranolol 66 in solution under physiological
conditions. The reduced O to N migration rate may be due to a combination of diminished
small molecule mobility within the membrane bound state, and steric considerations of the
long acyl chains. Furthermore, it is considered unlikely that the amine of propranolol 1
reacts directly with membrane phospholipids. Rather, it is increasingly likely that N -acylated
propranolol derivatives form solely via O to N migration. This assumption is supported by the
fact that at physiological pH the majority of the amine exists in a protonated form, making
nucleophilic activity challenging. Additional support is provided by the membrane bound
orientation of ionised propranolol 1, the primary species present under physiological conditions,
described in Fig. 6.29 in accordance with neutron diffraction and NMR studies.267 The cationic
ammonium moiety of ionised membrane bound propranolol 1 is localised within the phosphate
head group region, facilitating favourable electrostatic interactions. Within this orientation
the amine of propranolol 1 is not sufficiently proximal to a phospholipid ester linkage, an
issue predicted during the study of procaine 2 and tetracaine 3 to be problematic for the
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progression of intrinsic lipidation. By contrast, ionised propranolol’s 1 alcohol is located in
close proximity to the phospholipid ester linkage when membrane bound, a prime position to
facilitate intrinsic lipidation at this position. Neutral membrane bound propranolol 1, a minor
contributor to total propranolol 1 content under physiological conditions, penetrates further
into the membrane in accordance with the pH piston theory. Under basic environmental
conditions promoting neutral species formation, membrane binding orientation places the
amine moiety proximal to phosphate ester linkages, such that these conditions could facilitate
direct formation of N -acylated propranolol.
Figure 6.29 Membrane binding orientation of ionic propranolol 1 within a neutral DMPC
membrane as determined by neutron diffraction, and in accordance with the pH piston
theory.267
Temperature modification is predicted to influence the rate of both intramolecular O to N acyl
chain migration, and hydrolysis of O-acylated propranolol, thus modifying intrinsic lipidation
rate and product distribution. As major decomposition pathways of O-acylated propranolol,
influence of temperature upon both reactions can be studied via the stability of O-acylated
propranolol derivatives. Analogous experiments to those conducted for membrane bound
O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 at 37 ◦C were therefore conducted at
4 ◦C and 57 ◦C. Quantification of propranolol 1 derived species within each sample provides a
mechanism for determining the extent of decomposition at these temperatures. Decomposition
can then be further subdivided into the relative contributions from each of intramolecular O
to N acyl chain migration, and hydrolysis.
Reduction in temperature from 37 ◦C down to 4 ◦C is accompanied by a parallel drop
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in decomposition for both O-palmitoyl propranolol 62 and O-oleoyl propranolol 47. As
demonstrated in Fig. 6.30, following 144 hours of study 75 % of O-palmitoyl propranolol 62
and 40 % O-oleoyl propranolol 47 remains stabilised within the membrane. Decomposition via
hydrolysis is considered negligible at 4 ◦C, since proportion of propranolol 1 does not increase
beyond low level fluctuations attributed to instrument error. Reduced O-acyl hydrolysis is
due to a combination of lower molecular energy preventing the activation energy barrier being
overcome, and the presence of less fluid membrane limiting water availability. Decomposition
is therefore attributed wholly to intramolecular O to N migration, however this is also slowed
by the temperature decrease. After 144 hours only 20 % of total propranolol 1 derived content
is attributed to N -palmitoyl propranolol 12, and 53 % to N -oleoyl propranolol 13, as shown
in Fig. 6.30.
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1Figure 6.30 Analysis of propranolol 1 derived species present upon incubation at 4 ◦C for 144
hours: (a) O-palmitoyl propranolol 62 with a DOPC membrane; (b) O-oleoyl propranolol 47
with a DPPC membrane. Species presented include: (i) O-acylated propranolol experimental
data points are indicated by circles, and fitting by the solid line; (ii) N -acylated propranolol
experimental data points are indicated by squares, and fitting by the dashed line; (iii)
propranolol 1 experimental data points are indicated by triangles. Error bars are omitted for
clarity.
Plotting relevant time and concentration parameters in a semi-log plot, Fig. 6.31, reveals that
the rate of O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 decomposition at 4 ◦C
follows standard first order kinetics. Therefore, decomposition can be described using the
Equations 6.11 and 6.12:
[62] = [62]0e−kobst (6.11)
Where [62] = concentration of O-palmitoyl propranolol 62; [62]0 = concentration of O-
palmitoyl propranolol 62 at time point 0; kobs = observed rate constant; t = time.
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[47] = [47]0e−kobst (6.12)
Where [47] = concentration of O-oleoyl propranolol 47; [47]0 = concentration of O-oleoyl
propranolol 47 at time point 0; kobs = observed rate constant; t = time.
In accordance with Equations 6.11 and 6.12, fitting the experimental data can be achieved
with linear trends, as demonstrated by Fig. 6.31. Observed rate constants (kobs), equal to
trend gradients, were determined to be 0.7× 10−3 h−1 and 2.6× 10−3 h−1 for O-palmitoyl
propranolol 62 and O-oleoyl propranolol 47 respectively. Considering the lack of hydrolysis
at 4 ◦C, under these conditions kobs is equivalent to k1 the rate constant for O to N migration.
Strikingly, at 4 ◦C k1 for O-oleoyl propranolol 1 is three times that of O-palmitoyl propranolol
1. This observation is attributed to membrane disruption associated with the oleoyl double
bond, increasing fluidity and flexibility of molecular movement, compared to the rigid saturated
palmitoyl moiety.1,28,282 Observed k1 values at 4 ◦C are considerably reduced compared to 37
◦C, as highlighted in Table 6.12. Decreased temperature, and the corresponding reductions in
molecular energy and membrane fluidity act to facilitate this slowed rate of O to N migration.
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Figure 6.31 Plot of: (i) ln([O-palmitoyl propranolol 62]) present in a DOPC membrane at
4 ◦C over 144 hours with circles indicating experimental data, and the trend fitted with the
solid green line; (ii) ln([O-oleoyl propranolol 47]) present in a DPPC membrane at 4 ◦C over
144 hours with triangles indicating experimental data, and the trend fitted with the dashed
red line.
Temperature (◦C) O-Palmitoyl Propranolol 62 O-Oleoyl Propranolol 47
4 0.7× 10−3 h−1 2.6× 10−3 h−1
37 9.8× 10−3 h−1 9.5× 10−3 h−1
Table 6.12 Rate constants (k1) for intramolecular O to N migration determined for O-
palmitoyl propranolol 62 and O-oleoyl propranolol 47 at 4 ◦C and 37 ◦C.
Analysis of membrane bound O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 stability
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over 144 hours was also conducted at 57 ◦C. Unfortunately study of DPPC bound O-oleoyl
propranolol 47 at 24 hours and beyond proved impossible due to poor spectrum quality.
However, experimental data confirms that decomposition of O-palmitoyl propranolol 62 and
O-oleoyl propranolol 47 is dramatically increased at 57 ◦C compared to 37 ◦C and 4 ◦C,
Fig. 6.32. O-palmitoyl propranolol 62 is completely depleted prior to analysis at 144 hours,
and O-oleoyl propranolol 47 is reduced to less than 56 % of total propranolol 1 content
within 8 hours. Intramolecular O to N migration is the major decomposition pathway, with
N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 making up 44 % and 39 % of their
respective samples within 8 hours. Hydrolysis resulting in increased propranolol 1 is also
observed in both systems tested, as shown in Fig. 6.32.
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1 Figure 6.32 Analysis of propranolol 1 derived species present upon incubation at 57
◦C for 144 hours: (a) O-palmitoyl propranolol 62 with a DOPC membrane; (b) O-oleoyl
propranolol 47 with a DPPC membrane. Species presented include: (i) O-acylated propranolol
experimental data points are indicated by circles, and fitting by the solid line; (ii) N -acylated
propranolol experimental data points are indicated by squares, and fitting by the dashed
line; (iii) propranolol 1 experimental data points are indicated by triangles, and fitting by the
dotted and dashed line. Error bars are omitted for clarity.
Considering the available information it has proved impossible to fit experimental data, shown
in Fig. 6.32, obtained beyond 24 hours to standard rate laws. However, plotting relevant
time and concentration data obtained over the initial 8 hours of study, Fig. 6.33, suggests
that initial decomposition can be described by first order kinetics. Observed rate constants
(kobs) are therefore described by the previously defined Equations 6.11 and 6.12. Trend fitting
reveals kobs values of 52.2× 10−3 h−1 and 23.7× 10−3 h−1 for O-palmitoyl propranolol 62 and
O-oleoyl propranolol 47 at 57 ◦C. Since decomposition proceeds via both O to N migration
and hydrolysis, these observed rate constants can be further subdivided into their constituent
rate constants. Rate constants for migration (k1) are defined using Equations 6.13 and 6.14:
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k1 = kobs[62]/([62] + [1]) (6.13)
Where k1 = rate constant for O to N migration; kobs = observed rate constant; [62] =
concentration of O-palmitoyl propranolol 62; [1] = concentration of propranolol 1.
k1 = kobs[47]/([47] + [1]) (6.14)
Where k1 = rate constant for O to N migration; kobs = observed rate constant; [47] =
concentration of O-oleoyl propranolol 47; [1] = concentration of propranolol 1.
k1 values of 40.5× 10−3 h−1 and 19.3× 10−3 h−1 were determined for O-palmitoyl propranolol
62 and O-oleoyl propranolol 47 respectively. Observed values are increased compared to
observed k1 values at 4 ◦C and 37 ◦C, summarised in Table 6.13. Increased mobility associated
with both the liquid phase bulk membrane and membrane bound O-acylated propranolol
species aids in intramolecular O to N migration at higher temperatures. Furthermore, an
increased proportion of solution phase species present at higher temperatures may facilitate
O to N migration.153 O-palmitoyl propranolol 62 exhibits an increased k1 value compared to
O-oleoyl propranolol 47, in similar fashion to the observed pattern at 37 ◦C. This increased
rate constant may be attributed to differences in activation energies, or to the reduced steric
bulk of O-palmitoyl propranolol 62 compared to O-oleoyl propranolol 47.
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Figure 6.33 Plot of: (i) ln([O-palmitoyl propranolol 62]) present in a DOPC membrane at
57 ◦C over 8 hours with circles indicating experimental data, and the trend fitted with the
solid green line; (ii) ln([O-oleoyl propranolol 47]) present in a DPPC membrane at 57 ◦C over
8 hours with triangles indicating experimental data, and the trend fitted with the dashed red
line.
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Temperature (◦C) O-Palmitoyl Propranolol 62 O-Oleoyl Propranolol 47
4 0.7× 10−3 h−1 2.6× 10−3 h−1
37 9.8× 10−3 h−1 9.5× 10−3 h−1
57 40.5× 10−3 h−1 19.3× 10−3 h−1
Table 6.13 Rate constants (k1) for intramolecular O to N migration determined for O-
palmitoyl propranolol 62 and O-oleoyl propranolol 47 at 4 ◦C, 37 ◦C, and 57 ◦C.
Intramolecular O to N migration is the primary mechanism of O-acylated propranolol decom-
position at 57 ◦C, however decomposition by hydrolysis is also relevant. Contribution of the
rate constant for hydrolysis (k2) to kobs can be calculated using Equation 6.15:
k2 = kobs − k1 (6.15)
k2 = rate constant for hydrolysis; kobs = observed rate constant; k1 = rate constant for
intramolecular O to N migration.
k2 values for O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 at 57 ◦C were determined
to be 11.6× 10−3 h−1 and 4.4× 10−3 h−1 respectively. The calculated k2 value for O-palmitoyl
propranolol 62 is significantly higher than that of O-oleoyl propranolol 47 at 57 ◦C, suggesting
increased hydration and membrane fluidity. However, both k2 values are heightened compared
to data obtained at 4 ◦C and 37 ◦C, summarised in Table 6.14, where hydrolysis is only
observed for DOPC bound O-palmitoyl propranolol 47 at 37 ◦C. Increased hydrolysis rate
is testament to the increased molecular motion, hydration and fluidity achieved through an
increase in temperature.
Temperature (◦C) O-Palmitoyl Propranolol 62 O-Oleoyl Propranolol 47
4 0.0 h−1 0.0 h−1
37 2.7× 10−3 h−1 0.0 h−1
57 11.6× 10−3 h−1 4.4× 10−3 h−1
Table 6.14 Rate constants (k2) for hydrolysis determined for O-palmitoyl propranolol 62
and O-oleoyl propranolol 47 at 4 ◦C, 37 ◦C, and 57 ◦C.
Having analysed the behaviour of O-acylated propranolol derivatives at varying temperatures it
was possible to employ the experimental data in order to determine further kinetics information.
Hydrolysis was not observed across all systems tested, therefore further data interpretation is
impossible, however activation energies for intramolecular O to N migration can be calculated
by employing the Arrhenius Equation 6.16:
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k2 = Ae
Ea
RT (6.16)
Where k2 = rate constant for intramolecular O to N migration; A = pre-exponential factor;
Ea = activation energy; R = gas constant; T = temperature.
Plotting relevant temperature and rate constant parameters, shown in Fig. 6.34, reveals acti-
vation energies of 19.5 kJ mol−1 and 9.6 kJ mol−1 for intramolecular migration of O-palmitoyl
propranolol 62 and O-oleoyl propranolol 47 respectively. The higher activation energy as-
sociated with O-palmitoyl propranolol 62 migration explains the increased variation in k2
observed for this species over the temperature range tested, shown previously in Table 6.13.
Furthermore, activation energy variation suggests that intramolecular migration is more
challenging in O-palmitoyl propranolol 62 than O-oleoyl propranolol 47, which may explain
the increased likelihood of decomposition by hydrolysis within this system, highlighted by
rate constants previously presented in Table 6.14.
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Figure 6.34 Arrhenius plot utilising rate constants of O to N migration (k2) for: (i) O-
palmitoyl propranolol 62 in a DOPC membrane with circles indicating experimental data, and
the trend fitted with the solid green line; (ii) O-oleoyl propranolol 47 in a DPPC membrane
with triangles indicating experimental data, and the trend fitted with the dashed red line.
6.3.3 Reactivity Under Physiological Conditions
Quantification of intrinsic lipidation products, combined with the newly developed under-
standing of the pathway of propranolol 1 intrinsic lipidation, provides a useful tool for further
examining membrane reactivity of propranolol 1. Reactivity in vitro under physiological con-
ditions provides a biologically relevant starting point. In depth examination of propranolol 1
reactivity within different membrane models provides a route towards understanding reactivity
preferences related to phospholipid head group and acyl chain composition. A developed
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understanding of propranolol 1 intrinsic lipidation in vitro is vital in order to unravel the
biological and pharmaceutical potential. Furthermore, such investigation is expected to aid in
directing the future study of propranolol 1 intrinsic lipidation, with particular focus in vivo.
Initially, comparison of propranolol 1 intrinsic lipidation within three different membrane
models was attempted. Model membranes were prepared containing phospholipid compositions
of DOPC, DOPC:DOPS (4:1), and DOPE:DOPG (3:1) in order to mimic eukaryotic, viral
and prokaryotic membranes respectively. Whilst previous analysis shown in Chapter 5 of
this thesis indicated reactivity differences between these membrane types, it was hoped that
quantification could provide a more definitive comparison. Application of calibration data to
the analytical response within each membrane type provides concentration data for propranolol
1 derived species.
Total oleoylated propranolol product concentration ([O-oleoyl propranolol 47] plus [N -oleoyl
propranolol 13]) following a 72 hour incubation of propranolol 1 with each membrane type is
presented in Table 6.15. Concentration results are obtained as an average of samples prepared
and analysed in triplicate. Comparison reveals 68.7 ng mL−1 of oleoylated propranolol product
formed in the presence of a DOPC membrane, equivalent to 12 % of the total propranolol
1 derived content of the mixture. Modification of the membrane to contain DOPC:DOPS
(4:1) dramatically reduces the oleoylated product concentration to 3.6 ng mL−1, just under 2
% of the total propranolol 1 content. The observed reduction in reactivity is counter-intuitive
considering the increased membrane binding affinity of cationic amphiphilic propranolol 1
to a negatively charged PS membrane.270 Considering the increased electrostatic attraction,
reduced reactivity can be attributed to a slightly altered membrane binding orientation of
propranolol 1 within these negatively charged membranes, enhancing favourable electrostatics
but reducing alcohol proximity to the phospholipid ester linkages. Further binding orientation
modifications may arise as a result of inherent membrane asymmetry and domain formation,
given that PS containing phospholipids preferentially inhabit the membrane inner leaflet
in vivo.1,283,284 Propranolol 1 rich domain formation within the inner leaflet is a potential
outcome of this asymmetry, a phenomenon observed for other cationic amphiphilic drugs
binding to negatively charged membranes.27,285
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Membrane Composition
Total Oleoyl
Propranolol
Concentration
(ng mL−1)
Total Oleoyl
Propranolol as %
Total Propranolol
Content
DOPC 68.7 12.1
DOPC:DOPS (4:1) 3.6 1.6
DOPE:DOPG (3:1) 16.3 3.1
Table 6.15 Comparison of the total concentration of oleoyl propranolol (O-oleoyl propranolol
47 plus N -oleoyl propranolol 13) after 72 hours under physiological conditions within three
membrane types.
The prokaryotic model membrane DOPE:DOPG (3:1) resulted in a total oleoylated product
concentration of 16.3 ng mL−1, as shown in Table 6.15, corresponding to just over 3 % of
the propranolol 1 derived species. Reduced reactivity compared to the DOPC membrane
model supports the determination that increased propranolol 1 membrane binding affinity
does not guarantee increased intrinsic lipidation. However, increased reactivity compared to
DOPC:DOPS (4:1) suggests more favourable membrane properties such as a lack of domain
formation, altered position of the negative charge, or more favourable binding orientation.
Analysis of intrinsic lipidation product formation in eukaryotic, viral and prokaryotic membrane
models after 72 hours can be further separated into the component species, as shown in
Table 6.16. Interesting differences are evident when comparing the proportion of O-oleoyl
propranolol 47 and N -oleoyl propranolol 13 between systems. After 72 hours, DOPC and
DOPE:DOPG (3:1) membranes exhibit an increased proportion of N -oleoyl propranolol 13
compared to O-oleoyl propranolol 47. This observation is attributed to initial reactivity at
the alcohol moiety of propranolol 1, followed by an intramolecular O to N migration. By
contrast, the DOPC:DOPS (4:1) membrane exhibits increased levels of O-oleoyl propranolol
47 compared to N -oleoyl propranolol 13. Insufficient O-oleoyl propranolol 47 production, or
reduced rate of O to N migration compared to O-oleoyl propranolol 47 intrinsic lipidation, may
cause this. However, it is worth noting that product concentrations within the DOPC:DOPS
(4:1) membrane are close to the limit of quantitation. Instrument error associated with these
values is thus significant, resulting in reduced confidence in the reported relative proportions
of O-oleoyl propranolol 47 and N -oleoyl propranolol 13.
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Membrane Composition
O-oleoyl propranolol
47 as % Total
Propranolol 1
Content
N -oleoyl propranolol
13 as % Total
Propranolol 1
Content
DOPC 3.0 8.9
DOPC:DOPS (4:1) 1.0 0.6
DOPE:DOPG (3:1) 0.9 2.1
Table 6.16 Comparison of the proportion of O-oleoyl propranolol 47 and N -oleoyl propra-
nolol 13 as % of total propranolol 1 content after 72 hours under physiological conditions
within three membrane types.
Study of propranolol 1 intrinsic lipidation under physiological conditions after 72 hours
provides informative data regarding the reaction. However, more detailed information can be
gleaned through analysis of reaction mixtures at regular time points. As a result, portions
of propranolol 1 reaction mixture with each membrane model were taken and analysed in
triplicate at time points of 2, 4, 6, 8, 24, 72, 144, and 216 hours. To negate for error associated
with fluctuation in sample dilution prior to analysis, values are normalised and reported as a
percentage of total unmodified plus modified propranolol 1 content. Data describing total
oleoylated propranolol content in each membrane type over the time period studied is presented
in Fig. 6.35. Preliminary inspection suggests an increase in oleoylated product formation over
time for each membrane composition up to 72 hours. However, later time points 144 and
216 hours indicate a decrease in observed oleoylated product proportion for all membrane
types. Data normalisation combined with performance of experiments in triplicate prevents
this decrease in oleoylated product being attributed to dilution or sample preparation error.
Furthermore, chemical modification of the oleoylated product, such as diacylation or acyl
chain oxidation, which may contribute to oleoylated product depletion have been investigated
and eliminated as likely causes. Hydrolysis of O-acylated propranolol derivatives has been
noted previously in Section 6.3.2, providing a possible explanation or the observed decrease
in oleoylated product proportion. However, observed oleoylated product depletion at later
time points is better attributed to the known instability and loss of structural integrity within
liposome membrane models beyond 120 hours.241 This instability may be further exaggerated
by the attainment of a critical mass of oleoylated propranolol derivative, such that further
reactivity is prevented and hydrolysis is promoted. Considering this observed complexity in
later time points, analyses conducted at 144 and 216 hours were not taken forward for further
study.
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Figure 6.35 Comparison of total oleoyl propranolol product over time period up to 216
hours (9 days) within three membrane types: (i) DOPC shown by red circles; (ii) DOPC:DOPS
(4:1) shown by green squares; (iii) DOPE:DOPG (3:1) shown by blue triangles.
Closer inspection of membrane models DOPC, DOPC:DOPS (4:1) and DOPE:DOPG (3:1),
under physiological conditions over the first 8 hours of study, indicates oleoylated product
formation within 2 hours, Fig. 6.35. O-oleoyl propranolol 47 is the sole contributor to total
oleoylated product at this time point, as shown in Table 6.17, and continues to be over the
initial 8 hours of study. Considering observation of O-oleoyl propranolol 47 only and the lack
of ester hydrolysis determined previously, the rate constant attributed to transesterification
would be equal to the observed rate constant over the first 2 to 8 hours of study. Relevant plots
were therefore prepared, Fig. 6.36, in order to determine rate equation order as zero order
(Fig. 6.36 (a)), first order (Fig. 6.36 (b)), or second order (Fig. 6.36 (c)). However, following
analysis of the resulting data it remained unclear as to which order of reaction was most
relevant. Given challenges in observation and quantification of oleoylated product at these
early time points, with low abundance causing issues for both instrument detection and peak
modelling, the observed issues in rate constant determination are unsurprising. Furthermore,
results are complicated by potential variation in transesterification rate over time, evidenced
by reduced DOPC reactivity compared to viral and prokaryotic systems over the first 2 to 8
hours, a trend reversed at 72 hours as demonstrated in Table 6.15. These considerations act
to explain some of the discrepancies in oleoylated product content observed during this time
period, such as a perceived decrease over time.
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Total Oleoylated Product = O-Oleoyl
Propranolol 47
Time (h) DOPC PC:PS PE:PG
2 0.06 0.06 0.19
4 0.02 0.11 0.46
6 0.05 0.46 1.32
8 0.08 0.36 2.51
Table 6.17 Comparison of the proportion of oleoyl propranolol equal to O-oleoyl propranolol
47 as % of total propranolol 1 content over the first 8 hours of study plus under physiological
conditions within three membrane types: (i) DOPC; (ii) DOPC:DOPS (4:1); (iii) DOPE:DOPG
(3:1).
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47Figure 6.36 Plots prepared for the determination of rate equation order within DOPC (red
circles), DOPC:DOPS 4:1 (green squares) and DOPE:DOPG 3:1 (blue triangles) membrane
models: (a) zero order; (b) first order; (c) second order.
Between 24 hours and 72 hours, analytical results obtained from the study of propranolol 1
incubation under physiological conditions with three membrane models, prove most informative.
A linear increase in proportion of total oleoylated propranolol product is evident for each
membrane type, as shown in Fig. 6.37. The gradient attributed to each increase represents
the rate of oleoylated product formation, Table 6.18, however care must be taken considering
the low number of data points available. The steepest gradient of 0.17 h−1, attributed to
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the fastest rate of oleoylated propranolol formation, is credited to the eukaryotic DOPC
membrane. The prokaryotic model DOPE:DOPG (3:1) exhibits the second fastest rate with a
gradient of 0.04 h−1, and the viral model DOPC:DOPS (4:1) the slowest rate with a gradient
of 0.02 h−1. Variation in rate of oleoylated product formation presents a clear preference
towards propranolol 1 intrinsic lipidation in a eukaryotic membrane model, despite reduced
electrostatic attraction compared to DOPC:DOPS (4:1) and DOPE:DOPG (3:1) membranes.
It is impossible to attribute the increased reactivity of the eukaryotic DOPC membrane to a
single factor, such as binding orientation, hydration levels and nucleophile properties. This
conclusion highlights the complex nature of intrinsic lipidation, and supports the assumption
that numerous factors contribute to reactivity. Further, analysis of the rate of oleoylated
product formation must be considered in light of the broader and more complex picture of
propranolol 1 intrinsic lipidation. Several distinct reactions contributed to the production
of total oleoylated propranolol content. These reactions, which include transesterification,
hydrolysis, and intramolecular O to N migration, each have a unique associated rate constant.
It is unclear as to whether these individual rate constants remain consistent over time or are
altered by environmental factors such as membrane integrity or accumulation of a critical
proportion of oleoylated product.
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Figure 6.37 Comparison of total oleoyl propranolol product over time period up to 72 hours
within three membrane types: (i) DOPC shown by red circles and modelled with a solid red
line; (ii) DOPC:DOPS (4:1) shown by green squares and modelled by a green dahsed line; (iii)
DOPE:DOPG (3:1) shown by blue triangles and modelled by a blue dotted and dashed line.
Membrane Type Rate (h−1)
DOPC 0.17
DOPC:DOPS (4:1) 0.02
DOPE:DOPG (3:1) 0.04
Table 6.18 Comparison of the rate of oleoyl propranolol formation within three membrane
types, determined from gradients of trend fitted data shown in Fig. 6.37.
Chapter 6. Propranolol Intrinsic Lipidation in vitro 175
Separation of total oleoylated product proportion into its contributing species, O-oleoyl
propranolol 47 and N -oleoyl propranolol 13, aids in understanding the relative rates of
formation. Despite variation in absolute quantities over 72 hours, Fig. 6.38 indicates that the
three membrane models exhibit similar trends. As previously demonstrated in Table 6.17,
O-oleoyl propranolol 47 production via transesterification from a membrane phospholipid, is
observed within two hours. O-oleoyl propranolol 47 production then continues to increase
before starting to plateau as a result of competitive O to N migration. Considering both
the observed plateau in O-oleoyl propranolol 47 concentration reached over time, and the
determination of O to N migration as the primary mechanism of O-oleoyl propranolol 47
decomposition, the rate of initial intrinsic lipidation via transesterification is predicted to be
comparable to the rate of O to N migration.
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1Figure 6.38 Comparison of concentrations of O-oleoyl propranolol 47 (experimental data
as green circles) and N -oleoyl propranolol 13 (experimental data as red squares and trend
fitted by dashed red line) products over time period 24 and 72 hours within three membrane
types: (a) DOPC; (b) DOPC:DOPS (4:1); (c) DOPE:DOPG (3:1).
In contrast to O-oleoyl propranolol 47, production of N -oleoyl propranolol 13 is characterised
by an initial lag phase followed by a linear increase, shown in Fig. 6.38. The lag phase
is attributed to time designated for the accumulation of O-oleoyl propranolol 47, required
prior to N -oleoyl propranolol 13 formation via O to N migration. Extrapolating the rate of
N -oleoyl propranolol 13 production back from 24 hours, the lag phase can be estimated to last
approximately 4 to 5 hours, as highlighted by dashed vertical lines in Fig. 6.38. However, at
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experimental time points close to this, 6 and 8 hours, N -oleoyl propranolol 13 is not observed
by MS due to low abundance (<1 ng mL−1) preventing detection. This observation further
supports the issues raised previously, associated with validity of results obtained by mass
spectrometry at the limit of instrument detection. The subsequent linear increase in N -oleoyl
propranolol 13, irrespective of precursor concentration, indicates both a consistent rate of
formation and stability of N -oleoyl propranolol 13. The gradient associated with the linear
increase in N -oleoyl propranolol 13 can be correlated with rate of its production. In a now
familiar trend, the membrane model DOPC exhibits the fastest rate of product formation,
followed by DOPE:DOPG (3:1), and then DOPC:DOPS (4:1). It is unclear whether this rate
of N -oleoyl propranolol 13 formation continues indefinitely until no precursor propranolol 1
or O-oleoyl propranolol 47 remains, or whether production is capped at a critical proportion
of N -oleoyl propranolol 13.
Propranolol 1 intrinsic lipidation under physiological conditions clearly differs between model
membranes containing phospholipids with differing phosphate head groups. Reactivity varia-
tion between membranes containing different acyl chain types is also of interest. In particular,
investigation of preferential transfer of an acyl chain, either due to chemical composition or
position on the phosphate backbone, is required. Phospholipids POPC and OPPC, which
contain the same acyl chain moieties in alternate positions on the phosphate backbone, provide
an excellent means of probing preferential transfer. Additionally, both POPC and OPPC
contain a eukaryotic PC phosphate head group, optimising both predicted reactivity towards
intrinsic lipidation, and pharmaceutical relevance.
Comparison of total palmitoylated product and total oleoylated product observed within
POPC and OPPC membranes following 72 hours under physiological conditions, is presented
in Table 6.19. Liposomes containing POPC produced an increased quantity of palmitoylated
product, whereas liposomes containing OPPC present with increased oleoylated product.
These observations correspond to preferential transfer of the acyl chain at the sn-1 position of
the phosphate backbone. Acyl transfer dictated by backbone position rather than chemical
nature highlights the importance of membrane binding orientation, and suggests reactivity
facilitated by increased proximity between the alcohol of propranolol 1 and the sn-1 position
of the phosphate backbone.267 An alternative interpretation is that increased lability promotes
transesterification at the sn-1 position over the sn-2 position.
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Membrane
Composition
Total
Palmitoyl
Propranolol
Concentration
(ng mL−1)
Palmitoyl
Propranolol
(%)
Total Oleoyl
Propranolol
Concentration
(ng mL−1)
Oleoyl
Propranolol
(%)
POPC 100.7 36.8 49.8 18.2
OPPC 13.3 5.4 20.9 8.5
Table 6.19 Comparison of the total concentration of palmitoyl propranolol (O-palmitoyl
propranolol 62 plus N -palmitoyl propranolol 12) and the total concentration of oleoyl propra-
nolol (O-oleoyl propranolol 47 plus N -oleoyl propranolol 13) after 72 hours under physiological
conditions within POPC and OPPC membrane types.
Differences in total acylated product formation, the sum of palmitoylated product plus
oleoylated product, are also evident between POPC and OPPC membrane types, Table 6.19.
Intrinsic lipidation within a POPC membrane attributes 55 % of the total propranolol 1
derived species to acylated propranolol, compared to 14 % within an OPPC membrane. The
reason for this variation is unclear, but is hypothesised to be due to either minor differences in
propranolol 1 binding orientation, or to membrane fluidity variation considering the transition
temperatures of -2 ◦C and -9 ◦C for POPC and OPPC respectively. The conversion level of
55 % observed within the POPC membrane contrasts with earlier observations for lipidation
reactions in DOPC (Chapter 5) which suggested that acylated propranolol production is
capped at a final critical concentration.
In parallel to experiments conducted to test the influence of phosphate head group upon
propranolol 1 intrinsic lipidation, regular reaction monitoring was executed utilising POPC
and OPPC membranes. Analysis of total palmitoylated propranolol and total oleoylated
propranolol at time points of 2, 4, 6, 8, 24, 72, 144 and 216 hours, is presented in Fig. 6.39.
Observations discussed during comparison of eukaryotic, viral, and prokaryotic membrane
models regarding data complexity at time points of 144 and 216 hours also hold for the POPC
and OPPC models tested. The validity of results obtained at early time points, 8 hours and
prior, is also noted here given that low abundance causes instrumental challenges, and thus
results exhibit significant error. Despite these caveats, preferential sn-1 transfer is evident for
both membrane compositions as early as 2 hours into the study. The preference is maintained
for both membrane compositions throughout the time period up to 72 hours. Application
of linear trend fitting to data presented in Fig. 6.39 at time points up to 72 hours informs
upon the relative reaction rates, summarise in Table 6.20. Gradients of formation up to 72
hours for the species associated with sn-1 acyl transfer are steeper than those of their sn-2
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counterparts, indicating a faster associated rate. Beyond 72 hours, at time points 144 and
216 hours, preferential transfer becomes less obvious, attributed to an increased lysolipid
contribution to membrane composition and associated variation in intrinsic lipidation rate.
0 50 100 150 200 250
0
20
40
60
80
Time (h)
%
T
o
ta
l
P
ro
p
ra
n
o
lo
l
C
o
n
te
n
t (a)
0 50 100 150 200 250
0
5
10
15
Time (h)
%
T
o
ta
l
P
ro
p
ra
n
o
lo
l
C
o
n
te
n
t (b)
47Figure 6.39 Comparison of concentrations of total palmitoyl propranolol (green circles) and
total oleoyl propranolol (red squares) intrinsic lipidation products formed under physiological
conditions over a time period up to 216 hours (9 days) within two membrane models: (a)
POPC; (b) OPPC.
Membrane Composition Rate sn-1 Transfer (h−1) Rate sn-2 Transfer (h−1)
POPC 0.48 0.24
OPPC 0.13 0.08
Table 6.20 Rates of sn-1 and sn-2 transfer within POPC and OPPC membrane systems
under physiological conditions. Rates were calculated as the gradient of plots of relevant
product concentration vs. time up to 72 hours.
Data presented in Table 6.21 separates total palmitoylated product and total oleoylated
product formed within POPC and OPPC membranes after 72 hours under physiological
conditions into the constituent O-acylated and N -acylated species. Preferential sn-1 transfer
is exhibited for both POPC and OPPC membranes within both O-acylated and N -acylated
propranolol species. Irrespective of membrane composition and acyl chain chemistry, the
N -acylated propranolol analogue is identified as the major reaction product. The variation
between O-acylated propranolol and N -acylated propranolol concentration is striking, with
the latter present at four to eight times the abundance. This observation is consistent with
the behaviour of propranolol 1 within DOPC and DOPE:DOPG (3:1) membrane models,
previously presented in Table 6.16.
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Membrane
Composition
% O-palmitoyl
propranolol 62
% N -palmitoyl
propranolol 12
% O-oleoyl
propranolol 47
% N -oleoyl
propranolol 13
POPC 4.1 32.8 2.1 16.1
OPPC 1.0 4.4 1.3 7.2
Table 6.21 Comparison of the % of O-palmitoyl propranolol 62, N -palmitoyl propranolol
12, O-oleoyl propranolol 47, and N -oleoyl propranolol 13 after 72 hours under physiological
conditions within POPC and OPPC membranes.
Separation of acylated propranolol 1 derivatives into constituent species can also be achieved
utilising by performing reaction monitoring at regular time points, as demonstrated in Fig. 6.40.
Production of O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 within the POPC
membrane, Fig. 6.40 (a) and (b), increases initially from time point zero before reaching a
plateau. Comparison to data obtained for DOPC suggests a similar mechanism of action,
in which the rate of transesterification is similar to rate of O to N migration. By contrast,
proportion of O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 within an OPPC
membrane exhibits an initial increase followed by a fall, Fig. 6.40 (c) and (d). The decrease
observed between 24 and 72 hours suggests that rate of O to N migration plus hydrolysis
outstrips rate of transesterification. An increased rate of breakdown of the O-acylated products
may be attributed to facilitation of intramolecular transfer or hydrolysis by an increase in
membrane fluidity, or binding orientation of the small molecule.
As shown in Fig. 6.40, N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 formation
follows a pattern in both POPC and OPPC membranes which mimics observations in DOPC,
DOPC:DOPS (4:1), and DOPE:DOPG (3:1) systems. By considering palmitoylated and
oleoylated species together, Fig. 6.41, and fitting the data as shown by the dashed red lines,
an initial lag phase of 4 to 6 hours was determined to precede N -acylated propranolol 1
formation within POPC and OPPC membranes. This lag phase facilitates the required build
up of O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 prior to O to N migration.
Lag phase length calculated by data extrapolation is further supported by analytical detection
of N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 at time points of 4 and 6 hours
for OPPC and POPC respectively. Following the lag phase, proportions of N -palmitoyl
propranolol 12 and N -oleoyl propranolol 13 increase steadily in a linear fashion within both
membrane types. Further highlighting preferential acyl transfer, the rate of N -acylated product
formation is notably increased for species containing the acyl chain transferred from the sn-1
position on the phosphate backbone, Fig. 6.40.
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47Figure 6.40 Comparison of the proportion of total O-acyl propranolol (green circles), and N -
acyl propranolol (red squares) studied under physiological conditions over time period 24 to 72
hours within membrane models: (a) O-palmitoyl propranolol 62 and N -palmitoyl propranolol
12 within a POPC membrane; (b) O-oleoyl propranolol 47 and N -oleoyl propranolol 13
within a POPC membrane; (c) O-palmitoyl propranolol 62 and N -palmitoyl propranolol 12
within an OPPC membrane; (d) O-oleoyl propranolol 47 and N -oleoyl propranolol 13 within
an OPPC membrane.
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47Figure 6.41 Comparison of the proportion of total O-acyl propranolol (experimental data
as green circles and trend fitted by solid green line), and N -acyl propranolol (experimental
data as red squares and trend fitted by dashed red line) studied under physiological conditions
over time period 24 to 72 hours within membrane models: (a) POPC; (b) OPPC. Dashed
lines indicate end of N -acyl propranolol lag phase.
The kinetics of propranolol 1 intrinsic lipidation under physiological conditions across all
membrane types can be summarised into a discrete series of observations. The primary step of
propranolol 1 intrinsic lipidation is an initial transesterification reaction forming O-acylated
propranolol. Production of O-acylated propranolol can be described as a logarithmic curve,
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indicating at initial increase in product followed by a plateau. The plateau is attributed
to a competing intramolecular O to N migration reaction occurring at a similar rate to
transesterification. Migratory product N -acylated propranolol forms at a steady linear rate
following an initial 4 to 6 hour lag phase at 37 ◦C. In addition, two forms of preferential intrinsic
lipidation reactivity were observed under physiological conditions. Eukaryotic membrane
mimic DOPC, containing a PC phosphate head group, exhibits the highest observed levels
of intrinsic lipidation. Acylated product quantities are increased compared to viral and
prokaryotic membranes, despite their increased electrostatic attraction to cationic amphiphilic
propranolol 1. Furthermore, preferential transfer of the acyl chain located at the sn-1 position
on the phosphate backbone, compared to the sn-2 position, is observed irrespective of acyl
chain chemistry. Consideration of membrane binding orientation and proximity between
reactive moieties can explain these observations of preferential intrinsic lipidation.267
6.4 A Kinetic Model for Propranolol Intrinsic Lipidation
Quantification of the products of propranolol intrinsic lipidation has aided in developing
understanding of propranolol 1 reactivity at the membrane interface under physiological
conditions. Enhanced clarity of the mechanisms which facilitate product formation, and iden-
tification of preferential acyl chain transfer has been achieved. Application of these principles
and quantification techniques to intrinsic lipidation systems, whilst varying environmental
factors, provides a mechanism for studying reaction kinetics. Variation of parameters such as
temperature, pH, and form of the lipid aggregate, can determine how these factors impact
upon propranolol 1 reactivity. Understanding the impact of chemical and environmental
parameters upon reaction rate and product formation, provides a means of reaction control.
Potential future exploitation of propranolol 1 intrinsic lipidation relies upon the ability to
successfully command and manipulate reactivity. Determination of industrial and biological
relevance of propranolol 1 intrinsic lipidation is also aided by an improved grasp of the reaction
kinetics.
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Figure 6.42 Summary of the relevant steps required for consideration of propranolol 1
intrinsic lipidation reaction kinetics. A represents propranolol 1, B O-acylated propranolol
derivatives, and C N -acylated propranolol derivatives. Subscript N indicates the neutral
form, and I the ionised form. Inside the green box are membrane bound species, outside are
in solution. Blue arrows highlight transesterification steps, and red intramolecular O to N
migration.
Prior to considering the impact of altered environmental parameters upon propranolol 1
intrinsic lipidation kinetics, the complexity of the process must be noted. Subdivision of
the reaction into relevant steps, each with distinct associated rate constants, is shown by
differential colouring in Fig. 6.42. Several reaction steps can proceed via either the ionised (I)
or the neutral (N) form of propranolol 1, which cannot be distinguished by mass spectrometry.
Clarity can be obtained by considering each step in Fig. 6.42 individually as follows:
1. Association of propranolol 1 with the membrane - Environmental pH relative to the
pK a of propranolol 1 (9.42) determines the proportion of neutral to ionic species. Ionic
propranolol 1 exhibits a temperature dependent decreased logP value compared to
the temperature independent logP of its neutral counterpart.153 Neutral and ionic
propranolol 1 species also vary in membrane binding orientation in accordance with the
pH piston theory.255
2. Transesterification (highlighted blue in Fig. 6.42) - Reversible transesterification is
expected to proceed irrespective of membrane bound propranolol 1 ionisation state.
Comparable solution phase transesterification reactions suggest pH dependent acid and
base catalysed transesterification pathways exist.
3. Acid-base equilibrium of O-acylated propranolol - O-acylated propranolol species exhibit
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decreased pK a values compared to propranolol 1, increasing the proportion of neutral
species available at pH 7.4. Simultaneously, the hydrophobicity of O-acylated propranolol
species promotes the membrane bound state.278
4. Hydrolysis of O-acylated propranolol - Hydrolysis has been determined as a minor
pathway of O-acylated propranolol decomposition in the presence of a membrane.
Hydrolysis can proceed via acid or base catalysed pathways providing sufficient aqueous
content surrounds the species.274
5. Intramolecular O to N migration (highlighted red in Fig. 6.42) - Migration is the major
pathway for O-acylated propranolol decomposition in the presence of a membrane.
Neutral O-acylated propranolol is required as the precursor species to allow the amine
functionality to accept an acyl chain. Currently it is unclear whether O to N migration
proceeds in solution only, within the membrane bound state, or both.
Simplification of propranolol 1 intrinsic lipidation aids in probing the reaction kinetics. To
this end, the following assumptions have been drawn from literature data and previously
discussed experiments:
• Based upon evidence from control experiments, minor side reactions such as phospholipid
hydrolysis and oxidation are considered to have a negligible impact upon the overall
reaction process of intrinsic lipidation.
• Membrane phospholipids, utilised in a ten fold molar ratio compared to propranolol 1,
are considered to be in excess for purposes of kinetics studies.
• Diacylation of propranolol 1 via the intrinsic lipidation pathway does not occur.
• Under conditions studied, intrinsic lipidation does not occur at significant levels be-
tween propranolol 1 and lysolipid. Lysolipids are present solely following phospholipid
hydrolysis, thus abundance levels are low over the relevant time period.
• N -acylated propranolol species are stable thermodynamic reaction products, remaining
membrane bound upon formation due to associated hydrophobicity.
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6.4.1 Influence of Temperature
Reaction kinetics for both solution phase and biological systems are known to be greatly
altered by environmental temperature. Increased temperature provides reactive molecules
with higher energy, aiding their ability to overcome the activation energy barrier to reaction
participation. Further, higher energy levels increase molecular motion, facilitating the collisions
between reactive species required for solution phase reactivity. Influence of temperature upon
propranolol 1 intrinsic lipidation is predicted to be more complex than upon standard solution
phase reaction kinetics. Increased molecular energy within the phospholipid bilayer favours an
increasingly fluid and mobile membrane system, with heightened hydration levels. It is unclear
how increased membrane fluidity will impact the proximity between the phospholipid ester
linkage and the alcohol of membrane bound propranolol 1, however penetration is predicted to
be similar assuming no modification to membrane phase or propranolol 1 ionisation. Proximity
between reactive moieties is required for propranolol 1 intrinsic lipidation to successfully
proceed via transesterification. Further, within a heavily hydrated membrane, hydrolysis
of both O-acylated propranolol and membrane phospholipids is expected to be promoted.
Favoured hydrolysis compared to transesterification or intramolecular O to N migration would
diminish formation of acylated propranolol derivatives. Determining how these factors are
balanced, and the resulting impact upon propranolol 1 intrinsic lipidation requires study of
the reaction at temperatures above and below physiological conditions of 37 ◦C.
Examination of propranolol 1 intrinsic lipidation at varying temperature was conducted by
combining propranolol 1 with a phospholipid membrane at 4 ◦C, 37 ◦C, and 57 ◦C. Reaction
mixture analysis was conducted under optimised LCMS conditions at time points of 24, 72
and 144 hours. Time points beyond this range were not investigated during the course of this
study due to challenges associated with reaction mixture stability, and instrument detection
limitations. Eukaryotic DOPC, viral DOPC:DOPS (4:1), and prokaryotic DOPE:DOPG (3:1)
membranes were tested in order to investigate the effect of temperature upon reaction rate in
the presence of different phosphate head groups associated with different membrane models.
POPC and OPPC were also tested in order to determine whether preferential sn-1 acyl chain
transfer observed at 37 ◦C is maintained despite changes in temperature.
The dependence of propranolol 1 intrinsic lipidation at different temperatures can be examined
by considering total acylated product formation. Total acylated product is defined as the sum
of O-palmitoyl propranolol 62, O-oleoyl propranolol 47, N -palmitoyl propranolol 12, and
Chapter 6. Propranolol Intrinsic Lipidation in vitro 185
N -oleoyl propranolol 13. Total acylated product formation within each membrane type studied
following 72 hours is presented in Fig. 6.43 at 4 ◦C, 37 ◦C and 57 ◦C. Increased acylated
product formation, indicative of the extent of propranolol 1 intrinsic lipidation, is evident
for each membrane type upon temperature increase. Reactivity is promoted by increased
molecular energy available at higher temperatures, aiding in overcoming the activation energy
barrier for the preliminary transesterification step required for propranolol 1 intrinsic lipidation.
Increased molecular mobility attributed to higher temperatures is not noted to reduce reactivity
by disrupting the proximity of reactive moieties. One notable exception to these observations
is within the POPC membrane, Fig. 6.43 (b), where 55 % conversion to acylated product
is observed at 37 ◦C, compared to 45 % at 57 ◦C. At 37 ◦C substantial differences in peak
area of acylated products were observed between each of the triplicate samples analysed.
Identification of anomalous results therefore proves challenging, resulting in increased error
and reduced confidence in the data at this time point. Consequently, the value of 55 %
attributed to total acylated product within a POPC membrane at 37 ◦C may be higher than
the true value. Alternatively, propranolol 1 intrinsic lipidation within a POPC membrane may
be favoured at 37 ◦C compared to 57 ◦C. Unfavourable disruption to key reactivity factors
such as proximity of reactive moieties or membrane binding orientation may occur within the
POPC membrane at 57 ◦C, resulting in reduced propranolol 1 intrinsic lipidation.267
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1Figure 6.43 Total acylated product formed at varying temperatures (4 ◦C, 37 ◦C and 57
◦C) within 72 hours at pH 7.4, in the presence of five membrane systems: (a) DOPC (red
circles), DOPC:DOPS 4:1 (blue squares) and DOPE:DOPG 3:1 (green triangles) ; (b) POPC
(purple cicles) and OPPC (black squares).
Total acylated product formation can also be utilised to determine the extent of propranolol 1
intrinsic lipidation with varying temperature at time points of 24 and 144 hours, summarised
in Table 6.22 and Table 6.23 respectively. Increased total acylated product, indicative of
increased propranolol 1 intrinsic lipidation, is observed at higher temperatures across all
membrane types. Promotion of reactivity at higher temperatures at 24 hours and 144 hours,
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attributed to increased ability to overcome the activation energy barrier of transesterification,
supports the observations made following analysis at 72 hours.
Total Acylated Product (%)
Membrane Type 4 ◦C 37 ◦C 57 ◦C
DOPC 0.2 4.6 20.6
DOPC:DOPC (4:1) 0.0 0.9 5.2
DOPE:DOPG (3:1) 0.0 1.6 12.4
POPC 0.0 6.0 28.7
OPPC 0.0 9.3 23.6
Table 6.22 Proportion of total acylated product formed after 24 hour incubation at varying
temperatures (4 ◦C, 37 ◦C, and 57 ◦C) within five membrane types.
Total Acylated Product (%)
Membrane Type 4 ◦C 37 ◦C 57 ◦C
DOPC 0.2 10.2 56.8
DOPC:DOPC (4:1) 0.1 1.0 20.9
DOPE:DOPG (3:1) 0.1 2.8 22.2
POPC 0.7 1.6 47.5
OPPC 0.5 3.7 65.4
Table 6.23 Proportion of total acylated product formed after 144 hour incubation at varying
temperatures (4 ◦C, 37 ◦C, and 57 ◦C) within five membrane types.
Preferential reactivity at temperatures greater than 37 ◦C can be determined by comparison of
the proportion of total acylated product formed by propranolol 1 intrinsic lipidation. To this
end, eukaryotic membrane model DOPC, viral model DOPC:DOPS (4:1), and prokaryotic
model DOPE:DOPG (3:1) were examined at 4 ◦C and 57 ◦C. Under physiological conditions
the observed order of reactivity towards propranolol 1 intrinsic lipidation, reported in Section
6.3.3, is eukaryotic, followed by prokaryotic, and finally viral. Presented in Fig. 6.43, this
observed reactivity trend is retained at 4 ◦C and 57 ◦C following 72 hours incubation. Further,
the trend is also noted following analysis of samples incubated at 4 ◦C and 57 ◦C at 24 and
144 hours, as shown in Table 6.22 and Table 6.23. Conservation of this reactivity trend
occurs despite temperature variation, and the associated modifications to membrane phase
and fluidity. These membrane modifications may be expected to level subtle differences
between the three membrane systems, such as domain formation and propranolol 1 binding
orientation. However, given retention of the reactivity trend upon temperature variation,
sufficient differences between the three membrane types as related to propranolol 1 intrinsic
lipidation, must remain.
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Investigation of the impact of temperature change upon the preferential sn-1 acyl chain
transfer observed at 37 ◦C, was also conducted. Investigation was facilitated by comparison
of POPC and OPPC membranes, phospholipids comprised of identical acyl chain moieties
in opposing backbone positions. Fig. 6.44 presents total palmitoylated product and total
oleoylated product observed for each membrane type following 72 hour incubation at 4 ◦C,
37 ◦C, and 57 ◦C. Preferential sn-1 transfer, palmitoyl for POPC and oleoyl for OPPC,
is observed for both membrane compositions at 4 ◦C and 57 ◦C. This preference is noted
despite the low abundance of palmitoylated and oleoylated products formed by propranolol
1 intrinsic lipidation at 4 ◦C. Preferential sn-1 transfer at 4 ◦C and 57 ◦C after 72 hours is
attributed to increased proximity between the alcohol of membrane bound propranolol 1 and
the phospholipid sn-1 ester linkage, compared to the sn-2 linkage.
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1Figure 6.44 Total palmitoylated product (green circles) and total oleoylated product (red
squares) formed by propranolol 1 intrinsic lipidation after 72 hours at varying temperatures
(4 ◦C, 37 ◦C and 57 ◦C) in the presence of: (a) POPC membrane; (b) OPPC membrane.
Preferential sn-1 acyl chain transfer persists at 57 ◦C within both POPC and OPPC membranes
at the additional time points of 24 and 144 hours, as highlighted in Table 6.24. However,
more complex results are observed upon comparison of total palmitoylated product and total
oleoylated product formed at 4 ◦C after 24 and 144 hours. Following a 24 hour incubation at 4
◦C, neither palmitoylated propranolol nor oleoylated propranolol are observed analytically for
POPC or OPPC membranes, Table 6.25. Lack of product observation prevents determination
of preferential acyl chain transfer, and is attributed to reduced intrinsic lipidation reactivity at
low temperatures combined with altered product distribution. Insufficient molecular energy to
overcome reaction activation energy, combined with reduced molecular mobility, can explain
observed reactivity limits. Analysis of samples incubated at 4 ◦C for 144 hours with a POPC
membrane suggest retention of preferential sn-1 acyl chain transfer. However, this preferential
sn-1 transfer is not reflected within an OPPC membrane following 144 hours at 4 ◦C, Table 6.25.
By contrast, increased sn-2 transfer results in slightly higher levels of palmitoylated propranolol
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compared to oleoylated propranolol. Observed differences in preferential acyl chain transfer
may be attributed to the low levels of propranolol 1 intrinsic lipidation at 4 ◦C, resulting in
product abundance at the limit of instrument detection and thus increasing the associated
error. Alternatively, preferential sn-1 transfer may be replaced by either preferential sn-2
transfer or a distinction based upon acyl chain chemistry. A change in transfer preference
at low temperature is possible within the confines of the less fluid membrane present at 4
◦C, particularly considering the increased activation energy attributed to palmitoyl chain
migration in Section 6.3.2.
Membrane Type Time (hours) Palmitoylated Product (%) Oleoylated Product (%)
POPC 24 18.1 10.6
OPPC 24 9.5 14.1
POPC 144 29.9 17.7
OPPC 144 28.8 36.5
Table 6.24 Proportion of total palmitoylated product and total oleoylated product formed
at 57 ◦C within POPC and OPPC membranes after 24 and 144 hours.
Membrane Type Time (hours) Palmitoylated Product (%) Oleoylated Product (%)
POPC 24 0.0 0.0
OPPC 24 0.0 0.0
POPC 144 0.6 0.1
OPPC 144 0.3 0.2
Table 6.25 Proportion of total palmitoylated product and total oleoylated product formed
at 4 ◦C within POPC and OPPC membranes after 24 and 144 hours.
Analysis has been conducted to determine the influence of temperature upon propranolol 1
intrinsic lipidation rate and reactivity preferences. Temperature has also been determined to
influence the rate of intramolecular O to N migration within acylated propranolol species.
Combining these two phenomena, it is possible to determine the influence of temperature upon
the relative product distribution of O-acylated and N -acylated propranolol formed by intrinsic
lipidation. Lowering environmental temperature from 37 ◦C to 4 ◦C results in formation
of O-oleoyl propranolol 47 as sole intrinsic lipidation product within DOPC, DOPC:DOPS
(4:1) and DOPE:DOPG (3:1) membranes over the time period studied, Fig. 6.45. Lack of
N -oleoyl propranolol 13 formation is attributed to a diminished O to N migration rate at 4 ◦C.
O-oleoyl propranolol 47 formation at 4 ◦C is first observed at 24 hours within the eukaryotic
DOPC membrane, and at 72 hours within the viral and prokaryotic systems. Following initial
formation, a slow increase in O-oleoyl propranolol 47 is observed within DOPC:DOPS (4:1)
Chapter 6. Propranolol Intrinsic Lipidation in vitro 189
and DOPE:DOPG (3:1) membrane models, supporting a low rate of initial transesterification
and minimal O to N migration.
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Figure 6.45 Total oleoylated product equal to O-oleoyl propranolol 47 only, formed over
time at 4 ◦C and pH 7.4 in the presence of DOPC (red circles), DOPC:DOPS 4:1 (blue
squares) and DOPE:DOPG 3:1 (green triangles) membrane systems.
Study of acylated product formation at 4 ◦C within POPC and OPPC membranes, Fig. 6.46,
can also offer insight into the kinetics of propranolol 1 intrinsic lipidation. Acylated product
formation is observed within both membrane systems from 72 hours, however unlike other
membrane systems studied at 4 ◦C, both O-acylated propranolol and N -acylated propranolol
species contribute. N -palmitoyl propranolol 12 is noted as the sole N -acylated species in both
POPC and OPPC membrane systems. Increased rate of O to N migration for O-palmitoyl
propranolol 62 compared to O-oleoyl propranolol 47 could explain this observation. However,
previously determined rate constants for migration (k1) of 0.7× 10−3 h−1 and 2.6× 10−3 h−1
for O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 respectively do not support this
theory. Alternatively, the presence of N -palmitoyl propranolol 12 as sole N -acylated product
may suggest preferential transesterification of the palmitoyl moiety compared to the oleoyl
moiety at 4 ◦C. Despite low product abundance, it has been determined that N -palmitoyl
propranolol 12 formation within POPC and OPPC systems proceeds at 4 ◦C as observed
under physiological conditions. An initial lag phase of 45 to 50 hours, highlighted by the
vertical line in Fig. 6.46 (b), increased compared to 4 to 6 hours at 37 ◦C, is followed by
an increase in N -palmitoyl propranolol 12 concentration. Within the OPPC membrane the
increase in N -palmitoyl propranolol 12 concentration occurs more steadily, as shown by the
dashed line in Fig. 6.46 (b). By contrast, in the presence of the POPC membrane the increase
seems initially fast but then plateaus, suggestive of rate variation. Simultaneously, production
of O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 is observed to progress linearly
within POPC and OPPC membranes at 4 ◦C, as shown by the solid green lines in Fig. 6.46.
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Data extrapolation suggests transesterification commences at time point zero, with the lack
of observed product at 24 hours attributed to the low abundance of acylated product, less
that 0.05 % (<1 ng mL−1).
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1Figure 6.46 Total O-acylated product (experimental data as green circles and trend fitted
with a solid green line), and total N -acylated product (experimental data as red squares and
trend fitted with a dashed red line), formed from propranolol 1 at 4 ◦C in the presence of: (a)
POPC membrane; (b) OPPC membrane. The box indicates the proportion of O-acylated
product at 24 hours, below the limit of instument detection. The vertical line indicates end of
N -acylated derivative lag phase.
Increasing environmental temperature from 37 ◦C to 57 ◦C is also predicted to influence
the distribution of O-acylated and N -acylated products of propranolol 1 intrinsic lipidation.
Similar trends in product formation at 57 ◦C are observed for membranes containing a
PC phosphate head group, as shown in Fig. 6.47. Unlike at 4 ◦C and 37 ◦C, N -acylated
propranolol production at 57 ◦C does not exhibit a lag phase on the scale of the time period
studied. Data extrapolation shown by the red dashed lines in Fig. 6.47, suggests N -acylated
propranolol formation commences within minutes of time point zero, suggesting no requirement
for prior O-acylated propranolol accumulation. N -acylated product concentration proceeds to
increase linearly within DOPC and OPPC systems, Fig. 6.47 (a) and (c), with slope gradient
providing a means of formation rate comparison. At 57 ◦C the rate of N -acylated propranolol
formation by intramolecular O to N migration is increased compared to at 37 ◦C, as shown
in Table 6.26. O-acylated propranolol formation within PC membranes at 57 ◦C also differs
from the logarithmic curve observed under physiological conditions. As shown in Fig. 6.47,
an initial increase in O-acylated propranolol formation over 24 hours at 57 ◦C is followed
by a steady decrease in concentration at later time points of 72 and 144 hours. Decreasing
concentration is indicative of a faster rate of O-acylated propranolol decomposition by O to
N migration compared to O-acylated propranolol formation by transesterification.
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1Figure 6.47 Total O-acylated product (experimental data as green circles and trend fitted
with a solid green line), and total N -acylated product (experimental data as red squares and
trend fitted with a red dashed line), formed at 57 ◦C in the presence of: (a) DOPC; (b) POPC;
(c) OPPC.
Membrane Type Rate at 37 ◦C (h−1) Rate at 57 ◦C (h−1)
DOPC 0.13 0.36
OPPC 0.17 0.19
Table 6.26 Comparison of the rate of N -acyl propranolol formation within two membrane
types at 37 ◦C and 57 ◦C.
Study of N -oleoyl propranolol 13 production at 57 ◦C within viral DOPC:DOPS (4:1) and
prokaryotic DOPE:DOPG (3:1) membranes reveals similar results to those observed for PC
membranes, Fig. 6.48. N -oleoyl propranolol 13 formation commences within minutes of
time point zero in the prokaryotic membrane, indicating a diminished lag phase compared
to at physiological temperatures. Viral membrane DOPC:DOPS (4:1) exhibits a 5 hour lag
phase prior to N -oleoyl propranolol 13 production, consistent with the reduced membrane
reactivity. N -oleoyl propranolol 13 concentration increases linearly up to 144 hours within
the viral membrane model, Fig. 6.48 (a), whereas concentration increases and then plateaus
in the presence of DOPE:DOPG (3:1), shown in Fig. 6.48 (b). O-oleoyl propranolol 47
concentration at 57 ◦C does not exhibit a significant decrease over time within viral and
prokaryotic membranes, in contrast to PC membranes. A logarithmic curve is observed
for O-oleoyl propranolol 47 production within the viral membrane at 57 ◦C. Analogous to
observations under physiological conditions, this trend suggests similar reaction rates for
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transesterification and O-oleoyl propranolol 47 decomposition. At 57 ◦C, contributions from
both hydrolysis and O to N migration have previously been shown to influence decomposition
in approximately a 1:4 ratio. Within the prokaryotic membrane insufficient data points exist
to determine whether O-oleoyl propranolol 47 concentration is best characterised by a linear
decrease or a logarithmic curve. Consequently, transesterification rate must be similar or lower
than rate of O-oleoyl propranolol 47 decomposition by hydrolysis and migration pathways.
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1Figure 6.48 Total O-acylated product (experimental data as green circles and trend fitted
with a solid green line), and total N -acylated product (experimental data as red squares),
formed at 57 ◦C in the presence of: (a) DOPC:DOPS (4:1); (b) DOPE:DOPG (3:1).
The influence of temperature upon the reaction kinetics of propranolol 1 intrinsic lipidation
can be summarised into key findings. Increased temperature is observed to increase the rate
of both preliminary intrinsic lipidation step transesterification, and secondary intramolecular
O to N migration. Consequently, higher levels of total acylated intrinsic lipidation product
are evident across all membrane types upon temperature increase from 4 ◦C through to 57
◦C. Temperature is also observed to modify product distribution, with higher temperatures
favouring thermodynamic product N -acylated propranolol over kinetic product O-acylated
propranolol. Increased energy availability, aiding in molecular mobility and membrane flu-
idity at high temperatures is believed to facilitate this distribution. Additionally, higher
temperatures provide further energy to aid in overcoming the required activation energy
barrier, promoting reactivity. Vital reactivity parameters, membrane binding orientation and
proximity of reactive moieties, are not predicted to be negatively influenced by increased
temperature, as had been speculated. Preferential reactivity trends noted at 37 ◦C are broadly
retained at 4 ◦C and 57 ◦C. Included in these are favourable sn-1 acyl chain transfer, and
favourable eukaryotic reactivity compared to viral and prokaryotic analogues.
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6.4.2 Influence of pH
Modification to propranolol 1 intrinsic lipidation kinetics can be achieved by altering the
environmental parameter of pH from physiological conditions. Predicting the effect of modified
pH upon intrinsic lipidation reactivity is challenging due to the complex nature of the
multi-step reaction. Fundamentally, environmental pH alters the proportion of ionised to
neutral propranolol 1 available for membrane association. Altered ratio of ionised to neutral
propranolol 1, affects the rate of the preliminary membrane binding step required to facilitate
propranolol 1 intrinsic lipidation.158 Furthermore, altered proportion can modify propranolol 1
membrane penetration and binding orientation, influencing proximity of reactive moieties, and
nucleophilicity of the alcohol and amine residues.267 Nucleophilicity changes would present as a
modified rate of intrinsic lipidation, altering rate of both transesterification and intramolecular
O to N migration. O-acylated propranolol decomposition by hydrolysis can in principle be
influenced by pH if the decomposition is subject to general acid or base catalysis, ultimately
altering intrinsic lipidation product stability and distribution.278,280 Consideration must also
be given to phospholipid hydrolysis modulation by environmental pH and potentially by either
neutral or ionised propranolol 1 analogues. Resulting modified lysolipid proportion within
the bulk membrane impacts propranolol 1 reactivity towards intrinsic lipidation, membrane
disruption and possible micelle formation.31
Considering the appreciable and complex influence of pH upon the multi-step process of
intrinsic lipidation, experiments were designed to probe reactivity beyond physiological
conditions. Buffer solution of 10 mM ammonium bicarbonate adjusted with formic acid to
pH 4.30 was prepared in accordance with mobile phase preparation guidelines.286 Intrinsic
lipidation reaction mixtures were incubated within this pH 4.30 buffer at 37 ◦C using five
membrane types. Eukaryotic DOPC, viral DOPC:DOPS (4:1), and prokaryotic DOPE:DOPG
(3:1) for comparison of membrane models, POPC and OPPC to study preferential acyl transfer.
Triplicate sample analysis was conducted following incubation times of 24, 72 and 144 hours.
Reaction mixture constituents were quantified according to the previously defined methodology
presented in Section 6.3.1.
Propranolol 1 intrinsic lipidation is not observed within eukaryotic, viral or prokaryotic
membrane models following 24 or 72 hour incubation at pH 4.30, Table 6.27. The slow acid
catalysed transesterification rate reported for commercial biodiesel production likely applies
to the transesterification step of intrinsic lipidation.248,287 Combined with increased acid
194 6.4. A Kinetic Model for Propranolol Intrinsic Lipidation
catalysed hydrolysis suggested by the literature, O-oleoyl propranolol 47 formation may be
non-existent or transient, preventing analytical observation.278,280 Further, at pH 4.30 the
predominant forms of propranolol 1 and O-oleoyl propranolol 47 are their ionised analogue.
Amine protonation reduces nucleophilicity and makes the process of intramolecular O to
N acyl chain migration unfavourable. Analysis of samples incubated for 144 hours at pH
4.30, Table 6.27, indicate N -oleoyl propranolol 13 concentrations of <0.5 ng mL−1 across all
membrane models despite lack of O-oleoyl propranolol 47. Direct nucleophilic amine activity
is unlikely given its protonated nature, instead the theory of transient O-oleoyl propranolol 47
formation is supported. Competing transesterification and acid catalysed hydrolysis form low
level transient O-oleoyl propranolol 47. Slow O to N migration proceeds within the neutral
analogue of this transient species, resulting in formation of stable N -oleoyl propranolol 13.
Alternative theories such as acid catalysed oxidation or hydrolysis of the double bound resulting
in modified product formation have been discounted due to lack of analytical observation.
Further support is derived from intact double bond retention within parent phospholipid and
lysolipid species at pH 4.30. Insufficient product quantities prevented an accurate comparison
between models to determine preferential transfer.
O-Oleoyl
Propranolol 47
(%)
N -Oleoyl
Propranolol 13
(%)
Time
24 h
Time
72 h
Time
144 h
Time
24 h
Time
72 h
Time
144 h
DOPC 0.0 0.0 0.0 0.0 0.0 < 0.1
DOPC:DOPS (4:1) 0.0 0.0 0.0 0.0 0.0 < 0.1
DOPE:DOPG (3:1) 0.0 0.0 0.0 0.0 0.0 < 0.1
Table 6.27 Comparison % total propranolol 1 content attributed to O-oleoyl propranolol
47 and N -oleoyl propranolol 13 at pH 4.3 in the presence of three membrane models: (i)
DOPC; (ii) DOPC:DOPS (4:1); (iii) DOPE:DOPG (3:1).
Membranes containing two distinct acyl chain chemistries, such as POPC and OPPC, exhibit
interesting intrinsic lipidation reactivity differences at pH 4.30. Oleoyl transfer proceeds in a
similar fashion to the DOPC membrane, as shown in Table 6.29, with N -oleoyl propranolol
13 the sole intrinsic lipidation product at concentrations of <0.5 ng mL−1 following 144 hours.
This observation is attributed to transient O-oleoyl propranolol 47 formation followed by O
to N migration. Similarly, palmitoyl transfer to either the alcohol or amine moiety is not
definitively observed following 24 or 72 hour incubation, as shown in Table 6.28. The slow
transesterification rate combined with decreased O to N migration within the protonated
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species can explain this observation. However, at 144 hours the proportion of total propranolol 1
content attributed to O-palmitoyl propranolol 62 was calculated to be 4.0 % (24.9 ng mL−1) for
POPC, and 4.9 % (24.5 ng mL−1) for OPPC. Observed across triplicate samples, this sudden
increase in O-palmitoyl propranolol 62 content cannot be attributed to sample contamination
or dilution error. The sudden concentration jump is justified by either continuous O-palmitoyl
propranolol 62 build up, which was below instrument detection limit at earlier time points, or
by a sudden environment induced increase in transesterification rate as time progresses. In
tandem, O-palmitoyl propranolol 62 decomposition by acid catalysed hydrolysis and O to N
migratory pathways must be decreased compared to those of the oleoylated analogue.
O-Oleoyl
Propranolol 47
(%)
N -Oleoyl
Propranolol 13
(%)
Time
24 h
Time
72 h
Time
144 h
Time
24 h
Time
72 h
Time
144 h
POPC 0.0 0.0 4.0 0.0 0.0 0.0
OPPC 0.0 0.0 4.9 0.0 0.0 0.0
Table 6.28 Comparison % total propranolol 1 content attributed to O-palmitoyl propranolol
62 and N -palmitoyl propranolol 12 at pH 4.3 in the presence of two membrane models: (i)
POPC; (ii) OPPC.
O-Oleoyl
Propranolol 47
(%)
N -Oleoyl
Propranolol 13
(%)
Time
24 h
Time
72 h
Time
144 h
Time
24 h
Time
72 h
Time
144 h
POPC 0.0 0.0 0.0 0.0 0.0 < 0.1
OPPC 0.0 0.0 0.0 0.0 0.0 < 0.1
Table 6.29 Comparison % total propranolol 1 content attributed to O-oleoyl propranolol
47 and N -oleoyl propranolol 13 at pH 4.3 in the presence of two membrane models: (i) POPC;
(ii) OPPC.
Study of propranolol 1 intrinsic lipidation kinetics under basic conditions, above the pK a
of the propranolol 1 ammonium, also provides valuable reactivity information. Under basic
conditions propranolol 1 predominantly adopts the neutral form, expected to enhance base
catalysed transesterification and intramolecular O to N migration. Preparation of a 10 mM
ammonium bicarbonate buffer solution adjusted to pH 10.4 using aqueous ammonia.286 For
comparability to studies at pH 4 and pH 7, environmental temperature of 37 ◦C and use of
five model membranes were retained.
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Propranolol 1 intrinsic lipidation at pH 10.4 is evident across all five membrane models from
primary analysis at time point 24 hours through to final analysis at 144 hours, Fig. 6.49. After
144 hours between 12 % and 52 % of the total propranolol 1 derived content can be attributed to
acylated species. In the presence of all membrane systems studied, acylated product formation
exhibits an initially sharp increase in intrinsic lipidation, followed by a subsequent reduction
in rate after 24 hours. This variation in rate is attributed to reduced propranolol 1 content
combined with modified membrane composition and characteristics. Reactivity trends noted
at physiological pH are retained at pH 10.4, with eukaryotic model DOPC indicating increased
reactivity compared to prokaryotic and viral counterparts, Fig. 6.49 (a). Furthermore, in line
with observations made under physiological conditions, total reactivity is heightened within
the POPC membrane at pH 10.4 compared to the OPPC membrane, Fig. 6.49 (b). Despite
comparability in observed trends, overall reactivity differences are evident between intrinsic
lipidation at pH 7.4 and pH 10.4. Gradients of total acylated product formation for DOPC,
DOPC:DOPS (4:1), and DOPE:DOPG (3:1) membranes are steeper at pH 10.4 than pH 7.4,
indicating increased rate of intrinsic lipidation. For example, at pH 10.4 the gradient of total
acylated product concentration over time within the DOPC membrane is 0.38 h−1, more than
twice that of gradient 0.17 h−1 observed at pH 7.4. The increased rate of intrinsic lipidation
under basic conditions is attributed to base catalysis of the transesterification step of intrinsic
lipidation increasing its rate, combined with enhanced nucleophilicity of the reactive moieties
within propranolol 1. Diminished O-acylated propranolol decomposition by the hydrolysis
pathway in favour of O to N migration is known at basic pH in solution, which may also aid
in enhancing intrinsic lipidation product retention within the membrane.278,280
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Figure 6.49 Total acylated product formed at pH 10.4 and 37 ◦C within 72 hours, in the
presence of five membrane systems: (a) DOPC (experimental data as red circles and connected
with a solid red line), DOPC:DOPS 4:1 (experimental data as blue squares and connected
with a blue dashed line line) and DOPE:DOPG 3:1 (experimental data as green triangles
and connected with a dotted and dashed green line); (b) POPC (experimental data as purple
circles and connected with a solid purple line) and OPPC (experimental data as black squares
and connected with a dashed black line).
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Dividing total acylated product proportion within POPC and OPPC systems into its respective
palmitoylated and oleoylated constituents provides further insight into reactivity differences
within multi-acyl phospholipid membranes. Following 24 hour incubation at pH 10.4, Table 6.30,
preferential sn-1 acyl chain transfer occurs, correlating with observations at physiological
pH. Proximity between the sn-1 ester linkage on the phosphate backbone and the alcohol
of membrane bound propranolol 1 could explain this preference. However, comparison of
palmitoylated to oleoylated product ratio after 144 hours incubation at basic pH, Table 6.30,
indicates increased palmitoylated propranolol within both POPC and OPPC membranes.
Preferential palmitoyl transfer has been noted previously within temperature related kinetics
studies of intrinsic lipidation, and at acidic pH. Attribution of preferential palmitoyl transfer
to modification of oleoylated product by double bond hydrolysis, oxidation and diacylation,
or to instrument concentration limitations, can be disproved and discounted. Rather, a
concious modification in preferential transfer must occur as the intrinsic lipidation progresses
under these conditions, catalysed by changes in rates of the relevant steps or by variation
in environmental conditions. Study of the palmitoylated product distribution may aid in
providing further insight.
Membrane Composition P:O Ratio at 24 hours P:O Ratio at 144 hours
POPC 16.3 : 7.8 35.2 : 16.5
OPPC 6.8 : 9.5 16.1 : 14.5
Table 6.30 Comparison of the total palmitoylated product (P) to total oleoylated product
(O) ratio within POPC and OPPC membranes after 24 hours and 144 hours at pH 10.4 and
37 ◦C.
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Figure 6.50 N -oleoyl propranolol 13 formation over 144 hours at pH 10.4 and 37 ◦C within
DOPC (experimental data as red circles and fitted with a solid red line), DOPC:DOPS 4:1
(experimental data as blue squares and fitted with a blue dashed line line) and DOPE:DOPG
3:1 (experimental data as green triangles and fitted with a dotted and dashed green line)
membranes. Vertical lines indicate end of lag phase.
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The distribution of O-acylated and N -acylated propranolol 1 intrinsic lipidation products
is also altered by environmental pH. Fig. 6.50 shows the formation of N -oleoyl propranolol
13 within eukaryotic, viral and prokaryotic membrane models at pH 10.4. Analogously to
observations made at physiological pH, N -oleoyl propranolol 13 concentration increases linearly
over time following an initial lag phase. Extrapolation of available data determines the lag
phase lengths as approximately 6 hours, 17 hours, and 12 hours for DOPC, DOPC:DOPS (4:1),
and DOPE:DOPG (3:1) systems respectively. N -oleoyl propranolol 13 lag phase length across
all systems at pH 10.4 is increased compared to the 4 to 6 hours observed at physiological
pH. This increased lag time may be accounted for by a requirement for increased O-oleoyl
propranolol 47 concentrations prior to commencement of O to N migration. Alternatively, O
to N migration may not proceed when O-oleoyl propranolol 47 is membrane bound or within
certain binding orientations, slowing N -oleoyl propranolol 13 formation at basic pH where the
neutral species is predominantly membrane associated. Furthermore, under basic conditions
increased neutral membrane bound propranolol 1 may facilitate direct amine reactivity. Amine
proximity to the phospholipid ester linkages within the binding orientation of the neutral
species is expected to aid in direct reactivity. Overall the physiological pattern of reactivity,
eukaryotic followed by prokaryotic and finally viral, is retained for N -oleoyl propranolol 13 at
pH 10.4.
N -palmitoyl propranolol 12 and N -oleoyl propranolol 13 concentrations within POPC and
OPPC membranes under basic conditions are shown in Fig. 6.51. Acyl chain transfer from
the sn-1 position proceeds through a lag phase of less than one hour and approximately 4
hours for POPC and OPPC respectively, followed by linear increases of differing rates. Given
comparable migratory rate constants for palmitoyl and oleoyl moieties at 37 ◦C, preferential
transfer must result from favourable sn-1 reactivity at the transesterification step producing an
increased quantity of the relevant O-acylated precursor. Ultimately increased sn-1 precursor
availability results in an increased concentration of the relevant N -acylated analogue. Transfer
of sn-2 position acyl chains within POPC and OPPC membrane systems proceeds as a linear
increase in relevant product concentration following a lag phases 7 to 8 hours. Differences
in lag phase length support a hypothesis that O-acylated precursor availability is vital in
determining migratory rate and N -acylated species concentration.
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1Figure 6.51 N -palmitoyl propranolol 12 (experimental data as green circles and fitted with
a solid green line) and N -oleoyl propranolol 13 (experimental data as red squares and fitted
with a dashed red line) formation over 144 hours at pH 10.4 and 37 ◦C within membrane
systems of: (a) POPC; (b) OPPC. Vertical lines indicate end of lag phase.
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Figure 6.52 O-oleoyl propranolol 47 formation over 144 hours at pH 10.4 and 37 ◦C within
membrane systems of DOPC (experimental data as red circles and connected with a solid red
line), DOPC:DOPS 4:1 (experimental data as blue squares and fitted with a blue dashed line
line) and DOPE:DOPG 3:1 (experimental data as green triangles and fitted with a dotted
and dashed green line).
O-oleoyl propranolol 47 concentration within viral membrane model DOPC:DOPS (4:1)
increases and plateaus over 144 hours at pH 10.4, Fig. 6.52. The plateau, also observed
at physiological pH, indicates comparable rates of O-oleoyl propranolol 47 formation and
decomposition. By contrast, O-oleoyl propranolol 47 concentration within eukaryotic and
prokaryotic systems under basic conditions shows an initial increase over 24 hours, followed
by reduction to steady state concentrations. Also notable at high temperatures, reduction in
O-oleoyl propranolol 47 concentration is characteristic of a faster rate of ester decomposition
compared to formation. Given previous observations that membrane bound O-oleoyl propra-
nolol 47 decomposition proceeded by O to N migration only under physiological conditions,
this is presumed as the mechanism. Increased migration rate at pH 10.4 compared to pH 7
can be attributed to an increased proportion of neutral O-oleoyl propranolol 47 under basic
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conditions compared to physiological pH, facilitating acyl chain acceptance by the amine
functionality.
O-oleoyl propranolol 47 formation within POPC and OPPC membranes at pH 10.4 proceeds
in an analogous fashion to within the DOPC membrane Fig. 6.53. An initial concentration
increase is followed by a reduction to a steady state concentration, indicating a higher rate of O
to N migration compared to transesterification. O-palmitoylated propranolol 62 concentration
presents with a different trend, increasing to time point 24 hours, decreasing at 72 hours, and
subsequently increasing again at final time point 144 hours. The final concentration increase
at 144 hours in OPPC results in the previously discussed loss of preferential sn-1 transfer
in favour of palmitoyl chain transfer. Determining the underlying causes of the observed
trend in O-palmitoylated propranolol 62 concentration under basic conditions is challenging,
especially given that only three data points are available. Varied rate of formation or
decomposition over the time period studied provides the most likely explanation. O-palmitoyl
propranolol 62 decomposition by the hydrolysis pathway not utilised by O-oleoyl propranolol
47 potentially varies depending upon partition coefficients and membrane hydration levels.
These parameters alter as the reaction progresses, changing the concentration and nature of
membrane bound species, and disrupting the bulk membrane. Lysolipid concentration, upon
general base catalysed hydrolysis of phospholipids, also increases as reaction time progresses.
Intrinsic lipidation reactivity between lysolipids and propranolol 1 may occur, altering rate of
O-palmitoyl propranolol 62 formation.
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1Figure 6.53 O-palmitoyl propranolol 62 (experimental data as green circles and connected
with a solid green line) andO-oleoyl propranolol 47 (experimental data as red squares and
connected with a dashed red line) formation over 144 hours at pH 10.4 and 37 ◦C within
membrane systems of: (a) POPC; (b) OPPC.
The influence of pH alteration upon rate of propranolol 1 intrinsic lipidation and product
distribution can be summarised as follows. pH reduction from neutral 7 to acidic 4.3 diminishes
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intrinsic lipidation reactivity, producing N -oleoyl propranolol 13 as sole reaction product after
144 hours within oleoylated systems. Observations are attributed to an increased proportion
of ionised species within the reaction mixture, reducing base catalysis, membrane affinity,
nucleophilicity and amine availability for O to N migration. Combined with increased acid
catalysed hydrolysis of O-acylated intermediates, only transient low level formation occurs
preventing successful analysis. Low product abundance prevents identification of trends
in preferential transfer under acidic conditions. Conversely, at basic pH 10.4 an increased
proportion of neutral reactive propranolol 1 derived species are present, aiding in intrinsic
lipidation progression. As a result, total intrinsic lipidation product formation is increased
under these conditions compared to physiological pH. Furthermore, reactivity trends in
which eukaryotic membranes exhibit heightened reactivity compared to prokaryotic and viral
membrane systems are retained despite pH modification. Rate of intramolecular O to N
migration is faster than transesterification at pH 10.4 across most systems, despite increased
lag time compared to physiological pH, attributed to availability of the neutral amine. However,
O-palmitoyl propranolol 62 concentration variation over the time period of study indicates rate
fluctuations for relevant formation and decomposition processes as a result of environmental
changes.
6.4.3 Influence of Membrane Composition
Mimicry of natural membranes containing only diacyl phospholipids provides an informative
model for the study of propranolol 1 intrinsic lipidation. Whilst this model allows characteri-
sation of acyl transfer from diacyl phospholipids to propranolol 1, analogous non-enzymatic
reactivity between propranolol 1 and lysolipids has been overlooked. Lysolipid products of
phospholipid hydrolysis and propranolol 1 intrinsic lipidation contain a single ester-linked
acyl chain with a potential propensity to undergo similar transfer reactions.30,31,173 Probing
transfer of this single acyl chain in vitro will provide insight into intrinsic lipidation kinetics,
and improved understanding of reactivity in vivo by more accurately mimicking natural
membrane composition.32,34
Self assembly of lipid species into organised structures within an aqueous environment depends
upon both innate species properties and molecular geometry. Diacyl phospholipids are
known to adopt a bilayer structure within aqueous environments, promoting favourable
hydrophobic interactions between fatty acid chains. In contrast, lysolipids self-assemble into
micelles under aqueous conditions, providing their concentration is higher than their associated
202 6.4. A Kinetic Model for Propranolol Intrinsic Lipidation
CMC.208,211 CMC, the lowest concentration of lysolipid required to facilitate micelle formation,
is dependent upon lysolipid properties. Within the µM concentration range, lysolipid CMC is
inversely proportional to acyl chain length and level of saturation.33,214 Propranolol 1 binding
strength and orientation differs between bilayer and micellar structures, predicted to result in
corresponding changes to intrinsic lipidation reactivity.288,289 Further, differences in hydration
levels and membrane curvature associated with micelles compared to bilayers, may impact
intrinsic lipidation.208,211
Study of propranolol 1 intrinsic lipidation by lysolipids was facilitated by hydration and
vigorous mixing of a dried lysolipid film, resulting in micelle preparation. PPC and OPC
lysolipids, with CMC values of 4.0 µM to 8.3 µM, and 4.0 µM respectively, were selected for
study due to incorporation of the eukaryotic PC head group, and either a palmitoyl or oleoyl
acyl chain.33,214 Propranolol 1 was added to micelles in a 1:10 small molecule:lysolipid molar
ratio, and the mixture incubated under physiological conditions. Sample analysis under
optimised chromatographic and ionisation conditions was conducted at 24, 72 and 144 hours,
and mixture components quantified using calibration curves of synthetic standards. Anomalous
data points and dilution error were identified through study of each sample in triplicate.
Propranolol 1 intrinsic lipidation by PPC and OPC lysolipids was studied by determination
of total acylated propranolol 1 product content, compared to analogous reactivity within
DPPC and DOPC liposomes. Total acylated product is considered representative of rate of
propranolol 1 intrinsic lipidation within each membrane type. Evidenced in Fig. 6.54, total
acylated propranolol 1 product is increased at all studied time points within PPC and OPC
micelles compared to corresponding DPPC and DOPC bilayers. At 144 hours, 64 % of total
propranolol 1 derived content can be attributed to acylated species in the presence of PPC,
and 55 % in the presence of OPC. In contrast, figures determined in the presence of DPPC
and DOPC bilayers are 49 % and 15 % respectively. In addition to the observed increase
in propranolol 1 intrinsic lipidation by lysolipids compared to diacyl phospholipids, the two
exhibit differing production trends. Total acylated product formation within DPPC and
DOPC bilayers increases over the time period studied, however within PPC and OPC micelles
this initial linear increase tails off by 144 hours. Evidenced by the curvature in Fig. 6.54, the
observed trend variation suggests initial swift propranolol 1 intrinsic lipidation by lysolipids,
followed by a rate decrease over time.
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Figure 6.54 Total acylated product formation under physiological conditions in the presence
of DPPC (red circles), DOPC (green squares), PPC (blue triangles), and OPC (black inverted
triangles) membrane systems.
Despite intrinsic lipidation reactivity differences between phospholipid bilayers and lysolipid
micelles, both palmitoyl containing systems exhibit increased reactivity compared to their
oleoyl containing counterparts, Fig. 6.54. Corresponding preferential palmitoyl transfer
has previously been noted during the study of peptide intrinsic lipidation by lysolipids.40
However, intrinsic lipidation within DPPC membranes has not been observed prior to this
study, attributed to DPPC’s high transition temperature producing a gel phase bilayer at
physiological temperatures.59 The resulting reduction to hydration levels and penetration
of membrane active species, are anticipated to have negative effects on the rate of intrinsic
lipidation in gel phase DPPC bilayers. As a result, the reason for increased non-enzymatic
palmitoyl transfer to propranolol 1 within both PPC and DPPC systems compared to oleoyl
containing counterparts is unclear. However, tightened packing of saturated palmitoyl chains
compared to kinking of unsaturated oleoyl chains, provides a potential mechanism for increased
reactivity by increasing the proximity between reactive moieties.282
Beyond study of propranolol 1 intrinsic lipidation within lysolipid micelles by monitoring total
acylated product content, product distribution should also be considered. O-acylated propra-
nolol decomposition by intramolecular O to N migration increases 30 fold within a cationic
dodecyltrimethylammonium bromide micelle compared to solution phase decomposition.288
Increased decomposition is attributed to increased polarisation of the carbonyl bond within
micelle associated O-acylated propranolol. Accordingly, altered carbonyl polarisation within
O-acylated propranolol bound to zwitterionic PPC or OPC micelles, could potentially impact
O to N acylated product distribution following initial intrinsic lipidation by transesterification.
Fig. 6.55 depicts O-acylated propranolol and N -acylated propranolol concentrations within
PPC and OPC systems up to 144 hours. Similar product distribution and reactivity profiles
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are observed for intrinsic lipidation within both PPC and OPC micelles, in line with their
comparable physical properties.
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1Figure 6.55 O-acylated propranolol (green circles) and N -acylated propranolol (red squares)
product distribution under physiological conditions up to 144 hours within micelles containing:
(a) PPC; (b) OPC.
Formation of N -acylated propranolol within micellar systems commences following an initial
lag phase, in analogous fashion to DOPC and DPPC bilayer systems. Lag phase length is
calculated as between 14 hours to 15 hours within PPC and OPC, compared to the 4 to 6
hour lag phase observed within bilayer systems under physiological conditions. N -acylated
propranolol concentration within micellar systems then increases over 144 hours, following
a logarithmic curve rather than the linear increase associated with bilayer systems. Both
observations are consistent with a changing rate of N -acylated propranolol formation by O to N
migration within micelles over the time period studied. O-acylated propranolol concentration
within PPC and OPC micelles is also affected by the variation in rate of decomposition
by O to N migration, compared to rate of formation by transesterification. As shown in
Fig. 6.55, O-acylated propranolol concentration initially increases up to 24 hours, due to
species formation with minimal decomposition. O-acylated propranolol concentration then
decreases to steady state as rate of O to N migration eclipses rate of transesterification, before
finally plateauing as rate of formation and rate of decomposition become comparable.
Significant variation in propranolol 1 intrinsic lipidation reactivity and product distribution
in vitro is noted between phospholipid containing bilayers and lysolipid containing micelles.
However, increased biological relevance and mechanistic understanding can be achieved by
moving from the study of single component membranes to complex mixtures.1,3 Notably,
preparation of mixtures containing both micellar lysolipids and bilayer forming phospholipids
introduces interesting phase behaviour, predicted to impact intrinsic lipidation reactivity. NMR,
electron spin resonance (ESR), and spectrophotometry provide insight into the structure and
phase behaviour within these combined lipid systems, dependent upon the species involved and
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relative quantities.31,173,290 Lipid mixtures containing 95:5 molar ratio of phospholipid:lysolipid
were prepared containing DPPC:OPC and DOPC:PPC. At this molar ratio under physiological
conditions, studies indicate the DPPC:OPC phase behaviour is 100 % bilayer, whilst the
DOPC:PPC mixture is > 95 % bilayer in nature.32 Lysolipids PPC and OPC act as detergents
within the bilayer at 5 mol%, resulting in minor disruption and increased fluidity. For
comparison, lipid mixtures containing 5:95 molar ratio of DPPC:OPC and DOPC:PPC were
also studied. Primarily containing lysolipid, literature suggests that these lipid mixtures have
0 % bilayer content under physiological conditions, instead adopting a micellar structure with
inserted intact diacyl phospholipids.32 Pairing lipid species containing differing acyl chains
aids in determining the origin of acyl chain transfer, and informing on relative rates of intrinsic
lipidation for each species within the system.
Comparison of intrinsic lipidation reactivity within systems of differing phase behaviour can be
evaluated by considering total acylated propranolol 1 product formation. Table 6.31 presents
this data for lipid mixtures containing DPPC and OPC following 72 hour incubation under
physiological conditions. Total acylated product concentration decreases from 27.1 ng mL−1 to
13.1 ng mL−1 upon introduction of 5 mol% OPC into a DPPC membrane. Decreased product
formation is attributed to reduced DPPC reactivity within the disrupted OPC containing
bilayer compared to the intact DPPC bilayer. Increased membrane fluidity and the resulting
altered proximity of reactive moieties is predicted to play a role in reducing DPPC reactivity.
Lysolipid OPC reactivity remains unchanged, with scaling from 5 mol% to 100 mol% predicting
a total acylated product concentration of 42.2 ng mL−1, comparable to the observed value
of 41.1 ng mL−1. In contrast, addition of 5 mol% DPPC into an OPC micelle increases
total acylated product concentration from 41.4 ng mL−1 to 50.5 ng mL−1. Transfer from both
lysolipid and phospholipid components within the disrupted micelle is increased compared to
single component systems. Oleoyl transfer from lysolipid OPC increases from 41.4 ng mL−1 to
45.2 ng mL−1. Scaling DPPC transfer from 5 mol% to 100 mol% produces a total palmitoylated
product concentration of 107.2 ng mL−1 compared to 27.1 ng mL−1 observed within the DPPC
only bilayer. Differential propranolol 1 binding strength and orientation, combined with
increased structure associated with DPPC inclusion in the micelle, are predicted to facilitate
the observed increase in reactivity.
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Mixture Palmitoyl Propranolol (%) Oleoyl Propranolol (%)
DPPC 27.1 -
DPPC:OPC (95:5) 11.0 2.1
DPPC:OPC (5:95) 5.4 45.2
OPC - 41.4
Table 6.31 Proportion of total propranolol 1 content attributed to palmitoylated propranolol
and oleoylated propranolol within DPPC:OPC mixtures after 72 hours incubation under
physiological conditions.
Analogous studies were conducted monitoring total acylated propranolol 1 production within
DOPC:PPC lipid mixtures. Table 6.32 summarises the resulting data following 72 hour
incubation under physiological conditions. Total acylated product concentration is decreased
from 20.0 ng mL−1 to 9.0 ng mL−1 upon addition of 5 mol% PPC into a DOPC bilayer.
Reduced reactivity is attributed to both transfer from phospholipid DOPC, down from
20.0 ng mL−1 to 6.8 ng mL−1, and transfer from lysolipid PPC, which with scaling to 100
mol% is down from 49.2 ng mL−1 to 43.0 ng mL−1. Attributed to lysolipid induced bilayer
disruption and subsequent changes to phase behaviour and propranolol 1 binding, reduced
reactivity is consistent with observations made for the corresponding DPPC:OPC (95:5)
mixture. Decreased total acylated product concentration is also observed upon introduction
of 5 mol% DOPC into a PPC micelle. Reduced intrinsic lipidation is attributed to diminished
acyl transfer from the lysolipid PPC component within the disrupted micelle. Transfer from
phospholipid DOPC is increased within the DOPC:PPC (5:95) system, scaling transfer from
5 mol% to 100 mol% results in 71.2 ng mL−1 of oleoylated product.
Mixture Palmitoyl Propranolol (%) Oleoyl Propranolol (%)
DOPC - 20.0
DOPC:PPC (95:5) 6.8 2.2
DOPC:PPC (5:95) 3.6 24.4
PPC (0:100) 49.2 -
Table 6.32 Proportion of total propranolol 1 content attributed to palmitoylated propranolol
and oleoylated propranolol within DOPC:PPC mixtures after 72 hours incubation under
physiological conditions.
Discussion thus far has eluded to modified acyl chain transfer rates within lipid systems of
differing phase. Consideration of palmitoyl to oleoyl ratio, and comparison to the molar ratio of
lipid system components, provides further insight. Table 6.33 presents the normalised ratios of
palmitoylated product concentration to oleoylated product concentration for DPPC:OPC and
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DOPC:PPC systems at 95:5 molar ratio. Assuming comparable rate constants and reaction
order for each species, the predicted product ratio would be 19:1 for acyl chain transferred
from phospholipid:acyl chain transferred from lysolipid. Evidently, the observed product
ratios differ from the predicted 19:1 ratio indicating differing reactivity rates between the
species. Heightened lysolipid reactivity rate compared to phospholipid transfer rate results in
an increased proportion of lysolipid derived acylated propranolol 1 product. However, it is
noted that the ratio of phospholipid derived product to lysolipid derived product varies across
the time period studied, indicative of variation in relative reaction rates. Palmitoyl:oleoyl ratio
within the DPPC:OPC (95:5) system decreases from 7:1 to 5:1, whilst within the DOPC:PPC
(95:5) system the ratio increases from 1:3 to 1:5. A consistent intrinsic lipidation rate has
previously been observed within phospholipid bilayer systems, however the phenomenon of
rate variation over time has been described for intrinsic lipidation within lysolipid micelles. As
a result, variation in the palmitoyl to oleoyl ratio is attributed to changes in rate of lysolipid
reactivity over time, due to modified bilayer characteristics upon increasing concentration of
acylated propranolol 1 product.
Time P:O Ratio for DPPC:OPC P:O Ratio for DOPC:PPC
24 7.2 : 1.0 1.0 : 2.7
72 5.2 : 1.0 1.0 : 3.2
144 5.3 : 1.0 1.0 : 5.3
Table 6.33 Palmitoylated propranolol (P) to oleoylated propranolol (O) ratio observed under
physiological conditions within mixed membranes containing 95:5 ratio of either DPPC:OPC
or DOPC:PPC.
Analogous data regarding palmitoyl to oleoyl ratio within DPPC:OPC and DOPC:PPC
systems of molar ratio 5:95, is presented in Table 6.34. The predicted product ratio based
upon molar ratio of system components is 1:19 for acyl chain transferred from phospholipid:acyl
chain transferred from lysolipid. The observed ratios are decreased from the predicted value,
indicating increased rate of phospholipid reactivity compared to lysolipid reactivity. This
observation is in agreement with previous studies comparing intrinsic lipidation rate in
lysolipid micelles containing phospholipid, suggesting acyl transfer from phospholipids is
promoted by the presence of lysolipid within the system studied.40 Variation in ratio of
palmitoylated product to oleoylated product over time is observed within these micellar
systems. Palmitoyl:oleoyl ratio within the DPPC:OPC (5:95) system increases from 1:5 to
1:10, and the DOPC:PPC (5:95) system from 3:1 to 8:1. Consistent with observation made
within DPPC:OPC (95:5) and DOPC:PPC (95:5) systems, ratio variation is attributed to
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a altered reaction rate of lysolipids with propranolol 1 over time due to modified micellar
characteristics.
Time P:O Ratio for DPPC:OPC P:O Ratio for DOPC:PPC
24 1.0 : 5.5 2.8 : 1.0
72 1.0 : 8.4 6.9 : 1.0
144 1.0 : 10.2 8.1 : 1.0
Table 6.34 Palmitoylated propranolol (P) to oleoylated propranolol (O) ratio observed under
physiological conditions within mixed membranes containing 5:95 ratio of either DPPC:OPC
or DOPC:PPC.
6.5 Conclusions
Subject of the 1988 Nobel Prize in Medicine, propranolol 1 is a widely prescribed blockbuster
pharmaceutical, employed to treat a range of conditions including high blood pressure, angina
and migraines.263,264 Understanding the behaviour of propranolol 1 and its interactions within
the body, is vital to determine the impact of the drug upon human health and well being.
Propranolol 1 intrinsic lipidation in vitro is a previously undiscovered action of propranolol 1
occurring upon interaction of the drug with a cell membrane. This non-enzymatic mechanism
modifies drug properties and bulk membrane characteristics, ultimately predicted to impact a
range of important cellular and pharmaceutical processes.
Successful organic synthesis of predicted products of propranolol 1 intrinsic lipidation has
facilitated study of this membrane reactivity in vitro. Analytical characterisation of synthetic
O-acylated propranolol, N -acylated propranolol, and diacylated propranolol by optimised mass
spectrometry reveals O-acylated propranolol and N -acylated propranolol as intrinsic lipidation
products. Furthermore, the two species were determined to be related by an intramolecular
O to N migratory rearrangement, resulting in the following proposed mechanism for propra-
nolol 1 intrinsic lipidation. Initial propranolol 1 reactivity proceeds by a transesterification
reaction from membrane phospholipids to the alcohol functionality, forming kinetic product
O-acylated propranolol. Subsequent O to N migration promotes formation of the secondary
thermodynamic reaction product, N -acylated propranolol.
Quantification of propranolol 1 intrinsic lipidation reaction products has also been facilitated
by the preparation of synthetic standards. Under physiological conditions quantification
indicates over 50 % conversion of propranolol 1 into acylated derivatives is possible through
innate membrane reactivity. High levels of conversion indicate significant biological and
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pharmaceutical relevance of propranolol 1 intrinsic lipidation. Two instances of preferential
transfer have been identified under physiological conditions: (i) increased reactivity within
eukaryotic PC membrane models compared to prokaryotic (PE:PG) or viral counterparts
(PC:PS); (ii) preferential sn-1 transfer from the phospholipid backbone compared to transfer
from the sn-2 position. Furthermore, in addition to innate reactivity between propranolol
1 and diacyl phospholipids, analogous reactivity with lysolipids has been observed. An
increased acyl transfer rate is observed for lysolipids compared to diacyl phospholipids, with
lysolipids capable of promoting transfer from diacyl phospholipids within mixed lipid systems.
Finally, product quantification combined with temperature and pH variation has provided
insight into the influence of these environmental factors upon reactivity kinetics and product
distribution. Temperature increase has been observed to promote both the rate of propranolol
1 intrinsic lipidation, and the rate of intramolecular O to N migration, ultimately resulting in
up-regulation of the formation of N -acylated propranolol derivatives. Increased pH exhibits
similar effects on propranolol 1 intrinsic lipidation, promoting reactivity and formation of
N -acylated species. These observations are attributed to an increased proportion of the
neutral form of propranolol 1, facilitating both intramolecular O to N migration, and direct
amine reactivity with phospholipids. Conversely, intrinsic lipidation is only rarely observed to
proceed under acidic conditions, due to protonation of reactive moieties preventing reactivity.
Notably, preferential eukaryotic and sn-1 reactivity observed under physiological conditions
are largely maintained upon variation of these environmental parameters.
7 | Small Molecule Intrinsic Lipida-
tion in cellulo
7.1 Introduction
Small molecule intrinsic lipidation, and in particular intrinsic lipidation of propranolol 1, has
been well characterised in vitro (Chapter 6). Analytical simplification makes in vitro study
desirable, however true investigation of the biological relevance of intrinsic lipidation requires
use of an increasingly complex cellular system. Study of intrinsic lipidation in cellulo aims
to determine the feasibility of innate reactivity within the complex confines of a biological
system, filled with competing propranolol 1 binding sites and enzymatic reaction pathways.
Observed reactivity in cellulo would provide validation that the process is both biologically
and pharmaceutically relevant, warranting further investigation.
7.2 Development of Analytical Conditions
Study of small molecule intrinsic lipidation in cellulo creates an analytical challenge of increased
difficulty compared to in vitro liposomal systems. Membrane complexity, particularly the
presence of multiple acyl chain types, would result in an increased variety of low abundance
acylated intrinsic lipidation products. Chromatographic separation of these products, combined
with sufficient ionisation at low abundance, would be required in order to definitively distinguish
and characterise the species. Furthermore, increased lipid and lysolipid diversity in cellulo
creates a challenging sample medium, requiring suitable analytical conditions for the separation
of lipid species from desired products. Achieving analytical separation of lipid species provides
the added benefit of characterising cellular lipid profile under the influence of intrinsic lipidation.
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Optimised analytical conditions for the study of small molecule intrinsic lipidation in vitro
did not translate to the study of reactivity in cellulo, given the added analytical challenges.
Considerable coelution of lipid species and acylated small molecules, highlighted in Fig. 7.1,
result in ion suppression of low abundance species and significantly reduce data quality.
Renewed optimisation of both chromatographic and ionisation parameters was therefore
required in order to facilitate study of intrinsic lipidation within biological systems. Considering
that phospholipids and lysolipids are the major components of membrane systems in cellulo,
synthetic standards of these species were obtained (Avanti Polar Lipids Inc.) in order to aid
in optimisation.
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Figure 7.1 TIC of complex bovine liver extract analysed under optimised analytical con-
ditions for the study of small molecule intrinsic lipidation. Elution of phospholipid species
during the retention time window attributed to acylated small molecules resulting in ion
suppression is highlighted.
7.2.1 Optimisation of Positive ESI Parameters
Literature studies suggest that optimised analysis of neutral PC and PE phospholipids is
conducted using ESI mass spectrometry in positive ionisation mode.291,292 Optimisation was
therefore conducted using a Synapt G2-S (Waters Corp., UK) mass spectrometer fitted with
Z-spray ESI source. Phospholipid POPC, Fig. 7.2, was selected as the optimisation analyte,
being readily availability and containing the neutral PC head group in combination with
biologically common palmitoyl and oleoyl acyl chains. POPC stock solution at concentration
0.5 µg mL−1 in IPA:H2O:MeCN (2:1:1), was directly infused into the mass spectrometer at
a flow rate of 5 µL/min. Mass spectra were collected over one minute, and compared based
upon molecular ion intensity, signal to noise ratio, and level of in-source fragmentation.
212 7.2. Development of Analytical Conditions
Me3N
O
P
O
HO
O
O
O
O
O
(CH2)14CH3
(CH2)7CH3
1
Figure 7.2 The structure of zwitterionic phospholipid POPC.
Three key instrument parameters were identified to facilitate optimisation of phospholipid
ESI:
• Capillary voltage
• Sampling cone voltage
• Source offset voltage
Additional instrument parameters, including source temperature, desolvation temperature, and
desolvation gas flow, remained unchanged throughout the optimisation process. These param-
eters were considered to have reduced impact upon phospholipid ionisation, and maintaining
their consistency with other methodologies was considered useful for future analyses.
Capillary voltage describes the voltage applied at the tip of the ESI capillary needle, creating
a potential difference between the needle and the rest of the mass spectrometer.81 Correct
voltage selection aids in aerosol formation, desolvation, and ion motion through the mass
spectrometer. Initial analytical conditions, based upon optimised parameters for acylated small
molecule ionisation, used a capillary voltage of 1.0 kV. Under these conditions, visualisation
of desired POPC molecular ion [M+H]+ was observed at m/z 760.5870 corresponding to
molecular formula C42H83NO8P with 0.04 ppm. In-source fragmentation was not observed,
however sodium adduct [M+Na]+ and proton bound dimer [2M+H]+, were noted at m/z
782.5642 and 1520.1693 respectively. Observation of the undesired [M+Na]+ species was
attributed to the presence of environmental sodium, combined with increased POPC affinity
for sodiation compared to protonation.276 Dimerisation likely occurs due to high POPC
concentration combined with poor ionisation potential of the hydrophobic species.277
Table 7.1 presents the relative ion intensities of protonated and sodiated POPC species
utilising five different capillary voltages in the range 1.0 kV to 3.0 kV. Increased capillary
voltage result in both a desirable increase in [M+H]+ intensity, and an undesirable increase in
[M+H]+:[2M+H]+ ratio. Therefore, protonation is determined to be favoured by selection
of a higher capillary voltage. In contrast, [M+H]+:[M+Na]+ ratio reaches a minimum at
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2.0 kV, suggesting increased undesirable [M+Na]+ formation at capillary voltages both above
and below this value. Appropriate capillary voltages for ionisation of neutral phospholipids
were therefore determined as 2.0 kV and 2.5 kV. A 2.0 kV capillary voltage was selected for
future phospholipid analysis, due to problematic discharge being widely reported at high ESI
capillary voltages.250
Capillary Voltage (kV) [M+H]+ [M+H]+:[2M+H]+:[M+Na]+
1.0 2.37x107 1 : 0.16 : 0.73
1.5 8.07x107 1 : 0.13 : 0.35
2.0 2.25x108 1 : 0.20 : 0.24
2.5 2.34x108 1 : 0.25 : 0.28
3.0 1.76x108 1 : 0.26 : 0.30
Table 7.1 Ion intensity for [M+H]+ of POPC at m/z 760.5870, and ratio of [M+H]+ to
undesirable ion alternatives [2M+H]+ and [M+Na]+ at varying capillary voltages.
Sampling cone voltage aids in transmission of ions from the ESI capillary needle through the
ionisation source and towards the instrument mass analyser.81 Higher sampling cone voltages
increase transmission and therefore ion abundance, however the associated increase in ion
kinetic energy can result in unwanted inelastic collisions and in-source fragmentation. Results
of sampling cone voltage modification from the original value of 50 V to 30 V and 70 V are
presented in Table 7.2. Intensity of POPC molecular ion m/z 760.5870 drops upon alteration
of the sampling cone voltage. At 30 V reduced ion intensity is attributed to a reduced number
of ions being pulled through the sampling cone. At 70 V the change is associated with reduced
[M+H]+ transmission in favour of [M+Na]+ ions, combined with preferential fragmentation of
the [M+H]+ species due to its lower dissociation energy compared to [M+Na]+. This theory
is based upon the observed change in [M+H]+:[M+Na]+ ratio from 4:1 at sampling cone
voltage 50 V to 2:1 at sampling cone voltage 70 V. As a result, sampling cone voltage for
future phospholipid study by ESI in positive mode was selected to be 50 V.
Sampling Cone Voltage (V) [M+H]+ [M+H]+:[2M+H]+:[M+Na]+
30 1.61x108 1 : 0.20 : 0.33
50 2.25x108 1 : 0.20 : 0.24
70 1.09x108 1 : 0.17 : 0.49
Table 7.2 Ion intensity for [M+H]+ of POPC at m/z 760.5870, and ratio of [M+H]+ to
undesirable ion alternatives [2M+H]+ and [M+Na]+ at varying sampling cone voltages.
Source offset voltage defines the voltage difference applied in order to transmit ions from the
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ESI source into the StepWave ion transfer, and onwards to the analyser region of the mass
spectrometer.81 Analogously to sampling cone voltage, high source offset values promote ion
transmission but may inadvertently cause in-source fragmentation of ions in tandem. Table 7.3
presents the results of POPC ionisation using three distinct source offset voltages, 20 V, 30 V
and 40 V. Optimum [M+H]+ intensity of 2.25x108 is observed using a source offset voltage
of 30 V. Furthermore, both the [M+H]+:[2M+H]+ ratio and [M+H]+:[M+Na]+ ratio favour
desired ion [M+H]+ at 30 V to a greater extent than at 20 V and 40 V. In-source fragmentation
of POPC was not observed for any of the source offset voltages tested. Consideration of
the observed results suggests 30 V to be the optimum source offset value for future study of
phospholipids by positive ESI.
Source Offset Voltage (V) [M+H]+ [M+H]+:[2M+H]+:[M+Na]+
20 1.13x108 1 : 0.24 : 0.67
30 2.25x108 1 : 0.20 : 0.24
40 1.24x108 1 : 0.22 : 0.57
Table 7.3 Ion intensity for [M+H]+ of POPC at m/z 760.5870, and ratio of [M+H]+ to
undesirable ion alternatives [2M+H]+ and [M+Na]+ at varying source offset values.
Parameter Optimised Value
Capillary Voltage (kV) 2.0
Source Temperature (◦C) 150.0
Sampling Cone Voltage (V) 50.0
Source Offset Voltage (V) 30.0
Desolvation Temperature (◦C) 350.0
Cone Gas Flow (L/Hr) 60.0
Desolvation Gas Flow (L/Hr) 600.0
Nebuliser Gas Flow (Bar) 6.0
Table 7.4 Optimised positive mode ESI parameters for ionisation of neutral phospholipids
such as POPC.
Optimised positive ESI parameters for the study of neutral PC and PE phospholipids have
been successfully developed, as summarised in Table 7.4. Parameters mirror those optimised
for the study of acylated small molecules, with the exception of capillary voltage. Analysis of
additional neutral phospholipids and synthetically prepared acylated small molecules under
these conditions resulted in successful visualisation of all species. Ionisation of acylated small
molecules was observed to be comparable to ionisation using previously optimised small
molecule intrinsic lipidation parameters. As a result, these newly optimised positive ESI
parameters will be taken forward for future study of small molecule intrinsic lipidation and
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lipid profiling within complex biological systems.
7.2.2 Optimisation of Negative ESI Parameters
Phospholipids containing negatively charged PS or PG phosphate head groups are better
suited to ESI analysis in negative mode, rather than positive mode.291,292 Negative mode ESI
parameters have not previously been developed during the study of intrinsic lipidation, therefore
optimisation is required. Phospholipid POPS, Fig. 7.3, was selected as the optimisation analyte
in order to create parity with the optimisation of positive mode ESI parameters. POPS
is comprised of biologically relevant palmitoyl and oleoyl acyl chains, in combination with
a eukaryotic PS head group. POPS stock solution at a concentration of 0.5 µg mL−1 in
IPA:H2O:MeCN (2:1:1) was directly infused at a flow rate of 5 µL/min into the ESI source of
a Synapt G2-S mass spectrometer (Waters Corp., UK). Mass spectra were collected over a
one minute time period and compared upon modification of capillary voltage, sampling cone
voltage, and source offset voltage.
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Figure 7.3 The structure of negative phospholipid POPS.
Negative mode ESI optimisation was undertaken building on a base of available ionisation
parameters developed for the study of small molecules by another instrument user. POPS
analysis resulted in observation of the [M-H]- ion at m/z 760.5146 corresponding to molec-
ular formula C40H75NO10P with 2.28 ppm error. Neither adduct formation nor in-source
fragmentation of POPS was observed under these conditions. However, two contaminant
ions were observed at m/z 181.0642 and 265.1490, the later of which can be attributed to
plasticiser tributylphosphate.293 Table 7.5 summarises [M-H]- ion intensity values, the sole
available distinguishing factor, upon application of capillary voltages from 1.0 kV to 3.0 kV.
Ion intensity reaches a maximum at capillary voltage 2.5 kV, resulting in selection of this
voltage for future phospholipid ESI in negative mode.
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Capillary Voltage (kV) [M-H]-
1.0 5.70x106
1.5 6.95x107
2.0 1.91x108
2.5 2.77x108
3.0 1.60x108
Table 7.5 Ion intensity for [M-H]- of POPS at m/z 760.5146, at varying capillary voltages.
Table 7.6 summarises POPS [M-H]- ion intensity upon application of sampling cone voltages
from 20 V to 50 V. Intensity of the molecular ion at m/z 760.5146 reaches a maximum at
sampling cone voltage 30 V. Considering neither in-source fragmentation nor adduct formation
are observed under the instrumentation parameters studied, it is unclear as to why ion intensity
at 30 V exceeds that of higher sampling cone voltages known to promote ion transmission.
Despite this, an optimised sampling cone voltage of 30 V was selected for future phospholipid
study by negative mode ESI.
Sampling Cone Voltage (V) [M-H]-
20 2.53x108
30 3.15x108
40 2.33x108
50 2.77x108
Table 7.6 Ion intensity for [M-H]- of POPS at m/z 760.5146, at varying sampling cone
voltages.
Negative mode ESI source offset voltage was also altered in order to determine the influence
upon POPS ionisation. Given the observed lack of adduct formation or in-source dissociation
even at high voltages, POPS [M-H]- ion intensity was used to select the optimum source offset
value. Table 7.7 summarises m/z 760.5146 ion intensity for source offset values of 20 V to 40 V,
with a maximum of 3.15x108 observed at 30 V. Further negative mode ESI of phospholipids
was therefore conducted using an optimised 30 V source offset voltage.
Source Offset Voltage (V) [M-H]-
20 1.68x108
30 3.15x108
40 1.72x108
Table 7.7 Ion intensity for [M-H]- of POPS at m/z 760.5146, at varying source offset values.
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Optimised negative ESI parameters for the study of negatively charged PS and PG phospho-
lipids have been successfully developed, as summarised in Table 7.8. These newly optimised
ESI parameters will be taken forward for future study of negative lipid profiling within complex
biological systems.
Parameter Optimised Value
Capillary Voltage (kV) 2.5
Source Temperature (◦C) 150.0
Sampling Cone Voltage (V) 30.0
Source Offset Voltage (V) 30.0
Desolvation Temperature (◦C) 350.0
Cone Gas Flow (L/Hr) 60.0
Desolvation Gas Flow (L/Hr) 600.0
Nebuliser Gas Flow (Bar) 6.0
Table 7.8 Optimised negative mode ESI parameters for ionisation of negatively charged
phospholipids such as POPS.
7.2.3 Optimisation of Chromatographic Conditions
Analysis of complex biological systems by mass spectrometry can be aided by the application
of suitable chromatographic conditions. In fact, liquid chromatography can ultimately deter-
mine the success of analysis in the context of biological systems. Optimised chromatography
separates mixture components, minimising ion suppression and ensuring successful identi-
fication and characterisation of all species within the mixture. Considering that optimised
chromatography for the study of small molecule intrinsic lipidation in vitro has been shown
not to translate to study in cellulo, a novel chromatographic approach is needed.
Development of chromatography for the study of small molecule intrinsic lipidation and
lipid profiling in cellulo can be performed using a synthetic biological model. Synthetic
standards of lysolipids and phospholipids were obtained and combined at concentrations
of 0.5 µg mL−1 to create a lipid mixture. Standards selected, Table 7.9, cover a variety of
phospholipid classes including neutral PC and PE phospholipids observed in positive mode
ESI, and PS and PG phospholipids observed by negative ESI. Chromatographic separation
of phosphate head group classes within both lysolipid and phospholipid species is vital for
successful analysis. Furthermore, lysolipids such as PPC and OPC, and phospholipids such
as DOPG and SLPG, were included within the lipid mixture to ensure chromatographic
separation of species differing in their acyl chain chemistry. POPC and OPPC, comprised
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of the same acyl chains in opposing backbone positions, were also incorporated into the
lipid mixture, in order to determine whether chromatographic resolution of these structurally
similar species proved possible.
Species Observation Mode [M+H]+ [M-H]-
PPC Positive 496.3403 -
OPC Positive 522.3560 -
OPE Both 480.3090 478.2934
OPG Negative - 509.2879
DOPC Positive 786.6013 -
POPC Positive 760.5856 -
OPPC Positive 760.5856 -
DOPE Both 744.5543 742.5387
DOPG Negative - 773.5333
SLPG Negative - 773.5333
DOPS Negative - 786.5285
POPS Negative - 760.5129
Table 7.9 Mixture of phospholipid and lysolipid standards employed in order to optimise
chromatography for the study of intrinsic lipidation and lipid profiling in complex biological
systems.
Chromatographic conditions for study of lipid species were derived from the application note
"Lipid Separation using UPLC with Charged Surface Hybrid Technology" (Waters Corp.,
UK).294 The methodology utilises UPLC on a CSH C18 column (Waters Corp., UK) at 55
◦C to separate components of lipid extracts, which include both phospholipids and lysolipids.
Unusual mobile phases of high organic content are employed during analysis, due to the
hydrophobicity of lipid species increasing column retention and preventing solvation in MeCN
or H2O. Mobile phase A was therefore prepared as MeCN:H2O (6:4) with 10 mM ammonium
formate and 0.1 % formic acid, and mobile phase B IPA:MeCN (9:1) with 10 mM ammonium
formate and 0.1 % formic acid. Analysis of the prepared mixture of lipid standards under
these chromatographic conditions, in both positive and negative ESI modes, proved successful.
Chromatograms presented in Fig. 7.4 highlight the desirable peak shapes and excellent
separation of all species irrespective of head group class or acyl chain type. POPC and OPPC
prove the exception to this observation, coeluting due to structural similarities. Lysolipid
species elute between 1 min and 4 min, as shown in Fig. 7.4, whereas phospholipid species
elute later between 10 min and 14 min separated by head group class. Despite the observed
analytical success, it was noted that the chromatographic conditions employed contained
considerable dead time in which species did not elute. This dead time was determined as
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prior to 2 min, between 3 min to 10 min, and after 15 min. Undesirable dead time results in
a considerable 20 minute analysis time per sample, reduction of which would both increase
throughput and minimise solvent wastage.
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1Figure 7.4 Analysis of standard lipid mixture under chromatographic conditions described
in "Lipid Separation using UPLC with Charged Surface Hybrid Technology" (Waters Corp.,
UK) with % of mobile phase B (IPA:MeCN (9:1) with 10 mM ammonium formate and 0.1
% formic acid) shown in grey: (a) positive mode shown in red; (b) negative mode shown in
green.294
Modifications to initial chromatographic conditions were carried out stepwise, in hopes of
achieving excellent peak shape and separation within a shorted time period. Modified gradient
one focussed upon reduction of dead time prior to 2.0 minutes. An initial mobile phase
ratio of 50:50 (A:B) was therefore selected in favour of the 60:40 (A:B) ratio utilised under
preliminary chromatographic conditions. Resulting chromatograms retain excellent peak shape
and resolution for phospholipid species eluting between 8 min and 12 min, as shown in Fig. 7.5
(a). However, chromatographic modifications are observed within the first 5.0 minutes of
analysis, affecting lysolipid separation only. Under modified conditions dead time at the start
of analysis is reduced by only 0.5 min, resulting in a time period of 1.5 min prior to analyte
elution. Furthermore, as shown by comparison of Fig. 7.5 (b) and (c), chromatographic
resolution of lysolipids is completely lost using both positive and negative mode ESI under
the modified conditions. Modified gradient one was thus determined to be unsuccessful in
reducing analysis time whilst retaining resolution, and initial mobile phase conditions of 60:40
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(A:B) were applied to all future analyses.
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1Figure 7.5 Analysis of standard lipid mixture under modified chromatographic gradient
one: (a) TIC with positive mode shown in red, negative mode shown in green, and % of
mobile phase B (IPA:MeCN (9:1) with 10 mM ammonium formate and 0.1 % formic acid)
shown in grey; (b) lysolipids eluting under modified gradient one exhibiting loss of resolution;
(c) lysolipids eluting under initial chromatographic conditions.
Dead time between 3 min and 10.5 min was the second chromatographic issue tackled by
gradient alteration. Modified gradient two attempted to overcome this issue by reducing the
time period taken for mobile phase composition to change from 50:50 (A:B) to 46:54 (A:B).
Under initial chromatographic conditions this change occurs over the time period 2.1 min
to 12 min, whereas modified gradient two reduces this time period by 5 min such that the
change occurs over 2.1 min to 7 min, as shown in Fig. 7.6 (a). Reduction of dead time in this
fashion decreases analysis time and increases sample throughput. Lysolipid elution of both
neutral and negative classes between 2 min and 3 min is unchanged upon gradient modification.
Phospholipid elution in shifted from between 11 min to 13 min to the earlier retention time
of 9.0 minutes, as shown in Fig. 7.6 (a). However, under these chromatographic conditions
phospholipid species coelute irrespective of class and acyl chain type. This observation is
highlighted by comparing phospholipid elution under modified gradient two, shown in Fig. 7.6
(b), with elution under the initial gradient, shown in Fig. 7.6 (c). As a result, modified gradient
two was not considered feasible for the analysis of small molecule intrinsic lipidation within
complex biological samples.
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1Figure 7.6 Analysis of standard lipid mixture under modified chromatographic gradient
two: (a) TIC with positive mode shown in red, negative mode shown in green, and % of
mobile phase B (IPA:MeCN (9:1) with 10 mM ammonium formate and 0.1 % formic acid)
shown in grey; (b) phospholipids eluting under modified gradient two exhibiting loss of class
separation; (c) phospholipids eluting under initial chromatographic conditions.
Modified gradient three attempted to retain the shortened run time of modified gradient
two in combination with the excellent chromatographic separation observed under initial
analytical conditions. Decreased rate of mobile phase change over the time period immediately
prior to and throughout phospholipid elution was applied to modified gradient two in order
to achieve this, Fig. 7.7 (a). Modified gradient two undergoes a gradient change of 30:70
(A:B) to 1:99 (A:B) over the time period 7.1 min to 13 min. Modified gradient three alters
this gradient change, instead undergoing 30:70 (A:B) to 20:80 (A:B) over the time period
of 7.1 min to 10 min, followed by 20:80 (A:B) to 1:99 (A:B) over 10 min to 11 min. Further
reduction in run time was achieved by a reduced organic wash period from 2 min in duration
to 1 min. Despite modification, chromatographic separation of phospholipids by modified
gradient three largely mirrors that of modified gradient two, Fig. 7.7 (b) and Fig. 7.7 (c).
Minor resolution increases are observed for PC phospholipids, however complete separation of
classes achieved under initial chromatographic conditions and evidenced for comparison in
Fig. 7.7 (d), remains elusive. Considering these elution problems, the dead time between 3 min
and 10.5 min observed under initial analytical conditions is noted to be vital for phospholipid
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separation. Phospholipid separation during this time period occurs as analytes travel through
the column, ultimately resulting in chromatographic resolution upon elution. Retention of
this separatory period was therefore maintained for future analyses despite the associated
increase in run time.
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1Figure 7.7 Analysis of standard lipid mixture under modified chromatographic gradient
three: (a) TIC with positive mode shown in red, negative mode shown in green, and % of
mobile phase B (IPA:MeCN (9:1) with 10 mM ammonium formate and 0.1 % formic acid)
shown in grey; (b) phospholipids eluting under modified gradient three exhibiting loss of
class separation; (c) phospholipids eluting under modified gradient two exhibiting loss of class
separation; (d) phospholipids eluting under initial chromatographic conditions.
Chromatographic resolution of phospholipids is noted to be excellent under initial conditions,
attributed to the dead time between 3 min and 10.5 min. However, there remains room
for improvement. Modified gradient four builds upon original chromatographic conditions,
aiming to improve separation by decreasing the rate of mobile phase change immediately
prior to and throughout phospholipid elution. Mobile phase ratio changes from 30:70 (A:B)
to 1:99 (A:B) over the time period 12.1 min to 18 min under initial conditions. Modified
gradient four substitutes this mobile phase ratio change with a change of 30:70 (A:B) to 15:85
(A:B), as shown in Fig. 7.8, reducing the rate of mobile phase change within equivalent run
time. Resulting chromatographic changes were observed between 10 min and 15 min during
phospholipid elution, as shown in Fig. 7.8. Elution of earlier phospholipids, for example the PE
class at 11 min, remains unchanged under the new chromatographic conditions. However, later
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eluting PC, PS, and PG species exhibit increased class and acyl chain separation as a result
of application of the modified gradient. In summary, chromatographic results for modified
gradient four are comparable to those observed under initial chromatographic conditions,
providing a suitable alternative for analysis.
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1Figure 7.8 Analysis of standard lipid mixture under modified chromatographic gradient
four with % of mobile phase B (IPA:MeCN (9:1) with 10 mM ammonium formate and 0.1
% formic acid) shown in grey: (a) positive mode shown in red; (b) negative mode shown in
green.
Two sets of suitable chromatographic conditions for the study of small molecule intrinsic
lipidation within biological systems have been identified using a mixture of lipid standards. The
two analytical methods are matched in their capacity to separate lipid species, run time, and
solvent usage. As a result, the initial gradient was selected for future study, due to its robust
and reliable nature combined with a proven record of successful applications.294 However, prior
to further study two addition analytical challenges were noted in relation to chromatographic
development. Firstly, sensitivity of the Synapt G2-S (Waters Corp., UK) instrument requires
solvent qualities above and beyond those available commercially at HPLC/UPLC grade.
Reduced solvent quality results in severe contamination of analyses conducted using positive
ESI mode, resulting in suppression of desirable analytes. IPA distillation to remove low
boiling impurities was therefore conducted upon commercial solvent prior to use within a
mobile phase system. Furthermore, repeated analyses resulted in the observation of peak
broadening particularly for negatively charged phospholipid species. Broadening was ultimately
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determined to be dependent upon mobile phase pH, which underwent fluctuations due to
solvent evaporation and poor ammonium formate solubility in IPA. Issues were overcome by
regular determination and adjustment of mobile phase pH to values of 4.5 and 6.2 for A and
B respectively, resulting in consistent peak shapes and retention times.
7.3 Intrinsic Lipidation in E. coli Extracts
Prior to study of small molecule intrinsic lipidation in cellulo, optimised analytical conditions
were tested utilising an alternative biological system. Study of this alternative system aimed
to confirm successful method development, whilst providing insight into intrinsic lipidation
within a system of increased complexity compared to simple liposomes. Merging in vitro
study with increased molecular diversity, the alternative system selected comprised extrusion
prepared liposomes constructed from commercially available cell extracts. The first of these
extracts, polar E. coli extract, was obtained through CHCl3:MeOH extraction of E. coli B
(ATCC 11303), followed by acetone precipitation and further extraction with diethyl ether.295
Resulting E. coli extract liposomes contain PE, PG and cardiolipin (CL) species, whilst
incorporating a diverse range of fatty acyl chain types. Additional biological features, including
peptides and proteins, are not contained within the extract, providing increased simplicity
compared to a true cellular system.
Understanding of E. coli extract lipid content is required in order to facilitate successful
study of small molecule intrinsic lipidation within the liposomal system. Employing optimised
analytical conditions, extract lipid profiling was conduced by both positive and negative mode
ESI. Polar E. coli extract contains predominantly PE, PG and CL species, Fig. 7.9, resulting
in data obtained using negative mode ESI being most informative. Negative mode scans were
combined over the retention time window of lysololipid elution between 1.0 to 6.0 minutes,
and phospholipid elution between 13.0 minutes and 20.0 minutes. Ions exceeding the intensity
threshold of 1x105 were isolated and assigned through comparison with the LIPID MAPS
Gateway.296 Following removal of anomalies not observed across duplicate analyses, and those
exhibiting error of > 4.0 ppm, the lipid profile presented in Table 7.10 was obtained.
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Figure 7.9 TIC of phospholipid and lysolipid species identified withinE. coli extract
including positive mode ESI (red) and negative mode ESI (green). * indicate internal
standards LPC(17:0) eluting at 2.9 min and PC(17:0) eluting at 14.2 min.
Twenty-seven distinct phospholipid species were identified as components of polar E. coli
extract. Content was attributed to 61 % PE class phospholipids and 39 % PG class phospho-
lipids, comparable to the reported distribution of 67 % PE and 23 % PG.295,297 Percentage
discrepancy is attributed to lack of CL observation, reported as 9.8 % of total lipid content,
due to increased structural diversity of CL species and corresponding low abundance. CL,
found in most bacterial membranes, is a dimeric diphosphatidylglycerol lipid containing a
glycerol backbone and four distinct acyl moieties. Furthermore, comparison of the observed
lipid profile with available literature data suggests the absence of six phospholipid species
contained within the extract, (32:1) PE, (33:1) PE, (36:2) PE, (33:1) PG, (34:1) PG, and
(36:1) PG.297 High abundance ions corresponding to nominal masses of these phospholipid
species are observed, however mass accuracy prevents their assignment as the species in
question. Literature analysis was conducted using Autoflex I (Bruker Daltonics Ltd., UK)
instrumentation with external calibration, exhibiting 50-100 ppm accuracy, thus discrepencies
can be explained by diminished literature accuracy compared to the Synapt G2-S (Waters
Corp., UK) instrumentation employed herein.297,298
Observed m/z Theoretical m/z Error (ppm) Assignment
452.2743 452.2782 3.6 LPE(16:0)
464.2751 464.2782 3.6 LPE(17:1)
478.2907 478.2939 3.6 LPE(18:1)
660.4620 660.4610 1.5 PE(30:1)
686.4742 686.4766 3.5 PE(32:2)
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690.5097 690.5079 2.6 PE(32:0)
693.4714 693.4712 0.3 PG(30:0)
716.5262 716.5236 3.6 PE(34:1)
720.4960 720.4973 1.8 PE(36:5)‡
721.5034 721.5025 1.2 PG(32:0)
730.5397 730.5392 0.7 PE(35:1)
735.5152 735.5181 3.9 PG(33:0)
746.5138 746.5130 1.1 PE(38:6)‡
748.5286 748.5286 0.0 PE(38:6)† / PE(38:5)‡
749.5318 749.5338 2.7 PG(34:0)
762.4703 762.4715 1.6 PE(37:7(OH))
772.4933 772.4923 1.3 PE(39:8)
777.4683 777.4712 3.7 PG(37:7)
798.6023 798.6018 0.6 PE(40:2)
804.5884 804.5912 3.5 PE(42:6)† / PE(42:5)‡
805.6296 805.6328 4.0 PG(39:0)†
811.5496 811.5494 0.2 PG(39:4)
817.5013 817.5025 1.5 PG(40:8)
852.6826 852.6851 2.9 PE(45:3)† / PE(45:2)‡
873.6237 873.6226 1.3 PG(42:2(OH))
922.7305 922.727 3.8 PE(49:3)
1101.9003 1101.9043 3.6 PG(58:0(OH))
Table 7.10 Phospholipid and lysolipid species identified within E. coli lipid extract.295 †
indicates the presence of alkyl ether substituent; ‡ indicates the presence of alkenyl ether
(plasmalogen) substituent.
Fatty acid distribution within E. coli extract includes saturated and unsaturated acyl
moieties of varying carbon chain length.299,300 Five plasmalogen species, common to anaerobic
bacteria, are also observed within the PE lipid content of the system.301 Biosynthesised
within peroxisomes, plasmalogenic lipids contain an alkenyl ester functionality at their sn-1
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position. Further acyl chain insight can be gleaned from the presence of three lysolipids
with the lipid profile, LPE (16:0), LPE (17:1) and LPE (18:1). Considering abundance and
successful visualisation, these acyl chains are predicted to be most common within polar E.
coli extract. Observation of 16:0 (palmitoyl) and 18:1 (oleoyl) acyl chains is unsurprising
considering their reported abundance within E. coli extract, summarised in Table 7.11. In
contrast, presence of the 17:1 fatty acid chain is not reported within E. coli extract fatty acid
distribution. Consequently, this is assumed to be a misassignment by LIPID MAPS, and the
species observed is analogous cyclopropyl bacterial fatty acid cyclo 17:0.296
Fatty Acid E. coli PE (%) E. coli PG (%) E. coli CL (%)
14:0 1.5 1.6 2.2
15:0 0.0 1.2 4.8
16:0 33.6 43.6 33.3
16:1 9.3 7.4 10.2
17:0 17.7 0.5 1.4
cyclo 17:0 0.0 26.8 27.0
18:0 0.0 1.4 0.0
18:1 34.1 9.8 14.4
19:0 3.8 0.0 5.3
cyclo 19:0 0.0 5.6 2.2
Unknown 0.0 0.0 1.4
Table 7.11 Fatty acid distribution of E. coli lipid extract.295
7.3.1 Propranolol Reactivity
Following characterisation of lipid content within polar E.coli extract, study of small molecule
intrinsic lipidation within the system was conducted. Propranolol 1, studied significantly in
vitro, was incubated in 1:10 drug:lipid molar ratio with E. coli extract liposomes, based upon
an average phospholipid molecular weight of 719.3020. Incubation proceeded for 72 hours
under physiological conditions prior to analysis under optimised analytical conditions designed
for study of small molecule intrinsic lipidation within complex biological systems. Potential
acylated propranolol 1 products of intrinsic lipidation were predicted based upon the known
fatty acid distribution, and data screened for the presence of these species.
Multiple acylated propranolol 1 derivatives were observed upon incubation with E. coli extract,
as summarised in Table 7.12. CID MSMS performed upon species of sufficient abundance
confirmed these to be O-acylated derivatives, rather than their N -acylated counterparts.
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Product assignment is consistent with the hypothesised pathway of propranolol 1 intrinsic
lipidation at physiological pH. Initial reactivity proceeds through transesterification from
the phospholipid ester onto the alcohol moiety of propranolol 1, resulting in formation of
an O-acylated species. Subsequent N -acylated intramolecular migration products are not
observed within E. coli extract, indicating either a lack of migration within more complex
biological systems, or increased acyl chain diversity combined with poor ionisation potential
of N -acylated species preventing visualisation.
Fatty Acid Transferred Theoretical m/z Observed m/z Error (ppm) R.T. (min)
14:0 470.3634 470.3617 3.7 4.1
15:0 484.3791 - - -
16:0 498.3947 498.3956 1.8 5.4
16:1 496.3791 496.3805 2.9 4.3
17:0 512.4104 - - -
cyclo 17:0 510.3947 510.3960 2.5 5.1
18:0 526.4260 526.4290 5.8 5.6
18:1 524.4104 524.4106 0.4 5.1
19:0 540.4417 - - -
cyclo 19:0 538.4260 538.4264 0.7 6.9
Table 7.12 Acylated propranolol 1 derivatives observed following optimised LCMS analysis
of propranolol 1 incubation under physiological conditions with liposomes prepared from E.
coli extract.
O-acylated propranolol 1 derivatives corresponding to all known E. coli fatty acid chains
are observed, with the exceptions of 15:0, 17:0, and 19:0. Low abundance of 15:0 and 19:0
acyl chains within E. coli extract explains their lack of observable transfer, however lack of
17:0 transfer is surprising considering it comprises 17.7 % of PE fatty acid content. Taken in
tandem with the observation of abundant cyclo 17:0 transfer despite 0.0 % contribution to PE
fatty acid content, two theories can be predicted. The first theory suggests preferential acyl
chain transfer from PG and CL components of E. coli liposomes in favour of PE content, due
to increased proximity induced by electrostatic interactions between negative phospholipids
and cationic propranolol 1. Alternatively, as supported by literature studies, reported PE
fatty acid content is incorrect such that E. coli contains 17.7 % cyclo 17:0 rather than linear
17:0.137,297,302 In addition to cyclo 17:0, O-acylated propranol 1 derivatives present in highest
abundance result from transfer of 16:0 and 18:1 acyl moieties. This observation is consistent
with fatty acid distribution data, in which 16:0 appears in greatest abundance, and 18:1
as second and third most common for PE, and PG/CL components respectively. Further
predicted acyl chain transfers, 14:0, 16:1, and 18:0 are assigned based upon accurate mass
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and retention time data alone, due to low abundance preventing CID MSMS analysis.
Extracted ion chromatograms (EIC) for major O-acylated propranolol 1 derivatives formed
by intrinsic lipidation within E.coli extract liposomes, are presented in Fig. 7.10. Observed
retention times reflect known patterns of acyl chain retention exhibited by lysolipids and other
acylated species.11,40 Increased carbon chain length and associated hydrophobicity results
in a corresponding retention time increase, indicated by retention times of 14:0, 16:0 and
18:0 acyl chains as 4.1 min, 5.4 min, and 5.6 min respectively. Unsaturation is observed to
decrease analyte retention, exemplified by 16:0 and 16:1 acyl chains of retention time 5.4 min
and 4.3 min respectively, and 18:0 and 18:1 acyl chains at 5.6 min and 5.1 min respectively.
Retention time comparison for cyclopropyl derivatives is not possible due to lack of linear
counterparts. Intrinsic lipidation product ratios based upon observed chromatographic peak
area have not been determined due to known ionisation efficiency differences between acylated
propranolol 1 derivatives evidenced in Chapter 6 of this thesis.
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Figure 7.10 EIC for major acylated propranolol 1 derivatives observed following LCMS
analysis of propranolol 1 incubation under physiological conditions with liposomes prepared
from E. coli extract.
Small molecule intrinsic lipidation observed within E. coli liposomes has the capacity to alter
bulk membrane lipid profile. Optimised analytical conditions provide lipidomics of E. coli
PE and PG species using negative mode ESI, which can be compared with the untreated
E. coli profile given in Table 7.10. Lack of cellular proteins allows observed changes to be
attributed directly to the action of propranolol 1, rather than phospholipase or head group
exchange enzymes. Comparison of lipid profiles for untreated and propranolol 1 treated E. coli
indicates similarities between the two, with an identical majority of observed phospholipids.
Five phospholipid species were observed in untreated liposomes but not noted to be present
230 7.3. Intrinsic Lipidation in E. coli Extracts
upon propranolol 1 treatment, these were PG(33:0), PE(37:7(OH)), PG(39:4), PE(49:3), and
PG(58:0(OH)). Phospholipid loss can be attributed to reduced abundance below the prescribed
threshold for LIPID MAPS assignment following either intrinsic lipidation or hydrolysis.296
Furthermore, nine additional phospholipid species not found in untreated samples were
identified within propranolol 1 treated E. coli liposomes, summarised in Table 7.13. The
origin of these additional species remains unclear, however their presence can be explained
by either low level abundance fluctuations close to the limit of instrument detection, or to
increased lipid solubility in the presence of propranolol 1.
Observed m/z Theoretical m/z Error (ppm) Assignment
634.4489 634.4453 2.2 PE(28:0)
705.4685 705.4712 3.8 PG(31:1)
756.5560 756.5549 1.5 PE(37:2)
758.5713 758.5705 1.1 PE(37:1)
764.5198 764.5236 3.5 PE(38:5)
772.5841 772.5862 2.7 PE(38:1)
779.5842 779.5807 0.3 PG(36:0(OH))†
807.4835 807.4818 2.1 PG(38:7(OH))
815.6155 815.6171 2.0 PG(40:2)† / PG(40:1)‡
Table 7.13 Additional phospholipid species identified within E. coli lipid extract upon
treatment with propranolol 1. † indicates the presence of alkyl ether substituent; ‡ indicates
the presence of alkenyl ether (plasmalogen) substituent.
Lysolipid abundance provides a further distinguishing feature between propranolol 1 treated
and untreated E. coli extracts. LPE(16:0), LPE(cyclo 17:0), and LPE(18:1) lysolipids are
observed in both treated and untreated samples, whilst lysolipid LPG(18:1) is observed in
propranolol 1 treated samples only. Despite similar speciation, lysolipid abundances differ
between treated and untreated samples, as evidenced by semi-quantification using internal
standard LPC(17:0). Normalised peak areas, presented in Table 7.14, show a slight lysolipid
increase in response to propranolol 1 treatment, corresponding with in vitro observations using
liposome systems. Upregulation of phospholipid hydrolysis in the presence of propranolol
1 combined with lysolipid production through intrinsic lipidation facilitate this increase in
lysolipid concentration within the bulk membrane, decreasing membrane integrity.27
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Lysolipid Untreated Peak Area Treated Peak Area
LPE (16:0) 2.48 2.58
LPE (cyclo 17:0) 0.05 0.07
LPE (18:1) 0.08 0.09
Table 7.14 Chromatographic peak areas attributed to the three lysolipids present in E.
coli lipid extract: (i) untreated; (ii) treated with propranolol 1 in 1:10 small molecule:lipid
molar ratio. Peak areas are normalised and presented as % of internal standard LPC(17:0)
chromatographic peak area.
7.3.2 2-Aminomethylbenzimidazole Reactivity
Study of benzimidazole 11 intrinsic lipidation within E. coli extracts was also conducted.
Benzimidazole 11 was selected due to availability, combined with observed high levels of
intrinsic lipidation within membrane models in vitro. Acylated product characterisation in
vitro suggests formation of a single benzimidazole 11 intrinsic lipidation product, resulting
from reactivity of the free primary amine. Single product formation reduces product diversity
compared to propranolol 1, simplifying analysis by mass spectrometry. Following incubation
for 72 hours under physiological conditions, reaction mixtures were screened for acylated 11
derivatives predict by E. coli fatty acid distribution.
Observed acylated 11 derivatives, summarised in Table 7.15, reflect a similar pattern of acyl
chain transfer as described for propranolol 1. Low abundance 18:0 and cyclo 19:0 acyl chains,
where transfer is observed to propranolol 1 but not benzimidazole 11, are the exception to
this. High abundance transfer of 16:0, and 18:1 acyl chains to benzimidazole 11 is observed,
reflecting recorded fatty acid distribution. Furthermore, abundant transfer of cyclo 17:0 is
noted, whilst linear 17:0 is not, supporting previous suggestions of errors in reported fatty acid
distribution, or preferential transfer from PG and CL species. Transfer of 14:0 and 16:1 acyl
chains is noted based upon retention time and accurate mass, since low abundance prevents
CID MSMS confirmation. Observed reactivity of the 14:0 acyl chain is interesting considering
transfer is not noted for fatty acyl chains of similar or higher abundance, such as 18:0 and 19:0.
Preferential positioning of 14:0 acyl chains, or favourable transfer of shorter chain lengths
could explain this observation, however further data would be required for confirmation.
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Fatty Acid Transferred Theoretical m/z Observed m/z Error (ppm) R.T. (min)
14:0 358.2858 358.2861 0.7 3.7
15:0 372.3015 - - -
16:0 386.3171 386.3167 1.1 5.0
16:1 384.3015 384.3017 0.6 4.0
17:0 400.3328 - - -
cyclo 17:0 398.3171 398.3166 1.4 4.7
18:0 414.3484 - - -
18:1 412.3328 412.3318 2.4 5.3
19:0 428.3641 - - -
cyclo 19:0 426.3484 - - -
Table 7.15 Acylated benzimidazole 15 derivatives observed following LCMS analysis of
benzimidazole 15 incubation under physiological conditions with liposomes prepared from E.
coli extract.
EIC for acylated derivatives of benzimidazole 11, formed by intrinsic lipidation with E. coli
extract, are shown in Fig. 7.11. Despite reduced product diversity compared to study of
acylated propranolol 1 species, known patterns of acyl chain retention are observed. Increased
carbon chain length from 14:0 to 16:0 results in a corresponding retention time increase
from 3.7 min to 5.0 min. Inclusion of a double bond into the acyl chain structure reduces
product retention, as exhibited by acyl chains 16:0 and 16:1 having retention times of 5.0 min
and 4.0 min respectively. Intrinsic lipidation product ratios were not calculated based upon
observed chromatographic peak area, due to predicted ionisation efficiency variation between
acylated benzimidazole 11 derivatives.
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Figure 7.11 EIC for acylated benzimidazole 11 derivatives observed following LCMS
analysis of benzimidazole 11 incubation under physiological conditions with liposomes prepared
from E. coli extract.
Chapter 7. Small Molecule Intrinsic Lipidation in cellulo 233
Optimised analytical conditions facilitate lipid profile comparison between untreated and
benzimidazole 11 treated E. coli extracts. Lipidomics of treated samples reveal a majority
of shared lipid species with untreated and propranolol 1 treated E. coli, corresponding
to the lipid profile given in Table 7.10. However, seven phospholipid species observed in
the untreated membrane were lost upon benzimidazole 11 treatment, these were PE(30:1),
PE(35:1), PG(33:0), PE(38:6)‡, PE(37:7(OH)), PE(49:3), and PG(58:0(OH)). Three species,
PG(33:0), PE(49:3), and PG(58:0(OH)), correspond to species also lost following propranolol
1 treatment, and attributed to reduced abundance following intrinsic lipidation or hydrolysis.
Furthermore, eight additional phospholipid species, not found in untreated samples, were
identified within benzimidzole 11 treated E. coli liposomes, summarised in Table 7.16. Three
of the additional species, PE(28:0), PE(37:2), and PG(40:2)† / PG(40:1)‡, were also observed
upon treatment of E. coli extract with propranolol 1. The origin of these additional species
remains unclear, however their presence can be explained by either low level abundance
fluctuations close to the limit of instrument detection, or to increased lipid solubility in the
presence of benzimidazole 11.
Observed m/z Theoretical m/z Error (ppm) Assignment
634.4442 634.4453 1.7 PE(28:0)
676.4927 676.4923 0.6 PE(31:0)
687.4239 687.4242 0.4 PG(30:3)
756.5558 56.5549 1.2 PE(37:2)
771.5162 771.5181 2.5 PG(36:3)
793.4692 793.4661 3.9 PG(37:7(OH))
802.506 802.5028 3.5 PE(40:8(OH))
815.6155 815.6171 1.6 PG(40:2)† / PG(40:1)‡
Table 7.16 Additional phospholipid species identified within E. coli lipid extract upon
treatment with benzimidazole 11. † indicates the presence of alkyl ether substituent; ‡
indicates the presence of alkenyl ether (plasmalogen) substituent.
Lysolipid abundance was noted to vary in propranolol 1 treated E. coli liposomes, therefore
similarly modified lysolipid adundance was predicted in benzimidazole 11 treated systems.
Abundance was determined for major lysolipid species LPE(16:0), LPE(cyclo 17:0), and
LPE(18:1), through chromatographic peak area modelling and normalisation using internal
standard LPC(17:0). As summarised in Table 7.17, lysolipid abundance was noted to be
slightly upregulated in benzimidazole 11 treated E. coli compared to untreated systems.
Corresponding to observations made in vitro using simple liposomal systems, lysolipid upregu-
lation can be attributed to increased phospholipid hydrolysis combined with benzimidazole 11
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intrinsic lipidation. Variation in bulk membrane lysolipid concentration impacts membrane
stability and integrity, with significant disruption known to result in leakage of intracellular
contents and ultimately cell death.30,31,35
Lysolipid Untreated Peak Area Treated Peak Area
LPE (16:0) 2.48 2.73
LPE (cyclo 17:0) 0.05 0.07
LPE (18:1) 0.08 0.20
Table 7.17 Chromatographic peak areas attributed to the three lysolipids present in E. coli
lipid extract: (i) untreated; (ii) treated with benzimidazole 11 in 1:10 small molecule:lipid
molar ratio. Peak areas are normalised and presented as % of internal standard LPC(17:0)
chromatographic peak area.
7.4 Intrinsic Lipidation in Liver Extracts
Propranolol 1 and benzimidazole 11 exhibit intrinsic lipidation reactivity in the presence of
liposomes prepared from polar E. coli extract. However, study in vitro using simple eukaryotic
and prokaryotic models suggests both small molecules undergo preferential eukaryotic reactivity.
Merging in vitro study with increased molecular diversity, intrinsic lipidation within liposomes
prepared from polar liver extract was compared to the equivalent E. coli derived system. Polar
liver extract was obtained through CHCl3:MeOH extraction of bovine liver tissue, followed
by acetone precipitation and further extraction with diethyl ether.303 Resulting liver extract
liposomes contain PC, PE, PI and cholesterol species, whilst incorporating a diverse range of
fatty acyl chain types. Additional biological features, including peptides and proteins, are
not contained within the extract, providing increased simplicity compared to a true cellular
system.
Optimised analytical conditions facilitated successful study of small molecule intrinsic lipidation
within liver extract through lipid profile determination. Combined analyses by positive
and negative mode ESI provided insight into chromatographically resolved PC, PE and PI
species present within polar liver extract, Fig. 7.12. Scans were combined over the retention
time windows of lysololipid elution between 1.0 min to 6.0 min, and phospholipid elution
between 13.0 min and 20.0 min. Ions exceeding the intensity threshold of 1x105 were isolated
and assigned through comparison with the LIPID MAPS Gateway.296 Following removal of
anomalies not observed across duplicate analyses, and those exhibiting error of > 4.0 ppm,
the lipid profile presented in Table 7.18 was obtained. Unrealistic assignments attributed to
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acyl chain species known to be absent within eukaryotic liver cells were also removed.
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Figure 7.12 TIC of phospholipid and lysolipid species identified within Hep G2 cells
including positive mode ESI (red) and negative mode ESI (green). * indicate internal
standards LPC(17:0) eluting at 3.2 min and PC(17:0) eluting at 14.9 min.
Observed m/z Theoretical m/z Error (ppm) Assignment
438.2988 438.2979 2.1 LPE(16:0)‡
452.2762 452.2772 2.2 LPE(16:1)
466.3274 466.3292 3.9 LPE(18:0)‡
478.2938 478.2928 2.1 LPE(18:2)
482.3228 482.3241 2.7 LPE(18:0)
502.2926 502.2928 0.4 LPE(20:4)
508.3756 508.3762 1.2 LPC(18:0)‡
518.3239 518.3241 0.4 LPC(18:3)
544.3383 544.3398 2.8 LPC(20:4)
546.3540 546.3554 2.6 LPC(20:3)
568.3392 568.3398 1.1 LPC(22:6)
597.3057 597.3035 3.7 LPI(18:2)
601.3324 601.3348 4.0 LPI(18:0)
690.5065 690.5069 0.6 PE(32:1)
694.5036 694.5018 2.6 PC(28:0(OH))
698.5127 698.5119 1.1 PE(34:4)† / PE(34:3)‡
718.5381 718.5382 0.1 PE(34:1)
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738.5423 738.5432 1.2 PC(34:4)‡
748.5272 748.5276 0.5 PE(38:6)‡
748.6210 748.6215 0.7 PC(34:0)†
750.5461 750.5432 3.9 PE(38:6)† / PE(38:5)‡
756.5531 756.5538 0.9 PC(34:3)
756.5930 756.5902 3.7 PE(38:2)‡
768.5548 768.5538 1.3 PE(38:4)
770.6049 770.6058 1.2 PC(36:3)† / PC(36:2)‡
772.5859 772.5851 1.0 PE(38:2)
784.4915 784.4912 0.4 PE(40:10)
790.5955 790.5957 0.3 PE(38:1(OH))
808.5826 808.5851 3.1 PC(38:5)
828.5161 828.5174 1.6 PE(42:10(OH))
828.6099 828.6113 1.7 PC(38:3(OH))
830.5680 830.5695 1.8 PC(40:8)
832.6788 832.6790 0.2 PE(42:0)
837.5488 837.5488 0.0 PI(34:1)
842.6614 842.6634 2.4 PC(40:2)
845.5183 845.5175 0.9 PI(35:4)
846.6953 846.6947 0.7 PC(40:0)
850.5942 850.5957 1.8 PC(40:6(OH))
853.6163 853.6165 0.2 PI(36:0)†
856.7183 856.7154 3.4 PC(42:2)†
862.6303 862.6321 2.1 PC(42:6)
863.5669 863.5644 2.9 PI(36:2)
869.5526 869.5539 1.5 PI(38:6)† / PI(38:5)‡
884.7485 884.7467 2.0 PC(44:2)†
885.5472 885.5488 1.8 PI(38:5)
887.5615 887.5644 3.3 PI(38:4)
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889.5770 889.5801 3.5 PI(38:3)
891.5959 891.5957 0.2 PI(38:2)
905.6475 905.6478 0.3 PI(40:2)† / PI(40:1)‡
915.5927 915.5957 3.3 PI(40:4)
931.5306 931.5331 2.7 PI(42:10)
Table 7.18 Phospholipid and lysolipid species identified within polar bovine liver lipid
extract.303 † indicates the presence of alkyl ether substituent; ‡ indicates the presence of
alkenyl ether (plasmalogen) substituent.
Fatty Acid Liver PC (%) Liver PE (%) Liver PI (%)
16:0 14.0 5.0 0.0
16:1 0.0 0.1 0.0
18:0 33.0 33.7 46.0
18:1 17.0 9.8 8.0
18:2 12.0 10.9 6.0
18:3 0.0 0.8 0.0
20:3 8.0 4.1 13.0
20:4 7.0 19.5 17.0
22:6 0.0 2.1 0.0
Unknown 9.0 14.0 10.0
Table 7.19 Fatty acid chain distribution of bovine liver lipid extract.303
Fifty-one distinct lipid components were observed following analysis of bovine liver extract.
Species can be subdivide into thirty-eight phospholipid components, and thirteen lysolipid
components. Phosphate head groups observed cover the classes PC, PE, and PI in accordance
with available data dictating the mixture contains 42 % PC, 26 % PE, and 10 % PI/lyso
PI. Additional recorded components include 5 % cholesterol, a known sterol component
of eukaryotic membranes unable to undergo intrinsic lipidation with small molecules, and
17 % other lipid species including neutral lipids. Saturated and unsaturated acyl chain
types are represented within liver extract, in addition to both hydrolysed and plasmalogen
moieties.300,301,303 Plasmalogen presence within both PC and PE lipid classes is known within
liver cells, however proportions are usually low at <1 % PC and < 4 % PE within sheep liver.
Lysolipid species provide insight into specific acyl chains present, which include 16:0, 16:1,
18:0, 18:2, 18:3, 20:3, 20:4, and 22:6. Observed acyl chains reflect those attributed to liver
membrane lipids within available literature data, Table 7.19, with the exception of the 18:1
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chain.
7.4.1 Propranolol Reactivity
Study of propranolol 1 intrinsic lipidation, facilitated by lipid profile determination, was
conducted using polar bovine liver extract. Under physiological conditions, propranolol 1
was incubated for 72 hours in 1:10 drug:lipid molar ratio with liver extract liposomes, based
upon an average phospholipid molecular weight of 756.3360. Screening for predicted acylated
propranolol 1 derivatives was conducted following analysis under optimised conditions designed
for study of small molecule intrinsic lipidation within complex biological systems.
Table 7.20 summarises acylated propranolol 1 derivatives observed upon incubation with liver
extract. CID MSMS performed upon species of sufficient abundance confirmed these to be
O-acylated derivatives, rather than their N -acylated counterparts. Absence of N -acylated
species is attributed to either reduced intramolecular migration, or poor ionisation of the
multiple low abundant species. Product assignment is consistent with both the predicted
pathway of propranolol 1 intrinsic lipidation, and reactivity observations made during study
of propranolol 1 intrinsic lipidation within E. coli extract.
Fatty Acid Transferred Theoretical m/z Observed m/z Error (ppm) R.T. (min)
16:0 498.3947 498.3947 0.0 5.4
16:1 496.3791 - - -
18:0 526.4260 526.4276 3.0 7.4
18:1 524.4104 524.4099 0.9 5.6
18:2 522.3947 522.3951 0.7 4.6
18:3 520.3791 - - -
20:3 548.4104 548.4109 1.0 5.0
20:4 546.3947 546.3932 2.8 2.6
22:6 570.3947 - - -
Table 7.20 Acylated propranolol 1 derivatives observed following LCMS analysis of propra-
nolol 1 incubation under physiological conditions with liposomes prepared from bovine liver
extract.
Predicted O-acylated propranolol 1 derivatives not observed upon incubation with liver extract
include transfer of 16:1, 18:3, and 22:6 acyl chains. Minor membrane components, these chain
chemistries are attributed solely to PE class phospholipids in low proportions of 0.1 %, 0.8 %,
and 2.1 % respectively. Their low abundance explains their lack of observable transfer, with
acylated small molecule quantities predicted to fall below the limit of instrument detection. All
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additional acyl chain chemistries attributed to liver extract are represented in the formation
of acylated propranolol 1 derivatives, however 20:4 transfer is based upon accurate mass and
retention time only due to poor ion intensity preventing CID MSMS. Relatively poor 20:4
transfer combined with abundant transfer of other moieties, particularly 16:0, 18:0, and 18:1,
suggests observed transfer patterns correlate with PC fatty acid content. Preferential transfer
from PC class lipids is likely due to the increased ratio of PC species (42 %) compared to PE
(26 %) and PI (10 %) counterparts. However, absolute quantification of differential transfer
could be determined based upon peak area comparisons, due to known differences in ionisation
efficiencies for acylated propranolol 1 derivatives.
Fig. 7.13 presents EIC for O-acylated propranolol 1 derivatives formed by intrinsic lipidation
within liver extract liposomes, with the exception of low abundant 20:4 transfer. Observed
retention times reflect known patterns of acyl chain retention exhibited by lysolipids and
other acylated species. Reduced retention due to shorter carbon chain length or increased
unsaturation is evidenced by acyl chains 16:0 and 18:0 at retention times of 5.4 min and 7.4 min
respectively, and chains 18:0, 18:1 and 18:2 at retention times 7.4 min, 5.6 min and 4.6 min
respectively. Retention times of 16:0 and 18:1 acylated propranolol 1 formed within liver
extract liposomes are consistent with corresponding products formed within E. coli extract.
However, 18:0 acylated propranolol 1 exhibits markedly different retention between the two,
observed at 5.6 min within E. coli and 7.4 min within liver extract. Observed differences
suggests an incorrect assignment attributed to E. coli, due to increased mass accuracy error
and lack of 18:0 transfer observed within the analogous benzimidazole system.
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Figure 7.13 EIC for acylated propranolol 1 derivatives observed following LCMS analysis
of propranolol 1 incubation under physiological conditions with liposomes prepared from
bovine liver extract.
240 7.4. Intrinsic Lipidation in Liver Extracts
Lipid profile modifications to liver extract liposomes upon treatment with small molecule
propranolol 1 for 72 hours were determined using optimised analytical conditions. Lack of
cellular proteins allows observed changes to be attributed directly to the action of propranolol
1, rather than phospholipase or head group exchange enzymes. The observed lipid profile
of propranolol 1 treated liver liposomes resembles that of the untreated control, retaining
thirty of the thirty-eight phospholipids. Eight phospholipids covering PC, PE and PI classes
observed within untreated liver extract, were not observed during analysis of propranolol 1
treated extract. Increased phospholipid hydrolysis combined with intrinsic lipidation reactivity
likely diminished these species such that abundance falls below the prescribed threshold for
LIPID MAPS assignment.296 Simultaneously, eleven additional lipid species, summarised in
Table 7.21, were identified during analysis of propranolol 1 treated liver extract. The origin
of these species is unclear, however sufficient safeguards have been implemented to ensure the
observed increase in phospholipid diversity is real. Low level abundance fluctuations close to
the limit of instrument detection, or increased lipid solubility in the presence of propranolol 1
provide possible explanations.
Observed m/z Theoretical m/z Error (ppm) Assignment
610.4445 610.4443 0.32 PE(26:0(OH))†
643.3405 643.3453 2.12 PI(20:0)
648.4622 648.4599 3.5 PC(26:1)
710.4755 710.4756 0.1 PE(34:5)
764.5213 764.5225 1.6 PE(38:6)
798.6392 798.6371 2.6 PC(38:3)† / PC(38:2)‡
818.6633 818.6634 0.1 PC(38:0)
874.7305 874.726 0.7 PC(42:0)
886.7617 886.7623 0.7 PC(44:1)†
951.6877 951.6896 2.0 PI(42:0)
995.7169 995.7158 1.1 PI(44:0(OH))
Table 7.21 Additional phospholipid species identified within bovine liver lipid extract upon
treatment with propranolol 1. † indicates the presence of alkyl ether substituent; ‡ indicates
the presence of alkenyl ether (plasmalogen) substituent.
7.4.2 2-Aminomethylbenzimidazole Reactivity
For comparison with propranolol 1 and the E. coli system, benzimidazole 11 intrinsic
lipidation was also studied using bovine liver extract. Incubation proceeded for 72 hours
under physiological conditions prior to analysis under optimised analytical conditions designed
for study of small molecule intrinsic lipidation within complex biological systems. Potential
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acylated benzimidazole 11 products of intrinsic lipidation were predicted based upon the
known fatty acid distribution, and data screened for the presence of these species. In contrast
to propranolol 1, only a single acylated form of benzimidazole 11 is predicted.
Acylated benzimidazole 11 derivatives formed within liver extract liposomes, Table 7.22,
mirror acylated propranolol 1 derivatives. Lack of 16:1, 18:3, and 22:6 acyl chain transfer is
once again attributed to their status as only minor acyl chain components of PE class liver
lipids. Favourable acyl chain transfer from more abundant PC phospholipids compared to PE
and PI counterparts is exemplified by considerable formation of 16:0, 18:0 and 18:1 acylated
benzimidazole 11 products. Furthermore, low level transfer of 18:2, 20:3 and 20:4 acyl chains
are noted, resulting in formation of additional intrinsic lipidation products.
Fatty Acid Transferred Theoretical m/z Observed m/z Error (ppm) R.T. (min)
16:0 386.3171 386.3167 1.1 5.0
16:1 384.3015 - - -
18:0 414.3484 414.3489 1.1 6.7
18:1 412.3328 412.3313 3.6 5.3
18:2 410.3171 410.3168 0.8 4.3
18:3 408.3015 - - -
20:3 436.3328 436.3323 1.1 5.0
20:4 434.3171 434.3159 2.9 3.6
22:6 458.3171 - - -
Table 7.22 Acylated benzimidazole 11 derivatives observed following LCMS analysis of
benzimidazole 11 incubation under physiological conditions with liposomes prepared from
bovine liver extract.
EICs for chromatographically observable acylated benzimidazole 11 derivatives are presented
in Fig. 7.14. Observed retention times mirror known patterns, with reduced carbon chain
length and increased unsaturation resulting in earlier product elution. Comparable product
retention times are observed within liver extract as those attributed to products within E. coli,
supporting product identification. Examples include 16:0 benzimidazole 11 eluting at 5.0 min
in both liver liposomes and in E. coli extract. Similarly, 18:1 benzimidazole 11 consistently
elutes at the retention time 5.3 min within both liver and E. coli systems.
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Figure 7.14 EIC for acylated benzimidazole 11 derivatives observed following LCMS
analysis of benzimidazole 11 incubation under physiological conditions with liposomes prepared
from bovine liver extract.
Observed m/z Theoretical m/z Error (ppm) Assignment
621.3045 621.3035 1.6 LPI(20:4)
672.4593 672.4599 0.9 PC(28:3)
710.4723 710.4756 1.0 PE(34:5)
753.4553 753.4549 0.5 PI(28:1)
764.5245 764.5225 2.6 PE(38:6)
792.6466 792.6477 1.34 PC(36:0(OH))†
799.4929 799.4967 2.4 PI(30:0(OH))
806.6251 806.6270 2.4 PC(36:0(OH))
835.5323 835.5331 1.0 PI(34:2)
839.5637 839.5644 0.8 PI(34:0)
874.7299 874.726 1.34 PC(42:0)
959.6192 959.6219 2.8 PI(42:4(OH))
Table 7.23 Additional phospholipid species identified within bovine liver lipid extract upon
treatment with benzimidazole 11. † indicates the presence of alkyl ether substituent; ‡
indicates the presence of alkenyl ether (plasmalogen) substituent.
Lipodomics studies reveal the influence of benzimidazole 11 treatment upon the lipid profile
of bovine liver extract. Optimised analysis suggests retention of the majority of lipid species
observed within untreated and propranolol 1 treated liver systems. However, two lysolipid
species plus twelve of the thirty-eight phospholipid species were not visualised during analysis
of benzimidazole 11 treated samples. Four of the species lost compared to untreated liver
extract were also absent in the lipid profile of propranolol 1 treated liposomes. Increased
lysolipid abundance, consistent with observations in vitro and in E. coli extract, suggests that
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phospholipid hydrolysis reduces abundance of phospholipid species such that they fall below
the required threshold. In tandem, twelve novel lipid species not attributed to untreated
liver extract were observed in benzimidazole 11 treated samples, Table 7.23. Four species,
PC(42:0), PE(38:6), PI(28:1), and PE(34:5), are also observed within propranolol 1 treated
liver extract. Similarities between propranolol 1 and benzimidazole 11 treated liver extracts
suggest they employ analogous mechanisms to modify lipid profile.
7.5 Intrinsic Lipidation in Hep G2 Cells
Optimised analytical conditions for the study of lipidomics and small molecule intrinsic
lipidation within complex biological systems have been validated using polar E. coli and liver
extracts. Furthermore, cellular extracts have provided insight into acylated product formation
and distribution within complex systems, applicable to study of intrinsic lipidation in cellulo.
Hep G2 cells provide a suitable study medium for moving reactivity monitoring in cellulo,
enabling biological relevance of intrinsic lipidation to be explored. A well characterised human
liver cancer cell line, Hep G2 cells provide a comparable system to the eukaryotic bovine
liver cell extract studied in liposomal form. Selection of the Hep G2 cell line is attributed
to their use in the study of drug induced phospholipidosis, a side effect linked to intrinsic
lipidation.73,74
Additional experimental steps are required to facilitate study of intrinsic lipidation in cellulo,
compared to liposomal systems. Cell viability and survival is required over the 72 hour time
period of study to ensure successful analysis. Concentration of small molecule propranolol 1
must therefore be selected accordingly. Approximately 20000 cultured cells were added to
each well of a sterile 96-well plate, then left to adhere overnight at 37 ◦C in 5 % CO2 and
95 % humidity. Propranolol 1 stock solution in H2O was added to triplicate cell samples at
30 µM, along with ten further serial dilutions down to final concentration 29 nM. Following
72 hours, cell growth compared to an untreated control was determined by visual study. Cell
survival was observed across all samples, however at a propranolol 1 concentration of 30 µM cell
number was reduced by approximately 30 % compared to untreated counterparts. Successful
analysis of intrinsic lipidation products is facilitated by increased abundance relative to other
cellular species. Considering both cell viability and analytical requirements, a propranolol 1
concentration of 30 µM was selected for study of intrinsic lipidation in cellulo.
Analysis of intrinsic lipidation in cellulo requires a second additional experimental step
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compared to study in liposomal systems. Isolation of small molecule and lipid components
from Hep G2 cells is required prior to sample analysis, in order to minimise sample complexity
and ensure visualisation of intrinsic lipidation products. Isolation requires development of a
robust and reproducible method of cellular extraction. Optimised extraction conditions were
determined by comparison of an in vitro POPC and propranolol 1 reaction mixture under
different extraction conditions. Three extraction solvents were tested in accordance with the
literature:
• CHCl3
• CHCl3:MeOH (2:1) aka the Folch method304
• Methyl tert-butyl ether (MTBE)305
5.5 6.0 6.5 7.0 7.5 8.0
0
2×105
4×105
6×105
8×105
In
te
n
s
it
y
(a
rb
.
u
n
it
s
)
(a)
Time (min)
5.5 6.0 6.5 7.0 7.5 8.0
0
1×104
2×104
3×104
4×104
5×104
6×104
In
te
n
s
it
y
(a
rb
.
u
n
it
s
)
Time (min)
(b)
5.5 6.0 6.5 7.0 7.5 8.0
0
1×104
2×104
3×104
4×104
5×104
6×104
In
te
n
s
it
y
(a
rb
.
u
n
it
s
)
Time (min)
(c)
5.5 6.0 6.5 7.0 7.5 8.0
0
1×104
2×104
3×104
4×104
5×104
6×104
In
te
n
s
it
y
(a
rb
.
u
n
it
s
)
Time (min)
(d)
1Figure 7.15 EIC comparing palmitoylated propanolol species (green) and oleoylated pro-
pranolol species (red) before and after extraction: (a) no extraction; (b) CHCl3 extraction;
(c) CHCl3:MeOH (2:1) extraction; (d) MTBE extraction.
Comparable extraction of phospholipid POPC and small molecule propranolol 1 was exhibited
under all extraction conditions, resembling analysis conducted prior to extraction. However,
as shown in Fig. 7.15, differential extraction of acylated small molecules is noted between
experimental conditions. Neither CHCl3 not MTBE, Fig. 7.15 (b) and (d) respectively,
successfully extracted these low abundant species, particularly N -acylated derivatives, as
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denoted by their absence in the relevant EIC. In contrast, the Folch method, Fig. 7.15
(c), exhibits EIC comparable to those obtained prior to extraction, albeit with some loss of
oleoylated species. Successful extraction was noted for lysolipids, in addition to bothO-acylated
and N -acylated propranolol 1 derivatives. Successful extraction of acylated propranolol 1
derivatives is vital to ensure study of intrinsic lipidation in cellulo can be conducted reliably.
As a result CHCl3:MeOH (2:1) was selected as the optimum solvent for extraction of Hep G2
cells prior to intrinsic lipidation analysis.
Lipid profiling of Hep G2 cells was conducted, facilitated by optimised extraction methodology
and analytical conditions. Positive and negative mode ESI analysis was required to ensure Hep
G2 cell lipid diversity was captured, Fig. 7.16. However, literature reports suggest diacylglyc-
erophospholipids, especially PC and PE classes, to be the major cellular components.306,307
Summarised in Table 7.24, thirty-four phospholipid species and three lysolipids were identified
within Hep G2 cells. Identified phospholipids comprise chromatographically resolved 11 %
PS, 27 % PE, 30 % PC, and 32 % PI head group classes, Fig. 7.16, varying from reported
figures of 4 % PS, 24 % PE, 47 % PC, and 7 % PI. Furthermore, literature studies report
an additional 6 % PG and 12 % sphingomyelin (SM) content not observed during these lipid
profiling attempts for unknown reasons. Differential % calculation methods, for example %
of the total number of observed species versus % weight, accounts for some of the observed
variation. However, PI content presents the most startling contrast between observed and
reported lipid classes, attributed to either a reduced abundance of multiple PI species or
differences in cellular preparation.
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Figure 7.16 TIC of phospholipid and lysolipid species identified within Hep G2 cells
including positive mode ESI (red) and negative mode ESI (green). * indicate internal
standards LPC(17:0) eluting at 2.5 min and PC(17:0) eluting at 14.1 min.
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Observed m/z Theoretical m/z Error (ppm) Assignment
454.2918 454.2928 2.2 LPE(16:0)
482.3234 482.3241 1.5 LPE(18:0)
502.2926 502.2928 0.3 LPE(20:4)
680.4845 680.4861 2.4 PE(30:0(OH))
708.4623 708.4599 3.4 PE(34:6)
722.5305 722.5331 3.6 PC(30:0(OH))
728.4844 728.4861 2.3 PE(34:4(OH))
728.5236 728.5225 1.5 PC(32:3)
732.5518 732.5538 2.7 PC(32:1)
736.5463 736.5487 3.3 PE(34:0(OH))
738.5084 738.5069 2.0 PE(36:5)
746.6082 746.6058 3.2 PC(34:1)†
748.5247 748.5276 3.9 PE(38:6)‡
754.5399 754.5382 2.3 PC(34:4)
760.4916 760.4912 0.5 PE(38:8)
772.4771 772.4770 0.1 PS(34:3(OH))
776.6183 776.6164 2.4 PE(38:0)
784.5821 784.5851 3.8 PC(36:3)
790.5396 790.5382 1.8 PE(40:7)
794.5720 794.5695 3.1 PE(40:5)
806.5726 806.5695 3.8 PC(38:6)
810.5984 810.6008 2.9 PC(38:4)
813.5496 813.5488 1.0 PI(32:0(OH))†
822.5671 822.5654 2.1 PS(40:5)†
832.6467 832.6437 3.6 PS(40:0)†
834.6035 834.6008 3.2 PC(40:6)
837.5468 837.5488 2.4 PI(34:1)
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853.6168 853.6165 0.4 PI(36:0)†
855.4987 855.5018 3.6 PI(36:6)
860.6177 860.6164 1.5 PC(42:7)
860.6713 860.6739 3.0 PC(40:1(OH))
860.6757 860.6750 0.8 PS(42:0)†
863.5659 863.5644 1.7 PI(36:2)
881.5176 881.5175 0.1 PI(38:7)
885.5453 885.5488 4.0 PI(38:5)
887.5651 887.5644 0.8 PI(38:4)
889.5801 889.5801 0.0 PI(38:3)
911.5610 911.5644 3.7 PI(40:6)
929.5779 929.5750 3.1 PI(40:5(OH))
931.5313 931.5331 1.9 PI(42:10)
951.5598 951.5593 0.5 PI(42:8(OH))
959.5664 959.5644 2.1 PI(44:10)
Table 7.24 Phospholipid and lysolipid species identified within Hep G2 cells. Species
highlighted in green are unique to treated cells; species highlighted in pink are unique to
untreated cells; † indicates the presence of alkyl ether substituent; ‡ indicates the presence of
alkenyl ether (plasmalogen) substituent.
Lipidomics of untreated Hep G2 cells were compared to analogous data obtained following
incubation for 72 hours with 30 µM propranolol 1. Comparable lipid profiles are observed
for PC, PE and PS classes between the treated and untreated systems. Fifteen previously
characterised lipid species are not observed following propranolol 1 treatment, highlighted
pink in Table 7.24. Lost lipid components, which include one PC, one LPE, and two PE
species, are dominated by eleven high molecular weight PI phospholipids. The theory of
multiple low abundant PI species fits with reduced PI species visualisation as they fall below
the required abundance threshold for analysis. Alternatively, the observed reduction in PI
content can be attributed to a cellular response following propranolol 1 treatment. Five novel
lipid species, highlighted green in Table 7.24, are attributed solely to propranolol 1 treated
cells. Lipid proportions are therefore modified to 16 % PS, 36 % PE, 44 % PC, and 12 % PI,
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resembling more closely reported values.
Lysolipids LPE(16:0), LPE(18:0), and LPE(20:4) are observed in the lipid profile of untreated
and propranolol 1 treated Hep G2 cells. Preferential observation of LPE in favour of LPC
formed from the more abundance PC lipid class, suggests an innate preference in either
enzymatic formation, hydrolysis, or retention within the membrane. Semi-quantification
using internal standard LPC(17:0) enables variation in lysolipid abundance to be determined,
as shown in Table 7.25. Abundance of all lysolipid species are increased in propranolol 1
treated cell compared to untreated. Propranolol 1 intrinsic lipidation combined with increased
background hydrolysis likely contribute to the observed increase in lysolipid abundance, as
noted in vitro. Lysolipid upregulation is observed despite tightly controlled regulation of
membrane composition employed by cells in order to maintain their structure and integrity.
Lysolipid Untreated Peak Area Treated Peak Area
LPE (16:0) 0.03 0.06
LPE (18:0) 0.08 0.12
LPE (20:4) 0.37 0.44
Table 7.25 Chromatographic peak areas attributed to the three lysolipids present in Hep
G2 cells: (i) untreated; (ii) treated with propranolol 1 in 1:10 small molecule:lipid molar ratio.
Peak areas are normalised and presented as % of internal standard LPC(17:0) chromatographic
peak area.
Consideration of the reported Hep G2 fatty acid distribution summarised in Table 7.26,
suggests observed lysolipids do not reflect fatty acid abundances.308 Lysolipids containing
18:1 and 16:1 fatty acid chains are not observed, despite their high reported abundances of 39
% and 12 % respectively. Lysolipids are observed corresponding to the approximately 16 %
of Hep G2 fatty acid content attributed to second most abundant species 16:0, and also to
the less abundant 18:0 and 20:4 moieties, appearing at 8 % and 6 % respectively. Lack of
correlation between lysolipid observation and fatty acid distribution supports the proposed
theory of preferential formation or retention during membrane turnover. Within the complex
cellular system, membrane composition is vital to a plethora of biological processes, and thus
is predicted to be tightly regulated preventing undesirable phospholipid modification and
lysolipid build up.
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Fatty Acid Hep G2 (%)
14:0 1.0
16:0 16.4
16:1 12.3
18:0 8.0
18:1 38.8
18:2 5.0
18:4 1.3
20:3 2.4
20:4 6.0
20:5 1.2
22:5 0.7
22:6 2.7
Table 7.26 Fatty acid chain distribution of Hep G2 cell line.308
Fatty Acid Transferred Theoretical m/z Observed m/z Error (ppm) R.T (min)
14:0 470.3634 470.3637 0.6 2.88
16:0 498.3947 498.3965 3.6 3.77
16:1 496.3791 496.3762 5.8 3.34
18:0 526.4260 526.4283 4.3 4.86
18:1 524.4104 524.4106 0.4 3.88
18:2 522.3947 522.3917 5.8 1.76
18:4 518.3634 518.3622 2.4 1.76
20:3 548.4104 548.4078 4.7 3.70
20:4 546.3947 - - -
20:5 544.3791 - - -
22:5 572.4104 - - -
22:6 570.3947 - - -
Table 7.27 Acylated propranolol 1 derivatives observed following LCMS analysis of propra-
nolol 1 incubated under physiological conditions for 72 hours with Hep G2 cells.
Hep G2 cell lipid profiling facilitates understanding of propranolol 1 intrinsic lipidation in
cellulo. Potential acylated propranolol 1 products of intrinsic lipidation can be predicted using
the reported fatty acid composition of Hep G2 cells, and extracts screened for these species.
Observed ions, attributed by accurate mass and retention time data to acylated propranolol 1
derivatives, are summarised in Table 7.27. Observed errors are occasionally above instrument
recommendations of 4.0 ppm due to reduced ion intensity, requiring careful consideration of
assignment accuracy. Sufficient ion abundance facilitated CID MSMS of two species, products
resulting from 16:0 and 18:1 transfer, Fig. 7.17. Characterisation confirms the products to
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be O-acylated propranolol 1 derivatives, in agreement with observations made during cell
extract study. Additional acylated species are thus also presumed to be O-acylated derivatives,
with either reduced rate of intramolecular O to N migration or poor ionisation preventing
visualisation of N -acylated counterparts.
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Figure 7.17 CID MSMS carried out to determine identity of acylated products of propranolol
1 intrinsic lipidation in Hep G2 cells: (a) parent ion m/z 498.3961 attributed to [M+H]+ of
O-pamitoyl propranolol 62; (a) parent ion m/z 524.4111 attributed to [M+H]+ of O-oleoyl
propranolol 47;.
Eight distinct O-acylated propranolol derivatives are observed to form within Hep G2 cells,
Table 7.27. Transfer of 16:0 and 18:1 acyl chains represent the most abundant product
species, reflecting their position as the most abundant fatty acids within Hep G2 cells at
16.4 % and 38.8 % respectively. Beyond this, observed products do not mirror reported
fatty acid abundance, either due to incorrect reporting or low species abundance combined
with differing ionisation efficiencies. Preferential transfer of shorter carbon chain lengths is
observed irrespective of fatty acid distribution, suggesting acyl chain chemistry influences
transfer within Hep G2 cells. Preferential acyl chain transfer could also be attributed to
lipid class and propranolol 1 localisation within the asymmetric cellular membrane, however
insufficient phospholipid speciation is available to confirm this supposition. EIC for observed
acylated products are shown in Fig. 7.18. Known patterns of acyl chain elution dictated by
chain length and unsaturation are observed, supporting correct species assignment. Two low
abundant species are excluded for Fig. 7.18, 18:2 and 18:4 acylated propranolol 1 derivatives,
both of which are assigned a retention time of 1.8 min, Table 7.27. Identical retention suggests
either incorrect species assignment, or insufficient product separation prior to early elution.
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Figure 7.18 EIC for acylated propranolol 1 derivatives observed following LCMS analysis
of propranolol 1 incubated under physiological conditions for 72 hours with Hep G2 cells.
7.6 Conclusions
Instrument optimisation has facilitated the study of complex biological systems by mass
spectrometry, ensuring high quality informative data. Ionisation of phospholipid species
POPC and POPS has been studied using positive and negative mode ESI respectively.
Modification of parameters including capillary voltage, sampling cone voltage and source
offset, enabled the development of optimised phospholipid conditions. Successful application of
optimised ionisation parameters to the detection of acylated small molecules ensures conditions
are suitable for study of lipidomics and small molecule intrinsic lipidation within complex
biological systems. Chromatographic conditions have also been developed using a mixture of
lipid standards, ensuring chromatographic resolution between phospholipids of varying head
group classes and acyl chain types. Component separation and lipid solubility were aided by
application of a highly organic solvent mixture including IPA. Regular monitoring of mobile
phase pH proved vital in preventing elution time inconsistencies and peak broadening.
Employing optimised analytical conditions, small molecule intrinsic lipidation was studied
within complex biological systems. Reactive small molecules propranolol 1 and benzimidazole
11 were examined following 72 hour incubation with liposomes prepared from commercial cell
extracts. Diverse acylated small molecule products were characterised within both prokaryotic
E. coli extract, and eukaryotic bovine liver extract. Observed acylated products reflect
the fatty acid profile of systems studied, supporting a non-enzymatic transfer mechanism.
Propranolol 1 intrinsic lipidation was also studied in cellulo using the Hep G2 liver cancer
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cell line, resulting in the first evidence of intrinsic lipidation in cellulo. Acylated propranolol 1
products were predicted and identified in accordance with reported cellular fatty acid content.
CID MSMS confirmed products to be O-acylated species rather than the N -acylated analogues
formed in vitro via intramolecular migration. Preferential acyl chain transfer was noted in
cellulo, favouring shorter carbon chain lengths. Proof of innate intrinsic lipidation in cellulo
highlights the biological and pharmaceutical relevance of membrane reactivity.
Lipid profile modifications resulting from small molecule intrinsic lipidation were also monitored
under the optimised analytical conditions developed. E. coli and liver extract liposomes
exhibit increased lipid diversity across a range of classes following treatment with either
propranolol 1 or benzimidazole 11. Furthermore, systems exhibit heightened lysolipid levels in
the presence of small molecules, correlating with in vitro observations. Membranes containing
high proportions of lysolipid are known to exhibit modified membrane characteristics and
reduced structural integrity. Analogous lipid profiling of propranolol 1 treated Hep G2 cells
suggest phospholipid and lysolipid species are retained in similar abundance to untreated
cells. Cellular regulatory mechanisms are predicted to modulate membrane composition in
the presence of disruptive propranolol 1, ensuring cell survival.
8 | Expanding Small Molecule Hori-
zons
8.1 Introduction
Optimised analytical conditions provide proof of innate in vitro reactivity between small
molecules and membrane phospholipids, termed intrinsic lipidation. Furthermore, intrinsic
lipidation has been identified as a general process, affecting multiple membrane binding small
molecules rather than being the unique property of a single small molecule. Understanding
small molecule intrinsic lipidation as a generic process requires increased understanding of
two key areas:
1. Reactivity in relation to structural and functional small molecule features
2. The biological and pharmaceutical impact of reactivity
Increased knowledge of these two areas provides a mechanism for the application of intrinsic
lipidation reactivity to the drug development process. Structural and functional prediction
of the likelihood of small molecule intrinsic lipidation for a drug candidate allows early
identification, ultimately saving time and money. Understanding the relationship between
intrinsic lipidation and drug activity or side effect induction provides insight into the severity of
patient outcomes following treatment with a drug candidate exhibiting reactivity. Alternatively,
understanding of intrinsic lipidation could provide a mechanism for tuning reactivity within
a drug candidate, harnessing the process to obtain desirable biological or pharmaceutical
results.
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8.2 Investigating Reactivity
Despite the definition of small molecule intrinsic lipidation as a generic process, not all
membrane binding small molecules exhibit reactivity. Diminished reactivity is observed
despite the cationic amphiphilic nature of some small molecules, known to facilitate membrane
binding and nucleophile availability.28,65–68 Subtle structural and functional characteristics
must therefore play a role in controlling reactivity. Identifying structural and functional trends
influencing small molecule intrinsic lipidation is challenging considering the diverse range of
molecules tested thus far. An alternative approach subdivides small molecules into reactivity
families for study. Each reactivity family differs by a single structural or functional feature,
providing insight into the distinct role of that feature in influencing reactivity.
Cationic amphiphilic small molecules contain two distinct functional regions: (i) a hydrophobic
aromatic ring; (ii) a hydrophilic region containing a protonated amine at physiological pH.
Reactivity family design incorporated modifications to both regions, including modifying the
aromatic ring, differing nucleophile type, and altering nucleophile position relative to the
aromatic ring. Reactivity comparison between small molecules within a reactivity family
requires quantification, due to differing ionisation efficiencies between small molecule species.
The initial in vitro screen for small molecule intrinsic lipidation under physiological conditions
discussed during Chapter 5 of this thesis, served to further highlight this need. Absolution
quantification of acylated small molecules through calibration is unrealistic given time con-
straints and the multiple syntheses required. Introduction of a single acylated synthetic
standard at known concentration into all samples provides an alternative semi quantitative
approach. Addition of a standard with similar characteristics and ionisation efficiency to the
acylated products of interest facilitates conversion approximation, eliminating dilution and
instrumentation issues.42,43 Study of reaction mixtures in triplicate further aids in anomaly
identification, ensuring consistent results.
N
N
H
H2N
11
Figure 8.1 Compound 11, selected as the small molecule core for preparation of an acylated
synthetic standard.
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Semi quantification of small molecule intrinsic lipidation was achieved by preparation of
an acylated synthetic standard based upon core small molecule 11, Fig. 8.1. Selection of
compound 11 was based upon high levels of observed reactivity during preliminary intrinsic
lipidation studies discussed during Chapter 5 of this thesis, combined with simplicity and
flexibility of synthesis from readily available starting materials. Scheme 8.1 presents the
proposed synthetic route for the preparation of an oleoylated standard of compound 11, to
be known as compound 67.177,178 Synthetic acylation with an oleoyl moiety provides the
best ionisation efficiency mirror for acylated small molecules formed by intrinsic lipidation
within dioleoyl phospholipid membranes. Preparation of compound 11 in high yield and
purity was achieved despite slow reaction rate by refluxing glycine and o-phenylenediamine
in concentrated HCl for 5 days. An alternative literature methodology for the preparation,
boasting high product yield in the shorter reaction time of two hours, proved unsuccessful.309
Compound 67 was prepared through reaction of compound 11 with acid chloride 20 under
anhydrous conditions.310 Purification of compound 67 by flash column chromatography yielded
a yellow oil to be utilised as a synthetic semi quantification standard.
37 % HCl, reflux, 120 h
HO
O
NH2
H2N
H2N
N
N
H
H2N
Oleoyl chloride, 
pyridine, DCM, RT, 12 h N
N
H
NH
R1
O
R1 = (CH2)7CHCH(CH2)7CH3
94% 61%
11 67
Scheme 8.1 Synthetic protocol for the preparation of acylated standard 67.
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Figure 8.2 TIC of synthetically prepared acylated standard 67 under optimised LCMS
conditions. Inset shows fragmentation pattern following CID MSMS of the molecular ion of
acylated standard 67 of m/z 412.3324.
Stock solution of synthetic acylated standard 67 at concentration 1 µg mL−1 was prepared
in MeCN:H2O (1:1), and studied under optimised intrinsic lipidation analytical conditions.
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Analysis revealed a chromatographic peak at retention time 5.2 min corresponding to singly
charged ion m/z 412.3324, Fig. 8.2. Ion m/z 412.3324 can be attributed to molecular formula
C26H42N3O with 0.9 ppm error, corresponding to the [M+H]+ ion of acylated standard 67.
CID MSMS of molecular ion m/z 412.3324 revealed fragmentation into low abundance ion m/z
148.0865 of molecular formula C8H10N3, corresponding to the [M+H]+ ion of precursor small
molecule 11. Major CID MSMS product ion m/z 131.0608 can be attributed to molecular
formula C8H7N2 with 0.9 ppm error. Combined with a RDB value of 6.5, this product ion is
predicted to result from cleavage at the CH2-N bond proximal to the amide functionality.
8.2.1 Modification to Hydrophobic Regions
Successful synthesis and analysis of acylated standard 67 provides methodology for semi
quantitative study of reactivity families, designed to probe the influence of a single feature
upon intrinsic lipidation. Reactivity family one focussed on modification to the hydrophobic
portion of cationic amphiphilic small molecules, altering the aromatic ring. This aromatic
modified reactivity family, Fig. 8.3, was compiled from available small molecules in order to
avoid further synthetic preparation. Six aromatic ring types are represented within the family:
(i) benzene ring 68; (ii) naphthol ring 69; (iii) indoles 4 and 5; (iv) imidazoles 49 and 70;
(v) benzimidazoles 45 and 71; (vi) triazole 72. Beyond aromatic variation, highlighted red
in Fig. 8.3, small molecules within the family consistently contain a ring bound nucleophilic
amine, highlighted green. Selection of a reactive amine in favour of an alcohol or thiol moiety
is due to prevalence in marketed pharmaceuticals, proven reactivity record, and favourable
matching with the electrophilic phospholipid ester. Indole, imidazole and benzimidazole
rings are doubly represented within the reactivity family, localising the nucleophilic amine
at differing positions relative to the hydrophilic nitrogen rich portions of these particular
aromatic rings.
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72 5 70 71
Figure 8.3 Family of small molecules prepared to study the influence of ring type upon
small molecule intrinsic lipidation.
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Reactivity family members were incubated under physiological conditions for 72 hours in
triplicate with three liposomal membrane models, eukaryotic (DOPC), viral (DOPC:DOPS
4:1), and prokaryotic (DOPE:DOPG 3:1). Following addition of 1.25 µL of acylated standard
67 stock solution, samples were analysed under optimised chromatographic and ionisation
conditions. Analyses did not reveal acylated product formation above the limit of instrument
detection for any members of reactivity family one. Predicting the reasons behind this observed
lack of reactivity is challenging due to the complexity of small molecule intrinsic lipidation.
Family members exhibit differing physical parameters including pK a, logP and logD values
summarised in Table 8.1. However despite variation in logD from 0.23 (compound 71) to 2.13
(compound 69), and in pK a from 3.00 (compound 72) to 6.93 (compound 45), lack of reactivity
is retained for all small molecules studied. The sole consistent family feature, positioning of
the nucleophilic amine directly on the aromatic ring, provides one theory to explain lack of
reactivity. MDS and linear dichroism (LD) studies predict deep membrane penetration for
small molecules within reactivity family one, even those comprised of a heterocyclic aromatic
ring.156,158 Residing with the hydrophobic bilayer region, and with limited flexibility, reactive
amine moieties would be expected to have limited proximity to phospholipid ester linkages in
order to facilitate intrinsic lipidation.
Small Molecule pK a logP logD (pH 7.4)
68 4.64 1.14 1.14
69 4.13 2.13 2.13
4 5.31 1.55 1.53
49 3.72 1.46 1.46
45 6.93 1.15 0.72
72 3.00 0.96 0.96
5 4.94 0.85 0.85
70 3.74 0.65 0.65
71 6.10 0.28 0.23
Table 8.1 Calculated physicochemical properties of small molecules in reactivity family one,
studied to determine the influence of aromatic ring type upon intrinsic lipidation.262
8.2.2 Modification to Hydrophilic Regions
Investigating the impact of a modified hydrophobic aromatic ring region upon intrinsic
lipidation reactivity resulted in limited success. Theory suggests the lack of reactivity is due to
membrane binding orientation, combined with limited motion of the hydrophilic nucleophile.
Accordingly, it can be concluded that the aromatic region of cationic amphiphilic small
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molecules plays only a minor role in controlling intrinsic lipidation. As a result, attention
was turned to modification of the hydrophilic region of membrane binding small molecules in
order to understand the relationship between molecular structure, functionality, and intrinsic
lipidation. Given the heightened complexity within the hydrophilic region compared to its
hydrophobic counterpart, modifications to this area require further subdivision. Three families
form the basis of study, investigating nucleophile position on the aromatic ring, nucleophile
displacement from the aromatic ring, and nucleophile type.
8.2.2.1 Nucleophile Displacement
Limited nucleophile flexibility may be one possible cause of diminished reactivity observed
during the study of reactivity family one. Further investigation of this theory can be achieved
by modifying nucleophile displacement from the aromatic ring, through altered carbon linker
length. Resulting changes to nucleophile movement and membrane bound orientation are
predicted to aid in promoting intrinsic lipidation by facilitating proximity of reactive func-
tionalities. Reactivity family two, Fig. 8.4, aims to probe this theory by building upon two
unreactive small molecules present in reactivity family one. Unreactive indole 4 undergoes
a linker length increase of one carbon in compound 73, and three carbons in 56. Similarly,
benzimidazole 45 is joined by counterparts 11 and 58, with linker lengths of one and three
carbons respectively. Indole and benzimidazole cores were selected as a subset of reactivity
family one due to time constraints and compound availability.
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Figure 8.4 Family of small molecules prepared to study the influence of nucleophile dis-
placement upon small molecule intrinsic lipidation.
Reactivity family members were incubated under physiological conditions for 72 hours in
triplicate with three liposomal membrane models, eukaryotic (DOPC), viral (DOPC:DOPS
4:1), and prokaryotic (DOPE:DOPG 3:1). Following addition of 1.25µL of acylated standard
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67 stock solution, samples were analysed under optimised chromatographic and ionisation
conditions. Exception to the addition of acylated standard 67 is applied in the case of
benzimidazole 11, in which the desired intrinsic lipidation product is identical to the synthetic
acylated standard. Samples containing compound 11 were analysed both with and without
addition of acylated standard 67, in order to distinguish between innate reactivity and the
internal standard.
Intrinsic lipidation is not observed for small molecules 4, 73 and 56, containing an indole
core. Mirroring observations made during the study of reactivity family one, benzimidazole
45 similarly does not exhibit acylated product formation. However, analysis of benzimidazole
11 containing a single carbon linker, reveals a chromatographic peak at retention time 5.2 min
corresponding to m/z 412.3328 with 0.0 ppm error. Molecular formula C26H42N3O attributed
to this ion is consistent with oleoylation of benzimidazole 11 by intrinsic lipidation. Further-
more, analysis of benzimidazole 58 containing a three carbon linker, reveals a chromatographic
peak at retention time 5.2 min corresponding to m/z 440.3630 with -1.4 ppm error. Corre-
sponding molecular formula C28H46N3O suggests that this represents the molecular ion of
intrinsic lipidation product oleoylated benzimidazole 58. CID MSMS of the two oleoylated
benzimidazole species results in dissociation of the amide bond, producing analogous spectra
to that of acylated standard 67, presented in Fig. 8.2. Intrinsic lipidation of benzimidazoles 11
and 58 in comparison to unreactive 45, supports the hypothesis that nucleophilic flexibility
aids in promoting reactivity by facilitating proximity of reactive functionalities. Reactivity
is observed despite negative logD values at physiological pH, Table 8.2, indicating reduced
membrane affinity of benzimidazoles 11 and 58 compared to their unreactive counterpart
benzimidazole 45. Furthermore, increased pK a values of 12.24 and 11.91, attributed to
benzimidazoles 11 and 58 respectively, suggest species exist in predominantly in the ionised
form, expected to limit reactivity. These observations, combined with the unreactive nature
of indole species 73 and 56, suggests the relationship between nucleophile displacement and
intrinsic lipidation reactivity is not straightforward. Reduced logD values combined with
a predicted increase in membrane penetration of indoles compared to benzimidazoles, may
provide a barrier to direct reactivity of nucleophilic amine residues, which cannot be overcome
by increased nucleophile displacement.156 Alternatively, solution phase chemistry predicts
that acylation of benzimidazole species follows distinct pathway compared to their indole coun-
terparts. Application of solution phase observations to membrane studies suggests intrinsic
lipidation proceeds via initial reactivity of nitrogen within the aromatic heterocycle, followed
by swift intramolecular rearrangement into the observed product.311,312 This mechanism adds
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complexity to the benzimidazole intrinsic lipidation compared to indole counterparts, and
provides an explanation for observed reactivity variation.
Small Molecule pK a logP logD (pH 7.4)
4 5.31 1.55 1.53
73 10.16 1.88 -1.04
56 10.63 1.81 -1.18
45 6.93 1.15 0.72
11 12.24 0.87 -0.25
58 11.91 1.68 -0.97
Table 8.2 Calculated physicochemical properties of small molecules in reactivity family two,
studied to determine the influence of aromatic ring type upon intrinsic lipidation.262
Chromatographic peak areas corresponding to oleoylated benzimidazole products of intrinsic
lipidation within DOPC liposomes are presented in Table 8.3. Normalisation of peak areas as
a percentage of internal synthetic standard peak areas are also presented. Resulting analysis
concludes that the relationship between nucleophile displacement from a benzimidazole ring,
and reactivity towards intrinsic lipidation is not proportional. Despite containing a three
carbon linker of increased flexibility, benzimidazole 58 exhibits a 14 % normalised peak area
corresponding to acylated product, compared to 45 % for benzimidazole 11, containing a single
carbon linker. Explanation for this observation can be derived if the increased linker length of
benzimidazole 58 facilitates penetration of the nucleophilic amine into the hydrophilic bilayer
region. Favourable electrostatic interactions within this region retain the nucleophile such
that proximity to reactive phospholipid ester linkages is reduced. Alternatively, assuming
benzimidazole acylation proceed by an intramolecular migration pathway, decreased product
formation could be attributed to altered migration rate.
Small Molecule Acylated Small Molecule Peak Area Proportion of Internal Standard
45 0 0 %
11 2895.39 45 %
58 1460.00 14 %
Table 8.3 Raw peak area data, and normalised peak area as a proportion of internal standard
peak area, for acylated derivatives of reactivity family two members. Data based upon LCMS
analysis following 72 hour incubation under physiological conditions with a DOPC membrane.
Benzimidazoles 11 and 58 undergo intrinsic lipidation within viral DOPC:DOPS (4:1) and
prokaryotic DOPE:DOPG (3:1) membrane systems, in addition to eukaryotic DOPC. Nor-
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malised peak areas relative to an internal standard corresponding to acylated product are
presented for each membrane system in Table 8.4. Increased reactivity of benzimidazole 11
compared to increasingly flexible 58 is retained between membrane systems studied. However,
differing membrane dependent reactivity patterns are evident between the two benzimidazole
species. Compound 11 maximum reactivity within the eukaryotic DOPC membrane, followed
by DOPC:DOPS (4:1), and lest reactive DOPE:DOPG (3:1). In contrast, compound 58
exhibits reduced reactivity within the DOPC membrane compared to the equally reactive
DOPC:DOPS (4:1) and DOPE:DOPG (3:1) systems. Reactivity differences are hypothesised
to result from molecule specific alterations to intrinsic physical properties such as logP and
binding orientation, in the presence of negatively charged phospholipids.
Membrane Composition Peak Area Acylated 11 Peak Area Acylated 58
DOPC 45 % 14 %
DOPC:DOPS (4:1) 29 % 19 %
DOPE:DOPG (3:1) 23 % 19 %
Table 8.4 Normalised peak area, reported as a proportion of internal standard peak area, for
oleoylated derivatives of benzimidazoles 11 and 58. Data based upon LCMS analysis following
72 hour incubation under physiological conditions with membrane systems: (i) DOPC; (ii)
DOPC:DOPS (4:1); (iii) DOPE:DOPG (3:1).
8.2.2.2 Nucleophile Position
Observed small molecule intrinsic lipidation of benzimidazoles 11 and 58 is facilitated by
a nucleophilic amine localised close to hydrophilic ring nitrogens. Insight into structural
influences on intrinsic lipidation can be achieved by probing preservation of reactivity upon
nucleophile relocation to alternative ring positions. Given the unavailability of suitable
benzimidazole species, a family of chemically similar imidazole species, Fig. 8.5, provide an
alternative canvas for study. These indazoles exhibit similar hydrophobicity/hydrophilicity
balance, intramolecular migratory activity, and nucleophile displacement, as the reactive ben-
zimidazole species. Furthermore, study is simplified by similar physical properties attributed
to all indazole species within the family, including logP, logD, and pK a values summarised in
Table 8.5. Reactivity family three indazoles differ by nucleophilic amine localisation, small
molecule 46 is substituted at position 3, 74 at position 4, and subsequently compounds 75,
76 and 6 at positions 5, 6, and 7 respectively.
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Figure 8.5 Family of small molecules prepared to study the influence of nucleophile position
upon small molecule intrinsic lipidation.
Small Molecule pK a logP logD
46 8.16 0.83 -0.61
74 8.78 1.09 -0.94
75 8.91 0.96 -1.12
76 8.89 1.09 -0.98
6 8.99 1.19 -1.01
Table 8.5 Calculated physicochemical properties of reactivity family three small molecules,
predicted to influence small molecule intrinsic lipidation.262
Reactivity family members were incubated under physiological conditions for 72 hours in
triplicate with three liposomal membrane models, eukaryotic (DOPC), viral (DOPC:DOPS
4:1), and prokaryotic (DOPE:DOPG 3:1). Following addition of 1.25µL of acylated standard
67 stock solution, samples were analysed under optimised chromatographic and ionisation
conditions. Intrinsic lipidation of reactivity family three indazoles was observed for all species
irrespective of membrane composition. Table 8.6 summarises retention time and accurate mass
data for the observed oleoylated products of intrinsic lipidation, corresponding to molecular
formula C26H42N3O. Mass error of < 4.5 ppm is noted for observed products, consistent with
instrument accuracy considering low species abundance. Chromatographic analysis suggests
comparable retention times for all oleoylated product species, unsurprising considering their
structural and function similarities. Retention time similarities within the small molecule
family are reflected within analysis of the relevant parent indazoles.
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Small Molecule R.T. (min) Observed m/z Error (ppm) Molecular Formula RDB
46 6.3 412.3321 -1.7 C26H42N3O 7.5
74 6.2 412.3310 -4.4 C26H42N3O 7.5
75 6.4 412.3332 -3.2 C26H42N3O 7.5
76 6.2 412.3311 -4.1 C26H42N3O 7.5
6 6.5 412.3318 -2.4 C26H42N3O 7.5
Table 8.6 Analytical data corresponding to molecular ions of oleoylated derivatives of
compounds 46, 74, 75, 76 and 6, formed by intrinsic lipidation.
Small Molecule Acylated Product Peak Area Proportion of Internal Standard
46 700.00 3 %
74 490.00 2 %
75 333.33 4 %
76 416.67 6 %
6 1929.05 25 %
Table 8.7 Raw peak area data, and normalised peak area as a proportion of internal standard
peak area, for acylated derivatives of reactivity family three members. Data based upon
LCMS analysis following 72 hour incubation under physiological conditions with a DOPC
membrane.
Despite observed intrinsic lipidation of all family three indazoles, the extent of reactivity differs
between species. Differential reactivity is highlighted by absolute and normalised peak areas
of acylated small molecule products of intrinsic lipidation, presented in Table 8.7. Indazole 6
exhibits heightened reactivity levels within the DOPC membrane compared to other family
members, with a normalised peak area of 25 %. Substituted at position 7, indazole 6’s
nucleophile is localised on the hydrophilic ring face, facilitating membrane bound proximity to
phospholipid ester linkages. Indazole 76, substituted at position 6, exhibits the second highest
normalised product peak area at 6 %. Nucleophile localisation within compound 76 is at a
hydrophobic/hydrophilic ring interface, lowering reactivity compared to indazole 6. Further
family reactivity can be characterised by the trend 75 > 46 > 74. However, normalised peaks
areas for these species are comparable due to limited product abundance, thus the observed
trend may prove inaccurate. Low reactivity of species 74 and 75 is unsurprising considering
their nucleophile localisation on the hydrophobic indazole face, penetrating the hydrophobic
tail bilayer region and reducing phospholipid ester proximity. Diminished reactivity of indazole
46 proves more surprising considering the proximity of substitution position 3 to hydrophilic
ring nitrogens. Hypothetically, this observation could be explained by assuming indazole
membrane binding occurs such that ring position 3 is oriented away from the phospholipid
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head groups and glycerol backbone. This proposed orientation would also facilitate indazole 6
reactivity, however literature data to support or disprove the theory is unavailable.
Reactivity family three species also undergo intrinsic lipidation within viral DOPC:DOPS
(4:1) and prokaryotic DOPE:DOPG (3:1) liposomal systems, with normalised peak areas
presented in Table 8.8. The observed relationship between membrane composition and
reactivity is consistent across the indazoles studied, with increased reactivity observed within
the prokaryotic membrane, followed by the viral, and finally the eukaryotic. Favourable
intrinsic lipidation within prokaryotic model systems proves particularly interesting, providing
a possible mechanism of action for previously described antimicrobial activity of these small
molecules. Increased reactivity in the presence of negatively charged membrane lipids can be
attributed to a number of factors including modified membrane properties, altered indazole
logP, or binding orientation changes. Furthermore, the relative reactivity rates of family three
indazoles remains largely consistent across the three membrane systems studied. Indazole 6,
substituted at position 7, consistently exhibits the highest reactivity levels, followed by indazole
76, substituted at position 6. Indazoles 46, 74 and 75 indicate similarly low reactivity levels
across the membrane systems studied, although their relative reactivity order is membrane
specific. Reactivity observations made within viral and prokaryotic membranes serve to
support the theory that membrane bound indazoles orient with the hydrophilic face proximal
to phospholipid ester linkages, whilst directing substituents at ring positions 3, 4, and 5
towards the hydrophobic bilayer region.
Small Molecule Peak Area DOPC Peak Area PC:PS Peak Area PE:PG
46 3 % 7 % 10 %
74 2 % 9 % 16 %
75 4 % 8 % 12 %
76 6 % 13 % 17 %
6 25 % 61 % 108 %
Table 8.8 Normalised peak area, as a proportion of internal standard peak area, for acylated
derivatives of reactivity family three members. Data based upon LCMS analysis following
72 hour incubation under physiological conditions three membrane systems: (i) DOPC; (ii)
DOPC:DOPS (4:1); (iii) DOPE:DOPG (3:1).
8.2.2.3 Nucleophile Type
Small molecule reactivity families studied thus far have adopted an amine functionality
as the nucleophilic residue primed to undergo intrinsic lipidation. Reactivity family four,
Chapter 8. Expanding Small Molecule Horizons 265
Fig. 8.6, based upon a core of reactive benzimidazole 11, probes the influence of different
nucleophilic functionalities upon intrinsic lipidation reactivity. Benzimidazoles 77 and 78
contain nucleophilic alcohol and thiol functionalities respectively, in place of the reactive
amine of benzimidazole 11. The alcohol functionality is both a poor nucleophile and poor
match to the hard phospholipid ester compared to an amine, predicting a reduction in
intrinsic lipidation reactivity. Thiol reactivity is less predictable, as despite being a highly
reactive nucleophile compared to an amine, the soft thiol nature provides a poor match
to the electrophilic phospholipid carbonyl. Furthermore, the added capability of thiols to
undergo disulphide bond formation may provide a further challenge to intrinsic lipidation
reactivity. Additional members of reactivity family four, benzimidazoles 79, 80, 81 and 82
retain an amine nucleophile with methyl, ethyl, propyl and isopropyl substitutions respectively.
Modification of the reactive nucleophile from a primary to secondary amine introduces steric
hindrance as a barrier to reactivity.
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Figure 8.6 Family of small molecules prepared to study the influence of nucleophile type
upon small molecule intrinsic lipidation.
Benzimidazoles 11 and 77 are readily available, however other members of reactivity family
four require synthetic preparation prior to study. Secondary amines 79, 80, 81, and 82
can be prepared using a single generic methodology depicted in Scheme 8.2. Chlorinated
intermediate 83 was prepared using analogous methodology to that developed for the synthesis
of acylated standard 67, refluxing o-phenylenediamine with chloroacetic acid.313,314 Product
83 was collected by precipitation following addition of aqueous ammonium hydroxide, and
purified by recrystallisation from hexane. Bulk chlorinated intermediate 83 was then split
into portions, and each reacted with the relevant alkyl amine, to yield benzimidazoles 79, 80,
81, and 82.315,316 Products were purified as oils by Kugelrohr distillation.
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Scheme 8.2 Synthetic protocol for preparation of secondary amine containing benzimidazoles
79, 80, 81, and 82.
Preparation of thiol 78 follows the same methodology utilised during the synthesis of
chlorinated intermediate 83, and acylated standard 67, as depicted in Scheme 8.3. o-
phenylenediamine was refluxed with 2.4 equivalents of thioglycolic acid in 37 % HCl until
TLC indicated full product conversion after 15 hours.178,317 Benzimidazole 78 was isolated
as the HCl salt following removal of water and recystallisation from methanol, minimising
potential disulphide bond formation.
37 % HCl, reflux, 12 h
HO
O
SH
H2N
H2N
N
N
H
HS
91%
78
Scheme 8.3 Synthetic protocol for the preparation of benzimidazole 78 containing a thiol
nucleophile.
Reactivity family members were incubated under physiological conditions for 72 hours in
triplicate with three liposomal membrane models, eukaryotic (DOPC), viral (DOPC:DOPS
4:1), and prokaryotic (DOPE:DOPG 3:1). Following addition of 1.25µL of acylated standard
67 stock solution, samples were analysed under optimised chromatographic and ionisation
conditions. Alcohol containing 77 and thiol containing 78 were not observed to undergo
intrinsic lipidation irrespective of membrane composition. Their soft nucleophilic natures
provide poor matches to the hard electrophile of a phospholipid ester carbonyl, disfavouring
reactivity. Furthermore, despite increased membrane affinity, exemplified by logD values
presented in Table 8.9, reactivity may be diminished by altered binding orientation of neutral
alcohol and thiol substituted benzimidazoles, compared to the cationic amine of benzimidazole
11 at physiological pH. Subscription to an intramolecular migratory pathway of benzimidazole
acylation provides further unknown implications of amine exchange for a thiol or alcohol,
dependent upon relative migration rates and product stabilities.
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Small Molecule pK a logP logD (pH 7.4)
11 12.24 0.87 -0.25
79 11.49 0.89 -0.06
80 11.49 1.25 0.22
81 11.49 1.77 0.61
82 11.49 1.66 0.55
77 11.19 0.57 0.56
78 12.08 1.61 1.60
Table 8.9 Calculated physicochemical properties of small molecules in reactivity family
four, studied to determine the influence of aromatic ring type upon intrinsic lipidation.262
Benzimidazoles 81 and 82, containing secondary amines substituted with propyl and isopropyl
groups respectively, did not exhibit reactivity irrespective of membrane composition. Dimin-
ished reactivity is attributed to reduced nucleophilic reactivity of the secondary amine due to
steric hindrance, despite their increased logD values promoting membrane association. Altered
binding orientation to prevent hydrophobic propyl substitutions penetrating the hydrophilic
bilayer region, may also contribute to an observed lack of reactivity. However, in addition to
known reactivity of primary amine 11, secondary amines 79 and 80 exhibit product formation.
Methyl and ethyl substituted respectively, 79 reacts within the DOPC system, whereas 80
undergoes intrinsic lipidation across all membrane compositions. Table 8.10 summarises
relevant retention time and accurate mass data for oleoylated products of molecular formulae
C27H44N3O and C28H46N3O respectively. Observed error is above normal instrument levels,
however given a lack of alternative molecular formulae, this is attributed to low ion abundance.
This lack of abundance also prevented analysis of the species by CID MSMS in order to
confirm their identities. Peak area modelling and normalisation proved impossible due to areas
being less than 100, preventing reactivity comparison between species or membrane types.
Comparison to primary amine 11 indicates significant reactivity reduction within secondary
amines 79 and 80, assigned to the influence of steric hindrance and modified membrane
binding orientation.
Small Molecule R.T. (min) Observed m/z Error (ppm) Molecular Formula RDB
11 5.2 412.3328 0.0 C26H42N3O 7.5
79 5.3 426.3465 -4.5 C27H44N3O 7.5
80 5.0 440.3606 -7.9 C28H46N3O 7.5
Table 8.10 Analytical data corresponding to molecular ions of oleoylated benzimidazoles
11, 79, and 80 formed by intrinsic lipidation
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8.2.3 Towards the Synthesis of a Further Family
Membrane binding orientation has consistently been determined as a key influencer of small
molecule intrinsic lipidation. Even functionalities remote from the reactive nucleophile of a
cationic amphiphilic small molecule can promote interactions with membrane phospholipids,
ultimately determining binding orientation. Study of membrane binding orientation is chal-
lenging due to its complexity, however one final reactivity family has been designed it an
attempt to better understand its relationship with intrinsic lipidation. Reactivity family five,
Fig. 8.7, is designed to include small molecules containing an aniline ring core comprised of
both hydrophobicity and nucleophilic activity. One of three secondary amide substitutions is
also present upon each aniline ring, arranged ortho, meta, and para relative to the nucleophilic
aniline amine. Compounds 84, 85, and 86 are substituted with an aromatic benzene ring,
favouring hydrophobic interactions with phospholipid acyl chains. Compounds 87, 88, and
89 contain a saturated 16 carbon palmitoyl substitution, designed to interact favourably with
the hydrophobic phospholipid tail region. Finally, compounds 90, 91, and 92 are substituted
with a quarternary methylated glycine moiety, facilitating electrostatic interactions with
the phosphate head group region of a lipid bilayer. Differences in substitution properties
combined with location relative to the reactive nucleophile is expected produce different
binding orientations for each family five member, altering proximity of reactive moieties and
local hydration levels.
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Figure 8.7 Family of small molecules prepared to study the influence of membrane binding
orientation upon small molecule intrinsic lipidation.
The complex nature of reactivity family five prevents purchase, instead synthetic methodologies
must be designed to aid in preparation. Structural similarities within the family suggest
development of a single general methodology applicable to all members to be the most efficient
synthetic approach. Methodology was developed initially for compound 84, prior to synthesis
of other group members. Compound 84 excels as a method development model, due to its
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para substituted ring providing favourable steric and electronic characteristics for substitution.
Furthermore, benzoyl substitution requires only abundantly available commercial starting
material benzoyl chloride.
Literature methodology applicable to the synthesis of compound 84 is presented in Scheme 8.4.318
p-phenylenediamine reacts with benzoyl chloride in the presence of SDS, MeCN and H2O pro-
ducing a mixture of mono-substituted and di-substituted product. Isolation and purification
of the desired mono-substituted product proved impossible due to poor product solubility
and instability towards normal phase flash column chromatography. Modification of reaction
conditions to reduce formation of di-substituted byproduct in order to simplify purification
was attempted, as summarised in Table 8.11. Attempts proved unsuccessful in minimising
di-substituted byproduct formation to either negligible levels or achieving complete eradi-
cation. Di-substituted byproduct formation was also observed for an alternative literature
methodology reacting p-phenylenediamine with benzoyl chloride in the presence of NEt3 and
anhydrous DCM.319 As a result, direct preparation of reactivity family five members from
phenylenediamine precursors was not pursued further.
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Scheme 8.4 Initial methodology employed for the preparation of compound 84.
p-phenylenediamine (eq) Reactive Carbonyl Base Solvent Temp (◦C)
1.0 Benzoyl Chloride SDS H2O:MeCN (2:1) 20
1.0 Benzoyl Chloride SDS H2O:MeCN (2:1) 0
1.0 Benzoyl Chloride - H2O:MeCN (2:1) 20
1.0 Benzoic Anhydride SDS H2O:MeCN (2:1) 20
1.0 Benzoic Anhydride SDS H2O:MeCN (2:1) 0
1.0 Benzoic Anhydride - H2O:MeCN (2:1) 20
10.0 Benzoic Anhydride SDS H2O:MeCN (2:1) 20
1.0 Benzoic Anhydride SDS H2O:MeCN (15:1) 20
Table 8.11 Experimental conditions tested for the preparation of compound 84 from p-
phenylenediamine within 5 minute reaction time.
Modified methodology depicted in Scheme 8.5, was designed to avoid di-substituted byproduct
formation by employing a Boc protecting group. Small scale synthetic conditions successfully
produced singly Boc protected intermediate 93, and subsequent benzolyated intermediate
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94.320 At this point, increased quantities of compound 93 stock were required for synthesis of
other para substituted members of small molecule family five. However, scaled up preparation
of Boc protected intermediate 93 proved challenging. Despite high levels of conversion, several
equivalents of p-phenylenediamine starting material remain following reaction completion.
Limited solubility of both p-phenylenediamine and intermediate 93 prevented successful
purification by recrystallisation. Optimised normal phase flash column chromatography
conditions avoiding coelution were not achieved on a large scale, resulting in inability to purify
the product.
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Boc2O, DCM, 0 °C, 3.5 h
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Scheme 8.5 A second methodology designed for the preparation of compound 84.
The third designed synthetic methodology, presented in Scheme 8.6, seeks to avoid di-
substituted byproduct formation by employing p-nitroaniline as the starting material. Initially,
p-nitroaniline was substituted with benzoyl chloride, resulting in isolation of intermediate 95
following recrystallisation from methanol.321 The nitro functionality was then reduced into
the desired amine moiety, successfully producing reactivity family member 84. Three reduc-
tion methodologies were attempted in order to determine the optimum methodology.320,321
Hydrogenation (H2/Pd) produced the highest crude yield at 93 %, however product purifica-
tion and isolation proved challenging. Several recrystallisation solvents including two phase
recrystallisation failed to purify product 84, whilst product instability upon extended silica
exposure prevented use of preparative TLC or flash column chromatography. Reduction using
Zn/AcOH resulted in a lower yield of 55 %, however the product did not contain impurities
thus was deemed the preferred synthetic route.
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HN
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HN
NH2
Reduction
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56% 55%
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8495
Scheme 8.6 The third methodology successfully designed for the synthetic preparation of
compound 84.
The successful synthetic methodology developed during the preparation of compound 84 was
applied to benzoylated analogues 85 and 86. Synthesis and subsequent purification proved
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successful for both benzoylated species. Ortho substituted 86 exhibited lower product yields
compared to meta and para analogues, attributed to steric crowding limiting amide formation
in close proximity to the bulky nitro moiety. The synthetic methodology was also applied to
the preparation of palmitoylated counterparts 87, 88 and 89. Palmitoyl chloride prepared
under anhydrous conditions from palmitic acid and oxalyl chloride was utilised in place of
benzoyl chloride. Successful synthesis and purification of all three species was achieved, with
ortho analogue 89 exhibiting reducing yield due to steric hindrance.
Preparation of family members 90, 91 and 92 using the optimised synthetic methodology
proved challenging, due to the cationic quaternary glycine substitution. Initial preparation of
relevant acid chloride 96 required quaternisation of glycine into betaine 97 using methyl iodide,
as highlighted in Scheme 8.7.322 Subsequent conversion of betaine 97 into acid chloride 96
proved unsuccessful due to incompatibility with standard conditions. Acid chloride alternative
N -hydroxysuccinimide ester 98 was considered given the more favourable solvent systems
required for synthetic preparation, however formation proved unsuccessful. Reactivity issues
are attributed to the cationic nature of betaine 97, therefore could be avoided by an altered
order of synthetic steps, shown in Scheme 8.7. Given the zwitterionic nature of glycine,
similar reactivity problems were experienced during preparation of acid chloride 99 as were
observed for betaine 97. Charge state issues were eliminated by preparation of acid chloride
100 under standard conditions from Fmoc protected glycine.323 An additional deprotection
step is therefore required as a future synthetic state, as demonstrated in Scheme 8.7.
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Scheme 8.7 Modified synthetic methodology proposed for the preparation of quaternary
amine 90. Analogous methodology is appropriate for preparation of meta and ortho analogues
91, and 92.
Acid chloride 100 was utilised during continuation of the proposed synthetic methodology
depicted in Scheme 8.7, for the preparation of compounds 90, 91, and 92.321 Reactivity with p-
nitroaniline, m-nitroaniline, and o-nitroaniline successfully yielded corresponding intermediates
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101, 104, and 105 respectively. Unfortunately due to time constraints purification and
subsequent synthetic steps were not undertaken. Completion and testing of reactivity family
five remains for future study of the relationship between intrinsic lipidation and small molecule
membrane binding orientation.
8.3 The Phospholipidosis Link
Understanding intrinsic lipidation reactivity in relation to structural and functional small
molecule features is a vital step towards incorporation into the pharmaceutical drug develop-
ment process. The biological and pharmaceutical impact of reactivity is a further topic of
interest for the drug development industry, considering the propensity of commercial drugs to
be cationic amphiphilic and thus exhibit membrane affinity. Impacts on drug activity, efficacy,
and the induction of side effects are key areas of interest. Commercial beta-blocker propranolol
1 is the sole pharmaceutical candidate studied and proved undergo intrinsic lipidation in
vitro. In addition, propranolol 1 treatment is known to cause the phospholipid related side
effect, drug induced phospholipidosis.73–75 Phospholipidosis is a lysosomal storage disorder
characterised morphologically, Fig. 8.8. Two mechanisms of action are predicted for the side
effect:
1. Drug induced inhibition of phospholipase enzymes, resulting in reduced degradation and
subsequent accumulation of excess phospholipids
2. Formation of an insoluble drug-phospholipid complex which proves challenging to degrade
The unclear mechanism of action leads to characterisation of drug induced phospholipidosis as
a challenging drug side effect. Furthermore, inconsistencies in patient symptoms and lack of
research make long term effects and treatment options for the side effect unclear.271 Current
prevention of drug induced phospholipidosis requires discontinuation of patient treatment by
the pharmaceutical inducer, a problematic fact for both pharmaceutical companies and patients.
Beyond propranolol 1, over 50 FDA approved drugs are known to induce phospholipidosis,
spanning a variety of classes and structures.73 Cationic amphiphilicity is the sole unifying
feature of affected drugs, highlighting the need for improved understanding.
Chapter 8. Expanding Small Molecule Horizons 273
Figure 8.8 Electron micrographs of fluoxetine 106 treated cells exhibiting lysosomal bodies
characteristic of drug induced phospholipidosis.271 A shows several bodies highlighted with
arrows (Bar = 2 µm), whereas B is a high powered view of a single lamellar body (Bar =
0.2 µm).
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Figure 8.9 Small organic pharmaceuticals associated with the known side effect drug
induced phospholipidosis.
Considering propranolol’s 1 propensity towards both intrinsic lipidation and induction of
phospholipidosis, a relationship between the two phospholipid derived processes may exist.
Available cationic amphiphilic, phospholipidosis inducing pharmaceuticals were compiled in
order to test this theory, Fig. 8.9. Pharmaceutical candidates selected span a range of classes
and contain at least one nucleophilic residue primed to undergo intrinsic lipidation. Com-
parison of phospholipidosis induction can be achieved using NBD-PE assay EC50 values, the
concentration of drug required to induce phospholipidosis in 50 % of cells.324 For comparison,
propranolol 1 has a measured EC50 value of 12.9 µM. Antimalarial chloroquine 107 exhibits
low to moderate phospholipidosis induction, with an EC50 for phospholipidosis of 11.8 µM.
Fluoxetine 106, the active ingredient in antidepressent Prozac (Eli Lilly Ltd.), is known to
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have a high EC50 for phospholipidosis of 4.2 µM. Antidepressant sertraline 108 is characterised
as having a similarly high EC50 for phospholipids of 5.8 µM. Finally, appetite suppressant
phentermine 109 induces phospholipidosis to a lesser extent with an EC50 for phospholipidosis
of 314.7 µM.
Phospholipidosis inducing pharmaceuticals were incubated in 1:10 molar ratio with model
liposomal membranes for 72 hours under physiological conditions. Eukaryotic DOPC, viral
DOPC:DOPS (4:1), and prokaryotic DOPE:DOPG (3:1) liposomal systems were studied.
Sample analysis under optimised conditions revealed a lack of reactivity for all pharmaceuticals
other than propranolol 1, irrespective of membrane system. Further analyses were conducted
following 144 and 216 hour incubations, considering the relatively slow onset rate for drug
induced side effect phospholipidosis, rate of intrinsic lipidation could also be slow. However,
intrinsic lipidation was not observed for pharmaceuticals other than propranolol 1 at these
later time points. Structural and functional complexity of the pharmaceutical candidates
studied creates challenges in pinpointing underlying factors contributing to lack of reactivity.
Limited information is available regarding interactions between these pharmaceuticals and
membrane, including binding orientation which has proved vital in explaining observed small
molecule reactivity previously.
Despite lack of acylated product formation during analysis of phospholipidosis inducing
pharmaceutical species, consistently increased lysolipid levels were observed. Quantification of
lysolipid concentration following 72 hours incubation of pharmaceutical small molecules with
eukaryotic, viral, and prokaryotic membrane systems, was determined using a calibration curve
prepared from synthetic standards. LCMS analysis was conducted in positive ionisation mode,
facilitating visualisation of neutral OPC and OPE lysolipids only. Lysolipid concentrations
for each membrane system are presented in Table 8.12. Lysolipid concentration variation was
observed in viral and prokaryotic membranes treated with different small molecules, attributed
either to differential small molecule interactions, or to analysis preventing visualisation of
negatively charged lysolipids. By contrast, within the pharmaceutically relevant eukaryotic
DOPC membrane, small molecules consistently increase lysolipid formation above background
levels by up to 4 times. Intrinsic lipidation having been discounted for four small molecules, this
observed increase in lysolipid can be attributed to phospholipid hydrolysis, a process known
to be promoted in the presence of cationic amphiphilic small molecules.28 Quantification
of propranolol 1 species suggests the observed 89 pmol of OPC is above that predicted
from the sum of lysolipid production as an intrinsic lipidation by-product (63 pmol) and
through background hydrolysis (12 pmol). This observation further supports the theory that
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pharmaceutical small molecules catalyse phospholipid hydrolysis, likely by acting as a general
acid catalyst. Biologically, an alteration of membrane composition by addition of even 1 mol%
lysolipid is noted to disrupt membrane stability and integrity, highlighting the relevance of this
observation.31 Additional implications are also predicted, including variation to propranolol 1
intrinsic lipidation, and potential links to drug induced phospholipidosis.
Small Molecule DOPC (ng mL−1) PC:PS (ng mL−1) PE:PG (ng mL−1)
- 34.17 12.62 133.64
Propranolol 1 40.49 17.49 419.04
Fluoxetine 106 135.69 15.65 209.62
Chloroquine 107 49.05 23.38 293.76
Sertraline 108 104.25 10.14 90.77
Phentermine 109 51.29 7.29 303.46
Table 8.12 Lysolipid concentrations observed upon incubation of pharmaceutical small
molecules under physiological conditions for 72 hours with liposomal membrane models: (i)
DOPC; (ii) DOPC:DOPS (4:1); (iii) DOPE:DOPG (3:1).
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Figure 8.10 Concentration of OPC observed over 216 hour incubation of pharmaceutical
small molecules with DOPC liposomes under physiological conditions, normalised by subtrac-
tion of background OPC hydrolysis in untreated DOPC liposomes: (i) propranolol 1 shown by
red circles; (ii) fluoxetine 106 shown by blue triangles (iii) chloroquine 107 shown by green
squares; (iv) sertraline 108 shown by purple inverse triangles; (v) phentermine 109 shown by
black diamonds. Grey boxes highlight time periods exhibiting analytical challenges.
Considering the promotion of phospholipid hydrolysis observed within DOPC liposomes
following 72 hours of exposure to phospholipidosis inducing small molecules, in depth study of
the system was conducted. Analysis under optimised conditions was carried out at an increased
number of time points, and lysolipid concentration quantified to give data presented in Fig. 8.10.
Observed lysolipid concentrations in the presence of pharmaceutical small molecules are at
the limit of instrument quantitation at time points up to 8 hours, preventing collection of
meaningful data. Data collected at later time points 144 and 216 hours were also eliminated
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from further consideration, due to data inconsistencies, combined with increased data error
and differential small molecule behaviour. Furthermore, data at later time points requires
caution due to loss of membrane integrity at high lysolipid concentrations, and potential
reactivity between small molecules and lysolipids.
Exclusion of data prior to 8 hours and after 144 hours leaves three time points for continued
study, 24, 48 and 72 hours. Lysolipid concentration is increased above background hydrolysis
levels for all pharmaceutical species at these time points, however 24 hour data proves
particularly interesting in relation to the study of phospholipidosis. Following 24 hour
incubation, lysolipid concentration is observed to correlate with propensity of a given drug
to induce phospholipidosis, as defined by its EC50 value. Exponential decay provides the
optimum model curve for correlation of the two parameters, as shown in Fig. 8.11. Correlation
provides a definitive relationship between lysolipid production and phospholipidosis consistent
with literature findings.28 Additional research is required in order to determined whether the
correlation is due to direct causation or a side effect. Furthermore, the observed correlation,
despite the small sample size, provides the basis for an assay predicting propensity of a drug
candidate to induce phospholipidosis. Considering the unreliable and time consuming nature
of current methodologies, a simplified alternative assay would aid significantly in the drug
development process.
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Figure 8.11 Graph correlating OPC concentration following 72 hour incubation under
physiological conditions in the presences of a DOPC membrane, with EC50 values attributed
to pharmaceutical molecules: (i) propranolol 1 shown by red circles; (ii) fluoxetine 106 shown
by blue triangles (iii) chloroquine 107 shown by green squares; (iv) sertraline 108 shown by
purple inverse triangles; (v) phentermine 109 shown by black diamonds. The solid grey line
represents the fitted trend.
Highlighted in Fig. 8.12, phospholipidosis related lysolipids exhibit structural similarities to
acylated small molecule products of intrinsic lipidation. Therefore, whilst not a requirement
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for phospholipidosis induction, intrinsic lipidation products may be similarly related to the side
effect. Hypothesising induction of phospholipidosis by lysolipids, acylated small molecules have
the potential to adopt a similar mechanism of action, ultimately also inducing phospholipidosis.
Identification of the mechanism of action for phospholipidosis induction could therefore be
achieved by comparison of lysolipid and acylated small molecule properties. To further probe
this theory, key properties of synthetically prepared N -palmitoyl propranolol 12 and N -oleoyl
propranolol 13 were compared to those of lysolipids PPC and OPC. Lysolipids selected for
study mirror common eukaryotic acyl chains present in acylated propranolol 1 analogues,
incorporating a eukaryotic PC head group to ensure pharmaceutical relevance.
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Figure 8.12 Structural and electronic similarities observed for lysolipids PPC and OPC,
compared to N -acylated propranolol derivatives 12 and 13. Palm represents the palmitoyl
group (CH2)14CH3 and oleo represents the oleoyl group (CH2)7CHCH(CH2)7CH3. Hydropho-
bic regions are highlighted in red, and hydrophilic regions in green.
Membrane disruption is a known feature of increased lysolipid concentration, resulting in
leakage of intracellular contents and, if severe, cell death. Comparison of membrane disrup-
tion properties of lysolipids and N -acylated propranolol species can be achieved using an
8-aminonapthalene-1,3,6 trisulfonic acid (ANTS)/p-xylene-bis-pyridinium bromide (DPX)
assay.325 Fluorescent ANTS and quencher DPX are trapped within a liposome, then external
buffer is exchanged to remove ANTS and DPX from the medium outside vesicles. Membrane
disruption, relative to positive control Tritron X-100, is measured by the observed fluores-
cence increase associated with ANTS leakage and dilution, removing DPX quenching. Three
concentrations of each lysolipid or N -acylated propranolol were added to prepared liposomes,
with proportions mirroring 1 %, 5 % and 100 % intrinsic lipidation product conversion. Assay
data presented in Fig. 8.13, indicates that all species exhibit immediate membrane lysis and
disruption of above 85 %. Comparable values are observed for both lysolipids and N -acylated
propranolol species, and also for palmitoyl and oleoyl modifications. Increased proportion of
lysolipid or N -acylated propranolol from 1 % to 5 % results in a corresponding increase in
leakage % for all species. Further increase from 5 % to 100 % results in slightly decreased
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leakage % for PPC, OPC and N -oleoyl propranolol 13, attributed to competing micelle
formation above species respective CMC. Membrane disruption assay results highlight the
similar but significant impacts of both lysolipids and acylated small molecules upon membrane
integrity. Membrane disruption therefore provides a potential mechanism of action for the
induction of phospholipidosis by pharmaceutical species.
Figure 8.13 Normalised % leakage over 30 minutes for ANTS/DPX liposomes, treated
under physiological conditions (pH 7.4 and 37 ◦C) with 1 mol% (solid lines), 5 mol% (dashed
lines) and 100 mol% (dotted and dashed lines): (a) PPC; (b) OPC; (c) N -palmitoyl propranolol
12; (d) N -oleoyl propranolol 13.
Micelle formation is the known result of lysolipid self aggregation in aqueous solution above a
CMC, and has been similarly hypothesised for N -acylated propranolol species. Determination
of CMC, the critical concentration of molecules required for spontaneous micelle formation,
can be achieved using a Rhodamine 6G assay.326,327 Rhodamine 6G absorbs weakly at 542 nm
in aqueous solution due to poor solubility, however absorption increases upon encapsulation
within a hydrophobic micelle. Rhodamine 6G absorption was monitored over the concentration
range 0.1 µM to 10 µM for PPC, OPC, N -palmitoyl propranolol 12 and N -oleoyl propranolol
13. Calculated CMC values of 4 µM and 7 µM were obtained for PPC and OPC respectively,
in agreement with literature values.33,213,214 Data obtained through analogous study of N -
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palmitoyl propranolol 12 and N -oleoyl propranolol 13 is presented in Fig. 8.14. Absorption
increase suggests micelle formation for both species, with CMC values at graph minima
determined as 10µM and 9 µM respectively. Calculated lysolipid and acylated propranolol
CMC values fall within the same concentration range, explaining their similar behaviour and
providing a further mechanism of action for phospholipidosis induction.
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Figure 8.14 Rhodamine 6G absorbance in the presence of increasing concentrations of
N -palmitoyl propranolol 12 (solid green line) and N -oleoyl propranolol 13 (red dashed line).
Vertical lines indicate CMC values for each species.
8.4 Conclusions
Increased understanding of innate reactivity between membrane binding small molecules
and phospholipids has been probed through study of structural and functional features of
small molecules. Development or synthesis of reactivity families which differ in a single
feature have facilitated study of the impact of that sole feature upon intrinsic lipidation.
Synthetic preparation of acylated standard 67 has enabled studies to be conducted in a
semi quantitative manner. Modification to the hydrophobic aromatic ring portion of small
molecules did not result in observed reactivity, however alterations to the hydrophilic region
proved more informative. Steric and electronic features favour primary amine nucleophiles for
the promotion of intrinsic lipidation. Nucleophile flexibility and localisation on the hydrophilic
face of the small molecule further aid in promoting reactivity with membrane phospholipids.
Observations consistently point to membrane binding orientation and subsequent proximity
between reactivity residues as key features in facilitating intrinsic lipidation. Synthetic
methodology has been developed for preparation of a family of small molecules designed to test
this feature, however time constraints have prevented analysis. LogP, pK a, local hydration
levels and membrane composition have also been noted to influence reactivity within the
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families of small molecules studied. Ultimately, multiple influencing factors creates complexity
in understanding the relationship of intrinsic lipidation with structural and functional features
of small molecules.
Biological and pharmaceutical impacts of small molecule reactivity have been probed through
study of commercial pharmaceuticals. Research has been conducted in reference to the
poorly understood drug side effect phospholipidosis, a disorder resulting in phospholipid
aggregation. Propranolol 1 was the only commercial pharmaceutical studied observed to
undergo intrinsic lipidation, however all species promoted phospholipid hydrolysis in eukaryotic
membrane models. Quantification and monitoring of lysolipid levels revealed a correlation
between lysolipid concentration following 24 hour incubation, and phospholipidosis EC50.
This correlation proffers the basis for an improved commercial phospholipidosis assay, and
provides insight into potential mechanisms of drug induced phospholipidosis. Structural
similarities between lysolipids and acylated small molecules suggest analogous mechanisms of
phospholipidosis induction may be possible for intrinsic lipidation products. Work directed
towards understanding the mechanism of action revealed properties shared by lysolipids PPC
and OPC, and acylated small molecules N -palmitoyl propranolol 12 and N -oleoyl propranolol
13. Properties which may influence phospholipidosis onset include membrane disruption, and
micelle formation above µM CMC values.
9 | Conclusion
The cell membrane is vital for cell survival, providing cell stability, integrity, and regulation
of biological pathways. Chemical reactivity is an intriguing feature of the cell membrane,
characterised by non-enzymatic acyl transfer from membrane phospholipids to nucleophilic
membrane bound molecules. This reactivity, termed intrinsic lipidation, has been probed
within this thesis for membrane active molecules including peptides, proteins, and novel
reactive species, small molecules. Focus has been upon probing reactivity, in order to increase
fundamental and mechanistic understanding of intrinsic lipidation, through analytical method
development and kinetics studies. In tandem, biological and pharmaceutical implications of
intrinsic lipidation have been investigated by employing biophysical techniques, in cellulo
study, and disease relevant reactive species.
Effective study of intrinsic lipidation has been facilitated through development of informative
and robust analytical techniques. Solution state NMR, fluorescence spectroscopy, and TLC
have been investigated for routine high throughput screening of intrinsic lipidation. TLC
was identified as the optimum technique, and suitable solvent system and visualisation
conditions determined in reversed and normal phase for small molecule intrinsic lipidation.
Routine monitoring of peptide intrinsic lipidation proved challenging by TLC, fluorescence
and solution state NMR due to concentration deficiencies. Informative intrinsic lipidation
analysis provided by current LCMS methodology can be supplemented with complementary
ssNMR data. Preliminary screening indicated concentration limitations, resulting in the need
for isotopically labelled substrates. To this end, synthetic protocols have been developed for
successful preparation of 15N propranolol 1, and 13C labelled phospholipids DOPC and DPPC.
Preparation of labelled palmitoyl and oleoyl moieties have been attempted, towards POPC
synthesis, however further synthetic development is required due to the challenging nature of
alkyl bond formation.
Biological relevance of peptide intrinsic lipidation has been probed in order to determined
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the role of reactivity in natural peptide function or disease induction. Biophysical techniques
were applied to four acylated derivatives of model peptide melittin, N -palmitoyl melittin,
K23-palmitoyl melittin, N -oleoyl melittin, and K23-oleoyl melittin. Solution phase α-helical
structure with central proline kink was attributed to all acylated melittin derivatives by
CD and tryptophan fluorescence, in contrast to the random coil of solution phase melittin.
Furthermore, spontaneous micelle formation is observed for N -palmitoyl melittin and K23-
palmitoyl melittin above CMC of 1 µM and 5 µM respectively. Antimicrobial activity against
E. coli and S. aureus is diminished upon acylation of melittin, particularly in the case
of K23 and oleoyl modifications. Disease relevance of peptide intrinsic lipidation has been
probed using amyloids amylin, amyloid β, and β2-microglobulin. Thioflavin T assays and EM
confirm amyloid aggregation under standard peptide intrinsic lipidation conditions, suggesting
a link between acylation and amyloid nucleation. Attempts to diminish aggregation using
low salt, low temperatures, and sonication proved unsuccessful over the time period of study.
Furthermore, amyloid deaggregation by formic acid, HFIP, and enzymatic digestion were
explored with limited success. Further technical development is required in order to visualise
intrinsically lipidated amyloids, definitively proving a link between reactivity and amyloid
nucleation.
Novel reactivity at the membrane interface has been identified through small molecule intrinsic
lipidation. Study, facilitated by LCMS optimised using synthetically prepared acylated
standards, reveals acyl transfer to multiple cationic amphiphilic small molecules in vitro.
Reactivity is observed across multiple membrane models, including eukaryotic, viral, and
prokaryotic systems. Small molecule families, prepared to study the implications of molecular
structure and functionality upon reactivity, suggest reactivity is promoted by primary amine
nucleophiles on the hydrophilic small molecule face. Favourable binding orientation, promoting
proximity between reactive phospholipid and small molecule moieties, is predicted to drive
reactivity. However, the complex nature of intrinsic lipidation suggests multiple additional and
competing factors impact reactivity, including pK a, localised hydration levels, and nucleophile
mobility.
Several current pharmaceuticals are characterised as nucleophile containing and cationic
amphiphilic, suggesting a propensity towards intrinsic lipidation. Many of these molecules
are also known to induce drug side effect phospholipidosis, a lysosomal storage disorder
characterised by phospholipid aggregation. Study of intrinsic lipidation in five phospholipidosis
inducing pharmaceuticals revealed reactivity in only one case, however heighten lysolipid
formation was observed across all species. Observations suggest a correlation between lysolipid
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concentration and phospholipidosis induction, potentially due to innate lysolipid properties.
Biophysical techniques reveal similar structure and functionality of lysolipids and acylated
small molecules, including membrane disruption and micelle formation. Similar modes of
action may aid in phospholipidosis induction by both lysolipids and acylated small molecules,
however further study is required in order to probe this theory.
Pharmaceutical propranolol 1, has been extensively investigated as an interesting example
of small molecule intrinsic lipidation. Synthetic preparation of acylated standards combined
with CID MSMS reveal two distinct reaction products of propranolol 1 intrinsic lipidation in
vitro, O-acylated propranolol and N -acylated propranolol. Migratory studies under physio-
logical conditions suggest a reactivity mechanism, characterised by initial transesterification
from phospholipids, followed by intramolecular O to N migration. Quantitative study of
propranolol 1 intrinsic lipidation reveals preferential acyl transfer within eukaryotic model
systems, and from the sn-1 phospholipid backbone position. Kinetics studies reveal modified
product distribution and reaction rate in vitro as a result of temperature, pH, and membrane
composition. Acyl transfer reactivity to propranolol 1 from lysolipid containing micelles has
also been proved during these experiments, exhibiting preferential palmitoyl transfer despite
increasingly tight packing. Propranolol 1 intrinsic lipidation has also been characterised in
E. coli and bovine liposomes, and in Hep G2 cells, forming O-acylated propranolol species
mirroring cellular fatty acid profile.
10 | Experimental
10.1 General Techniques
Materials
Phospholipids and lysolipids were purchased as powders from Avanti Polar Lipids (via Instru-
chemie B.V., The Netherlands). Isotopically labelled materials were purchased from Goss
Scientific Instruments Ltd. (Cheshire, UK). Melittin (synthetic 97 % by HPLC) and amyloid
peptides were purchased from Enzo Life Sciences Ltd. (Exeter, UK), and acylated melittin
from Almac Group (Craigavon, UK). sn-glycerophosphocholine was purchased from Bachem
Holding AG (Bubendorf, Switzerland). Solvents, acids, and bases were purchased from Fisher
Scientific (Loughborough, UK). Solvent drying was carried out over molecular sieves, with
the exception of dry DCM which was refluxed over CaH2. All other chemicals were purchased
from Sigma Aldrich (Dorset, UK), Fluorochem (Derbyshire, UK), TCI UK Ltd. (Oxford,
UK), or Alfa Aesar (Lancashire, UK).
Solution State NMR
1H and 13C NMR were performed at 400 MHz using a Bruker-400 spectrometer. Samples
were prepared in CDCl3 (97 % D, Goss Scientific Instruments Ltd., Cheshire, UK), D2O (99.9
% D, Goss Scientific Instruments Ltd., Cheshire, UK) or CD3OD (99.8 % D, Goss Scientific
Instruments Ltd., Cheshire, UK). Chemical shifts (δ) are reported in ppm and are referenced
relative to the residual solvent signal (7.26 ppm for CHCl3/CDCl3; 4.80 ppm for H2O/D2O;
4.87 ppm for CH3OH/CD3OD). J values are reported in Hz.
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Mass Spectrometry
Routine accurate mass characterisation was conducted on a LCT Premier XE (Waters Corp.,
UK) or QToF Premier (Waters Corp., UK). Positive ESI was recorded between m/z 50
to 2000, and PDA absorbance measurement between 210 nm and 500 nm. Where relevant,
chromatography was performed on an Acquity UPLC, with 3 µL injection on to a BEH C18,
1.7 µm (2.1 x 100 mm) column. Mobile phase conditions ran a linear 400 µL/min gradient
from 1 % MeCN: 99 % H2O (0.1 % formic acid) to 99 % MeCN: 1 % H2O (0.1 % formic acid)
over 5 minutes, followed by a 4 minute organic wash.
IR Spectroscopy
IR spectroscopy was performed on a Perkin Elmer FT-IR spectrometer operating through the
wavenumber range 400 cm−1 and 4000 cm−1.
Liposome Preparation by Extrusion
Stock solutions of phospholipid in CHCl3 were prepared at a concentration of 10 mg mL−1
and stored at -20 ◦C. A 100 µL aliquot of phospholipid stock solution was added to a round-
bottomed flask, and solvent removed in vacuo resulting in formation of a lipid film. Following
overnight dessication, the phospholipid film was rehydrated in buffer solution and agitated
using a vortex mixer. The dispersion was subjected to 5 freeze-thaw cycles between -196 ◦C
and 30 ◦C, before 10 extrusion cycles at 50 ◦C using a LIPEX thermobarrel extruder under a
positive pressure of nitrogen and a 100 nm Whatman Nucleopore laser-etched polycarbonate
filter.
Liposome Preparation by Sonication
Stock solutions of phospholipid in CHCl3 were prepared at a concentration of 10 mg mL−1
and stored at -20 ◦C. A 100 µL aliquot of phospholipid stock solution was added to a round-
bottomed flask, and solvent removed in vacuo resulting in formation of a lipid film. Following
overnight dessication, the phospholipid film was rehydrated in buffer solution and agitated
using a vortex mixer. The dispersion was subjected to 5 freeze-thaw cycles between -196 ◦C
and 30 ◦C, before bath sonication for 20 min at room temperature.
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Peptide Buffer pH 7.41
90 mm NaCl and 10 mm NaHCO3 were fully dissolved in H2O. pH was measured and adjusted
to a value of 7.41 using HCl.
Peptide Stock Solutions
Peptides were dissolved in H2O (melittin) or HFIP (amyloids) at approximate concentration
1 mg mL−1. Accurate concentrations were determined by measuring absorbance from 200 nm
to 400 nm at 21 ◦C using a CARY100 UV-Visible spectrophotometer with Cary WinUV Scan
Software 3.00(182). Absorbance was measured in triplicate following addition of 5 µL, 10µL,
15 µL and 20 µL aliquots of peptide stock solution to a 1 mm quartz cuvette containing H2O
(1 mL). Following dilution correction, concentrations were calculated using the Beer-Lambert
Law, with relevant physical parameters given in Table 10.1.
Peptide Absorbance Wavelength (nm) Extinction Coefficient (M−1 cm−1)
Melittin 280 5600
Acylated Melittin 280 5600
Amyloid β 274 1400
Amylin 257 200
β-2 Microglobulin 280 19600
Table 10.1 Extinction coefficients and absorbance wavelengths used for the measurement
of amyloid concentrations
Small Molecule Buffer pH 7.41
10 mm NH4HCO3 was fully dissolved in H2O. pH was measured and adjusted to a value of
7.41 using formic acid.98
Small Molecule Stock Solutions
Small molecule stock solution were prepared at concentration 1.27 mm in H2O or H2O:EtOH
depending upon solubility.
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Small Molecule Incubation
1.27 mm liposomes in buffer of desired pH were added in 1:10 molar ratio to 1.27 mm small
molecule stock solution. Samples were incubated at the desired temperature for the relevant
time period prior to analysis.
Optimised Small Molecule LCMS in vitro
Samples were diluted in MeCN:H2O (1:1) to small molecule concentration 1 µg mL−1. LCMS
analyses were conducted on a Synapt G2-S (Waters Corp., UK) recording ESI ions between
m/z 50 to 2000, and PDA absorbance measurement between 210 nm and 500 nm. Optimised
chromatography was conducted by 3 µL injection on to an Acquity UPLC with BEH Phenyl
1.7 µm (2.1 x 50 mm) column. Mobile phase conditions are summaried in Table 10.2 positive
ESI ionisation parameters are presented in Table 10.3.
Time (min) Flow Rate (mL/min) % H2O (0.1 % FA) % MeCN (0.1 % FA) Curve
0.00 0.4 95 5 6
0.50 0.4 95 5 6
7.50 0.4 5 95 6
8.80 0.4 5 95 6
8.90 0.4 95 5 6
10.00 0.4 95 5 6
Table 10.2 Optimised chromatography gradient for small molecule LCMS.
Parameter Optimised Value
Capillary Voltage (kV) 1.0
Source Temperature (◦C) 150.0
Sampling Cone Voltage (V) 50.0
Source Offset Voltage (V) 30.0
Desolvation Temperature (◦C) 350.0
Cone Gas Flow (L h−1) 60.0
Desolvation Gas Flow (L h−1) 600.0
Nebuliser Gas Flow (Bar) 6.0
Table 10.3 Optimised positive ESI parameters for small molecule LCMS.
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Small Molecule CID MSMS
CD MSMS was carried out in the trap region of a Synapt G2-S (Waters Ltd., UK). Desired
precursor ions were isolated in the quadrapole, and subsequently underwent CID fragmentation
ramping from 30 V to 50 V.
Data Processing
Data was processed using MassLynx software version 4.1. In built elemental composition
software was applied to the determination of error and RDB values. Peak area calculations were
determined from EIC of desired m/z using Microsoft Excel 2013 Solver. Error calculations were
determined based upon peak area variation between triplicate samples identically prepared
and analysed.
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Fluorescence Spectroscopy
Fluorescence spectroscopy was carried out on a PerkinElmer LS 55 Fluorescence Spectrometer
using a tryptophan excitation wavelength of 280 nm and a detection range of 300 nm to 450 nm.
Slit widths were selected as 10 nm for excitation and 50 nm for emission, and the scan speed
was 100 nm min−1. Melittin stock solution (20 µL) and H2O (1 mL) were added to a quartz
cuvette with 1 mL insert and analysed as a background control. Acylated melittin stock
solution was then added in sequential amounts from 1 mol% up to 20 mol%, and emission
recorded in triplicate to account for instrument error.
NP/RP TLC Stains
• UV (254 nm UV lamp)
• PMA (6.25 g PMA, 2.50 g Ce(SO4)2, 15 mL H2SO4, 230 mL H2O)
• Ninhydrin (0.50 g ninhydrin, 10 mL EtOH, 1 mL AcOH)
• Coomassie (0.03 % brilliant blue, 20 % MeOH, 80 % H2O)
Chapter 10. Experimental 289
• p-Anisaldehyde (4 mL p-anisaldehyde, 5 mL H2SO4, 2 mL AcOH, 150 mL EtOH)
• I2 (crystals of elemental iodine)
• KMnO4 (3.00 g KMnO4, 10.00 g K2CO3 in 300 mL H2O)
Small Molecule NP TLC
1 µL of 1.27 mm stock solutions of propranolol 1, N -palmitoyl propranolol 12, and N -oleoyl
propranolol 13 were spotted onto a NP TLC plate (Fisher Scientific Loughborough, UK).
Preliminary staining was conducted with NP TLC stains. Reaction mixture concentration
solutions of propranolol 1 (127 nm), N -palmitoyl propranolol 12 (1.27 nm), and N -oleoyl
propranolol 13 (1.27 nm) were prepared. 1 µL to 20µL of reaction mixture solutions were
spotted on to a NP TLC plate and dried under a flow of compressed air using 1 µL graduated
TLC spotters (Sigma Aldrich Dorset, UK). Sensitivity staining was conducted with relevant
NP TLC stains. Solvent system optimisation was carried out using 1.27 mm stock solutions of
propranolol 1, N -palmitoyl propranolol 12, and N -oleoyl propranolol 13, and 12.7 mm stock
solutions of POPC, PPC, and OPC. 1 µL of each was spotted on to a NP TLC plate, exposed
to solvent conditions, and visualised using PMA.
Peptide RP TLC
1 µL of melittin and acylated melittin stock solutions (approximately 1 mg mL−1) were spotted
onto a RP TLC plate (Fisher Scientific Loughborough, UK). Preliminary staining was
conducted with NP TLC stains. Reaction mixture concentration solutions (approximately
50µg mL−1) of melittin and acylated analogues were applied to RP TLC plate using 1 µL
graduated TLC spotters (Sigma Aldrich Dorset, UK). Sensitivity staining was conducted
with relevant RP TLC stains. Solvent system optimisation was not pursed due to insufficient
TLC plate hydrophobicity.
High Performance RP TLC Stains
• PMA (6.25 g PMA, 100 mL EtOH)
• Ninhydrin (0.20 g ninhydrin, 100 mL EtOH)
290 10.2. Chapter 3
• Ninhydrin (0.20 g ninhydrin, 100 mL IPA)
• Ninhydrin (0.20 g ninhydrin, 100 mL t-BuOH)
Peptide High Performance RP TLC
1 µL of melittin and acylated melittin stock solutions (approximately 1 mg mL−1) were spotted
onto a high performance RP TLC plate (Fisher Scientific Loughborough, UK). Preliminary
staining was conducted with high performance RP TLC stains. Reaction mixture concentration
solutions (approximately 50µg mL−1) of melittin and acylated analogues were applied to RP
TLC plate using 1 µL graduated TLC spotters (Sigma Aldrich Dorset, UK). Sensitivity
staining was conducted with PMA in EtOH only. Solvent system optimisation was not pursed
due to insufficient visualisation sensitivity.
Small Molecule High Performance RP TLC
1 µL of 1.27 mm stock solutions of propranolol 1, N -palmitoyl propranolol 12, and N -oleoyl
propranolol 13 were spotted onto a high performance RP TLC plate (Fisher Scientific Lough-
borough, UK). Preliminary staining was conducted with high performance RP TLC stains.
Reaction mixture concentration solutions of propranolol 1 (127 nm), N -palmitoyl propranolol
12 (1.27 nm), and N -oleoyl propranolol 13 (1.27 nm) were prepared. 1 µL to 20 µL of reaction
mixture solutions were spotted on to a high performance RP TLC plate and dried under
a flow of compressed air using 1 µL graduated TLC spotters (Sigma Aldrich Dorset, UK).
Sensitivity staining was conducted using PMA in EtOH. Solvent system optimisation was
carried out using 1.27 mm stock solutions of propranolol 1, N -palmitoyl propranolol 12, and
N -oleoyl propranolol 13, and 12.7 mm stock solutions of POPC, PPC, and OPC. 1 µL of each
was spotted on to a high performance RP TLC plate, exposed to solvent conditions, and
visualised using PMA in EtOH.
Solid State NMR
DPPC liposomes were prepared by extrusion and sonication methodologies at a concentration of
0.2 mg mL−1 in D2O. ssNMR analysis revealed insufficient sample concentration for detection.
DPPC liposomes at concentration 2.0 mg mL−1 in D2O were prepared by sonication. 31P
ssNMR was successfully carried out over 12 hours on a Bruker Avance III HD spectrometer
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with 9.4 T magnet and 4 mm HX MAS probe. Analysis was repeated using 2.0 mg mL−1
DPPC liposomes D2O containing 5 mol% lysolipid PPC.
Synthesis of 1-chloro-3-(1-naphthoxy)-2-propanol 14
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1-Naphthol (1.00 g, 6.94 mmol), epichlorohydrin (2.69 mL, 34.68 mmol) and pyridine (0.06 mL,
0.69 mmol) were stirred at 35 ◦C for 24 hours. Excess epichlorohydrin was removed by
distillation under reduced pressure using a Kugelrohr. Product was redissolved in CHCl3
(0.750 mL) and 37 % HCl(aq) (0.375 mL) and stirred for 1 hour at 5 ◦C. Mixture was diluted
in CHCl3, washed with H2O three times, dried over MgSO4 and solvent removed in vacuo.
Product 14 was obtained as a dark oil (1.49 g, 91 %): 1H (400 MHz; CDCl3) δ 2.86 (s, 1H,
OH), 3.85 (d, J = 5.5 Hz, 2H, H1), 4.23 (m, 2H, H3), 4.35 (m, 1H, H2), 6.82 (d, J = 7.5 Hz,
1H, H5), 7.36 (t, J = 7.9 Hz, 1H, H6), 7.44-7.54 (m, 3H, H7,10,11), 7.80 (d, J = 6.9 Hz, 1H,
H9), 8.18 (d, J = 7.1 Hz, 1H, H12); 13C (100 MHz; CDCl3) δ 46.5 (C1), 68.8 (C2), 70.1 (C3),
105.2 (C5), 121.2 (C7), 121.7 (C12), 125.5 (C4), 125.7 (C11), 125.9 (C6), 126.7 (C10), 127.7
(C9), 134.6 (C8), 153.9 (C13); IR (neat) vmax/cm–1 3485; LRMS (ASAP) m/z 237.1 [M+H]+;
HRMS (ASAP) calculated for C13H14O2Cl [M+H]+ 237.0682, found 237.0686.174
Synthesis of N -Isopropylphthalimide 15 - Method 1
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2-Bromopropane (0.40 mL, 2.48 mmol) and potassium phthalimide (0.55 mg, 2.98 mmol in dry
DMF (3 mL) were stirred under argon for 12 hours. TLC analysis did not indicate product
formation.175,176
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Synthesis of N -Isopropylphthalimide 15 - Method 2
2-Bromopropane (0.40 mL, 2.48 mmol), potassium phthalimide (0.23 mg, 1.24 mmol) and
potassium carbonate (0.34 mg, 2.48 mmol) in dry DMF (3 mL) were stirred under argon at 40
◦C for 18 hours. Reaction mixture was poured on to H2O (30 mL) and the resulting white
solid 15 collected by Büchner filtration (0.12 g, 26 %): 1H (400 MHz; DMSO-d6) δ 1.48 (d, J
= 7.2 Hz, 6H, H10,11), 4.47-4.57 (m, 1H, H9), 7.79 (m, 4H, H2,3,4,5); 13C (100 MHz; DMSO-d6)
δ 20.1 (C10,11), 43.0 (C9), 123.0 (C3,4), 132.1 (C2,5), 133.8 (C1,6), 168.4 (C7,8); IR (neat)
vmax/cm–1 1692, 2981; LRMS (ASAP) m/z 190.1 [M+H]+; HRMS (ASAP) calculated for
C11H12NO2 [M+H]+ 190.0868, found 190.0858; m.p. = 83-84 ◦C.175,176
Synthesis of 15N -Isopropylphthalimide 15
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2-Bromopropane (0.40 mL, 2.48 mmol), 15N -potassium phthalimide (0.23 mg, 1.24 mmol) and
K2CO3 (0.34 mg, 2.48 mmol) in dry DMF (3 mL) were stirred under argon at 40 ◦C for 18
hours. Reaction mixture was poured on to H2O (30 mL) and the resulting white solid 15N 15
collected by Büchner filtration (0.16 g, 34 %): 1H (400 MHz; DMSO-d6) δ 1.48 (d, J = 7.2 Hz,
6H, H10,11), 4.47-4.57 (m, 1H, H9), 7.79 (m, 4H, H2,3,4,5); 13C (100 MHz; DMSO-d6) δ 20.1
(C10,11), 43.0 (C9), 123.0 (C3,4), 132.1 (C2,5), 133.8 (C1,6), 168.4 (C7,8); IR (neat) vmax/cm–1
1692, 2981; LRMS (ASAP) m/z 191.1 [M+H]+; HRMS (ASAP) calculated for C11H1215NO2
[M+H]+ 191.0833, found 191.0838; m.p. = 83-84 ◦C.175,176
Synthesis of Isopropylamine 16 - Method 1
H2N
1
3
216
N -Isopropylphthalimide (0.50 g, 2.65 mmol) was refluxed for 2 hours in 37 % HCl(aq) (10 mL),
cooled to allow crystallisation of phthalic acid, and refluxed for a further 2 hours. Upon
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cooling phthalic acid was removed by filtration, and the remaining aqueous solution freeze-
dried to yield white solid 16. Product characterisation proved challenging due to limited
conversion.175,176
Synthesis of Isopropylamine 16 - Method 2
H2N
1
3
216
N -Isopropylphthalimide (1.26 g, 8.66 mmol) was refluxed for 1 hour in the presence of hydrazine
hydrate (1.01 g, 20.16 mmol) and MeOH (1.8 mL). The mixture was filtered and solvent
removed in vacuo to yield white solid product 16 as the HCl salt (0.41 g, 81 %): 1H (400
MHz; D2O) δ 1.31 (d, J = 7.0 Hz, 6H, H2,3), 3.51 (sept, J = 7.0 Hz, 1H, H1); 13C (100 MHz;
D2O) δ 25.8 (C2,3), 42.1 (C1); IR (neat) vmax/cm–1 3421; LRMS (EI) m/z 60.1 [M+H]+; m.p.
= 151-152 ◦C.175,176
Synthesis of 15N -Isopropylamine 16
H2N
1
3
216
15N -Isopropylphthalimide (1.26 g, 8.66 mmol) was refluxed for 1 hour in the presence of
hydrazine hydrate (1.01 g, 20.16 mmol) and MeOH (1.8 mL). The mixture was filtered and
solvent removed in vacuo to yield white solid product 15N 16 as the HCl salt (0.40 g, 77 %):
1H (400 MHz; D2O) δ 1.31 (d, J = 7.0 Hz, 6H, H2,3), 3.51 (sept, J = 7.0 Hz, 1H, H1); 13C
(100 MHz; D2O) δ 25.8 (C2,3), 42.1 (C1); IR (neat) vmax/cm–1 3405; LRMS (EI) m/z 61.1
[M+H]+; m.p. = 151-152 ◦C.175,176
Synthesis of Propranolol 1
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Isopropylamine HCl salt 16 (1.03 g, 10.73 mmol) was dissolved in 20 % NaOH solution
(2.30 mL) to pH 14. 1-chloro-3-(1-naphthoxy)-2-propanol 14 (0.10 mL, 0.53 mmol) in IPA
(2.30 mL) was added, and the mixture stirred for 16 hours. Excess isopropylamine was removed
by distillation under reduced pressure using a Kugelrohr. Remaining aqueous mixture was
washed with DCM, dried under MgSO4, and solvent removed in vacuo. Purification by silica
gel chromatography using EtOAc:MeOH:H2O (98:1:1) eluent yielded a racemic mixture of
propranolol 1 as a white solid (0.12 g, 85 %): 1H (400 MHz; CDCl3) δ 1.36 (d, J = 6.0 Hz,
6H, H16,17), 3.11-3.17 (m, 1H, H14), 3.27-3.31 (m, 1H, H15), 3.32-3.38 (m, 1H, H14), 3.97-4.02
(m, 1H, H12), 4.05-4.12 (m, 1H, H12), 4.68-4.77 (m, 1H, H13), 5.42 (s, 1H, OH), 6.49-6.55 (m,
1H, H9), 7.10-7.19 (m, 1H, H8), 7.24-7.33 (m, 3H, H1,2,7), 7.61-7.67 (m, 1H, H3), 8.10-8.14
(m, 1H, H6), 8.50 (s, 1H, NH), 9.62 (s, 1H, NH); 13C (100 MHz; CDCl3) δ 23.1 (C16,17), 48.9
(C15), 68.1 (C14), 68.9 (C12), 70.7 (C13) 104.9 (C9) 120.6 (C7), 121.9 (C6), 125.3 (C5), 125.6
(C1), 125.8 (C8), 126.4 (C2), 127.3 (C3), 134.6 (C4), 154.4 (C10); IR (neat) vmax/cm–1 1572,
1581, 2842, 2990, 3260, 3286; LRMS (ESI) m/z 260.2 [M+H]+; HRMS (ESI) calculated for
C16H22NO2 [M+H]+ 260.1651, found 260.1649; m.p. = 91-92 ◦C.174
Synthesis of 15N -Propranolol 1
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15N -Isopropylamine HCl salt 16 (1.03 g, 10.73 mmol) was dissolved in 20 % NaOH solution
(2.30 mL) to pH 14. 1-chloro-3-(1-naphthoxy)-2-propanol 14 (0.10 mL, 0.53 mmol) in IPA
(2.30 mL) was added, and the mixture stirred for 16 hours. Excess isopropylamine was removed
by distillation under reduced pressure using a Kugelrohr. Remaining aqueous mixture was
washed with DCM, dried under MgSO4, and solvent removed in vacuo. Purification by silica
gel chromatography using EtOAc:MeOH:H2O (98:1:1) eluent yielded yielded a racemic mixture
of 15N propranolol 1 as a white solid (0.12 g, 84 %): 1H (400 MHz; CDCl3) δ 1.36 (d, J =
6.0 Hz, 6H, H16,17), 3.11-3.17 (m, 1H, H14), 3.27-3.31 (m, 1H, H15), 3.32-3.38 (m, 1H, H14),
3.97-4.02 (m, 1H, H12), 4.05-4.12 (m, 1H, H12), 4.68-4.77 (m, 1H, H13), 5.42 (s, 1H, OH),
6.49-6.55 (m, 1H, H9), 7.10-7.19 (m, 1H, H8), 7.24-7.33 (m, 3H, H1,2,7), 7.61-7.67 (m, 1H,
H3), 8.10-8.14 (m, 1H, H6), 8.50 (s, 1H, NH), 9.62 (s, 1H, NH); 13C (100 MHz; CDCl3) δ
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23.1 (C16,17), 48.9 (C15), 68.1 (C14), 68.9 (C12), 70.7 (C13) 104.9 (C9) 120.6 (C7), 121.9 (C6),
125.3 (C5), 125.6 (C1), 125.8 (C8), 126.4 (C2), 127.3 (C3), 134.6 (C4), 154.4 (C10); IR (neat)
vmax/cm–1 1572, 1581, 2842, 2990, 3260, 3286; LRMS (ESI) m/z 261.2 [M+H]+; HRMS (ESI)
calculated for C16H2215NO2 [M+H]+ 261.1621, found 261.1617; m.p. = 91-92 ◦C.174
Synthesis of 2-Aminomethylbenzimidazole 11 - Method 1
3
4
5
6
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N
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o-Phenylenediamine (1.08 g, 10.00 mmol) and glycine (1.50 g, 20.00 mmol) were refluxed in 37
% HCl (4 mL) for 5 days until NMR indicated full conversion. After cooling, the resulting solid
was isolated by filtration and combined with the solid obtained by freeze drying the reaction
mixture. Purification by recrystallisation from MeOH yielded the HCl salt of compound 11
as a tan solid (2.06 g, 94 %): 1H (400 MHz; DMSO-d6) δ 3.54 (t, J = 5.7 Hz, 2H, H8), 4.48
(t, J = 5.7 Hz, 2H, NH2), 7.43-7.48 (m, 2H, H3,4), 7.77-7.81 (m, 2H, H2,5), 9.08 (s, 1H, NH);
13C (100 MHz; DMSO-d6) δ 39.2 (C8), 116.8 (C2,5), 125.4 (C3,4), 136.4 (C1,6), 148.7 (C7); IR
(neat) vmax/cm–1 1581, 1605, 2930, 3021, 3248, 3360, 3387; LRMS (ESI) m/z 148.1 [M+H]+;
HRMS (ESI) calculated for C8H10N3 [M+H]+ 148.0875, found 148.0872; m.p. = 269-270
◦C.177,178
Synthesis of 2-Aminomethylbenzimidazole 11 - Method 2
o-Phenylenediamine (1.08 g, 10.00 mmol) and glycine (0.90 g, 12.00 mmol) were refluxed in 37
% HCl (4 mL) for 5 days until NMR indicated full conversion. After cooling, the resulting solid
was isolated by filtration and combined with the solid obtained by freeze drying the reaction
mixture. Purification by recrystallisation from MeOH yielded the HCl salt of compound 11
as a tan solid (0.26 g, 12 %): 1H (400 MHz; DMSO-d6) δ 3.54 (t, J = 5.7 Hz, 2H, H8), 4.48
(t, J = 5.7 Hz, 2H, NH2), 7.43-7.48 (m, 2H, H3,4), 7.77-7.81 (m, 2H, H2,5), 9.08 (s, 1H, NH);
13C (100 MHz; DMSO-d6) δ 39.2 (C8), 116.8 (C2,5), 125.4 (C3,4), 136.4 (C1,6), 148.7 (C7); IR
(neat) vmax/cm–1 1581, 1605, 2930, 3021, 3248, 3360, 3387; LRMS (ESI) m/z 148.1 [M+H]+;
HRMS (ESI) calculated for C8H10N3 [M+H]+ 148.0875, found 148.0872; m.p. = 269-270
◦C.177,178
296 10.2. Chapter 3
Synthesis of 15N 2-Aminomethylbenzimidazole 11
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11
o-Phenylenediamine (1.08 g, 10.00 mmol) and glycine (0.90 g, 12.00 mmol) were refluxed in 37
% HCl (4 mL) for 5 days until NMR indicated full conversion. After cooling, the resulting
solid was isolated by filtration and combined with the solid obtained by freeze drying the
reaction mixture. Product formation was not observed under experimental conditions.177,178
Synthesis of Palmitoyl Chloride 18
Cl
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To palmitic acid (0.05 g, 0.19 mmol) in dry DCM (8 mL) under argon was added oxalyl chloride
(0.03 mL, 0.38 mmol) and the mixture refluxed for 2 hours. Solvent was removed in vacuo to
give yellow oil (0.03 g, 65 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0 Hz, 3H, H17), 1.26 (br,
24H, HAlkyl), 1.70 (quint, J = 24.0 Hz, 2H, H4), 2.87 (q, J = 12.0 Hz, 2H, H3); 13C (100 MHz;
CDCl3) δ 14.3 (C17), 22.9 (CAlkyl), 25.2 (CAlkyl), 28.7 (CAlkyl), 29.3 (CAlkyl), 29.5 (CAlkyl),
29.6 (CAlkyl), 29.7 (CAlkyl), 29.8 (CAlkyl), 29.9 (CAlkyl), 29.9 (CAlkyl), 32.1 (C4), 48.5 (C3),
173.8 C2); IR (neat) vmax/cm–1 1473, 1800, 2861, 2931.179
Synthesis of Palmitic Anhydride 17
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To NBu4Br (0.01 g, 0.01 mmol) in toluene (0.1 mL) at -10 ◦C was added 20 % NaOH solution
(0.6 mL) followed by palmitoyl chloride (0.03 g, 0.12 mmol) in toluene (0.3 mL) over 20 minutes.
After stirring for 3.5 hours the reaction was allowed to warm to room temperature, washed
with brine, the organic layer dried over MgSO4 and solvent removed in vacuo to yield white
powder 17 (0.02 g, 35 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0 Hz, 6H, H1), 1.25 (br,
48H, HAlkyl), 1.61-1.71 (m, 4H, H14), 2.45 (t, J = 8.0 Hz, 4H, H15); 13C (100 MHz; CDCl3)
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δ 14.3 (C1), 22.0 (C2), 22.9 (C3), 29.3-29.9 (CAlkyl), 32.1 (C14), 34.9 (C15), 169.8 C16); IR
(neat) vmax/cm–1 1745, 1803, 2961, 3011; m.p. 60-62 ◦C.180,181
Synthesis of GPC-CdCl2 Complex 110
To sn-glycero-3-phosphocholine (0.50 g, 1.67 mmol) in MeOH (3.5 mL) at 0 ◦C was added
CdCl2 (0.44 g, 2.40 mmol) in cold H2O (1.5 mL) and stirred for 4 hours. The resulting
precipitate was collected by fitration and lyophilised to dryness yielding a white powder
carried forward without further purification (0.71 g, 88 %).183,184
Synthesis of DPPC - Method 1
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To sn-glycero-3-phosphocholine (0.003 g, 0.01 mmol) in pyridine (0.5 mL) was added palmitic
anhydride 17 (0.018 g, 0.03 mmol) and stirred for 7 days. The reaction mixture was poured
into crushed ice (0.5 g), extracted with EtOAc three times, dried over MgSO4 and solvent
removed in vacuo. Product formation was not observed.182
Synthesis of DPPC - Method 2
To sn-glycero-3-phosphocholine (0.003 g, 0.01 mmol) in dry DCM (0.1 mL) under argon was
added palmitic anhydride 17 (0.002 g, 0.01 mmol) and DMAP (0.001 g, 0.01 mmol). Stirring
continued for 72 hours with exclusion of light, prior to solvent removal in vacuo. Product
formation was not observed.182
Synthesis of DPPC - Method 3
To palmitic acid (0.10 g, 0.39 mmol) in dry DCM (3 mL) under argon was added GCP-CdCl2
110 (0.05 g, 0.10 mmol), DMAP (0.03 g, 0.20 mmol) and DIC (0.105 mL, 0.68 mmol) in dry
DCM (1 mL) and stirred for 72 hours. Solid was removed by filtration and DOWEX added
to dislodge Cd. After stirring for 0.5 hours the mixture was filtered, and solvent removed
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in vacuo to yield a white powder. DPPC was purified by trituration with ethyl acetate,
acetone and water (0.05 g, 65%): 1H (400 MHz; CDCl3) δ 0.89 (t, J = 6.6 Hz, 6H, H24,40),
1.27 (s, 48H, HAlkyl), 1.54-1.67 (m, 4H, H11,27), 2.25-2.37 (m, 4H, H10,26), 3.31 (s, 9H, H1,2,3),
3.62–3.70 (m, 2H, H4), 4.00-4.06 (m, 2H, H6), 4.24–4.36 (m, 2H, H5), 4.41-4.48 (m, 2H, H8),
5.25 (m, 1H, H7); 13C (100 MHz; CDCl3) delta 13.9 (C24,40), 22.8 (C23,39), 25.1 (CAlkyl), 29.2
(CAlkyl), 29.5 (CAlkyl), 29.8 (CAlkyl), 32.2 (CAlkyl), 34.2 (CAlkyl), 35.4 (CAlkyl), 54.2 (C1,2,3),
60.1 (C4), 63.7 (C8), 65.1 (C5), 67.7 (C6), 70.3 (C7), 173.9 (C9,25); IR (neat) vmax/cm–1 1737,
2897, 2951, 2981; LRMS (ESI) m/z 734.6 [M+H]+; HRMS (ESI) calculated for C40H81NO8P
[M+H]+ 734.5700, found 734.5701.183,184
Synthesis of DPPC - Method 4
To palmitic acid (0.13 g, 0.51 mmol) in dry DCM (3 mL) under argon was added GCP-CdCl2
110 (0.09 g, 0.20 mmol), DMAP (0.05 g, 0.40 mmol) and DIC (0.210 mL, 1.36 mmol) in dry
DCM (1 mL) and stirred for 72 hours. Solid was removed by filtration and DOWEX added
to dislodge Cd. After stirring for 0.5 hours the mixture was filtered, and solvent removed in
vacuo to yield a white powder. DPPC was purified by trituration with ethyl acetate, acetone
and water (0.02 g, 11 %): 1H (400 MHz; CDCl3) δ 0.89 (t, J = 6.6 Hz, 6H, H24,40), 1.27
(s, 48H, HAlkyl), 1.54-1.67 (m, 4H, H11,27), 2.25-2.37 (m, 4H, H10,26), 3.31 (s, 9H, H1,2,3),
3.62–3.70 (m, 2H, H4), 4.00-4.06 (m, 2H, H6), 4.24–4.36 (m, 2H, H5), 4.41-4.48 (m, 2H, H8),
5.25 (m, 1H, H7); 13C (100 MHz; CDCl3) delta 13.9 (C24,40), 22.8 (C23,39), 25.1 (CAlkyl), 29.2
(CAlkyl), 29.5 (CAlkyl), 29.8 (CAlkyl), 32.2 (CAlkyl), 34.2 (CAlkyl), 35.4 (CAlkyl), 54.2 (C1,2,3),
60.1 (C4), 63.7 (C8), 65.1 (C5), 67.7 (C6), 70.3 (C7), 173.9 (C9,25); IR (neat) vmax/cm–1 1737,
2897, 2951, 2981; LRMS (ESI) m/z 734.6 [M+H]+; HRMS (ESI) calculated for C40H81NO8P
[M+H]+ 734.5700, found 734.5701.183,184
Synthesis of 13C DPPC
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To 13C palmitic acid (0.10 g, 0.39 mmol) in dry DCM (3 mL) under argon was added GCP-
CdCl2 110 (0.05 g, 0.10 mmol), DMAP (0.03 g, 0.20 mmol) and DIC (0.105 mL, 0.68 mmol)
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in dry DCM (1 mL) and stirred for 72 hours. Solid was removed by filtration and DOWEX
added to dislodge Cd. After stirring for 0.5 hour the mixture was filtered, and solvent
removed in vacuo to yield a white powder. 13C DPPC was purified by trituration with ethyl
acetate, acetone and water (0.03 g, 41 %): 1H (400 MHz; CDCl3) δ 0.89 (t, J = 6.6 Hz, 6H,
H24,40), 1.27 (s, 48H, HAlkyl), 1.54-1.67 (m, 4H, H11,27), 2.25-2.37 (m, 4H, H10,26), 3.31 (s,
9H, H1,2,3), 3.62–3.70 (m, 2H, H4), 4.00-4.06 (m, 2H, H6), 4.24–4.36 (m, 2H, H5), 4.41-4.48
(m, 2H, H8), 5.25 (m, 1H, H7); 13C (100 MHz; CDCl3) delta 13.9 (C24,40), 22.8 (C23,39), 25.1
(CAlkyl), 29.2 (CAlkyl), 29.5 (CAlkyl), 29.8 (CAlkyl), 32.2 (CAlkyl), 34.2 (CAlkyl), 35.4 (CAlkyl),
54.2 (C1,2,3), 60.1 (C4), 63.7 (C8), 65.1 (C5), 67.7 (C6), 70.3 (C7), 173.9 (C9,25); IR (neat)
vmax/cm–1 1739, 2897, 2951, 2981; LRMS (ESI) m/z 736.6 [M+H]+; HRMS (ESI) calculated
for C4813C2H81NO8P [M+H]+ 736.5767, found 734.5750.183,184
Synthesis of DOPC
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To oleic acid (0.11 g, 0.39 mmol) in dry DCM (3 mL) under argon was added GCP-CdCl2
110 (0.05 g, 0.10 mmol), DMAP (0.03 g, 0.20 mmol) and DIC (0.105 mL, 0.68 mmol) in dry
DCM (1 mL) and stirred for 72 hours. Solid was removed by filtration and DOWEX added
to dislodge Cd. After stirring for 0.5 hours the mixture was filtered, and solvent removed in
vacuo to yield a white powder. DOPC was purified by trituration with ethyl acetate, acetone
and water (0.02 g, 57 %): 1H (400 MHz; CDCl3) δ 0.87 (t, J = 7.0 Hz, 6H, H26,44), 1.07-1.31
(m, 16H, HAlkyl), 1.57-1.53 (m, 4H, H11,29), 1.93-2.01 (m, 8H, H16,19,34,37), 2.18-2.27 (m, 4H,
H10,28), 3.32 (s, 9H, H1,2,3), 3.59–3.66 (m, 2H, H4), 4.01-4.07 (m, 2H, H6), 4.30–4.39 (m, 2H,
H5), 4.40-4.48 (m, 2H, H8), 5.26 (m, 1H, H7), 5.30-5.40 (m, 4H, H17,18,35,36); 13C (100 MHz;
CDCl3) delta 14.7 (C26,44), 23.3 (C25,43), 32.8 (C24,42), 25.8 (C11,29), 28.1 (C16,19,34,37),30.0-
30.4 (CAlkyl), 34.6 (C10,28), 54.6 (C1,2,3), 60.2 (C4), 63.5 (C8), 67.0 (C6), 71.4 (C7), 130.2
(C17,18,35,36, 175.2 (C9,27); IR (neat) vmax/cm–1 1738, 2850, 2920; LRMS (ESI) m/z 786.6
[M+H]+; HRMS (ESI) calculated for C44H85NO8P [M+H]+ 786.6013, found 786.6025.183,184
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Synthesis of 13C DOPC
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To 13C oleic acid (0.11 g, 0.39 mmol) in dry DCM (3 mL) under argon was added GCP-CdCl2
110 (0.05 g, 0.10 mmol), DMAP (0.03 g, 0.20 mmol) and DIC (0.105 mL, 0.68 mmol) in dry
DCM (1 mL) and stirred for 72 hours. Solid was removed by filtration and DOWEX added to
dislodge Cd. After stirring for 0.5 hours the mixture was filtered, and solvent removed in vacuo
to yield a white powder. 13C DOPC was identified by MS, however low abundance prevented
successful purification and characterisation: LRMS (ESI) m/z 788.6 [M+H]+; HRMS (ESI)
calculated for C4213C2H85NO8P [M+H]+ 788.6080, found 788.6097.183,184
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sn-glycero-3-phosphocholine (0.01 g, 0.05 mmol) and dibutyltin oxide (0.01 g, 0.05 mmol) were
suspended in anhydrous IPA (1 mL) and refluxed under argon for 1 hour. After cooling,
NEt3 (0.014 mL, 0.10 mmol) and palmitoyl chloride 18 (0.029 mL, 0.10 mmol) were added.
Following stirring for 1 further hour H2O (2 mL) was added to the reaction and washed with
hexane (5 mL) three times. Alcohol was removed in vacuo and water by lyophilisation to yield
a off-white solid. PPC was purified by trituration with acetone, ethyl acetate and hexane
although excess tin remained (0.06 g, 97 %): 1H (400 MHz; CDCl3) δ 0.88 (t, 3H, J = 8.0 Hz,
H24), 1.25 (s, 24H, HAlkyl), 1.55-1.57 (m, 2H, H8), 2.30 (t, 2H, J = 8.0 Hz, H10), 3.29 (s, 9H,
H1,2,3), 3.71-3.76 (m, 2H, H4), 3.79-3.85 (m, 2H, H6), 3.90-3.99 (m, 1H, H7), 4.19-4.23 (m,
2H, H5), 4.32-4.40 (m, 2H, H8); LRMS (ESI) m/z 496.3 [M+H]+; HRMS (ESI) calculated for
C24H51NO7P [M+H]+ 496.3403, found 496.3396.185,186
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Synthesis of Oleoyl Chloride 20
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To oleic acid (0.25 g, 0.89 mmol) in dry DCM (40 mL) under argon was added oxalyl chloride
(0.585 mL, 1.70 mmol) and the mixture refluxed for 2 hours. Solvent was removed in vacuo to
yield oleoyl chloride 20 as a yellow oil (0.24 g, 89 %): 1H (400 MHz; CDCl3) δ 0.88 (t, 3H, J
= 8.0 Hz, H19), 1.23-1.28 (m, 20H, HAlkyl), 1.70 (quin, 2H, J = 12.0 Hz, H4), 2.18-2.21 (m,
4H, H9,12), 2.88 (t, 2H, J = 8.0 Hz, H3), 5.29-5.39 (m, 2H, H10,11); 13C (100 MHz; CDCl3) δ
14.1 (C19), 22.8 (C18), 25.0 (CAlkyl), 28.7 (CAlkyl), 29.3 (CAlkyl), 29.5 (CAlkyl), 29.6 (CAlkyl),
29.7 (CAlkyl), 29.8 (CAlkyl), 29.9 (CAlkyl), 31.1 (CAlkyl), 46.5 (C3), 130.5 (C10), 130.7 (C11),
172.4 (C2); IR (neat) vmax/cm–1 1801, 2845, 2926, 3002.244,245
Synthesis of POPC - Method 1
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To PPC (0.06 g, 0.12 mmol) in dry DCM (1 mL) was added oleic acid (0.07 g, 0.24 mmol),
DIC (0.036 mL, 0.24 mmol) and DMAP (0.02 g, 0.14 mmol). The mixture was stirred with
exclusion of light for 48 hours. DCM was removed in vacuo and the resulting white solid
triturated with water, acetone and ethyl acetate. POPC formation was unsuccessful due to
excess tin remaining in PPC.185,186
Synthesis of POPC - Method 2
sn-glycero-3-phosphocholine (0.10 g, 0.39 mmol) and dibutyltin oxide (0.1 g, 0.39 mmol) were
suspended in IPA (4 mL) and refluxed for 1 hour. After cooling the reaction mixture was
treated with NEt3 (0.098 mL, 0.70 mmol) and palmitoyl chloride 18 (0.19 g, 0.70 mmol), and
stirred for 0.5 hour. Oleoyl chloride 20 (0.21 g, 0.70 mmol) and NEt3 (0.098 mL, 0.70 mmol)
were added and stirring continued for 48 hours. Solvent was removed in vacuo, and the
resulting solid was triturated with water, acetone, ethyl acetate and hexane. POPC formation
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was successful, however excess tin prevented complete characterisation (0.15 g, 49 %): 1H (400
MHz; CDCl3) δ 0.90 (t, 6H, J = 8.0 Hz, H24,41), 1.24-1.30 (m, 44H, HAlkyl), 1.58-1.60 (m, 4H,
H11,26), 2.29-2.34 (m, 4H, H31,34), 3.37-3.40 (m, 4H, H10,25), 3.86 (s, 9H, H1,2,3), 3.92-3.98 (m,
2H, H4), 4.11-4.16 (m, 2H, H6), 4.24–4.36 (m, 2H, H5), 4.35-4.41 (m, 2H, H8), 5.37 (m, 1H,
H7), 5.38-5.43 (m, 2H, H32,33); LRMS (ESI) m/z 760.6 [M+H]+; HRMS (ESI) calculated for
C42H83NO8P [M+H]+ 760.5856, found 760.5851.183,185,186
Synthesis of Ethyl Bromoacetate 22 - Method 1
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Bromoacetic acid (0.25 g, 1.80 mmol) was suspended in EtOH (5 mL) and H2SO4 (0.1 mL),
and refluxed for 12 hours. The reaction was diluted with ether, washed with water three times,
dried over MgSO4 and solvent removed in vacuo. Product formation was not observed.189
Synthesis of Ethyl Bromoacetate 22 - Method 2
Bromoacetic acid (0.25 g, 1.80 mmol) and oxalyl chloride (0.282 mL, 2.70 mmol) in dry DCM
(2 mL) was stirred at room temperature under argon for 30 minutes. Dry EtOH (1 mL) was
added and stirring continued for a further 30 minutes. Solvent was removed in vacuo to give
yellow oil 22 along with oxalic acid ethyl ester which proved problematic to separate.189
Synthesis of Ethyl Bromoacetate 22 - Method 3
Bromoacetic acid (0.25 g, 1.80 mmol) and oxalyl chloride (0.282 mL, 2.70 mmol) in dry DCM
(2 mL) was stirred at room temperature under argon for 1 hour. Solvent was removed in
vacuo, dry EtOH (1 mL) added, and stirring continued for 30 minutes. Solvent was removed
in vacuo to yield ethyl bromoacetate 22 as a yellow oil (0.29 g, 98 %): 1H (400 MHz; CDCl3)
δ 1.29 (t, J = 7.1 Hz, 3H, H4), 3.84 (s, 2H, H1), 4.25 (q, J = 7.1 Hz, 2H, H3); 13C (100 MHz;
CDCl3) δ 14.1 (C4), 25.0 (C3), 62.3 (C1), 168.6 (C2); IR (neat) vmax/cm–1 1735, 2980; LRMS
(ASAP) m/z 167.0 [M+H]+; HRMS (ASAP) calculated for C4H8BrO2 [M+H]+ 166.9708,
found 166.9716.189
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Synthesis of 13C Ethyl Bromoacetate 22
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13C bromoacetic acid (0.25 g, 1.80 mmol) and oxalyl chloride (0.282 mL, 2.70 mmol) in dry
DCM (2 mL) was stirred at room temperature under argon for 1 hour. Solvent was removed in
vacuo, dry EtOH (1 mL) added, and stirring continued for 30 minutes. Solvent was removed in
vacuo to yield 13C ethyl bromoacetate 22 as a yellow oil (0.20 g, 94 %): 1H (400 MHz; CDCl3)
δ 1.29 (t, J = 7.1 Hz, 3H, H4), 3.84 (s, 2H, H1), 4.25 (q, J = 7.1 Hz, 2H, H3); 13C (100 MHz;
CDCl3) δ 14.1 (C4), 25.0 (C3), 62.3 (C1), 168.6 (C2); IR (neat) vmax/cm–1 1743, 2981; LRMS
(ASAP) m/z 168.0 [M+H]+; HRMS (ASAP) calculated for C313CH8BrO2 [M+H]+ 167.9741,
found 167.9731.189
Synthesis of N,N’-Bis(p-toluenesulfonyl)hydrazine 24
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p-Toluenesulfonyl hydrazide (0.93 g, 5.00 mmol) and p-toluenesulfonyl chloride (1.43 g, 7.50 mmol)
were combined under argon in dry DCM (5 mL). Pyridine (0.60 mL, 7.5 mmol) was added
dropwise over 1 minute, and the solution stirred for 1.5 hours. Ether (20 mL) and H2O (10 mL)
were added, and the solution stirred at 0 ◦C for a further 15 minutes. Solid was collected by
Büchner filtration and washed with cold ether. Recrystallisation from MeOH yielded catalyst
24 (1.49 g, 88 %): 1H (400 MHz; DMSO-d6) δ 2.39 (s, 6H, H7), 7.37–7.40 (m, 4H, H3,5),
7.62–7.70 (m, 4H, H2,6), 9.59 (s, 2H, NH); 13C (100 MHz; DMSO-d6) δ 21.8 (C7), 127.8 (C3,5),
130.0 (C2,6), 136.1 (C4), 143.7 (C1); IR (neat) vmax/cm–1 1590, 3202, 3235; LRMS (ASAP)
m/z 341.1 [M+H]+; HRMS (ASAP) calculated for C14H17N2O4S2 [M+H]+ 341.0629, found
341.0616; m.p. = 225-226 ◦C.190
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Synthesis of Diazoacetic Acid Ethyl Ester 25
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Ethyl bromoacetate 22 (0.11 g, 1.00 mmol) was added to N,N’-Bis(p-toluenesulfonyl)hydrazine
24 (0.68 g, 2.00 mmol) at 0 ◦C in THF (5 mL). DBU (0.75 mL, 5.00 mmol) was added dropwise
over 5 minutes, and the mixture stirred for a further 0.5 hours. Ether was added, washed
with saturated NaHCO3 solution, dried over MgSO4, and solvent removed in vacuo. Product
formation proved unsuccessful.187,188
Synthesis of 1-bromo-7-hexadecyne 27
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1-decyne (0.02 g, 0.14 mmol) in dry THF (1 mL) under argon was cooled to -78 ◦C for dropwise
addition of n-BuLi (0.06 mL, 0.14 mmol). After 1 hour 1,6-dibromohexane (0.18 g, 0.73 mmol)
was added and the reaction refluxed for 44 hour. THF was removed in vacuo to yield a
yellow oil which was redissolved in hexane, washed with water and brine, dried over MgSO4
and solvent removed in vacuo. Distillation purified 1-bromo-7-hexadecyne 27 as a yellow oil
(0.04 g, 85 %): 1H (400 MHz; CDCl3) δ 0.87 (t, J = 8.0 Hz, 3H, H16), 1.27-1.48 (m, 18H,
HAlkyl), 1.86 (quin, 2H, J = 16 Hz, H2), 2.14 (m, 4H, H6,9), 3.40 (t, J = 8.0 Hz, 2H, H1);
13C (100 MHz; CDCl3) δ 14.1 (C16), 18.8 (C15), 19.0 (C14), 23.0 (CAlkyl), 28.2 (CAlkyl), 28.3
(CAlkyl), 29.1 (CAlkyl), 29.3 (CAlkyl), 29.5-29.7 (CAlkyl), 32.1 (CAlkyl), 33.3 (C2), 33.8 (C1),
79.9 (C8), 80.2 (C7); IR (neat) vmax/cm–1 1458, 2160, 2854, 2925; LRMS (ASAP) m/z 299.1
[M+H]+; HRMS (ASAP) calculated for C16H28Br [M+H]+ 299.1374, found 299.1355.328
Synthesis of 1-pinacolborane-7-hexadecyne 29
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A flask containing CuI (0.002 g, 0.01 mmol), KOtBu (0.012 g, 0.13 mmol), NBu4I (0.024 g,
0.07 mmol) and bis(pinacolato)diboron (0.025 g, 0.10 mmol) was evacuated and filled with
argon three times. Dry THF (1 mL) and 1-bromo-7-hexadecyne 27 (0.02 g, 0.07 mmol) were
added and stirred. After 24 hours the reaction mixture was diluted with EtOAc, washed with
H2Oand brine, dried over MgSO4, and solvent removed in vacuo. Further purification of crude
oil 29 was not conducted (0.02 g, 82 %): 1H (400 MHz; CDCl3) δ 0.87 (t, J = 8.0 Hz, 3H,
H22), 1.06 (s, 12H, H3,4,5,6), 1.27-1.48 (m, 32H, HAlkyl), 2.13 (m, 4H, H13,14); 11B (400 MHz;
CDCl3) δ 22.4; IR (neat) vmax/cm–1 1462, 1632, 2858, 2922.193
Synthesis of Octadec-9-ynoic Acid Ethyl Ester 28 - Method 1
O 3
2
O
1
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
28
Dried zinc dust (0.005 g, 0.08 mmol) and ethyl bromoacetate 22 (0.011 g, 0.07 mmol) in toluene
(0.8 mL) and ether (0.2 mL) was stirred with gentle warming until the start of a reaction.
After 15 minutes 1-bromo-7-hexadecyne 27 (0.020 g, 0.07 mmol) in toluene (0.4 mL) and ether
(0.1 mL) was added slowly, and the reaction brought to reflux. After 30 minutes the reaction
mixture was filtered and washed with H2O three times to remove zinc byproducts. Product
formation was not observed.329,330
Synthesis of Octadec-9-ynoic Acid Ethyl Ester 28 - Method 2
Zinc dust (0.005 g, 0.08 mmol) was stirred with 10 % HCl solution (0.25 mL) for 2 minutes,
filtered and washed with H2O, EtOH and ether. To activated zinc in toluene (0.8 mL) and
ether (0.2 mL) under argon was added ethyl bromoacetate 22 (0.011 g, 0.07 mmol) dropwise
and refluxed for 1 hour. In a second flask, 1-bromo-7-hexadecyne 27 (0.020 g, 0.07 mmol) and
n−Bu4NI (0.049 g, 0.13 mmol) were stirred in toluene (0.4 mL) and ether (0.1 mL) for 1 hour.
The contents of the two flasks were combined and stirred for 12 hours before solvent removal
in vacuo. The resulting oil was redissolved in toluene, washed with H2O three times, dried
over MgSO4 and solvent removed in vacuo. Product formation was not observed.329,330
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Synthesis of Octadec-9-ynoic Acid Ethyl Ester 28 - Method 3
Zinc dust (0.005 g, 0.08 mmol) was stirred with 10 % HCl solution (0.25 mL) for 2 minutes,
filtered and washed with H2O, EtOH and ether. To activated zinc in toluene (1.2 mL) and
ether (0.3 mL) was added 1-bromo-7-hexadecyne 27 (0.020 g, 0.07 mmol) and brought to reflux.
After 1 hour the reaction was cooled, ethyl bromoacetate 22 (0.011 g, 0.07 mmol) was added
and stirring continued for 12 hour before solvent removal in vacuo. The resulting oil was
redissolved in toluene, washed with H2O three times, dried over MgSO4 and solvent removed
in vacuo. Product formation was not observed.329,330
Synthesis of Octadec-9-ynoic Acid Ethyl Ester 28 - Method 4
1-bromo-7-hexadecyne 27 (0.020 g, 0.07 mmol) was cooled to -78 ◦C in dry THF (0.7 mL)
under argon. 1.6m n-BuLi in hexanes (0.825 mL, 0.13 mmol) was added, and the mixture
stirred for 0.5 hour. 99-Borabicyclo[3.3.1]nonane dimer (0.008 g, 0.04 mmol) was added and
the reaction allowed to warm to room temperature with stirring. After 12 hours the contents
of the flask were added to a second flask containing Pd(OAc)2 (0.001 g, 0.01 mmol), PCy3
(0.001 g, 0.01 mmol), K3PO4 ·H2O (0.015 g, 0.07 mmol) and ethyl bromoacetate 22 (0.008 g,
0.05 mmol) which hasd been purged with argon for 15 minutes. Stirring continued for 24 hours
before dilution with ether, filtration through celite, washing with H2O three times, drying
over MgSO4 and solvent remove in vacuo. Product formation was not observed.192,193
Synthesis of Octadec-9-ynoic Acid Ethyl Ester 28 - Method 5
A flask containing Pd(OAc)2 (0.001 g, 0.01 mmol), PCy3 (0.001 g, 0.01 mmol), K3PO4 (0.014 g,
0.07 mmol) and H2O (0.001 g, 0.07 mmol) was purged with argon for 15 minutes. To this was
added crude 1-pinacolborane-7-hexadecyne 29 (0.024 g, 0.07 mmol), ethyl bromoacetate 22
(0.008 g, 0.05 mmol), and dry THF (1.5 mL). Stirring continued for 24 hours before dilution
of the reaction mixture with ether, washing with H2O three times, filtration through a silica
plug, drying over MgSO4 and solvent removal in vacuo. Synthesis proved unsuccessful.193
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Synthesis of Octadec-9-ynoic Acid Ethyl Ester 28 - Method 6
A flask containing Pd(OAc)2 (0.001 g, 0.01 mmol), PCy3 (0.001 g, 0.01 mmol), K3PO4 (0.014 g,
0.07 mmol) was purged with argon for 15 minutes. To this was added crude 1-pinacolborane-
7-hexadecyne 29 (0.024 g, 0.07 mmol), ethyl bromoacetate 22 (0.008 g, 0.05 mmol), and dry
THF (1.5 mL). Stirring continued for 24 hours before dilution of the reaction mixture with
ether, washing with H2O three times, filtration through a silica plug, drying over MgSO4 and
solvent removal in vacuo. Synthesis proved unsuccessful.193
Synthesis of Octadec-9-ynoic Acid Ethyl Ester 28 - Method 7
Ethyl bromoacetate 22 (0.010 g, 0.06 mmol), crude 1-pinacolborane-7-hexadecyne 29 (0.024 g,
0.07 mmol), Pd(OAc)2 (0.001 g, 0.01 mmol), and PPh3 (0.008 g, 0.03 mmol) in dry THF (1 mL)
was deoxygenated. Under argon, KOtBu (0.014 g, 0.12 mmol) was added, and the reaction
brought to reflux. After 36 hours the reaction was diluted with ether, washed with H2O three
times, brine once, dried over MgSO4 and solvent removed in vacuo. Purification by silica gel
chromatography with hexane:DCM (8:2) eluent, washing with ethanolamine, and by vacuum
distillation yielded yellow oil 28 (0.007 g, 32 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0 Hz,
3H, H20), 1.20-1.28 (m, 20H, HAlkyl), 2.04-2.15 (m, 7H, H1,4,5), 4.04 (t, J = 4.0 Hz, 2H, H2);
LRMS (EI) m/z 308.3 [M]+.331
Synthesis of Oleic Acid Ethyl Ester 30 - Method 1
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Octadec-9-ynoic Acid Ethyl Ester 28 (0.007 g, 0.01 mmol) and Lindlar’s catalyst (0.001 g)
were prepared in hexane:EtOH (1:1) (2 mL). The reaction mixture was degassed using freeze
thaw methodology three times, and left under an atmosphere of H2 for 36 hours. Product
formation proved unsuccessful.195,196
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Synthesis of Oleic Acid Ethyl Ester 30 - Method 2
Octadec-9-ynoic Acid Ethyl Ester (0.007 g, 0.01 mmol) and Lindlar’s catalyst (0.001 g) were
prepared in EtOAc (2 mL). The reaction mixture was degassed using freeze thaw methodology
three times and left under an atmosphere of H2 for 36 hours. Product formation proved
unsuccessful.195,196
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Circular Dichroism of Acylated Melittin
CD analysis was performed on a JASCO J-810 Spectropolarimeter at 21 ◦C using a 2 mm quartz
cuvette. Background scattering was determined through analysis of a blank sample containing
(0.5 mL) buffer solution (90 mm NaCl, 10 mm NaHCO3 in H2O at pH 7.41). Peptide (20 µL)
of approximate concentration 1× 10−6 m was added, and the spectrum collected over a range
of 180 nm to 300 nm at a continuous scanning speed of 50 nm/min for 8 accumulations. Each
peptide was analysed in triplicate in order to determine instrument error. Data was processed
with in-built JASCO software, Spectra Manager version 1.53.05
Acylated Melittin Emission
Emission spectroscopy was carried out on a PerkinElmer LS 55 Fluorescence Spectrometer
using a tryptophan excitation wavelength of 280 nm and a detection range of 300 nm to 450 nm.
Slit widths were selected as 10 nm for excitation and 50 nm for emission, and the scan speed
was 100 nm min−1. H2O (1 mL) was added to a quartz cuvette with 1 mL insert and analysed
as a blank control. Peptide stock solution was then added in sequential amounts 5 µL, 10µL,
15 µL and 20 µL, and spectra recorded. Peptide samples were analysed in triplicate in order
to account for instrument error.
CMC Determination for Acylated Melittin
Rhodamine 6G stock solution (250 µm) prepared in H2O was diluted 330 fold to 0.08 µm for
use. Rhodamine 6G (45 µL) was added to a 40 µL ultra-micro quartz cuvette, excited with
a wavelength of 480 nm and the emission recorded between 500 nm to 600 nm. Analysis was
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repeated upon sequential addition of peptide stock solution (approximately 1 mg mL−1) over
the concentration range 1× 10−6 m to 1× 10−4 m. Absorbance at 550 nm was corrected for
dilution.
Antimicrobial Activity of Acylated Melittin
Bacterial cultures were prepared by streaking strains of Staphylococcus aureus (Oxford)
and Escherichia coli (W3110) onto agar plates with inoculation loop. Following overnight
incubation at 37 ◦C a colony was selected, placed into iso-sensitest broth (5 mL) and shaken
at 37 ◦C overnight. Into iso-sensitest broth (1 mL) was added overnight culture (50 µL) and
growth continued at 37 ◦C with shaking until exhibiting absorbance of 0.07 at 650 nm relative
to a control. Inoculum was then diluted ten-fold with iso-sensitest broth prior to use. Into the
96 well plate was placed five controls of each of iso-sensitest broth (100 µL) and iso-sensitest
broth (50µL):inoculum (50 µL). Peptide stock solutions (32 µm) were serially diluted to cover
the concentration range 32 µm to 0.5 µm. Inoculum (50 µL) and peptide solution of relevant
concentration (50µL) were added and incubated at 37 ◦C with shaking for 16 hours. Optical
density was measured on Synergy H4 Plate Reader (BioTek, UK) to approximate bacterial
growth.216
Amyloid Incubation
Amyloid stock solution in HFIP (approximately 1 mg mL−1) was combined with POPC:SLPS
(4:1) extruded liposomes in 1:10 peptide:lipid molar ratio. Samples were diluted to 100 µL
with buffer (90 mm NaCl, 10 mm NaHCO3 in H2O at pH 7.41), and incubated at 37 ◦C for
72 hours.
MALDI Mass Spectrometry
MALDI MS was carried out on an Autoflex II Tof/ToF (Bruker Daltonics Ltd., UK) equipped
with 337 nm nitrogen laser used in both linear and reflectron mode. α-cyano-4-hydroxy-
cinnamic acid matrix (9 µL) and vortexed amyloid incubation sample (1 µL) were mixed and
applied (1 µL) to a MALDI target for analysis.
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Thioflavin T Assay
Thioflavin T stock solution (0.8 µg mL−1) was prepared in buffer (150 mm NaCl, 10 mm
NaHCO3 in H2O at pH 7.4) and stored with exclusion of light. Ten-fold diluted Thioflavin
T stock (150 µL) was added to amyloid incubation sample (50µL) for analysis. Emission at
482 nm was measured on a Synergy H4 Plate Reader (BioTek, UK) following excitation at
437 nm.
Electron Microscopy
Electron microscopy was carried out on a Hitachi H7600 TEM. Amyloid incubation sample
(3 µL) was added to a TEM grid and excess liquid removed. Staining solution containing 2 %
uranyl acetate in water (3 µL) was also added and allowed to completely dry. Samples were
analysed at high and low magnification.
Low Salt Amyloid Incubation
Amyloid stock solution in HFIP (approximately 1 mg mL−1) was combined with POPC:SLPS
(4:1) extruded liposomes in 1:10 peptide:lipid molar ratio. Samples were diluted to 100 µL
with buffer (10 mm NaHCO3 in H2O at pH 7.41), and incubated at 37 ◦C for 72 hours.
Low Temperature Amyloid Incubation
Amyloid stock solution in HFIP (approximately 1 mg mL−1) was combined with POPC:SLPS
(4:1) extruded liposomes in 1:10 peptide:lipid molar ratio. Samples were diluted to 100 µL
with buffer (90 mm NaCl, 10 mm NaHCO3 in H2O at pH 7.41), and incubated at 4 ◦C for 72
hours.
Sonicated Amyloid Incubation
Amyloid stock solution in HFIP (approximately 1 mg mL−1) was combined with POPC:SLPS
(4:1) extruded liposomes in 1:10 peptide:lipid molar ratio. Samples were diluted to 100 µL
with buffer (90 mm NaCl, 10 mm NaHCO3 in H2O at pH 7.41), and incubated at 37 ◦C for
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72 hours. Vortexed samples were sonicated at 40 ◦C within a bath for 20 minutes prior to
MALDI analysis.
Amyloid Depolymerisation with HFIP
Amyloid incubation samples were centrifuged at 45000 rpm for 45 minutes, aqueous liquid
decanted, and replaced with HFIP (100 µL). Samples were incubated for 12 hours at 37 ◦C
prior to MALDI analysis.
Amyloid Depolymerisation with Formic Acid
Amyloid incubation samples (100 µL) were diluted with formic acid (900 µL) and acidic pH
confirmed. Samples were incubated at 37 ◦C for 12 hours (β2-Microglobulin) or 3 hours
(Amyloid-β and Amylin) prior to MALDI analysis.
β2-Microglobulin Digestion
Experimental protocol varied during optimisation as described in Table 10.4. β2-Microglobulin
stock solution (10µL at 1 mg mL−1) was diluted 1:1 with relevant NH4CO3 buffer (10µL).
When employing IAA, DTT (3 µL at 15 mg mL−1) was added and incubated at 65 ◦C for 10
minutes. Upon cooling, IAA (5 µL at 100 mM) was added and further incubated at room
temperature with light exclusion for 30 minutes. Following on, or in the absence of IAA, DTT
(2 µL at 15 mg mL−1) and enzyme (1 µL at 0.2 mg mL−1 for 1:40 ratio) were added. Incubation
at 37 ◦C continued for the relevant time period defined in Table 10.4.
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Enzyme Enzyme:Protein Time NH4HCO3 Buffer DTT IAA
Trypsin 1:40 24 hours 25 mM Yes No
Pepsin 1:40 24 hours 25 mM Yes No
Trypsin:Lys C 1:40 24 hours 25 mM Yes No
Trypsin:Lys C 1:40 24 hours 25 mM Yes Yes
Trypsin:Lys C 1:40 3 hours 50 mM No No
Trypsin:Lys C 1:40 5 hours 50 mM No No
Trypsin:Lys C 1:40 3 hours 50 mM Yes No
Trypsin:Lys C 1:40 3 hours 50 mM Yes Yes
Trypsin:Lys C 1:40 3 hours 100 mM No No
Trypsin:Lys C 1:20 3 hours 50 mM Yes No
Table 10.4 Enzymatic digestion conditions for β2-microglobulin, and resulting sequence
coverage
Optimised Digestion
Amyloid stock solution (10 µL at 1 mg mL−1) was diluted 1:1 with NH4CO3 buffer (10µL at
50 mm). DTT (2 µL at 15 mg mL−1) and trypsin:lys C (1 µL at 0.2 mg mL−1) were added.
Samples were incubated at 37 ◦C for 3 hours prior to analysis.
Amyloid Digestion LCMS
Amyloid digestions were diluted with H2O to final concentration 2 pmol µL−1 for LCMS
analysis. LCMS analyses were conducted on a Synapt G2-S (Waters Corp., UK) recording ESI
ions between m/z 50 to 2000, and PDA absorbance measurement between 210 nm and 500 nm.
Chromatography was conducted by 5 µL injection on to an Acquity UPLC with Xbridge C18
1.7 µm (2.1 x 100 mm) column. Mobile phase conditions are summaried in Table 10.5. Positive
mode ESI parameters are summarised in Table 10.6
Time (min) Flow Rate (mL/min) % H2O (0.1 % FA) % MeCN (0.1 % FA) Curve
0.00 0.4 95 5 6
8.00 0.4 5 95 6
10.00 0.4 5 95 6
12.00 0.4 95 5 6
Table 10.5 Chromatography gradient for amyloid digestion LCMS.
Chapter 10. Experimental 313
Parameter Optimised Value
Capillary Voltage (kV) 1.0
Source Temperature (◦C) 150.0
Sampling Cone Voltage (V) 20.0
Source Offset Voltage (V) 40.0
Desolvation Temperature (◦C) 300.0
Cone Gas Flow (L h−1) 60.0
Desolvation Gas Flow (L h−1) 450.0
Nebuliser Gas Flow (Bar) 6.0
Table 10.6 Positive ESI parameters for amyloid digestion LCMS.
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Preliminary Small Molecule LCMS
Preliminary small molecule LCMS was conducted on a QToF Premier (Waters Corp., UK)
with positive ions recorded between m/z 50-1500 and PDA absorbance measurement between
210 nm and 500 nm. Chromatography was performed with an Acquity UPLC BEH C18,
1.7 µm (2.1 x 100 mm) column using a 3 µL injection volume. Mobile phase gradient ran at
400 µL/min from H2O (0.1 % formic acid):MeOH (99:1) to H2O (0.1 % formic acid):MeOH
(1:99) over 5 minutes, followed by a 4 minute organic wash at H2O (0.1 % formic acid):MeOH
(1:99).
Synthesis of Palmitoyl Procaine 35
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To procaine 2 (0.050 g, 0.18 mmol) in dry DCM (4 mL) was added pyridine (0.016 mL,
0.20 mmol) and palmitoyl chloride 18 (0.061 mL, 0.20 mmol). The mixture was stirred for 12
hours at room temperature, diluted with DCM and washed three times with saturated NH4Cl
solution. The organic layer was dried over MgSO4 and solvent removed in vacuo. Purification
by silica gel chromatography using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded palmitoyl
procaine 35 as a white solid (0.065 g, 76 %): 1H (400 MHz; CDCl3) δ 0.89 (t, J = 8.0 Hz, 3H,
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H29), 1.22-1.45 (m, H, HAlkyl), 1.75 (quin, J = 24.0 Hz, 2H, H16), 2.49 (q, J = 12.0 Hz, 2H,
H15), 3.00-3.10 (m, 4H, H2,4), 3.21-3.28 (m, 2, H5), 4.69-4.72 (m, 2H, H6), 7.71 (d, J = 8.5
Hz, 2H, H9,13), 7.96 (d, J = 8.5 Hz, 2H, H10,12); 13C (100 MHz; CDCl3) δ 12.2 (C1,3), 14.3
(C28), 22.9 (CAlkyl), 25.2 ((CAlkyl), 28.7 (CAlkyl), 29.3 (CAlkyl), 29.5 (CAlkyl), 29.6 (CAlkyl),
29.7 (CAlkyl), 29.8 (CAlkyl), 29.9 (CAlkyl), 29.9 (CAlkyl), 32.1 (C16), 47.9 (C2,4), 48.5 (C15), 51.4
(C5), 62.7 (C6), 113.8 (C10,12), 119.9 (C8), 131.5 (C9,13), 155.0 (C11), 166.7 (C7), 174.0 C14);
IR (neat) vmax/cm–1 1598, 1602, 1720, 2855, 2925, 2985; LRMS (ESI) m/z 475.4 [M+H]+;
HRMS (ESI) calculated for C29H51N2O3 [M+H]+ 475.3900, found 475.3900.242,243,246
Synthesis of Oleoyl Procaine 36
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To procaine 2 (0.050 g, 0.18 mmol) in dry DCM (4 mL) was added pyridine (0.016 mL,
0.20 mmol) and oleoyl chloride 20 (0.061 mL, 0.20 mmol). The mixture was stirred for 12
hours at room temperature, diluted with DCM and washed three times with saturated NH4Cl
solution. The organic layer was dried over MgSO4 and solvent removed in vacuo. Purification
by silica gel chromatography using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded oleoyl
procaine 36 as a yellow oil (0.063 g, 70 %): 1H (400 MHz; CDCl3) δ 0.87 (t, J = 8.0 Hz,
3H, H29), 1.20-1.42 (m, H, 20HAlkyl), 1.71 (quin, 2H, J = 12.0 Hz, H16), 2.18-2.24 (m, 4H,
H21,24), 2.90 (t, 2H, J = 8.0 Hz, H15), 3.00-3.10 (m, 4H, H2,4), 3.20-3.25 (m, 2, H5), 4.69-4.73
(m, 2H, H6), 5.20-5.25 (m, 2H, H22,23), 7.75 (d, J = 8.5 Hz, 2H, H9,13), 8.0 (d, J = 8.5 Hz,
2H, H10,12); 13C (100 MHz; CDCl3) δ 12.5 (C1,3), 14.0 (C31), 22.8 (C30), 25.6 (CAlkyl), 28.9
(CAlkyl), 29.2 (CAlkyl), 29.5 (CAlkyl), 29.6 (CAlkyl), 29.8 (CAlkyl), 29.9 (CAlkyl), 30.0 (CAlkyl),
32.1 (C16), 47.9 (C2,4), 48.0 (C15), 51.4 (C5), 62.7 (C6), 113.8 (C10,12), 119.9 (C8), 130.2 (C22),
130.5 (C23) 131.5 (C9,13), 155.0 (C11), 166.7 (C7), 179.2 C14); IR (neat) vmax/cm–1 1598,
1602, 1720, 2855, 2925, 2985, 3010; LRMS (ESI) m/z 501.4 [M+H]+; HRMS (ESI) calculated
for C31H53N2O3 [M+H]+ 501.4056, found 501.4051.242,243,246
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Synthesis of Palmitoyl Tetracaine 37
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To tetracaine 3 (0.050 g, 0.16 mmol) in dry DCM (4 mL) was added pyridine (0.015 mL,
0.18 mmol) and palmitoyl chloride 18 (0.055 mL, 0.18 mmol). The mixture was stirred for 12
hours at room temperature, diluted with DCM and washed three times with saturated NH4Cl
solution. The organic layer was dried over MgSO4 and solvent removed in vacuo. Purification
by silica gel chromatography using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded palmitoyl
tetracaine 37 as a white solid (0.058 g, 72 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0 Hz,
3H, H15), 0.98 (t, J = 8.0 Hz, 3H, H31), 1.13-1.35 (m, 26H, HAlkyl), 1.40-1.49 (m, 2H, H13),
1.51-1.60 (m, 2H, H18), 2.91 (m, 2H, H17), 2.93 (s, 6H, H1,2), 3.46 (m, 2H, H12), 3.71 (t, J
= 6.0 Hz, 2H, H3), 4.85 (m, 2H, H4), 7.28 (d, J = 8.0 Hz, 2H, H7,11), 8.18 (d, J = 8.0 Hz,
2H, H8,10); 13C (100 MHz; CDCl3) δ 13.7 (C15), 14.3 (C31), 19.7 (CAlkyl), 22.4 (CAlkyl), 22.6
(CAlkyl), 25.5 (CAlkyl), 27.8 (CAlkyl), 28.9 (CAlkyl), 29.3 (CAlkyl), 29.4 (CAlkyl), 29.5 (CAlkyl),
29.6 (CAlkyl), 29.8 (CAlkyl), 31.8 (C13), 32.7 (C18), 43.7 (C3), 45.5 (C1,2), 48.5 (C17), 53.6
(C12), 58.9 (C4), 131.7 (C8,10), 139.2 (C7,11), 144.0 (C9), 151.3 (C6), 174.0 (C5) 177.6 (C16);
IR (neat) vmax/cm–1 1606, 1728, 2902, 2915, 2927; LRMS (ESI) m/z 503.4 [M+H]+; HRMS
(ESI) calculated for C31H55N2O3 [M+H]+ 503.4213, found 503.4214.242,243,246
Synthesis of Oleoyl Tetracaine 38
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To tetracaine 3 (0.050 g, 0.16 mmol) in dry DCM (4 mL) was added pyridine (0.015 mL,
0.18 mmol) and oleoyl chloride 20 (0.055 mL, 0.18 mmol). The mixture was stirred for 12
hours at room temperature, diluted with DCM and washed three times with saturated NH4Cl
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solution. The organic layer was dried over MgSO4 and solvent removed in vacuo. Purification
by silica gel chromatography using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded oleoyl
tetracaine 38 as a yellow oil (0.056 g, 66 %): 1H (400 MHz; CDCl3) δ 0.87 (t, J = 8.0 Hz,
3H, H15), 0.96 (t, J = 8.0 Hz, 3H, H33), 1.15-1.33 (m, 22H, HAlkyl), 1.38-1.50 (m, 2H, H13),
1.53-1.63 (m, 2H, H18), 1.94-2.20 (m, 4H H23,26) 2.73 (m, 2H, H17), 2.82 (s, 6H, H1,2), 3.32-3.36
(m, 2H, H12), 3.71 (t, J = 8.0 Hz, 2H, H3), 4.67-4.77 (m, 2H, H4), 5.26-5.34 (m, 2H, H24,25),
7.23 (d, J = 8.0 Hz, 2H, H7,11), 8.13 (d, J = 8.0 Hz, 2H, H8,10); 13C (100 MHz; CDCl3) δ
13.8 (C15), 14.1 (C33), 20.0 (CAlkyl), 22.7 (CAlkyl), 25.5 (CAlkyl), 27.2 (CAlkyl), 29.1 (CAlkyl),
29.3 (CAlkyl), 29.5 (CAlkyl), 29.7 (CAlkyl), 31.3 (C13), 31.9 (C18), 43.0 (C3), 43.6 (C1,2), 44.2
(C17), 53.4 (C12), 58.6 (C4), 129.7 (C25), 129.8 (C24), 131.3 (C8,10), 131.9 (C7,11), 147.7 (C9),
152.7 (C6), 165.3 (C5), 172.4 (C16); IR (neat) vmax/cm–1 1606, 1726, 2840, 2915, 2931; LRMS
(ESI) m/z 529.4 [M+H]+; HRMS (ESI) calculated for C33H57N2O3 [M+H]+ 529.4369, found
529.4371.242,243,246
Synthesis of Diacetyl Propanolol 39
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To propranolol 1 (0.100 g, 0.34 mmol) in dry DCM (8 mL) was added pyridine (0.030 mL,
0.36 mmol) and acetyl chloride (0.029 g, 0.37 mmol). The mixture was stirred for 12 hours at
room temperature, diluted with DCM and washed three times with saturated NH4Cl solution.
The organic layer was dried over MgSO4 and solvent removed in vacuo. Purification by silica
gel chromatography using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded diacetyl propranolol
39 as a yellow oil (0.103 g, 88 %): 1H (400 MHz; CDCl3) δ 1.22–1.26 (m, 3.75H, H19,20), 1.31
(d, J = 6.8 Hz, 2.25H, H19,20), 2.08 (s, 2.25H, H17), 2.11 (s, 0.75H, H17), 2.16 (s, 2.25H, H14),
2.23 (s, 0.75H, H14), 3.41 (dd, J = 6.9, 14.3 Hz, 0.75 H, H15), 3.64 (dd, J = 4.0, 15.8 Hz,
0.25 H, H15), 3.82 (dd, J = 5.3, 14.3 Hz, 1H, H15), 4.03–4.07 (m, 0.75H, H18), 4.23–4.38 (m,
2H, H11), 4.48–4.52 (m, 0.25H, H18), 5.47–5.50 (m, 0.25H, H12), 5.57–5.62 (m, 0.75H, H12),
6.79-6.82 (m, 1H, H9), 7.34-7.38 (m, 1H, H8), 7.43 (d, J = 8.0 Hz, 1H, H7), 7.46–7.55 (m, 2H,
H1,2), 7.78–7.83 (m, 1H, H3), 8.18–8.23 (m, 1H, H6); 13C (100 MHz; CDCl3) δ 20.2 (C19,20),
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20.6 (C14), 21.0 (C19,20), 21.2 (C19,20), 21.7 (C14), 22.1 (C17), 22.7 (C17), 41.4 (C15), 45.5
(C15), 47.2 (C18), 49.5 (C18), 66.9 (C11), 68.4 (C11), 71.0 (C12), 71.6 (C12), 104.8 (C9), 104.9
(C9), 120.6 (C7), 121.2 (C7), 121.4 (C6), 121.8 (C6), 125.3 (C5), 125.4 (C5), 125.5 (C1), 125.7
(C1), 125.8 (C8), 126.4 (C2), 126.6 (C8), 127.4 (C4), 127.6 (C2), 128.2 (C4), 134.5 (C4), 134.6
(C4), 153.7 (C10), 154.2 (C10), 170.2 (C16), 170.5 (C16), 171.3 (C13); IR (neat) vmax/cm–1
1645, 1743, 2940, 2992, 3147; LRMS (ESI) m/z 344.2 [M+H]+; HRMS (ESI) calculated for
C20H26O4N [M+H]+ 344.1862, found 344.1852.247
Synthesis of N -Acetyl Propranolol 40
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Diacetyl propranolol 39 (0.050 g, 0.14 mmol) and K2CO3 (0.059 g, 0.43 mmol) were stirred
in MeOH (1.5 mL) for 2 hours prior to solvent removal in vacuo. Purification by silica gel
chromatography using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded N -acetyl propranolol
40 as a white solid (0.032 g, 76 %): 1H (400 MHz; CDCl3) δ 1.22 (d, J = 6.6 Hz, 3H, H17,18),
1.36 (d, J = 6.6 Hz, 3H, H17,18), 2.25 (s, 3H, H15), 3.52 (dd, J = 1.5, 14.6 Hz, 1H, H13), 3.79
(dd, J = 8.4, 14.6 Hz, 1H, H13), 4.04-4.29 (m, 4H, H11,12,16), 5.74 (s, 1H, OH), 6.82-6.88 (m,
1H, H9), 7.38-7.43 (m, 1H, H8), 7.46–7.59 (m, 3H, H1,2,7), 7.81–7.87 (m, 1H, H3), 8.21–8.28
(m, 1H, H6); 13C (100 MHz; CDCl3) δ 20.7 (C17,18), 21.3 (C17,18), 22.0 (C15), 46.1 (C13),
50.3 (C16), 69.8 (C11), 72.5 (C12), 104.8 (C9), 120.7 (C7), 121.5 (C6), 125.2 (C5), 125.4 (C1),
126.0 (C8), 126.3 (C2), 127.7 (C3), 134.5 (C4), 154.0 (C10), 173.9 (C14); IR (neat) vmax/cm–1
1619, 2916, 2986, 3000, 3403; LRMS (ESI) m/z 302.2 [M+H]+; HRMS (ESI) calculated for
C18H24O3N [M+H]+ 302.1756, found 302.1758.246,247
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Synthesis of Dipalmitoyl Propanolol 41
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To propranolol 1 (0.050 g, 0.17 mmol) in dry DCM (4 mL) was added pyridine (0.015 mL,
0.19 mmol) and palmitoyl chloride 18 (0.112 mL, 0.37 mmol). The mixture was stirred for 12
hours at room temperature, diluted with DCM and washed three times with saturated NH4Cl
solution. The organic layer was dried over MgSO4 and solvent removed in vacuo. Purification
by silica gel chromatography using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded dipalmitoyl
propranolol 41 as a yellow oil (0.105 g, 84 %): 1H (400 MHz; CDCl3) δ 0.87 (t, J = 7.0 Hz,
6H, H28,45), 1.11-1.36 (m, 54H, HAlkyl), 1.57-1.65 (m, 4H, H15,32), 2.29-2.41 (m, 6H, H14,31),
3.42 (dd, J = 6.9, 14.3 Hz, 0.75 H, H29), 3.62 (dd, J = 4.0, 15.8 Hz, 0.25 H, H29), 3.82 (dd, J
= 5.3, 14.3 Hz, 1H, H29), 4.08–4.15 (m, 0.75H, H46), 4.22–4.32 (m, 2H, H11), 4.42–4.47 (m,
0.25H, H46), 5.42–5.47 (m, 0.25H, H12), 5.52–5.58 (m, 0.75H, H12), 6.79-6.82 (m, 1H, H9),
7.33-7.38 (m, 1H, H8), 7.43 (d, J = 8.0 Hz, 1H, H7), 7.44–7.50 (m, 2H, H1,2), 7.75–7.82 (m,
1H, H3), 8.18–8.21 (m, 1H, H6); 13C (100 MHz; CDCl3) δ 14.1 (C28,45), 20.3 (CAlkyl), 20.7
(CAlkyl), 21.1 (CAlkyl), 21.9 (CAlkyl), 22.7 (CAlkyl), 24.7 (CAlkyl), 25.0 (CAlkyl), 25.5 (CAlkyl),
29.0 (CAlkyl), 29.3 (CAlkyl), 29.6 (CAlkyl), 31.9 (CAlkyl), 33.9 (C14,31), 34.4 (C14,31), 41.3 (C15),
48.5 (C46), 68.5 (C11), 70.7 (C11), 71.6 (C12), 72.5 (C12), 104.8 (C9), 120.5 (C7), 121.4 (C6),
121.9 (C6), 125.1 (C5), 125.2 (C5), 125.6 (C1), 125.5 (C1), 125.6 (C8), 125.8 (C2), 125.9 (C8),
126.3 (C4), 127.4 (C2), 127.6 (C4), 134.4 (C4), 154.3 (C10), 173.4 (C30), 173.9 (C13); IR (neat)
vmax/cm–1 1676, 1745, 2855, 2926; LRMS (ESI) m/z 736.6 [M+H]+; HRMS (ESI) calculated
for C48H82NO4 [M+H]+ 736.6244, found 736.6256.247
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Synthesis of N -Palmitoyl Propanolol 12
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Dipalmitoyl propranolol 41 (0.050 g, 0.14 mmol) and K2CO3 (0.059 g, 0.43 mmol) were stirred
in MeOH (1.5 mL) for 2 hours prior to solvent removal in vacuo. Solid was resuspended in
MeOH (6 mL) and H2SO4 (0.12 mL), and refluxed for 1 hour to methylate excess fatty acid.
The solution was diluted with DCM, washed with saturated NaHCO3 solution until neutral,
dried over MgSO4, and solvent removed in vacuo. Purification by silica gel chromatography
using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded N -palmitoyl propranolol 12 as a white
solid (0.049 g, 70 %): 1H (400 MHz; CDCl3) δ 0.87 (t, J = 7.0 Hz, 3H, H29), 1.11-1.36 (m,
54H, HAlkyl), 1.59-1.65 (m, 2H, H16), 2.32-2.38 (m, 2H, H15), 3.51 (dd, J = 1.5, 14.6 Hz, 1H,
H13), 3.81 (dd, J = 8.4, 14.6 Hz, 1H, H13), 4.04-4.29 (m, 4H, H11,12,30), 5.74 (s, 1H, OH),
6.82-6.88 (m, 1H, H9), 7.38-7.43 (m, 1H, H8), 7.46–7.59 (m, 3H, H1,2,7), 7.81–7.87 (m, 1H, H3),
8.21–8.28 (m, 1H, H6); 13C (100 MHz; CDCl3) δ 14.4 (C29), 20.3 (CAlkyl), 20.7 (CAlkyl), 21.3
(CAlkyl), 21.7 (CAlkyl), 21.8 (CAlkyl), 22.7 (CAlkyl), 24.7 (CAlkyl), 25.0 (CAlkyl), 25.3 (CAlkyl),
25.6 (CAlkyl), 29.1 (CAlkyl), 29.2 (CAlkyl), 30.3 (C15), 46.1 (C13), 50.3 (C30), 69.8 (C11), 72.5
(C12), 104.8 (C9), 120.7 (C7), 121.5 (C6), 125.2 (C5), 125.4 (C1), 126.0 (C8), 126.3 (C2), 127.7
(C3), 134.5 (C4), 154.07 (C10), 176.9 (C14); IR (neat) vmax/cm–1 1745, 2914, 2926, 3391;
LRMS (ESI) m/z 498.4 [M+H]+; HRMS (ESI) calculated for C32H52NO3 [M+H]+ 498.3947,
found 498.3943.246,247
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To propranolol 1 (0.050 g, 0.17 mmol) in dry DCM (4 mL) was added pyridine (0.015 mL,
0.19 mmol) and oleoyl chloride 20 (0.112 mL, 0.37 mmol). The mixture was stirred for 12
hours at room temperature, diluted with DCM and washed three times with saturated NH4Cl
solution. The organic layer was dried over MgSO4 and solvent removed in vacuo. Purification
by silica gel chromatography using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded dioleoyl
propranolol 42 as a yellow oil (0.110 g, 82 %): 1H (400 MHz; CDCl3) δ 0.88 (t, 6H, J = 8.0 Hz,
H30,49), 1.13-1.37 (m, 46H, HAlkyl), 1.55-1.67 (m, 4H, H15,34), 1.97-2.03 (m, 8H, H20,23,39,42),
2.31-2.51 (m, 4H, H14,33), 3.38 (dd, J = 6.9, 14.3 Hz, 0.75 H, H31), 3.66 (dd, J = 4.0, 15.8
Hz, 0.25 H, H31), 3.85 (dd, J = 5.3, 14.3 Hz, 1H, H31), 4.08–4.17 (m, 0.75H, H50), 4.24–4.34
(m, 2H, H11), 4.48–4.52 (m, 0.25H, H50), 5.27-5.37 (m, 4H, H21,22,40,41), 5.42–5.47 (m, 0.25H,
H12), 5.55–5.58 (m, 0.75H, H12), 6.79-6.88 (m, 1H, H9), 7.33-7.38 (m, 1H, H8), 7.40–7.53 (m,
3H, H1,2,7), 7.77–7.83 (m, 1H, H3), 8.19–8.22 (m, 1H, H6); 13C (100 MHz; CDCl3) δ 14.1
(C30,49), 21.1 (CAlkyl), 22.7 (CAlkyl), 25.5 (CAlkyl), 27.1 (CAlkyl), 27.2 (CAlkyl), 29.9 (CAlkyl),
29.1 (CAlkyl), 29.2 (CAlkyl), 29.4 (CAlkyl), 29.7 (CAlkyl), 29.8 (CAlkyl), 41.3 (C31), 48.4 (C50),
49. (C50), 53.4 (C14,33), 68.5 (C11), 70.7 (C12), 71.7 (C12), 72.5 (C21,22,40,41), 104.7 (C9), 104.8
(C9), 120.5 (C7), 121.2 (C7), 121.5 (C6), 121.9 (C6), 125.1 (C5), 125.5 (C1), 125.8 (C8), 126.3
(C2), 126.6 (C8), 127.4 (C4), 127.6 (C2), 129.8 (C4), 129.9 (C4), 134.4 (C4), 154.3 (C10), 173.3
(C32), 173.9 (C13); IR (neat) vmax/cm–1 1652, 1746, 2915, 2986, 2930; LRMS (ESI) m/z 788.7
[M+H]+; HRMS (ESI) calculater for C52H86NO4 [M+H]+ 788.6557, found 788.6573.247
Synthesis of N -Oleoyl Propanolol 13
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Dioleoyl propranolol 42 (0.050 g, 0.14 mmol) and K2CO3 (0.059 g, 0.43 mmol) were stirred
in MeOH (1.5 mL) for 2 hours prior to solvent removal in vacuo. Solid was resuspended in
MeOH (6 mL) and H2SO4 (0.12 mL), and refluxed for 1 hour to methylate excess fatty acid.
The solution was diluted with DCM, washed with saturated NaHCO3 solution until neutral,
dried over MgSO4, and solvent removed in vacuo. Purification by silica gel chromatography
using eluent EtOAc:MeOH:NH314% aq (98:1:1) yielded N -oleoyl propranolol 13 as a yellow oil
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(0.051 g, 70 %): 1H (400 MHz; CDCl3) δ 0.88 (t, 3H, J = 8.0 Hz, H31), 1.09 (d, J = 6.6 Hz,
6H, H33,34), 1.19-1.39 (m, 20H, HAlkyl), 1.59-1.72 (m, 2H, H16), 194-2.08 (m, 4H, H21,24), 2.86
(quin, J = 20.0 Hz, 0.75H, H15), 3.05 (quin, J = 20.0 Hz, 1.25H, H15), 3.54 (dd, J = 1.5, 14.6
Hz, 1H, H13), 3.75 (dd, J = 8.4, 14.6 Hz, 1H, H13), 4.11-4.35 (m, 4H, H11,12,32), 5.27-5.57 (m,
2H, H22,23); 5.74 (s, 1H, OH), 6.80-6.87 (m, 1H, H9), 7.37-7.40 (m, 1H, H8), 7.40–7.51 (m, 3H,
H1,2,7), 7.79–7.83 (m, 1H, H3), 8.20 (d, J = 6.0 Hz, 1H, H6); 13C (100 MHz; CDCl3) δ 14.1
(C31), 20.7 (CAlkyl), 21.5 (CAlkyl), 22.7 (CAlkyl), 23.0 (CAlkyl), 25.0 (CAlkyl), 25.4 (CAlkyl), 27.2
(CAlkyl), 29.0 (CAlkyl), 29.1 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl), 29.5 (CAlkyl), 29.7 (CAlkyl),
31.9(CAlkyl), 33.8 (CAlkyl), 34.0 (CAlkyl), 46.2 (C13), 47.3 (C13), 48.6 (C32), 49.1 (C32), 67.8
(C11), 69.9 (C11), 71.7 (C12), 72.5 (C12), 104.8 (C9), 120.6 (C7), 121.6 (C7), 121.9 (C6), 125.2
(C6), 125.4 (C5), 125.7 (C1), 125.9 (C8), 126.3 (C2), 127.4 (C8), 127.6 (C2), 129.7 (C3), 130.0
(C22,23), 134.5 (C4), 154.0 (C10), 173.6 (C14), 176.4 (C14); IR (neat) vmax/cm–1 1628, 2858,
2930, 3415; LRMS (ESI) m/z 524.4 [M+H]+; HRMS (ESI) calculated for C34H54NO3 [M+H]+
524.4104, found 524.4103.246,247
Ionisation Optimisation
Palmitoyl procaine 35 (0.5 µg mL−1) in H2O:MeCN (1:1) was direct infused into the ESI
source of the Synapt G2-S (Waters Corp., UK) at a constant flow rate of 5 µL/min using a
syringe pump. Full scan data was collected in positive mode over m/z range 50-2000 for one
minute. Ionisation parameters were varied as desired. Conditions tested are summarised in
Table 10.7, with source temperature (150 ◦C), desolvation temperature (350 ◦C), cone gas
flow (60 L h−1), and desolvation gas flow (600 L h−1) kept consistent.
Capillary Voltage (kV) Sampling Cone Voltage (V) Source Offset Voltage (V)
0.5 50 30
1.0 50 30
1.5 50 30
2.0 50 30
2.5 50 30
1.0 30 30
1.0 40 30
1.0 60 30
1.0 70 30
1.0 50 20
1.0 50 40
Table 10.7 Positive ESI parameters tested during optimisation for small molecule LCMS.
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Chromatographic Optimisation
Chromatographic optimisation was conducted on a Synapt G2-S (Waters Corp., UK) recording
ESI ions between m/z 50 to 2000, and PDA absorbance measurement between 210 nm and
500 nm. Full scan data was collected in positive mode, with optimised ionisation conditions
employed throughout. Stock solutions (0.5 µg mL−1) of procaine 2, palmitoyl procaine 35,
and OPC were prepared in H2O:MeCN (1:1). 3 µL was injected on to each stationary phase
of interest, summarised in Table 10.8. Varied mobile phases were applied to each column in
order to determine optimum mobile phase conditions, including: (i) linear 9 minute gradient
shown in Table 10.9; (ii) modified gradient one shown in Table 10.10; (iii) modified gradient
two shown in Table 10.11.
Column Type
Acquity BEH C18
Acquity CSH C18
Acquity BEH Phenyl
Acquity BEH Shield RP18
Acquity BEH C8
Table 10.8 Stationary phases tested.
Time (min) Flow Rate (mL/min) % H2O (0.1 % FA) % Mobile Phase B Curve
0.00 0.4 95 5 6
0.50 0.4 95 5 6
7.00 0.4 5 95 6
8.30 0.4 5 95 6
8.40 0.4 95 5 6
9.00 0.4 95 5 6
Table 10.9 Linear gradient employed on column types listed in Table 10.8 during optimisa-
tion of small molecule intrinsic lipidation chromatography. Mobile phase B was either MeCN
(0.1 % formic acid) or MeOH.
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Time (min) Flow Rate (mL/min) % H2O (0.1 % FA) % MeCN (0.1 % FA) Curve
0.00 0.4 95 5 6
0.50 0.4 95 5 6
4.00 0.4 30 70 6
7.00 0.4 5 95 6
8.00 0.4 5 95 6
8.50 0.4 95 5 6
9.00 0.4 95 5 6
Table 10.10 Modified gradient one employed during optimisation of small molecule intrinsic
lipidation chromatography.
Time (min) Flow Rate (mL/min) % H2O (0.1 % FA) % MeCN (0.1 % FA) Curve
0.00 0.4 95 5 6
0.50 0.4 95 5 6
3.00 0.4 30 70 6
7.00 0.4 5 95 6
8.00 0.4 5 95 6
8.50 0.4 95 5 6
9.00 0.4 95 5 6
Table 10.11 Modified gradient two employed during optimisation of small molecule intrinsic
lipidation chromatography.
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Synthesis of N -Boc Propanolol 63
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To propanolol 1 (0.048 g, 0.18 mmol) and NEt3 (0.127 mL, 0.92 mmol) in DCM (2 mg) was
added Boc2O (0.080 mg, 0.37 mmol) and stirred for 12 hours. The mixture was diluted with
DCM, washed three times with saturated NH4Cl solution, dried over MgSO4 and solvent
removed in vacuo. Product 63 was isolated as a yellow oil by Kugelrohr distillation (0.051 g,
79 %): 1H (400 MHz; CDCl3) δ 1.23 (d, J = 5.8 Hz, 6H, H20,21), 1.57 (s, 9H, H16,17,18),
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3.50-3.55 (m, 2H, H13), 4.01-4.09 (m, 1H, H19), 4.17-4.21 (m, 2H, H11,12), 4.24-29 (m, 1H,
H11), 5.13 (s, 1H, OH), 6.86 (d, J = 8.0 Hz, 1H, H9), 7.33-7.38 (m, 1H, H8), 7.43-7.45 (m,
1H, H7), 7.47-7.51 (m, 2H, H1,2), 7.80 (d, J = 8.0 Hz, 1H, H3), 8.22 (d, J = 8.0 Hz, 1H,
H6); 13C (100 MHz; CDCl3) δ 20.5 (C20,21), 28.5 (C16,17,18, 47.1 (C13), 48.8 (C19), 69.9 (C11),
72.1 (C12), 80.9 (C15), 104.9 (C9) 120.6 (C7), 121.6 (C6), 125.1 (C5), 125.4 (C1), 125.9 (C8),
126.4 (C2), 127.6 (C3), 134.5 (C4), 154.3 (C10), 158.8 (C14); IR (neat) vmax/cm–1 1692, 2953,
2983, 3476; LRMS (ESI) m/z 360.2 [M+H]+; HRMS (ESI) calculated for C21H30NO4 [M+H]+
360.2175, found 360.2168.272
Synthesis of O-Palmitoyl N -Boc Protected Propanolol 64
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To N -Boc propanolol 63 (0.031 g, 0.09 mmol) in dry DCM (2 mL) was added pyridine
(0.008 mL, 0.10 mmol) and palmitoyl chloride 18 (0.029 mL, 0.10 mmol). The mixture was
stirred for 12 hours at room temperature, diluted with DCM and washed three time with
saturated NH4Cl solution. The organic layer was dried over MgSO4 and solvent removed
in vacuo. Purification by silica gel chromatography with eluent EtOAc:MeOH:NH3(14 % aq)
(98:1:1) yielded 64 as a yellow oil (0.035 g, 65 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0
Hz, 3H, H28), 1.11-1.33 (m, 30H, HAlkyl), 1.51 (s, 9H, H32,33,34), 1.61 (quint, J = 24.0 Hz, 2H,
H15), 2.32 (q, J = 12.0 Hz, 2H, H14), 3.39-3.52 (m, 2H, H29), 3.58-3.66 (m, 1H, H35), 4.19-4.22
(m, 2H, H11,12), 4.28-4.33 (m, 1H, H11), 6.78 (d, J = 8.0 Hz, 1H, H9), 7.34 (t, J = 8.0 Hz, 1H,
H8), 7.41-7.44 (m, 1H, H7), 7.45-7.51 (m, 2H, H1,2), 7.79 (d, J = 8.0 Hz, 1H, H3), 8.21 (d,
J = 8.0 Hz, 1H, H6); 13C (100 MHz; CDCl3) δ 14.1 (C28), 22.7 (CAlkyl), 24.9 (CAlkyl), 28.4
(CAlkyl), 29.1 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl), 29.6 (CAlkyl), 29.7 (CAlkyl), 31.9 (CAlkyl),
34.3 (CAlkyl), 47.1 (C29), 48.8 (C35), 68.1 (C11), 72.8 (C12), 80.0 (C31), 104.6 (C9) 120.6 (C7),
121.9 (C6), 125.4 (C5), 125.5 (C1), 125.7(C8), 126.4 (C2), 127.4 (C3), 134.5 (C4), 154.3 (C10),
173.4 (C30), 178.8 (C13); IR (neat) vmax/cm–1 1600, 1715, 2916, 2998; LRMS (ESI) m/z 598.4
[M+H]+; HRMS (ESI) calculated for C37H60NO5 [M+H]+ 598.4471, found 598.4571.242,243
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Synthesis of O-Oleoyl N -Boc Protected Propanolol 65
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To N -Boc propanolol 63 (0.031 g, 0.09 mmol) in dry DCM (2 mL) was added pyridine
(0.008 mL, 0.10 mmol) and oleoyl chloride 20 (0.029 mL, 0.10 mmol). The mixture was stirred
for 12 hours at room temperature, diluted with DCM and washed three time with saturated
NH4Cl solution. The organic layer was dried over MgSO4 and solvent removed in vacuo.
Purification by silica gel chromatography with eluent EtOAc:MeOH:NH3(14 % aq) (98:1:1)
yielded 65 as a yellow oil (0.035 g, 63 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0 Hz, 3H,
H30), 1.18-1.36 (m, 24H, HAlkyl), 1.51 (s, 9H, H34,35,36), 1.97-2.01 (m, 4H, H20,23), 2.15 (q, J
= 12.0 Hz, 2H, H15), 2.88 (t, 2H, J = 8.0 Hz, H14), 3.39-3.52 (m, 2H, H31), 3.58-3.66 (m, 1H,
H37), 4.19-4.22 (m, 2H, H11,12), 4.28-4.33 (m, 1H, H11), 5.30-5.35 (m, 2H, H21,22), 6.78 (d, J
= 8.0 Hz, 1H, H9), 7.36 (t, J = 8.0 Hz, 1H, H8), 7.42-7.44 (m, 1H, H7), 7.45-7.51 (m, 2H,
H1,2), 7.80 (d, J = 8.0 Hz, 1H, H3), 8.22 (d, J = 8.0 Hz, 1H, H6); 13C (100 MHz; CDCl3) δ
14.1 (C30), 22.7 (CAlkyl), 24.9 (CAlkyl), 28.4 (CAlkyl), 29.1 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl),
29.6 (CAlkyl), 29.7 (CAlkyl), 31.9 (CAlkyl), 34.3 (CAlkyl), 47.1 (C31), 48.8 (C37), 68.1 (C11), 72.8
(C12), 80.0 (C33), 104.6 (C9) 120.6 (C7), 121.9 (C6), 125.4 (C5), 125.5 (C1), 125.7(C8), 126.4
(C2), 127.4 (C3), 130.5 (C21), 130.7 (C22), 134.5 (C4), 154.3 (C10), 173.9 (C32), 178.8 (C13);
IR (neat) vmax/cm–1 1598, 1741, 2915, 2929; LRMS (ESI) m/z 624.5 [M+H]+; HRMS (ESI)
calculated for C39H62NO5 [M+H]+ 624.4628, found 624.4710.242,243
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TFA (0.4 mL) was added dropwise to O-palmitoyl N -Boc propranolol 64 (0.05 g, 0.09 mmol)
in DCM (0.4 mL) and stirred for 2 hours. Solvent and impurities were removed in vacuo to
yield the TFA salt of 62 (0.044 g, 98 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0 Hz, 3H,
H28), 1.11-1.33 (m, 30H, HAlkyl), 1.61 (quint, J = 24.0 Hz, 2H, H15), 2.32 (q, J = 12.0 Hz, 2H,
H14), 3.39-3.52 (m, 2H, H29), 3.58-3.66 (m, 1H, H30), 4.19-4.22 (m, 2H, H11,12), 4.28-4.33 (m,
1H, H11), 6.78 (d, J = 8.0 Hz, 1H, H9), 7.34 (t, J = 8.0 Hz, 1H, H8), 7.41-7.44 (m, 1H, H7),
7.45-7.51 (m, 2H, H1,2), 7.79 (d, J = 8.0 Hz, 1H, H3), 8.21 (d, J = 8.0 Hz, 1H, H6), 9.70 (s,
1H, NH); 13C (100 MHz; CDCl3) δ 14.1 (C28), 22.7 (CAlkyl), 24.9 (CAlkyl), 28.4 (CAlkyl), 29.1
(CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl), 29.6 (CAlkyl), 29.7 (CAlkyl), 31.9 (CAlkyl), 34.3 (CAlkyl),
47.1 (C29), 48.8 (C30), 68.1 (C11), 72.8 (C12), 104.6 (C9) 120.6 (C7), 121.9 (C6), 125.4 (C5),
125.5 (C1), 125.7(C8), 126.4 (C2), 127.4 (C3), 134.5 (C4), 154.3 (C10), 173.4 (C13); IR (neat)
vmax/cm–1 1745, 2856, 2924; LRMS (ESI) m/z 498.4 [M+H]+; HRMS (ESI) calculated for
C32H52NO3 [M+H]+ 498.3947, found 498.3943.272
Synthesis of O-Palmitoyl Propranolol 62 - Method 2
37 % HCl(aq) (0.1 mL) was added dropwise to O-palmitoyl N -Boc propranolol 64 (0.05 g,
0.09 mmol) in EtOAc (0.9 mL) and stirred for 1.5 hours. The mixture was diluted with EtOAc,
washed with 5 % HCl solution, and dried over MgSO4. Solvent removal in vacuo yielded the
N -acylated migration product only.272
Synthesis of O-Palmitoyl Propranolol 62 - Method 3
37 % HCl(aq) (0.6 mL) was added dropwise to O-palmitoyl N -Boc propranolol 64 (0.06 g,
0.09 mmol) in DCM (0.6 mL) and stirred for 1.5 hours. Solvent and impurities were removed
in vacuo to yield the HCl salt of 62 (0.044 g, 98 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J =
8.0 Hz, 3H, H28), 1.11-1.33 (m, 30H, HAlkyl), 1.61 (quint, J = 24.0 Hz, 2H, H15), 2.32 (q,
J = 12.0 Hz, 2H, H14), 3.39-3.52 (m, 2H, H29), 3.58-3.66 (m, 1H, H30), 4.19-4.22 (m, 2H,
H11,12), 4.28-4.33 (m, 1H, H11), 6.78 (d, J = 8.0 Hz, 1H, H9), 7.34 (t, J = 8.0 Hz, 1H, H8),
7.41-7.44 (m, 1H, H7), 7.45-7.51 (m, 2H, H1,2), 7.79 (d, J = 8.0 Hz, 1H, H3), 8.21 (d, J =
8.0 Hz, 1H, H6), 9.70 (s, 1H, NH); 13C (100 MHz; CDCl3) δ 14.1 (C28), 22.7 (CAlkyl), 24.9
(CAlkyl), 28.4 (CAlkyl), 29.1 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl), 29.6 (CAlkyl), 29.7 (CAlkyl),
31.9 (CAlkyl), 34.3 (CAlkyl), 47.1 (C29), 48.8 (C30), 68.1 (C11), 72.8 (C12), 104.6 (C9) 120.6
(C7), 121.9 (C6), 125.4 (C5), 125.5 (C1), 125.7(C8), 126.4 (C2), 127.4 (C3), 134.5 (C4), 154.3
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(C10), 173.4 (C13); IR (neat) vmax/cm–1 1745, 2856, 2924; LRMS (ESI) m/z 498.4 [M+H]+;
HRMS (ESI) calculated for C32H52NO3 [M+H]+ 498.3947, found 498.3943.272
Synthesis of O-Oleoyl Propranolol 47 - Method 1
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TFA (0.4 mL) was added dropwise to O-oleoyl N -Boc propranolol 65 (0.05 g, 0.08 mmol) in
DCM (0.4 mL) and stirred for 2 hours. Solvent and impurities were removed in vacuo to yield
the TFA salt of 47 (0.045 g, 96 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0 Hz, 3H, H30),
1.18-1.36 (m, 24H, HAlkyl), 1.97-2.01 (m, 4H, H20,23), 2.15 (q, J = 12.0 Hz, 2H, H15), 2.88
(t, 2H, J = 8.0 Hz, H14), 3.39-3.52 (m, 2H, H31), 3.58-3.66 (m, 1H, H32), 4.19-4.22 (m, 2H,
H11,12), 4.28-4.33 (m, 1H, H11), 5.30-5.35 (m, 2H, H21,22), 6.78 (d, J = 8.0 Hz, 1H, H9), 7.36
(t, J = 8.0 Hz, 1H, H8), 7.42-7.44 (m, 1H, H7), 7.45-7.51 (m, 2H, H1,2), 7.80 (d, J = 8.0
Hz, 1H, H3), 8.22 (d, J = 8.0 Hz, 1H, H6), 9.58 (s, 1H, NH); 13C (100 MHz; CDCl3) δ 14.1
(C30), 22.7 (CAlkyl), 24.9 (CAlkyl), 28.4 (CAlkyl), 29.1 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl), 29.6
(CAlkyl), 29.7 (CAlkyl), 31.9 (CAlkyl), 34.3 (CAlkyl), 47.1 (C31), 48.8 (C32), 68.1 (C11), 72.8
(C12), 104.6 (C9) 120.6 (C7), 121.9 (C6), 125.4 (C5), 125.5 (C1), 125.7(C8), 126.4 (C2), 127.4
(C3), 130.5 (C21), 130.7 (C22), 134.5 (C4), 154.3 (C10), 175.2 (C13); IR (neat) vmax/cm–1
1744, 2859, 2930; LRMS (ESI) m/z 524.4 [M+H]+; HRMS (ESI) calculated for C34H54NO3
[M+H]+ 524.4104, found 524.4103.272
Synthesis of O-Oleoyl Propranolol 47 - Method 2
37 % HCl(aq) (0.1 mL) was added dropwise toO-oleoylN -Boc propranolol 65 (0.05 g, 0.08 mmol)
in EtOAc (0.9 mL) and stirred for 1.5 hours. The mixture was diluted with EtOAc, washed
with 5 % HCl solution, and dried over MgSO4. Solvent removal in vacuo yielded the N -acylated
migration product only.272
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Synthesis of O-Oleoyl Propranolol 47 - Method 3
37 % HCl(aq) (0.6 mL) was added dropwise toO-oleoylN -Boc propranolol 65 (0.06 g, 0.09 mmol)
in DCM (0.6 mL) and stirred for 1.5 hours. Solvent and impurities were removed in vacuo to
yield the HCl salt of 47 (0.045 g, 96 %): 1H (400 MHz; CDCl3) δ 0.88 (t, J = 8.0 Hz, 3H,
H30), 1.18-1.36 (m, 24H, HAlkyl), 1.97-2.01 (m, 4H, H20,23), 2.15 (q, J = 12.0 Hz, 2H, H15),
2.88 (t, 2H, J = 8.0 Hz, H14), 3.39-3.52 (m, 2H, H31), 3.58-3.66 (m, 1H, H32), 4.19-4.22 (m,
2H, H11,12), 4.28-4.33 (m, 1H, H11), 5.30-5.35 (m, 2H, H21,22), 6.78 (d, J = 8.0 Hz, 1H, H9),
7.36 (t, J = 8.0 Hz, 1H, H8), 7.42-7.44 (m, 1H, H7), 7.45-7.51 (m, 2H, H1,2), 7.80 (d, J =
8.0 Hz, 1H, H3), 8.22 (d, J = 8.0 Hz, 1H, H6), 9.58 (s, 1H, NH); 13C (100 MHz; CDCl3) δ
14.1 (C30), 22.7 (CAlkyl), 24.9 (CAlkyl), 28.4 (CAlkyl), 29.1 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl),
29.6 (CAlkyl), 29.7 (CAlkyl), 31.9 (CAlkyl), 34.3 (CAlkyl), 47.1 (C31), 48.8 (C32), 68.1 (C11), 72.8
(C12), 104.6 (C9) 120.6 (C7), 121.9 (C6), 125.4 (C5), 125.5 (C1), 125.7(C8), 126.4 (C2), 127.4
(C3), 130.5 (C21), 130.7 (C22), 134.5 (C4), 154.3 (C10), 175.2 (C13); IR (neat) vmax/cm–1
1744, 2859, 2930; LRMS (ESI) m/z 524.4 [M+H]+; HRMS (ESI) calculated for C34H54NO3
[M+H]+ 524.4104, found 524.4103.272
Solvation of Diacylated Propranolol
Dipalmitoyl propranolol 41 and dioleoyl propranolol 42 were dissolved in solvent mixtures
listed in Table 10.12 at concentration 1 µg mL−1. Each sample was then analysed according
to optimised small molecule LCMS conditions.
Solvent System
MeCN
MeCN:H2O (9:1)
MeCN:H2O (1:1)
MeCN:DCM (10:0.01)
MeCN:H2O:DCM (9:1:0.01)
MeCN:H2O:DCM (1:1:0.01)
MeCN:DCM (10:0.1)
MeCN:H2O:DCM (9:1:0.1)
MeCN:H2O:DCM (1:1:0.1)
Table 10.12 Solvent systems applied to analysis of dipalmitoyl propranolol 41 and dioleoyl
propranolol 42
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Diacylated Propranolol Chromatographic Optimisation
Chromatographic optimisation was conducted on a Synapt G2-S (Waters Corp., UK) recording
ESI ions between m/z 50 to 2000, and PDA absorbance measurement between 210 nm and
500 nm. Full scan data was collected in positive mode, with optimised ionisation conditions
employed throughout. Stock solutions (0.5 µg mL−1) of dipalmitoyl propranolol 41 and dioleoyl
propranolol 42 were injected at volume 3 µL on to a BEH Phenyl stationary phase (Waters
Corp., UK). Mobile phases were applied to each column in order to determine optimum
mobile phase conditions, including: (i) linear 9 minute gradient shown in Table 10.13; (ii)
extended ten minute gradient shown in Table 10.14.
Time (min) Flow Rate (mL/min) % H2O (0.1 % FA) % MeCN (0.1 % FA) Curve
0.00 0.4 95 5 6
0.50 0.4 95 5 6
7.00 0.4 5 95 6
8.00 0.4 5 95 6
8.50 0.4 95 5 6
9.00 0.4 95 5 6
Table 10.13 Initial gradient optimised for small molecule LCMS in Chapter 5, and applied
to the separation of diacylated propranolol species on a BEH Phenyl column (Waters Corp.,
UK).
Time (min) Flow Rate (mL/min) % H2O (0.1 % FA) % MeCN (0.1 % FA) Curve
0.00 0.4 95 5 6
0.50 0.4 95 5 6
7.50 0.4 5 95 6
8.80 0.4 5 95 6
8.90 0.4 95 5 6
10.00 0.4 95 5 6
Table 10.14 Extended gradient applied to separation of diacylated propranolol species of a
BEH Phenyl column (Waters Corp., UK) and taken forwards as the optimised chromatography
gradient for small molecule LCMS in vitro.
Quantitative Mass Spectrometry
Stock solutions of small molecules were prepared in H2O:MeCN (1:1) at concentration
1 mg mL−1 . A 1 µL aliquot was further diluted into H2O:MeCN (1:1) to final concentration
1 µg mL−1. Serial dilution (1:1) in H2O:MeCN (1:1) was carried out down to concentration
330 10.5. Chapter 6
7.8 ng mL−1. Each concentration was prepared in triplicate and analysed under optimised
small molecule LCMS conditions. Peak areas were modelled for each concentration, and
averaged in order to produce a calibration curve for the species.
O to N Intramolecular Migration Rate - Method 1
Synthetic O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 stock solutions were
prepared in H2O:MeCN at 1.27 mm. Small molecule stock solution (3 µL) was added to
extruded liposomes (30µL) containing DOPC or DPPC in a 1:10 small molecule:lipid ratio.
Samples were incubated under physiological conditions (pH 7.41 and 37 ◦C), and analysed at
relevant time points by optimised small molecule LCMS.
O to N Intramolecular Migration Rate - Method 2
Synthetic O-palmitoyl propranolol 62 and O-oleoyl propranolol 47 stock solutions were
prepared in MeCN at 1.27 mm. Small molecule stock was combined with DOPC or DPPC
stock solutions in CHCl3 in 1:10 small molecule:lipid ratio, and solvent removed in vacuo
creating a thin film. Mixed small molecule and phospholipid liposomes were prepared from
this film by applying extrusion methodology. Samples were incubated under physiological
conditions (pH 7.41 and 37 ◦C), and analysed at relevant time points by optimised small
molecule LCMS.
Small Molecule Buffer pH 4.30
10 mm NH4HCO3 was fully dissolved in H2O. pH was measured and adjusted to a value of
4.30 using formic acid.
Small Molecule Buffer pH 10.40
10 mm NH4HCO3 was fully dissolved in H2O. pH was measured and adjusted to a value of
10.40 using NH4OH(aq).
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Micelle Preparation
Stock solutions of lysolipid in CHCl3:MeOH (2:1) were prepared at a concentration of
10 mg mL−1 and stored at -20 ◦C. A 100 µL aliquot of lysolipid stock solution was added
to a round-bottomed flask, and solvent removed in vacuo resulting in formation of a lipid
film. Following overnight dessication, the lysolipid film was rehydrated in buffer solution and
agitated using a vortex mixer creating micelles
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Positive Ionisation Optimisation
POPC (0.5 µg mL−1) in IPA:H2O:MeCN (2:1:1) was direct infused into the ESI source of
the Synapt G2-S (Waters Corp., UK) at a constant flow rate of 5 µL/min using a syringe
pump. Full scan data was collected in positive mode over m/z range 50-2000 for one minute.
Ionisation parameters were varied as desired. Conditions tested are summarised in Table 10.15,
with source temperature (150 ◦C), desolvation temperature (350 ◦C), cone gas flow (60 L h−1),
and desolvation gas flow (600 L h−1) kept consistent.
Capillary Voltage (kV) Sampling Cone Voltage (V) Source Offset Voltage (V)
1.0 50 30
1.5 50 30
2.0 50 30
2.5 50 30
3.0 50 30
2.0 30 30
2.0 70 30
2.0 50 20
2.0 50 40
Table 10.15 Positive ESI parameters tested during optimisation for POPC LCMS.
Negative Ionisation Optimisation
POPS (0.5 µg mL−1) in IPA:H2O:MeCN (2:1:1) was direct infused into the ESI source of
the Synapt G2-S (Waters Corp., UK) at a constant flow rate of 5 µL/min using a syringe
pump. Full scan data was collected in positive mode over m/z range 50-2000 for one minute.
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Ionisation parameters were varied as desired. Conditions tested are summarised in Table 10.16,
with source temperature (150 ◦C), desolvation temperature (350 ◦C), cone gas flow (60 L h−1),
and desolvation gas flow (600 L h−1) kept consistent.
Capillary Voltage (kV) Sampling Cone Voltage (V) Source Offset Voltage (V)
1.0 50 30
1.5 50 30
2.0 50 30
2.5 50 30
3.0 50 30
2.5 20 30
2.5 30 30
2.5 40 30
2.5 30 20
2.5 30 40
Table 10.16 Positive ESI parameters tested during optimisation for small molecule LCMS.
Chromatographic Optimisation
Chromatographic optimisation was conducted on a Synapt G2-S (Waters Corp., UK) recording
ESI ions between m/z 50 to 2000, and PDA absorbance measurement between 210 nm and
500 nm. Full scan data was collected in positive and negative mode, with optimised ionisation
conditions employed throughout. Lipid mixture was prepared containing components listed in
Table 10.17 at concentration 0.5 µg mL−1 in IPA:H2O:MeCN (2:1:1). 3 µL was injected on to
Acquity CSH C18 1.7 µm (2.1 x 150 mm) column at 60 ◦C. Varied gradients of mobile phases
A (H2O:MeCN 4:6 with 10 mm NH4HCO2 and 0.1 % formic acid) and B (MeCN:IPA 1:9 with
10 mm NH4HCO2 and 0.1 % formic acid) were applied to each column in order to determine
optimum mobile phase conditions.
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Lipid
PPC
OPC
OPE
OPG
DOPC
POPC
OPPC
DOPE
DOPG
SLPG
DOPS
POPS
Table 10.17 Components of lipid mix prepared for chromatography optimisation.
Optimised Small Molecule LCMS in cellulo
Samples were diluted in MeCN:H2O (1:1) to small molecule concentration 1 µg mL−1. LCMS
analyses were conducted on a Synapt G2-S (Waters Corp., UK) recording ESI ions between
m/z 50 to 2000, and PDA absorbance measurement between 210 nm and 500 nm. Optimised
chromatography was conducted by 3 µL injection on to an Acquity UPLC with CSH C18 1.7 µm
(2.1 x 150 mm) column at 60 ◦C. Mobile phase conditions are summarised in Table 10.18
positive ESI ionisation parameters are presented in Table 10.19.
Time (min) Flow Rate (mL/min) % A % B Curve
0.00 0.4 60 40 6
2.00 0.4 57 43 6
2.10 0.4 50 50 6
12.00 0.4 46 54 6
12.10 0.4 30 70 6
18.00 0.4 1 99 6
18.10 0.4 60 40 6
20.0 0.4 60 40 6
Table 10.18 Optimised chromatography gradient for small molecule LCMS in cellulo. Mobile
phase A is H2O:MeCN 4:6 (10 mm NH4HCO2 and 0.1 % formic acid), and B is MeCN:IPA
1:9 (10 mm NH4HCO2 and 0.1 % formic acid).
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Parameter Positive Mode Negative Mode
Capillary Voltage (kV) 2.5 2.0
Source Temperature (◦C) 150.0 150.0
Sampling Cone Voltage (V) 50.0 30.0
Source Offset Voltage (V) 30.0 30.0
Desolvation Temperature (◦C) 350.0 350.0
Cone Gas Flow (L h−1) 60.0 60.0
Desolvation Gas Flow (L h−1) 600.0 600.0
Nebuliser Gas Flow (Bar) 6.0 6.0
Table 10.19 Optimised ESI parameters for small molecule LCMS in cellulo.
CHCL3 Extraction
Small molecule incubations were prepared under standard conditions containing propranolol
1 (3 µL at 1.27 mm) and POPC (30 µL at 1.27 mm). Following 72 hour incubation under
physiological conditions, CHCl3 (33 µL) was added and vortexed to mix. Layer separation
occurred, and an aliquot was removed from the lower organic layer for LCMS analysis.
CHCL3:MeOH Extraction
Small molecule incubations were prepared under standard conditions containing propranolol
1 (3 µL at 1.27 mm) and POPC (30 µL at 1.27 mm). Following 72 hour incubation under
physiological conditions, CHCl3:MeOH (2:1) (33µL) was added and vortexed to mix. Layer
separation occurred, and an aliquot was removed from the lower organic layer for LCMS
analysis.
MTBE Extraction
Small molecule incubations were prepared under standard conditions containing propranolol
1 (3 µL at 1.27 mm) and POPC (30 µL at 1.27 mm). Following 72 hour incubation under
physiological conditions, MTBE (33 µL) was added and vortexed to mix. Layer separation
occurred, and an aliquot was removed from the lower organic layer for LCMS analysis.
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Hep G2 Cell Growth
Hep G2 cells were grown at 37 ◦C, 5 % CO2, and 95 % humidity in Dulbecco’s modified
Eagle medium supplemented with foetal bovine medium (10 % v/v). Media was removed
from confluent cells, washed with PBS solution, and Triplex (1 mL) added to facilitate cell
detachment. Following 10 minutes further incubation, media (10 mL) was added to the cloudy
solution. Solution (10µL) was removed to determine cell number using a haemocytometer,
and concentration adjusted accordingly.332,333
Hep G2 Concentration Test
Hep G2 cells (50 µL equal to 2× 104) were added to each well of a 95 well plate and incubated
at 37 ◦C, 5 % CO2, and 95 % humidity for 5 hours to adhere. Sterilised propranolol 1 stock
solution at concentration 60 µm in H2O was serially diluted (1:1) down to concentration
117 nm. Propranolol 1 (50 µL) at desired concentration was added to cells in triplicate, and
incubated at 37 ◦C, 5 % CO2, and 95 % humidity. Cell growth was examined by light
microscopy following 72 hours.
Intrinsic Lipidation in Hep G2 Cells
Hep G2 cells (1× 106) were added to each of four T-75 flasks and incubated at 37 ◦C, 5
% CO2, and 95 % humidity overnight to adhere. Media was removed and replaced with
either fresh media (5 mL) for two controls, or medium containing 30 µm propranolol 1 (5 mL).
Following 72 hour incubation, media was removed from flasks and replaced with PBS (5 mL).
Cells were removed from surface by manual scraping, and washed three times with PBS. Solid
cells were collected by 10 minute centrifugation at 1000 g, and decanted into a glass tube for
extraction. CHCl3:MeOH (2:1) (3 mL) was added, shaken for 30 minutes, and centrifuged
to isolate remaining solid. The CHCl3:MeOH (2:1) solution was washed with H2O (0.6 mL),
isolated, and solvent removed in vacuo. Samples were resuspended in IPA:MeCN:H2O (2:1:1)
for analysis by optimised in cellulo LCMS.
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Synthesis of 2-Aminomethylbenzimidazole 11 - Method 1
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o-Phenylenediamine (1.080 g, 10.00 mmol) and glycine (1.060 g, 14.00 mmol) were refluxed in
toluene (20 mL) for 9 hours. After cooling the resulting solid was collected by filtration but
revealed only starting material.309
Synthesis of 2-Aminomethylbenzimidazole 11 - Method 2
o-Phenylenediamine (1.08 g, 10.00 mmol) and glycine (0.90 g, 20.00 mmol) were refluxed in 37
% HCl (4 mL) for 5 days until NMR indicated full conversion. After cooling, the resulting
solid was isolated by filtration and combined with the solid obtained by freeze drying the
reaction mixture. Purification by recrystallisation from MeOH yielded compound 11 as a tan
solid (2.06 g, 94 %): 1H (400 MHz; DMSO-d6) δ 3.54 (t, J = 5.7 Hz, 2H, H8), 4.48 (t, J = 5.7
Hz, 2H, NH2), 7.43-7.48 (m, 2H, H3,4), 7.77-7.81 (m, 2H, H2,5), 9.08 (s, 1H, NH); 13C (100
MHz; DMSO-d6) δ 39.2 (C8), 116.8 (C2,5), 125.4 (C3,4), 136.4 (C1,6), 148.7 (C7); IR (neat)
vmax/cm–1 1581, 1605, 2930, 3021, 3248, 3360, 3387; LRMS (ESI) m/z 148.1 [M+H]+; HRMS
(ESI) calculated for C8H10N3 [M+H]+ 148.0875, found 148.0872; m.p. = 269-270 ◦C.177,178
Synthesis of N -Oleoyl 2-Aminomethylbenzimidazole 67
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2-Aminomethylbenzimidazole 11 (0.15 g), 1.02 mmol), pyridine (0.09 mL), 1.12 mmol), and
oleoyl chloride 20 (0.37 mL), 1.12 mmol) were stirred in dry DCM (10 mL) under argon for
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12 hours. The organic phase was washed with saturated NH4Cl solution three times, dried
over MgSO4, and solvent removed in vacuo. Purification by Kugelrohr distillation yielded
compound 67 as a yellow oil (0.26 g, 61 %): 1H (400 MHz; DMSO-d6) δ 0.87 (t, 3H, J =
8.0 Hz, H26), 1.23-1.28 (m, 20H, HAlkyl), 1.63 (quin, 2H, J = 12.0 Hz, H11), 1.95-2.01 (m,
4H, H16,19), 2.27 (t, 2H, J = 8.0 Hz, H10), 4.58 (m, 2H, H8), 5.28-5.37 (m, 2H, H17,18),
7.43-7.48 (m, 2H, H3,4), 7.77-7.81 (m, 2H, H2,5); 13C (100 MHz; DMSO-d6) δ 14.1 (C26), 22.6
(CAlkyl), 25.6 (CAlkyl), 27.1 (CAlkyl), 27.2 (CAlkyl), 29.1 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl),
29.5 (CAlkyl), 29.7 (CAlkyl), 31.9 (CAlkyl), 36.3 (C10), 37.9 (C8), 122.7 (C2,5), 129.6 (C3,4),
129.8 (C1,6), 130.0 (C17,18), 152.0 (C7) 175.8 (C9; IR (neat) vmax/cm–1 1635, 2930, 2995, 3347;
LRMS (ESI) m/z 412.3 [M+H]+; HRMS (ESI) calculated for C26H42N3O [M+H]+ 412.3328,
found 412.3325.310
Semi Quantitative Mass Spectrometry
Small molecules were incubated in vitro under standard conditions. Samples were diluted
with H2O:MeCN (1:1) to approximate concentration 1 µg mL−1 of small molecule. Acylated
standard 67 stock solution (1.25 µL at 1 µg mL−1 in H2O) was added into MS sample prior to
analysis under optimised LCMS conditions. Acylated standard 67 peak areas were determined
and utilised to normalise data between samples.
Synthesis of 2-Chloromethyl-1H-benzimidazole 83
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Monochloroacetic acid (3.75 g, 0.04 mol), and o-phenylenediamine (3.79 g, 0.04 mol) were
refluxed in 37 % HCl(aq) (30 mL) for 12 hours. Upon cooling to 5 ◦C, the solution was
neutralised with NH4OH(aq) and the resulting precipitate collected. Hexane recyrstallisation
yielded orange solid 83 (5.18 g, 78 %): 1H (400 MHz; DMSO-d6) δ 4.53 (s, 2H, H8), 7.25-7.31
(m, 2H, H3,4), 7.50-7.56 (m, 2H, H2,5), 12.21 (s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 42.1
(C8), 116.5 (C2,5), 124.1 (C3,4), 138.4 (C1,6), 150.0 (C7); IR (neat) vmax/cm–1 1626, 2916,
3000, 3177; LRMS (ESI) m/z 167.0 [M+H]+; HRMS (ESI) calculated for C8H8ClN2 [M+H]+
167.0376, found 167.0375; m.p. = 153-155 ◦C.313,314
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Synthesis of 2-(Methylaminomethyl)benzimidazole 79 - Method 1
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To 33 % methylamine in EtOH (1.23 mL, 10.00 mmol), and K2CO3 (0.92 g, 6.00 mmol) in
MeOH (3.3 mL) was added 2-chloromethyl-1H-benzimidazole 83 (0.55 g, 3.00 mmol) in MeOH
(8 mL) dropwise. Reaction mixture was stirred for 30 minutes, and solvent removed in vacuo.
Product formation was not observed.315,316
Synthesis of 2-(Methylaminomethyl)benzimidazole 79 - Method 2
Finely powdered 2-chloromethyl-1H-benzimidazole 83 (0.46 g, 1.64 mmol) was added to 33
% methylamine in EtOH (9 mL at 0 ◦C. Stirring continued at 0 ◦C for 45 minutes, then
the reaction mixture was allowed to warm to room temperature over 15 minutes. Reaction
mixture was diluted with H2O, extracted with DCM three times, dried over MgSO4, and
solvent removed in vacuo. Kugelrohr distillation under reduced pressure yielded compound
79 as a yellow oil (0.18 g, 69 %): 1H (400 MHz; DMSO-d6) δ 2.38 (s, 3H, H9), 4.03 (s, 2H,
H8), 7.19-7.22 (m, 2H, H3,4), 7.50-7.56 (m, 2H, H2,5), 12.13 (s, 1H, NH); 13C (100 MHz;
DMSO-d6) δ 34.8 (C9), 48.1 (C8), 114.8 (C2,5), 123.0 (C3,4), 138.1 (C1,6), 151.3 (C7); IR
(neat) vmax/cm–1 1626, 2855, 2999, 3065; LRMS (ASAP) m/z 162.1 [M+H]+; HRMS (ASAP)
calculated for C9H12N3 [M+H]+ 162.1031, found 162.1027.315,316
Synthesis of 2-(Ethylaminomethyl)benzimidazole 80
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Finely powdered 2-chloromethyl-1H-benzimidazole 83 (0.46 g, 1.64 mmol) was added to ethy-
lamine (3 mL in EtOH (6 mL at 0 ◦C. Stirring continued at 0 ◦C for 45 minutes, then the
reaction mixture was allowed to warm to room temperature over 15 minutes. Reaction
mixture was diluted with H2O, extracted with DCM three times, dried over MgSO4, and
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solvent removed in vacuo. Kugelrohr distillation under reduced pressure yielded compound
80 as a yellow oil (0.20 g, 71 %): 1H (400 MHz; DMSO-d6) δ 1.32 (t, J = 8.0 Hz, 3H, H10),
2.68 (q, J = 8.0 Hz, 2H, H9), 4.04 (s, 2H, H8), 7.21-7.24 (m, 2H, H3,4), 7.50-7.55 (m, 2H,
H2,5), 12.13 (s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 14.0 (C10), 42.3 (C9), 47.9 (C8), 115.3
(C2,5), 123.0 (C3,4), 138.2 (C1,6), 149.3 (C7); IR (neat) vmax/cm–1 1626, 2858, 3000, 3065;
LRMS (ESI) m/z 176.1 [M+H]+; HRMS (ESI) calculated for C10H14N3 [M+H]+ 176.1188,
found 176.1186.315,316
Synthesis of 2-(Propylaminomethyl)benzimidazole 81
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Finely powdered 2-chloromethyl-1H-benzimidazole 83 (0.46 g, 1.64 mmol) was added to propy-
lamine (3 mL in EtOH (6 mL at 0 ◦C. Stirring continued at 0 ◦C for 45 minutes, then the
reaction mixture was allowed to warm to room temperature over 15 minutes. Reaction
mixture was diluted with H2O, extracted with DCM three times, dried over MgSO4, and
solvent removed in vacuo. Kugelrohr distillation under reduced pressure yielded compound
81 as a yellow oil (0.21 g, 68 %): 1H (400 MHz; DMSO-d6) δ 1.29 (t, J = 8.0 Hz, 3H, H11),
1.49-1.58 (m, 2H, H10), 2.75 (t, J = 8.0 Hz, 2H, H9), 4.01 (s, 2H, H8), 7.15-7.19 (m, 2H, H3,4),
7.52-7.58 (m, 2H, H2,5), 12.29 (s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 14.1 (C11), 29.8 (C10),
42.3 (C9), 47.8 (C8), 115.3 (C2,5), 122.0 (C3,4), 138.2 (C1,6), 149.3 (C7); IR (neat) vmax/cm–1
1630, 2853, 3017, 3078; LRMS (ASAP) m/z 190.1 [M+H]+; HRMS (ASAP) calculated for
C11H16N3 [M+H]+ 190.1344, found 190.1343.315,316
Synthesis of 2-(iso-Propylaminomethyl)benzimidazole 82
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Finely powdered 2-chloromethyl-1H-benzimidazole 83 (0.46 g, 1.64 mmol) was added to iso-
propylamine (3 mL in EtOH (6 mL at 0 ◦C. Stirring continued at 0 ◦C for 45 minutes, then
the reaction mixture was allowed to warm to room temperature over 15 minutes. Reaction
mixture was diluted with H2O, extracted with DCM three times, dried over MgSO4, and
solvent removed in vacuo. Kugelrohr distillation under reduced pressure yielded compound
82 as a yellow oil (0.18 g, 59 %): 1H (400 MHz; DMSO-d6) δ 1.27 (d, J = 8.0 Hz, 6H, H10,11),
2.78 (sept, J = 8.0 Hz, 1H, H9), 4.01 (s, 2H, H8), 7.15-7.20 (m, 2H, H3,4), 7.52-7.58 (m, 2H,
H2,5), 12.29 (s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 15.0 (C10,11), 42.3 (C9), 47.8 (C8),
115.3 (C2,5), 122.0 (C3,4), 138.2 (C1,6), 149.3 (C7); IR (neat) vmax/cm–1 1631, 2855, 3008,
3077; LRMS (ASAP) m/z 190.1 [M+H]+; HRMS (ASAP) calculated for C11H16N3 [M+H]+
190.1344, found 190.1343.315,316
Synthesis of (1H-benzimidazol-2-yl)methanethiol 78
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Thioglycolic acid (1.40 mL, 20.00 mmol) and o-phenylenediamine (1.89 g, 17.50 mmol) were
refluxed in 37 % HCl(aq) (15 mL) for 12 hours. Aqeous solvent was removed by freeze drying,
and MeOH recrystallisation yielded the HCl salt of compound 78 as a white powder (2.61 g,
91 %): 1H (400 MHz; DMSO-d6) δ 4.18 (s, 2H, H8), 7.19 (dd, J = 3.2, 5.9 Hz, 2H, H3,4), 7.53
(dd, J = 3.2, 5.9 Hz, 2H, H2,5); 13C (100 MHz; DMSO-d6) δ 36.1 (C8), 115.4 (C2,5), 122.3
(C3,4), 139.7 (C1,6), 151.0 (C7); IR (neat) vmax/cm–1 1624, 2879, 2946, 2995, 3155; LRMS
(ESI) m/z 165.0 [M+H]+; HRMS (ESI) calculated for C8H9N2S [M+H]+ 165.0486, found
165.0474.178,317
Synthesis of N -Boc-1,4-Phenylenediamine 93
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p-phenylenediamine (0.100 g, 0.92 mmol) in DCM (5 mL) was added dropwise at 0 ◦C to
Boc2O (0.039 g, 0.18 mmol) in DCM (1 mL). Following stirring at 0 ◦C for 3.5 hours, solvent
was removed in vacuo to yield a white powder. Purification by silica gel chromatography
using DCM:Acetone (4:1) as eluent yielded white powder 93 (0.035 g, 18 %): 1H (400 MHz;
CDCl3) δ 1.52 (s, 9H, H9,10,11), 3.55 (s, 2H, NH2), 6.29 (s, 1H, NH), 6.67 (d, J = 8.0 Hz, 2H,
H2,4), 7.12 (d, J = 8.0 Hz, 2H, H1,5; 13C (100 MHz; DMSO-d6) δ 28.1 (C9,10,11), 77.6 (C8),
114.0 (C2,4), 120.6 (C1,5), 128.6 (C3), 144.1 (C6), 153.1 (C7).320
Synthesis of t-Butyl(4-Benzamidophenyl)Carbamate 94
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To N -Boc-1,4-phenylenediamine 93 (0.035 g, 0.17 mmol) in DCM (3 mL) at 0 ◦C was added
dropwise NEt3 (0.020 g, 0.20 mmol) and benzoyl chloride (0.028 g, 0.20 mmol). The reaction
mixture was allowed to warm to room termperature and stirred for 4 hours. Solvent removal
in vacuo yielded white powder 94 however low abunadance and problematic large scale
purification prevented complete characterisation (0.028 g, 53 %): 1H (400 MHz; CDCl3) δ
1.52 (s, 9H, H9,10,11), 7.38 (d, J = 8.0 Hz, 1H, H2), 7.47-7.59 (m, 4H, H1,4,5,17), 7.68 (t, J =
8.0 Hz, 1H, H15), 7.86 (d, J = 8.0 Hz, 1H, H16), 8.17 (d, J = 8.0 Hz, 2H, H14,18).320
Synthesis of p-Nitrobenzanilide 95
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p-nitroaniline (0.100 g, 0.72 mmol) in dry THF (2.4 mL) under argon was treated with K2CO3
(0.200 g, 1.45 mmol) and benzoyl chloride (0.110 g, 0.76 mmol). After 12 hours, the reaction
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mixture was poured on to 10 % HCl(aq) (2.0 mL) and the resulting precipitate collected.
Following washing with H2O and hexane, MeOH recrystallisation yielded compound 95
(0.097 g, 56 %): 1H (400 MHz; DMSO-d6) δ 7.54 (t, J = 7.9 Hz, 2H, H12,10), 7.61 (t, J =
7.4 Hz, 1H, H11), 7.96 (d, J = 8.3 Hz, 2H, H9,13), 8.05 (d, J = 9.3 Hz, 2H, H1,5), 8.25 (d, J
= 9.3 Hz, 2H, H2,4) 10.78 (br s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 120.3 (C2,4), 125.2
(C1,5), 128.4 (C9,13), 129.0 (C10,12), 132.6 (C11), 134.7 (C8), 142.9 (C6), 145.9 (C3), 166.7 (C7);
IR (neat) vmax/cm–1 1341, 1502, 3332; LRMS (ASAP) m/z 243.1 [M+H]+; HRMS (ASAP)
calculated for C13H11N2O3 [M+H]+ 243.0769, found 243.0762.321
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 1
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p-Phenylenediamine (0.100 g, 0.92 mmol) and SDS (0.040 g, 0.14 mmol) were warmed in H2O
(2 mL) until a clear solution formed. Benzoyl chloride (0.129 g, 0.92 mmol) in MeCN (1 mL)
was added and the reaction mixture stirred for 5 minutes. MeCN was removed in vacuo,
and the remaining aqueous solution neutralised with NaHCO3 solution. The resulting white
precipitate collected by Büchner filtration was determined to be an inseparable mixture of
monosubstituted and disubstituted product.318
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 2
p-Phenylenediamine (0.100 g, 0.92 mmol) and SDS (0.040 g, 0.14 mmol) were warmed in H2O
(2 mL) until a clear solution formed. Reaction mixture was cooled to 0 ◦C, benzoyl chloride
(0.129 g, 0.92 mmol) in MeCN (1 mL) was added and the reaction mixture stirred at 0 ◦C for
5 minutes. MeCN was removed in vacuo, and the remaining aqueous solution neutralised
with NaHCO3 solution. The resulting white precipitate collected by Büchner filtration was
determined to be an inseparable mixture of monosubstituted and disubstituted product.318
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Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 3
p-Phenylenediamine (0.100 g, 0.92 mmol) was warmed in H2O (2 mL) until a clear solution
formed. Benzoyl chloride (0.129 g, 0.92 mmol) in MeCN (1 mL) was added and the reaction
mixture stirred for 5 minutes. MeCN was removed in vacuo, and the remaining aqueous
solution neutralised with NaHCO3 solution. The resulting white precipitate collected by
Büchner filtration was determined to be an inseparable mixture of monosubstituted and
disubstituted product.318
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 4
p-Phenylenediamine (0.100 g, 0.92 mmol) and SDS (0.040 g, 0.14 mmol) were warmed in H2O
(2 mL) until a clear solution formed. Benzoic anhydride (0.218 g, 0.92 mmol) in MeCN (1 mL)
was added and the reaction mixture stirred for 5 minutes. MeCN was removed in vacuo,
and the remaining aqueous solution neutralised with NaHCO3 solution. The resulting white
precipitate collected by Büchner filtration was determined to be an inseparable mixture of
monosubstituted and disubstituted product.318
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 5
p-Phenylenediamine (0.100 g, 0.92 mmol) and SDS (0.040 g, 0.14 mmol) were warmed in H2O
(2 mL) until a clear solution formed. Reaction mixture was cooled to 0 ◦C, benzoic anhydride
(0.218 g, 0.92 mmol) in MeCN (1 mL) was added and the reaction mixture stirred at 0 ◦C for
5 minutes. MeCN was removed in vacuo, and the remaining aqueous solution neutralised
with NaHCO3 solution. The resulting white precipitate collected by Büchner filtration was
determined to be an inseparable mixture of monosubstituted and disubstituted product.318
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 6
p-Phenylenediamine (0.100 g, 0.92 mmol) was warmed in H2O (2 mL) until a clear solution
formed. Benzoic anhydride (0.218 g, 0.92 mmol) in MeCN (1 mL) was added and the reaction
mixture stirred for 5 minutes. MeCN was removed in vacuo, and the remaining aqueous
solution neutralised with NaHCO3 solution. The resulting white precipitate collected by
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Büchner filtration was determined to be an inseparable mixture of monosubstituted and
disubstituted product.318
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 7
p-Phenylenediamine (1.000 g, 9.20 mmol) and SDS (0.040 g, 0.14 mmol) were warmed in H2O
(2 mL) until a clear solution formed. Benzoic anhydride (0.218 g, 0.92 mmol) in MeCN (1 mL)
was added and the reaction mixture stirred for 5 minutes. MeCN was removed in vacuo,
and the remaining aqueous solution neutralised with NaHCO3 solution. The resulting white
precipitate collected by Büchner filtration was determined to be an inseparable mixture of
monosubstituted and disubstituted product.318
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 8
p-Phenylenediamine (0.100 g, 0.92 mmol) and SDS (0.040 g, 0.14 mmol) were warmed in H2O
(15 mL) until a clear solution formed. Benzoic anhydride (0.218 g, 0.92 mmol) in MeCN (1 mL)
was added and the reaction mixture stirred for 5 minutes. MeCN was removed in vacuo,
and the remaining aqueous solution neutralised with NaHCO3 solution. The resulting white
precipitate collected by Büchner filtration was determined to be an inseparable mixture of
monosubstituted and disubstituted product.318
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 9
To p-phenylenediamine (0.100 g, 0.92 mmol) in dry DCM (4 mL) under argon was added
benzoyl chloride (0.037 g, 0.26 mmol) and NEt3 (0.044 mL, 0.32 mmol). Th reaction mixture
was tirred at room temperature for 2 hours. The resulting white precipitate collected by
Büchner filtration and washed with DCM, was determined to be an inseparable mixture of
monosubstituted and disubstituted product.319
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 10
SnCl2 (0.117 g, 0.62 mmol) in 37 % HCl (2.0 mL) was added dropwise to p-nitrobenzanilide 95
(0.050 g, 0.21 mmol) in EtOH (2.5 mL). The reaction mixture was stirred with gentle warming
for 1 hour, and the resulting precipitate removed by filtration. Remaining aqueous solution
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was neutralised with saturated NaHCO3 solution, yielding a white flocculation isolated by
centrifugation. Reduction proved unsuccessful, with starting material only retained.320
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 11
p-Nitrobenzanilide 95 (0.100 g, 0.42 mmol) and 10 % Pd on charcoal (0.010 g, 10% w/w) in
EtOAc (2.0 mL) was degassed under an environment of H2, and stirred for 12 hours. Excess Pd
was removed by celite filtration, and solvent removed in vacuo to yield impure compound 84
(0.083 g, 93 %): 1H (400 MHz; DMSO-d6) δ 4.93 (s, 2H, NH2), 6.55 (d, J = 8.8 Hz, 2H, H1,5),
7.37 (d, J = 8.4 Hz, 2H, H2,4), 7.48-7.60 (m, 3H, H10,11,12), 7.92 (d, J = 7.6 Hz, 2H, H9,13),
9.87 (s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 113.6 (C1,5), 122.3 (C2,4), 127.4 (C6), 128.3
(C9,13), 128.8 (C10,12), 131.6 (C11), 135.3 (C8), 145.4 (C3), 164.7 (C7); IR (neat) vmax/cm–1
1322, 1521, 1637, 3332; LRMS (ASAP) m/z 213.1 [M+H]+; HRMS (ASAP) calculated for
C13H13N2O [M+H]+ 213.1028, found 213.1016.321
Synthesis of N -(4-Aminophenyl)Benzamide 84 - Method 12
To p-nitrobenzanilide 95 (0.100 g, 0.42 mmol) and zinc dust (0.546 g, 8.35 mmol) in THF:AcOH
(1:1) (5 mL), saturated CuSO4 solution (0.8 mL) was added dropwise at 0 ◦C. After warming
to room temperature the reaction mixture was stirred for 12 hours, then filtered through
celite, diluted with EtOAc, washed twice with saturated NaHCO3 solution, and once with
brine. The organic phase was dried over MgSO4, and solvent removed in vacuo to yield
compoundcmpd:HB7 (0.049 g, 55 %): 1H (400 MHz; DMSO-d6) δ 4.93 (s, 2H, NH2), 6.55 (d,
J = 8.8 Hz, 2H, H1,5), 7.37 (d, J = 8.4 Hz, 2H, H2,4), 7.48-7.60 (m, 3H, H10,11,12), 7.92 (d, J
= 7.6 Hz, 2H, H9,13), 9.87 (s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 113.6 (C1,5), 122.3 (C2,4),
127.4 (C6), 128.3 (C9,13), 128.8 (C10,12), 131.6 (C11), 135.3 (C8), 145.4 (C3), 164.7 (C7); IR
(neat) vmax/cm–1 1322, 1521, 1637, 3332; LRMS (ASAP) m/z 213.1 [M+H]+; HRMS (ASAP)
calculated for C13H13N2O [M+H]+ 213.1028, found 213.1016.320
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Synthesis of m-Nitrobenzanilide 111
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m-nitroaniline (0.100 g, 0.72 mmol) in dry THF (2.4 mL) under argon was treated with K2CO3
(0.200 g, 1.45 mmol) and benzoyl chloride (0.110 g, 0.76 mmol). After 12 hours, the reaction
mixture was poured on to 10 % HCl(aq) (2.0 mL) and the resulting precipitate collected.
Following washing with H2O and hexane, MeOH recrystallisation yielded compound 111
(0.124 g, 71 %): 1H (400 MHz; DMSO-d6) δ 7.55-7.69 (m, 4H, H5,10,11,12), 7.98-7.80 (m, 3H,
H4,9,13), 8.19-8.22 (m, 1H, H6), 8.82-8.84 (m, 1H, H2), 10.72 (s, 1H, NH); 13C (100 MHz;
DMSO-d6) δ 114.8 (C2), 118.6 (C6), 126.6 (C4), 128.2 (C9,13), 129.0 (C10,12), 130.5 (C5),
132.5 (C11), 134.7 (C8), 140.8 (C1), 148.4 (C3), 166.5 (C7); IR (neat) vmax/cm–1 1351, 1521,
3362; LRMS (ASAP) m/z 243.1 [M+H]+; HRMS (ASAP) calculated for C13H11N2O3 [M+H]+
243.0769, found 243.0762.321
Synthesis of N -(3-Aminophenyl)Benzamide 85
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Tom-nitrobenzanilide 111 (0.100 g, 0.42 mmol) and zinc dust (0.546 g, 8.35 mmol) in THF:AcOH
(1:1) (5 mL), saturated CuSO4 solution (0.8 mL) was added dropwise at 0 ◦C. After warming
to room temperature the reaction mixture was stirred for 12 hours, then filtered through
celite, diluted with EtOAc, washed twice with saturated NaHCO3 solution, and once with
brine. The organic phase was dried over MgSO4, and solvent removed in vacuo to yield
compoundcmpd:HB47 (0.050 g, 56 %): 1H (400 MHz; DMSO-d6) δ 5.09 (s, 2H, NH2), 6.31
(d, J = 11.1 Hz, 1H, H2), 6.86 (d, J = 8.0 Hz, 1H, H5), 6.96 (t, J = 8.0 Hz, 1H, H6), 7.11 (t,
J = 2.0 Hz, 1H, 4H4), 7.47-7.63 (m, 3H, H10,11,12), 7.92 (d, J = 6.9 Hz, 2H, H9,13), 9.96 (s,
1H, NH); 13C (100 MHz; DMSO-d6) δ 106.6 (C6), 108.8 (C5), 110.2 (C4), 128.1 (C1), 128.8
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(C9,13), 129.3 (C10,12), 131.8 (C11), 135.8 (C8), 140.2 (C2), 149.4 (C3), 165.7 (C7); IR (neat)
vmax/cm–1 1320, 1538, 1636, 3329; LRMS (ASAP) m/z 213.2016 [M+H]+; HRMS (ASAP)
calculated for C13H13N2O [M+H]+ 213.1028, found 213.2016.320
Synthesis of o-Nitrobenzanilide 112
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o-nitroaniline (0.100 g, 0.72 mmol) in dry THF (2.4 mL) under argon was treated with K2CO3
(0.200 g, 1.45 mmol) and benzoyl chloride (0.110 g, 0.76 mmol). After 12 hours, the reaction
mixture was poured on to 10 % HCl(aq) (2.0 mL) and the resulting precipitate collected.
Following washing with H2O and hexane, MeOH recrystallisation yielded compound 112
(0.075 g, 43 %): 1H (400 MHz; DMSO-d6) δ 7.34-7.38 (m, 1H, H6), 7.64 (tt, J = 1.3, 7.3 Hz,
1H, H5), 7.70-7.74 (m, 3H, H5,10,12), 8.00-8.02 (m, 2H, H9,13), 8.21 (dd, J = 1.5, 8.4 Hz, 1H,
H4), 8.42 (dd, J = 1.5, 8.4 Hz, 1H, H1), 10.23 (br s, 1H, NH); 13C (100 MHz; DMSO-d6) δ
125.0 (C1), 125.5 (C4), 125.9 (C5), 127.8 (C6), 128.8 (C9,13), 131.6 (C10,12), 132.5 (C11), 133.6
(C3), 134.0 (C8), 142.8 (C2), 166.0 (C7); IR (neat) vmax/cm–1 1341, 1596, 1685, 3366; LRMS
(ASAP) m/z 243.1 [M+H]+; HRMS (ASAP) calculated for C13H11N2O3 [M+H]+ 243.0769,
found 243.0762.321
Synthesis of N -(2-Aminophenyl)Benzamide 86
2
1
6
5
4
3
HN 7
8
O
13
12
11
10
9
H2N
To o-nitrobenzanilide 112 (0.100 g, 0.42 mmol) and zinc dust (0.546 g, 8.35 mmol) in THF:AcOH
(1:1) (5 mL), saturated CuSO4 solution (0.8 mL) was added dropwise at 0 ◦C. After warming
to room temperature the reaction mixture was stirred for 12 hours, then filtered through
celite, diluted with EtOAc, washed twice with saturated NaHCO3 solution, and once with
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brine. The organic phase was dried over MgSO4, and solvent removed in vacuo to yield
compoundcmpd:HB13 (0.064 g, 72 %): 1H (400 MHz; DMSO-d6) δ 4.91 (s, 2H, NH2), 6.60
(t, J = 7.6 Hz, 1H, H5), 6.79 (d, J = 8.0 Hz, 1H, H1), 6.98 (t, J = 8.8 Hz, 1H, H6), 7.17
(d, J = 7.0 Hz, 1H, H4), 7.48-7.62 (m, 3H, H10,11,12), 7.99 (d, J = 7.1 Hz, 2H, H9,13), 9.68
(s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 116.6 (C1), 116.7 (C4), 123.8 (C5), 127.0 (C6),
127.2 (C9,13), 128.2 (C10,12), 128.7 (C11), 131.8 (C3), 135.1 (C8), 143.6 (C2), 165.8 (C7); IR
(neat) vmax/cm–1 1336, 1564, 1637, 3395; LRMS (ASAP) m/z 213.1 [M+H]+; HRMS (ASAP)
calculated for C13H13N2O [M+H]+ 213.1028, found 213.1022.318,320
Synthesis of p-Nitropalmanilide 113
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p-nitroaniline (0.100 g, 0.72 mmol) in dry THF (2.4 mL) under argon was treated with K2CO3
(0.200 g, 1.45 mmol) and palmitoyl chloride 18 (0.209 g, 0.76 mmol). After 12 hours, the
reaction mixture was poured on to 10 % HCl(aq) (2.0 mL) and the resulting precipitate
collected. Following washing with H2O and hexane, IPA recrystallisation yielded compound
113 (0.157 g, 58 %): 1H (400 MHz; DMSO-d6) δ 0.87 (t, J = 8.0 Hz, 3H, H22), 1.17-1.39
(m, 24H, HAlkyl), 1.73 (quin, J = 15.0 Hz, 2H, H8), 2.41 (t, J = 7.3 Hz, 2H, H8), 7.60 (s,
1H, NH), 7.72 (d, J = 9.2 Hz, 2H, H2,4), 8.20 (d, J = 9.2 Hz, 2H, H1,5); 13C (100 MHz;
DMSO-d6) δ 14.1 (C22), 22.7 (CAlkyl), 25.3 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl), 29.4 (CAlkyl),
29.6 (CAlkyl), 29.7 (CAlkyl), 31.9 (C9), 37.9 (C8), 118.9 (C1,5), 125.1 (C2,4), 143.4 (C3), 143.8
(C6), 171.8 (C7); IR (neat) vmax/cm–1 1670, 2852, 2921, 3355; LRMS (ASAP) m/z 377.3
[M+H]+; HRMS (ASAP) calculated for C22H37N2O3 [M+H]+ 377.2804, found 377.2797.321
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Synthesis of N -(4-Aminophenyl)Palmamide 87
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To p-nitropalmanilide 113 (0.050 g, 0.21 mmol) and zinc dust (0.273 g, 4.18 mmol) in THF:AcOH
(1:1) (2.5 mL), saturated CuSO4 solution (0.4 mL) was added dropwise at 0 ◦C. After warming
to room temperature the reaction mixture was stirred for 12 hours, then filtered through
celite, diluted with EtOAc, washed twice with saturated NaHCO3 solution, and once with
brine. The organic phase was dried over MgSO4, and solvent removed in vacuo to yield
compoundcmpd:HB65 (0.045 g, 62 %): 1H (400 MHz; DMSO-d6) δ 0.87 (t, J = 8.0 Hz, 3H,
H22), 1.18-1.37 (m, 24H, HAlkyl), 1.46-1.60 (m, 2H, H8), 2.20 (t, J = 7.3 Hz, 2H, H8), 4.90 (s,
2H, NH2, 6.48 (d, J = 8.8 Hz, 2H, H1,5), 7.20 (d, J = 8.8 Hz, 2H, H2,4), 9.41 (s, 1H, NH); 13C
(100 MHz; DMSO-d6) δ 14.4 (C22), 22.6 (CAlkyl), 25.8 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl),
29.6 (CAlkyl), 29.7 (CAlkyl), 31.8 (C9), 36.8 (C8), 114.3 (C1,5), 121.3 (C2,4), 136.5 (C3), 143.3
(C6), 162.0 (C7); IR (neat) vmax/cm–1 1660, 2913, 2920, 3300; LRMS (ASAP) m/z 347.3
[M+H]+; HRMS (ASAP) calculated for C22H39N2O [M+H]+ 347.3062, found 347.4066.320
Synthesis of m-Nitropalmanilide 114
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m-nitroaniline (0.100 g, 0.72 mmol) in dry THF (2.4 mL) under argon was treated with K2CO3
(0.200 g, 1.45 mmol) and palmitoyl chloride 18 (0.209 g, 0.76 mmol). After 12 hours, the
reaction mixture was poured on to 10 % HCl(aq) (2.0 mL) and the resulting precipitate
collected. Following washing with H2O and hexane, IPA recrystallisation yielded compound
114 (0.171 g, 63 %): 1H (400 MHz; DMSO-d6) δ 0.88 (t, J = 8.0 Hz, 3H, H22), 1.20-1.44 (m,
24H, HAlkyl), 1.74 (quin, J = 15.0 Hz, 2H, H8), 2.40 (t, J = 7.3 Hz, 2H, H8), 7.35 (s, 1H, NH),
350 10.7. Chapter 8
7.49 (t, J = 4.7 Hz, 1H, H5), 7.93-7.97 (m, 2H, H4,6), 8.34-8.37 (m, 1H, H2); 13C (100 MHz;
DMSO-d6) δ 14.1 (C22), 22.7 (CAlkyl), 25.4 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl), 29.4 (CAlkyl),
29.6 (CAlkyl), 29.7 (CAlkyl), 31.9 (C9), 37.7 (C8), 114.3 (C2), 118.7 (C6), 125.3 (C4), 129.8
(C5), 139.0 (C3), 148.5 (C1), 175.7 (C7); IR (neat) vmax/cm–1 1668, 2851, 2934, 3358; LRMS
(ASAP) m/z 377.3 [M+H]+; HRMS (ASAP) calculated for C22H37N2O3 [M+H]+ 377.2804,
found 377.2779.321
Synthesis of N -(3-Aminophenyl)Palmamide 88
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Tom-nitropalmanilide 114 (0.050 g, 0.21 mmol) and zinc dust (0.273 g, 4.18 mmol) in THF:AcOH
(1:1) (2.5 mL), saturated CuSO4 solution (0.4 mL) was added dropwise at 0 ◦C. After warming
to room temperature the reaction mixture was stirred for 12 hours, then filtered through
celite, diluted with EtOAc, washed twice with saturated NaHCO3 solution, and once with
brine. The organic phase was dried over MgSO4, and solvent removed in vacuo to yield
compoundcmpd:HB49 (0.049 g, 67 %): 1H (400 MHz; DMSO-d6) δ 0.86 (t, J = 8.0 Hz, 3H,
H22), 1.17-1.32 (m, 24H, HAlkyl), 1.51-1.59 (m, 2H, H8), 2.24 (t, J = 7.3 Hz, 2H, H8), 5.10 (s,
2H, NH2, 6.23 (d, J = 10.0 Hz, 1H, H6), 6.67 (d, J = 1.0 Hz, 1H, H4), 6.89 (t, J = 8.0 Hz, 1H,
H5), 6.94 (s, 1H, H2), 9.53 (s, 1H, NH); 13C (100 MHz; DMSO-d6) δ 14.4 (C22), 22.6 (CAlkyl),
25.8 (CAlkyl), 29.2 (CAlkyl), 29.3 (CAlkyl), 29.6 (CAlkyl), 29.7 (CAlkyl), 31.8 (C9), 36.9 (C8),
117.6 (C2,6), 124.1 (C4), 129.3 (C5), 137.8 (C3), 140.4 (C1), 171.4 (C7); IR (neat) vmax/cm–1
1658, 2915, 2927, 3298; LRMS (ASAP) m/z 347.3 [M+H]+; HRMS (ASAP) calculated for
C22H39N2O [M+H]+ 347.3062, found 347.3070.320
Synthesis of o-Nitropalmanilide 115
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o-nitroaniline (0.100 g, 0.72 mmol) in dry THF (2.4 mL) under argon was treated with K2CO3
(0.200 g, 1.45 mmol) and palmitoyl chloride 18 (0.209 g, 0.76 mmol). After 12 hours, the
reaction mixture was poured on to 10 % HCl(aq) (2.0 mL) and the resulting precipitate
collected. Following washing with H2O and hexane, IPA recrystallisation yielded compound
115 (0.141 g, 52 %): 1H (400 MHz; DMSO-d6) δ 0.88 (t, J = 8.0 Hz, 3H, H22), 1.18-1.40 (m,
24H, HAlkyl), 1.69-1.73 (m, 2H, H8), 2.42 (t, J = 7.3 Hz, 2H, H8), 7.31 (s, 1H, NH), 7.12–7.15
(m, 1H, H6), 7.57–7.61 (m, 1H, H4), 8.17 (dd, J = 1.5, 8.5 Hz, 1H, H5), 8.79 (dd, J = 1.5, 8.6
Hz, 1H, H1); 13C (100 MHz; CDCl3) δ 14.2 (C22), 22.7 (CAlkyl), 25.4 (CAlkyl), 29.2 (CAlkyl),
29.3 (CAlkyl), 29.4 (CAlkyl), 29.6 (CAlkyl), 29.7 (CAlkyl), 31.8 (C9), 38.2 (C8), 122.3 (C1),
123.1 (C4), 125.8 (C5), 135.2 (C6), 136.0 (C3), 136.3 (C2), 172.3 (C7); IR (neat) vmax/cm–1
1662, 2854, 2927, 3352; LRMS (ASAP) m/z 377.3 [M+H]+; HRMS (ASAP) calculated for
C22H37N2O3 [M+H]+ 377.2804, found 377.2800.321
Synthesis of N -(2-Aminophenyl)Palmamide 89
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Tom-nitropalmanilide 115 (0.050 g, 0.21 mmol) and zinc dust (0.273 g, 4.18 mmol) in THF:AcOH
(1:1) (2.5 mL), saturated CuSO4 solution (0.4 mL) was added dropwise at 0 ◦C. After warming
to room temperature the reaction mixture was stirred for 12 hours, then filtered through
celite, diluted with EtOAc, washed twice with saturated NaHCO3 solution, and once with
brine. The organic phase was dried over MgSO4, and solvent removed in vacuo to yield
compoundcmpd:HB48 (0.047 g, 64 %): 1H (400 MHz; DMSO-d6) δ 0.86 (t, J = 8.0 Hz, 3H,
H22), 1.19-1.35 (m, 24H, HAlkyl), 1.54-1.62 (m, 2H, H8), 2.30 (t, J = 7.3 Hz, 2H, H8), 4.81 (s,
2H, NH2, 6.53 (td, J = 1.4, 7.9 Hz, 1H, H5), 6.71 (dd, J = 1.4, 8.0 Hz, 1H, H1), 6.89 (td, J
= 1.5, 7.9 Hz, 1H, H6), 7.08-7.18 (m, 1H, H4), 9.09 (s, 1H, NH); 13C (100 MHz; DMSO-d6) δ
14.2 (C22), 22.6 (CAlkyl), 25.8 (CAlkyl), 29.1 (CAlkyl), 29.3 (CAlkyl), 29.6 (CAlkyl), 29.8 (CAlkyl),
31.9 (C9), 36.7 (C8), 115.6 (C1), 118.7 (C4), 122.9 (C5), 129.7 (C6), 134.5 (C3), 138.9 (C2),
173.8 (C7); IR (neat) vmax/cm–1 1649, 2913, 2926, 3304; LRMS (ASAP) m/z 347.3 [M+H]+;
HRMS (ASAP) calculated for C22H39N2O [M+H]+ 347.3062, found 347.3049.320
352 10.7. Chapter 8
Synthesis of Betaine 97
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MeI (3.025 g, 21.31 mmol) was added dropwise to glycine (0.100 g, 1.33 mmol) and NaHCO3
(1.330 g, 15.83 mmol) in MeOH:H2O (1:1) (20 mL). Following 16 hours with exclusion of
light, solvent was removed in vacuo. EtOH was added, filtered to remove excess salt, and
solvent removed in vacuo yielding betaine 97 as a white solid (0.128 g, 82 %): 1H (400 MHz;
DMSO-d6) δ 3.14 (s, 9H, H3,4,5), 3.56 (s, 2H, H2); 13C (100 MHz; CDCl3) δ 52.5 (C3,4,5),
66.7 (C2), 164.9 (C1); IR (neat) vmax/cm–1 1557, 1597, 2853, 3386; LRMS (ASAP) m/z 118.1
[M+H]+; HRMS (ASAP) calculated for C5H12NO2 [M+H]+ 118.0868, found 118.0867; m.p.
= 293-294 ◦C.322
Synthesis of Betainyl Chloride 96
Cl 1
O
2
N
3
5
4
Betaine 97 (0.050 g, 0.85 mmol) and oxalyl chloride (0.073 mL, 1.70 mmol) in dry DCM
(10 mL) were refluxed under argon for 2 hours. Solvent was removed in vacuo, however
product formation was not observed.
Synthesis of Betaine-N -Hydroxysuccinimide Ester 98 - Method 1
O 1
O
2
N
67
8
9
O
O
N
3
5
4
To betaine 97 (0.050 g, 0.85 mmol) and N -hydroxysuccinimide (0.040 g, 0.43 mmol) in dry
DMF (3.5 mL) was added DIC (0.071 g, 0.55 mmol). Stirring continued for 12 hours, however
product formation was not observed.
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Synthesis of Betaine-N -Hydroxysuccinimide Ester 98 - Method 2
To betaine 97 (0.050 g, 0.85 mmol) and N -hydroxysuccinimide (0.080 g, 0.86 mmol) in dry
DMF (3.5 mL) was added DIC (0.142 g, 1.10 mmol). Stirring continued for 12 hours at 65 ◦C,
however product formation was not observed.
Synthesis of Glycinyl Chloride 99 - Method 1
Cl 1
O
2
NH2
Glycine (0.071 g, 0.95 mmol) and oxalyl chloride (0.165 mL, 1.90 mmol) in dry DCM (40 mL)
were refluxed under argon for 2 hours. Solvent was removed in vacuo, however product
formation was not observed.
Synthesis of Glycinyl Chloride 99 - Method 2
Glycine (0.071 g, 0.95 mmol) and oxalyl chloride (0.165 mL, 1.90 mmol) in dry DCM:DMF
(19:1) (40 mL) were refluxed under argon for 2 hours. Solvent was removed in vacuo, however
product formation was not observed.
Synthesis of Fmoc Glycinyl Chloride 100
Cl 1
O
2
H
N 3
O
O
4
5
17
12
11
6
10
9
8
7
16 15
14
13
Fmoc glycine (0.200 g, 0.67 mmol) was dissolved in a combination of dry DCM (1.0 mL), dry
DMF (6.0 µL) and dry THF (0.2 mL). Oxalyl chloride (0.117 mL, 1.35 mmol) was added
dropwise, and the mixture refluxed for 1.5 hours. Solvent removal in vacuo yielded compound-
cmpd:HB76 as a pale yellow solid (0.188 g, 89 %): 1H (400 MHz; DMSO-d6) δ 3.65 (d, J =
5.6 Hz, 2H, H2), 4.21-4.28 (m, 3H, H4,5), 7.33 (t, J = 7.2 Hz, 2H, H8,15), 7.41 (t, J = 7.3 Hz,
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2H, H9,14), 7.72 (d, J = 7.3 Hz, 2H, H7,16), 7.87 (d, J = 7.4 Hz, 2H, H10,13); 13C (100 MHz;
DMSO-d6) δ 42.1 (C2), 46.6 (C5), 66.3 (C4), 120.1 (C10,13), 125.2 (C7,16), 127.1 (C8,15), 127.6
(C9,14), 140.7 (C11,12), 143.8 (C6,17), 156.5 (C3), 174.7 (C1); IR (neat) vmax/cm–1 1689, 1701,
1742, 2916, 2955.323
Synthesis of p-NitroFmocglycylanilide 101
2
1
6
5
4
3
HN 7
8
O
H
N 9
O
O
10
11
23
18
17
12
22
21
20
19
16
15
14
13
NO2
p-nitroaniline (0.100 g, 0.72 mmol) in dry THF (2.4 mL) under argon was treated with K2CO3
(0.200 g, 1.45 mmol) and acid chloride 100 (0.182 mL, 0.76 mmol). After 12 hours, the reaction
mixture was poured on to 10 % HCl(aq) (2.0 mL) and the resulting precipitate compound 101
collected however time constraints prevented charactersation.321
Synthesis of m-NitroFmocglycylanilide 104
2
1
6
5
4
3
HN 7
8
O
H
N 9
O
O
10
11
23
18
17
12
22
21
20
19
16
15
14
13
O2N
m-nitroaniline (0.050 g, 0.36 mmol) in dry THF (1.2 mL) under argon was treated with K2CO3
(0.100 g, 0.73 mmol) and acid chloride 100 (0.091 mL, 0.38 mmol). After 12 hours, the reaction
mixture was poured on to 10 % HCl(aq) (1.0 mL) and the resulting precipitate compound 104
collected however time constraints prevented charactersation.321
Chapter 10. Experimental 355
Synthesis of o-NitroFmocglycylanilide 105
2
1
6
5
4
3
HN 7
8
O
H
N 9
O
O
10
11
23
18
17
12
22
21
20
19
16
15
14
13
O2N
o-nitroaniline (0.050 g, 0.36 mmol) in dry THF (1.2 mL) under argon was treated with K2CO3
(0.100 g, 0.73 mmol) and acid chloride 100 (0.091 mL, 0.38 mmol). After 12 hours, the reaction
mixture was poured on to 10 % HCl(aq) (1.0 mL) and the resulting precipitate compound 105
collected however time constraints prevented charactersation.321
Marker Release Assay
Stock solutions of phospholipid in CHCl3 were prepared at a concentration of 10 mg mL−1
and stored at -20 ◦C. A 100 µL aliquot of phospholipid stock solution was added to a
round-bottomed flask, and solvent removed in vacuo resulting in formation of a lipid film.
Following overnight dessication, the phospholipid film was rehydrated in 12.5 mm ANTS and
45.0 mm DPX solution, and agitated using a vortex mixer. The dispersion was subjected to 5
freeze-thaw cycles between -196 ◦C and 30 ◦C, before 10 extrusion cycles at 50 ◦C using a
LIPEX thermobarrel extruder under a positive pressure of nitrogen and a 100 nm Whatman
Nucleopore laser-etched polycarbonate filter. External buffer was exchanged for osmotically
equivalent buffer (10 mm NH4HCO3 in H2O at pH 7.4) using a PD-10 desalting column.
Liposomes (100 µL) were added to each well of a 96 well plate, along with substrate (10 µL)
of interest. Emission at 530 nm was measured at one minute intervals following excitation at
360 nm using a Synergy H4 Plate Reader (BioTek, UK). Data was normalised to a positive
control of 20 % Triton X.325
CMC Determination for Acylated Propranolol
Stock solution of Rhodamine 6G was prepared in H2O at 20 mg mL−1. Stock (1 mL) was added
to a 1 mL cuvette, and absorbance measured over the range 520 nm to 560 nm at 21 ◦C using a
CARY100 UV-Visible spectrophotometer with Cary WinUV Scan Software 3.00(182). 100 µm
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solution of desired substrate in H2O was added in 1 µL portions over the total concentration
range 0.1 µm to 100 µm, and absorbance measurements repeated. Data was corrected for
dilution.326,327
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